,source,target,value,type,source layer,target layer,normalized value
0,IGLC7,Initial triggering of complement,0.00594463904077808,0,0,1,0.006414312241677825
1,IGLC7,Initial triggering of complement,0.0057582416319443535,1,0,1,0.006213187972719233
2,IGLC7,Regulation of Complement cascade,0.00594463904077808,0,0,1,0.006414312241677825
3,IGLC7,Regulation of Complement cascade,0.0057582416319443535,1,0,1,0.006213187972719233
4,IGLC7,FCGR activation,0.00594463904077808,0,0,1,0.006414312241677825
5,IGLC7,FCGR activation,0.0057582416319443535,1,0,1,0.006213187972719233
6,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.00594463904077808,0,0,1,0.006414312241677825
7,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.0057582416319443535,1,0,1,0.006213187972719233
8,IGLC7,Role of phospholipids in phagocytosis,0.00594463904077808,0,0,1,0.006414312241677825
9,IGLC7,Role of phospholipids in phagocytosis,0.0057582416319443535,1,0,1,0.006213187972719233
10,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.00594463904077808,0,0,1,0.006414312241677825
11,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.0057582416319443535,1,0,1,0.006213187972719233
12,IGLC7,FCERI mediated MAPK activation,0.00594463904077808,0,0,1,0.006414312241677825
13,IGLC7,FCERI mediated MAPK activation,0.0057582416319443535,1,0,1,0.006213187972719233
14,IGLC7,FCERI mediated Ca+2 mobilization,0.00594463904077808,0,0,1,0.006414312241677825
15,IGLC7,FCERI mediated Ca+2 mobilization,0.0057582416319443535,1,0,1,0.006213187972719233
16,IGLC7,FCERI mediated NF-kB activation,0.00594463904077808,0,0,1,0.006414312241677825
17,IGLC7,FCERI mediated NF-kB activation,0.0057582416319443535,1,0,1,0.006213187972719233
18,IGLC7,Parasite infection,0.00594463904077808,0,0,1,0.006414312241677825
19,IGLC7,Parasite infection,0.0057582416319443535,1,0,1,0.006213187972719233
20,IGLC7,Leishmania parasite growth and survival,0.00594463904077808,0,0,1,0.006414312241677825
21,IGLC7,Leishmania parasite growth and survival,0.0057582416319443535,1,0,1,0.006213187972719233
22,IGLC7,Potential therapeutics for SARS,0.00594463904077808,0,0,1,0.006414312241677825
23,IGLC7,Potential therapeutics for SARS,0.0057582416319443535,1,0,1,0.006213187972719233
24,IGLC7,CD22 mediated BCR regulation,0.00594463904077808,0,0,1,0.006414312241677825
25,IGLC7,CD22 mediated BCR regulation,0.0057582416319443535,1,0,1,0.006213187972719233
26,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00594463904077808,0,0,1,0.006414312241677825
27,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0057582416319443535,1,0,1,0.006213187972719233
28,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00594463904077808,0,0,1,0.006414312241677825
29,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0057582416319443535,1,0,1,0.006213187972719233
30,IGLC7,Scavenging of heme from plasma,0.00594463904077808,0,0,1,0.006414312241677825
31,IGLC7,Scavenging of heme from plasma,0.0057582416319443535,1,0,1,0.006213187972719233
32,RB27B,Platelet degranulation ,0.00012520463205873967,0,0,1,0.00013509678192740623
33,RB27B,Platelet degranulation ,0.00017391808020571868,1,0,1,0.00018765897529863032
34,RB27B,RAB GEFs exchange GTP for GDP on RABs,0.00012520463205873967,0,0,1,0.00013509678192740623
35,RB27B,RAB GEFs exchange GTP for GDP on RABs,0.00017391808020571868,1,0,1,0.00018765897529863032
36,RB27B,RAB geranylgeranylation,0.00012520463205873967,0,0,1,0.00013509678192740623
37,RB27B,RAB geranylgeranylation,0.00017391808020571868,1,0,1,0.00018765897529863032
38,QSOX1,Platelet degranulation ,0.0038611262549238744,0,0,1,0.004166185572199222
39,QSOX1,Platelet degranulation ,0.0039032206705693776,1,0,1,0.004211605777484872
40,QSOX1,Neutrophil degranulation,0.0038611262549238744,0,0,1,0.004166185572199222
41,QSOX1,Neutrophil degranulation,0.0039032206705693776,1,0,1,0.004211605777484872
42,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038611262549238744,0,0,1,0.004166185572199222
43,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0039032206705693776,1,0,1,0.004211605777484872
44,QSOX1,Post-translational protein phosphorylation,0.0038611262549238744,0,0,1,0.004166185572199222
45,QSOX1,Post-translational protein phosphorylation,0.0039032206705693776,1,0,1,0.004211605777484872
46,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0002775209883414694,0,0,1,0.00029944732735332267
47,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0003254725825324082,1,0,1,0.0003511874743188562
48,NRP1,Semaphorin interactions,0.0002775209883414694,0,0,1,0.00029944732735332267
49,NRP1,Semaphorin interactions,0.0003254725825324082,1,0,1,0.0003511874743188562
50,NRP1,L1CAM interactions,0.0002775209883414694,0,0,1,0.00029944732735332267
51,NRP1,L1CAM interactions,0.0003254725825324082,1,0,1,0.0003511874743188562
52,NRP1,Signaling by ROBO receptors,0.0002775209883414694,0,0,1,0.00029944732735332267
53,NRP1,Signaling by ROBO receptors,0.0003254725825324082,1,0,1,0.0003511874743188562
54,NRP1,SARS-CoV-2 Infection,0.0002775209883414694,0,0,1,0.00029944732735332267
55,NRP1,SARS-CoV-2 Infection,0.0003254725825324082,1,0,1,0.0003511874743188562
56,APOL1,Scavenging of heme from plasma,0.0002728758593832481,0,0,1,0.00029443519670308374
57,APOL1,Scavenging of heme from plasma,0.00016893909351741362,1,0,1,0.00018228660953396885
58,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002728758593832481,0,0,1,0.00029443519670308374
59,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00016893909351741362,1,0,1,0.00018228660953396885
60,APOL1,Post-translational protein phosphorylation,0.0002728758593832481,0,0,1,0.00029443519670308374
61,APOL1,Post-translational protein phosphorylation,0.00016893909351741362,1,0,1,0.00018228660953396885
62,ARPC3,RHO GTPase Effectors,0.0009243725049600471,0,0,1,0.000997405197147103
63,ARPC3,RHO GTPase Effectors,0.0009469106432031064,1,0,1,0.0010217240254301
64,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0009243725049600471,0,0,1,0.000997405197147103
65,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0009469106432031064,1,0,1,0.0010217240254301
66,ARPC3,EPH-Ephrin signaling,0.0009243725049600471,0,0,1,0.000997405197147103
67,ARPC3,EPH-Ephrin signaling,0.0009469106432031064,1,0,1,0.0010217240254301
68,ARPC3,Parasite infection,0.0009243725049600471,0,0,1,0.000997405197147103
69,ARPC3,Parasite infection,0.0009469106432031064,1,0,1,0.0010217240254301
70,ACTN4,Platelet degranulation ,0.0005500335338486669,0,0,1,0.0005934905055290009
71,ACTN4,Platelet degranulation ,0.0006225870827620383,1,0,1,0.0006717763549775314
72,ACTN4,Nephrin family interactions,0.0005500335338486669,0,0,1,0.0005934905055290009
73,ACTN4,Nephrin family interactions,0.0006225870827620383,1,0,1,0.0006717763549775314
74,FLNB,Antiviral mechanism by IFN-stimulated genes,0.0001714761264641614,0,0,1,0.0001850240880210957
75,FLNB,Antiviral mechanism by IFN-stimulated genes,0.00017242493910695582,1,0,1,0.0001860478643190319
76,PGRP1,Neutrophil degranulation,0.000310548924850688,0,0,1,0.00033508473040087767
77,PGRP1,Neutrophil degranulation,0.0003026121075284512,1,0,1,0.0003265208421377274
78,FCN3,Initial triggering of complement,0.0011582120928020838,0,0,1,0.0012497199500858703
79,FCN3,Initial triggering of complement,0.0012412209333585147,1,0,1,0.0013392871413814595
80,IDHC,NADPH regeneration,0.00033342882755581135,0,0,1,0.0003597723252242399
81,IDHC,NADPH regeneration,0.0005648631352717833,1,0,1,0.0006094917620047933
82,IDHC,KEAP1-NFE2L2 pathway,0.00033342882755581135,0,0,1,0.0003597723252242399
83,IDHC,KEAP1-NFE2L2 pathway,0.0005648631352717833,1,0,1,0.0006094917620047933
84,IDHC,Neutrophil degranulation,0.00033342882755581135,0,0,1,0.0003597723252242399
85,IDHC,Neutrophil degranulation,0.0005648631352717833,1,0,1,0.0006094917620047933
86,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00033342882755581135,0,0,1,0.0003597723252242399
87,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0005648631352717833,1,0,1,0.0006094917620047933
88,UTS2,Class A/1 (Rhodopsin-like receptors),0.0021716703282436355,0,0,1,0.0023432493505137052
89,UTS2,Class A/1 (Rhodopsin-like receptors),0.0019262109155533836,1,0,1,0.0020783967152478884
90,UTS2,G alpha (q) signalling events,0.0021716703282436355,0,0,1,0.0023432493505137052
91,UTS2,G alpha (q) signalling events,0.0019262109155533836,1,0,1,0.0020783967152478884
92,APOM,Retinoid metabolism and transport,0.0004081222079075057,0,0,1,0.00044036706961084974
93,APOM,Retinoid metabolism and transport,0.0004639073676798944,1,0,1,0.000500559695399808
94,VNN1,Vitamin B5 (pantothenate) metabolism,0.0010402883655236414,0,0,1,0.0011224793216342921
95,VNN1,Vitamin B5 (pantothenate) metabolism,0.001105978160436886,1,0,1,0.0011933591265770294
96,VNN1,Neutrophil degranulation,0.0010402883655236414,0,0,1,0.0011224793216342921
97,VNN1,Neutrophil degranulation,0.001105978160436886,1,0,1,0.0011933591265770294
98,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0010402883655236414,0,0,1,0.0011224793216342921
99,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.001105978160436886,1,0,1,0.0011933591265770294
100,FSTL3,Antagonism of Activin by Follistatin,5.6524792474495676e-05,0,0,1,6.09906952870263e-05
101,FSTL3,Antagonism of Activin by Follistatin,4.920953748523971e-05,1,0,1,5.3097477665786546e-05
102,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),5.6524792474495676e-05,0,0,1,6.09906952870263e-05
103,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),4.920953748523971e-05,1,0,1,5.3097477665786546e-05
104,FSTL3,Post-translational protein phosphorylation,5.6524792474495676e-05,0,0,1,6.09906952870263e-05
105,FSTL3,Post-translational protein phosphorylation,4.920953748523971e-05,1,0,1,5.3097477665786546e-05
106,K2C75,Formation of the cornified envelope,0.00029726176629386224,0,0,1,0.0003207477818992902
107,K2C75,Formation of the cornified envelope,0.0003440964303687603,1,0,1,0.00037128275249208276
108,PAK4,RHO GTPase cycle,0.0009643996403610799,0,0,1,0.0010405947908029923
109,PAK4,RHO GTPase cycle,0.0011412557125974369,1,0,1,0.0012314238825912535
110,PAK4,Signaling by ROBO receptors,0.0009643996403610799,0,0,1,0.0010405947908029923
111,PAK4,Signaling by ROBO receptors,0.0011412557125974369,1,0,1,0.0012314238825912535
112,ADH1B,Ethanol oxidation,0.0007831065197630475,0,0,1,0.0008449780889633919
113,ADH1B,Ethanol oxidation,0.000724746149838514,1,0,1,0.0007820067911826631
114,LDHA,Pyruvate metabolism,0.0011759016604628413,0,0,1,0.0012688071326074747
115,LDHA,Pyruvate metabolism,0.0012009179316616306,1,0,1,0.0012957998858244173
116,AL1A1,Ethanol oxidation,0.001445208910445217,0,0,1,0.0015593917717226602
117,AL1A1,Ethanol oxidation,0.0014282634433281298,1,0,1,0.0015411074795352823
118,AL1A1,RA biosynthesis pathway,0.001445208910445217,0,0,1,0.0015593917717226602
119,AL1A1,RA biosynthesis pathway,0.0014282634433281298,1,0,1,0.0015411074795352823
120,AL1A1,Fructose catabolism,0.001445208910445217,0,0,1,0.0015593917717226602
121,AL1A1,Fructose catabolism,0.0014282634433281298,1,0,1,0.0015411074795352823
122,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0007041966906399466,0,0,1,0.0007598337632169522
123,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0007260156465539088,1,0,1,0.0007833765881150705
124,DHE3,Glutamate and glutamine metabolism,0.0007041966906399466,0,0,1,0.0007598337632169522
125,DHE3,Glutamate and glutamine metabolism,0.0007260156465539088,1,0,1,0.0007833765881150705
126,CERU,Metal ion SLC transporters,0.0016792663531001986,0,0,1,0.0018119415917166343
127,CERU,Metal ion SLC transporters,0.00161465059436523,1,0,1,0.0017422206802507026
128,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0016792663531001986,0,0,1,0.0018119415917166343
129,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.00161465059436523,1,0,1,0.0017422206802507026
130,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.0016792663531001986,0,0,1,0.0018119415917166343
131,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.00161465059436523,1,0,1,0.0017422206802507026
132,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0016792663531001986,0,0,1,0.0018119415917166343
133,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00161465059436523,1,0,1,0.0017422206802507026
134,CERU,Post-translational protein phosphorylation,0.0016792663531001986,0,0,1,0.0018119415917166343
135,CERU,Post-translational protein phosphorylation,0.00161465059436523,1,0,1,0.0017422206802507026
136,OTC,Urea cycle,0.0010148924418899696,0,0,1,0.0010950769204565657
137,OTC,Urea cycle,0.0012062963578500785,1,0,1,0.0013016032499487775
138,OTC,Mitochondrial protein import,0.0010148924418899696,0,0,1,0.0010950769204565657
139,OTC,Mitochondrial protein import,0.0012062963578500785,1,0,1,0.0013016032499487775
140,F13A,Interleukin-4 and Interleukin-13 signaling,0.005555676497291036,0,0,1,0.005994618600545236
141,F13A,Interleukin-4 and Interleukin-13 signaling,0.006159219889013912,1,0,1,0.0066458466632343186
142,F13A,Platelet degranulation ,0.005555676497291036,0,0,1,0.005994618600545236
143,F13A,Platelet degranulation ,0.006159219889013912,1,0,1,0.0066458466632343186
144,F13A,Common Pathway of Fibrin Clot Formation,0.005555676497291036,0,0,1,0.005994618600545236
145,F13A,Common Pathway of Fibrin Clot Formation,0.006159219889013912,1,0,1,0.0066458466632343186
146,PGK1,Glycolysis,0.0005704622281579456,0,0,1,0.0006155332272301237
147,PGK1,Glycolysis,0.0006922383327037096,1,0,1,0.0007469306010275234
148,PGK1,Gluconeogenesis,0.0005704622281579456,0,0,1,0.0006155332272301237
149,PGK1,Gluconeogenesis,0.0006922383327037096,1,0,1,0.0007469306010275234
150,PGK1,Response of Mtb to phagocytosis,0.0005704622281579456,0,0,1,0.0006155332272301237
151,PGK1,Response of Mtb to phagocytosis,0.0006922383327037096,1,0,1,0.0007469306010275234
152,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.01920185326501572,0,0,1,0.020718950573081495
153,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.018397191087327278,1,0,1,0.01985071375981881
154,THRB,Regulation of Complement cascade,0.01920185326501572,0,0,1,0.020718950573081495
155,THRB,Regulation of Complement cascade,0.018397191087327278,1,0,1,0.01985071375981881
156,THRB,Class A/1 (Rhodopsin-like receptors),0.01920185326501572,0,0,1,0.020718950573081495
157,THRB,Class A/1 (Rhodopsin-like receptors),0.018397191087327278,1,0,1,0.01985071375981881
158,THRB,G alpha (q) signalling events,0.01920185326501572,0,0,1,0.020718950573081495
159,THRB,G alpha (q) signalling events,0.018397191087327278,1,0,1,0.01985071375981881
160,THRB,Defective factor XII causes hereditary angioedema,0.01920185326501572,0,0,1,0.020718950573081495
161,THRB,Defective factor XII causes hereditary angioedema,0.018397191087327278,1,0,1,0.01985071375981881
162,THRB,Defective factor VIII causes hemophilia A,0.01920185326501572,0,0,1,0.020718950573081495
163,THRB,Defective factor VIII causes hemophilia A,0.018397191087327278,1,0,1,0.01985071375981881
164,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.01920185326501572,0,0,1,0.020718950573081495
165,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.018397191087327278,1,0,1,0.01985071375981881
166,THRB,Common Pathway of Fibrin Clot Formation,0.01920185326501572,0,0,1,0.020718950573081495
167,THRB,Common Pathway of Fibrin Clot Formation,0.018397191087327278,1,0,1,0.01985071375981881
168,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01920185326501572,0,0,1,0.020718950573081495
169,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.018397191087327278,1,0,1,0.01985071375981881
170,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.01920185326501572,0,0,1,0.020718950573081495
171,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.018397191087327278,1,0,1,0.01985071375981881
172,C1R,Initial triggering of complement,0.0021146640407702457,0,0,1,0.0022817391183389845
173,C1R,Initial triggering of complement,0.0022126744227837967,1,0,1,0.0023874930907582677
174,C1R,Regulation of Complement cascade,0.0021146640407702457,0,0,1,0.0022817391183389845
175,C1R,Regulation of Complement cascade,0.0022126744227837967,1,0,1,0.0023874930907582677
176,HPT,Neutrophil degranulation,0.005173771569752716,0,0,1,0.0055825401824844655
177,HPT,Neutrophil degranulation,0.005327382530473794,1,0,1,0.005748287616273167
178,HPT,Scavenging of heme from plasma,0.005173771569752716,0,0,1,0.0055825401824844655
179,HPT,Scavenging of heme from plasma,0.005327382530473794,1,0,1,0.005748287616273167
180,HPTR,Scavenging of heme from plasma,0.00022425118269969364,0,0,1,0.00024196878843851623
181,HPTR,Scavenging of heme from plasma,0.00024059954813158887,1,0,1,0.000259608803215175
182,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.009768491040570855,0,0,1,0.010540278599666265
183,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.009556377962993187,1,0,1,0.010311406922043208
184,FA9,Defective factor VIII causes hemophilia A,0.009768491040570855,0,0,1,0.010540278599666265
185,FA9,Defective factor VIII causes hemophilia A,0.009556377962993187,1,0,1,0.010311406922043208
186,FA9,Defective factor IX causes hemophilia B,0.009768491040570855,0,0,1,0.010540278599666265
187,FA9,Defective factor IX causes hemophilia B,0.009556377962993187,1,0,1,0.010311406922043208
188,FA9,Defective factor IX causes thrombophilia,0.009768491040570855,0,0,1,0.010540278599666265
189,FA9,Defective factor IX causes thrombophilia,0.009556377962993187,1,0,1,0.010311406922043208
190,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.009768491040570855,0,0,1,0.010540278599666265
191,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.009556377962993187,1,0,1,0.010311406922043208
192,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.009768491040570855,0,0,1,0.010540278599666265
193,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.009556377962993187,1,0,1,0.010311406922043208
194,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.017889746487154905,0,0,1,0.019303177048416914
195,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.017468759808646914,1,0,1,0.01884892911393111
196,FA10,Defective factor VIII causes hemophilia A,0.017889746487154905,0,0,1,0.019303177048416914
197,FA10,Defective factor VIII causes hemophilia A,0.017468759808646914,1,0,1,0.01884892911393111
198,FA10,Defective factor IX causes hemophilia B,0.017889746487154905,0,0,1,0.019303177048416914
199,FA10,Defective factor IX causes hemophilia B,0.017468759808646914,1,0,1,0.01884892911393111
200,FA10,Defective factor IX causes thrombophilia,0.017889746487154905,0,0,1,0.019303177048416914
201,FA10,Defective factor IX causes thrombophilia,0.017468759808646914,1,0,1,0.01884892911393111
202,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.017889746487154905,0,0,1,0.019303177048416914
203,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.017468759808646914,1,0,1,0.01884892911393111
204,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.017889746487154905,0,0,1,0.019303177048416914
205,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.017468759808646914,1,0,1,0.01884892911393111
206,FA10,Common Pathway of Fibrin Clot Formation,0.017889746487154905,0,0,1,0.019303177048416914
207,FA10,Common Pathway of Fibrin Clot Formation,0.017468759808646914,1,0,1,0.01884892911393111
208,CFAD,Initial triggering of complement,0.0010007635772732706,0,0,1,0.0010798317645017241
209,CFAD,Initial triggering of complement,0.0012645993100401634,1,0,1,0.0013645125935428117
210,CFAD,Platelet degranulation ,0.0010007635772732706,0,0,1,0.0010798317645017241
211,CFAD,Platelet degranulation ,0.0012645993100401634,1,0,1,0.0013645125935428117
212,CFAD,Neutrophil degranulation,0.0010007635772732706,0,0,1,0.0010798317645017241
213,CFAD,Neutrophil degranulation,0.0012645993100401634,1,0,1,0.0013645125935428117
214,PLMN,Platelet degranulation ,0.007808065753488335,0,0,1,0.008424964308660585
215,PLMN,Platelet degranulation ,0.007642793231328445,1,0,1,0.008246633958435586
216,PLMN,Dissolution of Fibrin Clot,0.007808065753488335,0,0,1,0.008424964308660585
217,PLMN,Dissolution of Fibrin Clot,0.007642793231328445,1,0,1,0.008246633958435586
218,PLMN,Activation of Matrix Metalloproteinases,0.007808065753488335,0,0,1,0.008424964308660585
219,PLMN,Activation of Matrix Metalloproteinases,0.007642793231328445,1,0,1,0.008246633958435586
220,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007808065753488335,0,0,1,0.008424964308660585
221,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007642793231328445,1,0,1,0.008246633958435586
222,PLMN,Signaling by PDGF,0.007808065753488335,0,0,1,0.008424964308660585
223,PLMN,Signaling by PDGF,0.007642793231328445,1,0,1,0.008246633958435586
224,FA12,Defective factor XII causes hereditary angioedema,0.00039259777715301426,0,0,1,0.0004236160868261019
225,FA12,Defective factor XII causes hereditary angioedema,0.0004414726743789288,1,0,1,0.00047635248502226485
226,FA12,Defective SERPING1 causes hereditary angioedema,0.00039259777715301426,0,0,1,0.0004236160868261019
227,FA12,Defective SERPING1 causes hereditary angioedema,0.0004414726743789288,1,0,1,0.00047635248502226485
228,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.00039259777715301426,0,0,1,0.0004236160868261019
229,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0004414726743789288,1,0,1,0.00047635248502226485
230,CFAB,Initial triggering of complement,0.0038690692223705505,0,0,1,0.004174756096494973
231,CFAB,Initial triggering of complement,0.00396004921324978,1,0,1,0.004272924221631129
232,CFAB,Activation of C3 and C5,0.0038690692223705505,0,0,1,0.004174756096494973
233,CFAB,Activation of C3 and C5,0.00396004921324978,1,0,1,0.004272924221631129
234,CFAB,Regulation of Complement cascade,0.0038690692223705505,0,0,1,0.004174756096494973
235,CFAB,Regulation of Complement cascade,0.00396004921324978,1,0,1,0.004272924221631129
236,CAH1,Interleukin-12 family signaling,0.003973573829049807,0,0,1,0.004287517388364219
237,CAH1,Interleukin-12 family signaling,0.004338523009755591,1,0,1,0.004681300422343857
238,CAH1,Reversible hydration of carbon dioxide,0.003973573829049807,0,0,1,0.004287517388364219
239,CAH1,Reversible hydration of carbon dioxide,0.004338523009755591,1,0,1,0.004681300422343857
240,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.003973573829049807,0,0,1,0.004287517388364219
241,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.004338523009755591,1,0,1,0.004681300422343857
242,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.003973573829049807,0,0,1,0.004287517388364219
243,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.004338523009755591,1,0,1,0.004681300422343857
244,CAH2,Reversible hydration of carbon dioxide,0.0014630008226959035,0,0,1,0.0015785893848610853
245,CAH2,Reversible hydration of carbon dioxide,0.0015641438755361985,1,0,1,0.0016877235337209053
246,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.0014630008226959035,0,0,1,0.0015785893848610853
247,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.0015641438755361985,1,0,1,0.0016877235337209053
248,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.0014630008226959035,0,0,1,0.0015785893848610853
249,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.0015641438755361985,1,0,1,0.0016877235337209053
250,ASSY,Urea cycle,0.0004478280450712191,0,0,1,0.00048320997994370963
251,ASSY,Urea cycle,0.00040904161432990803,1,0,1,0.00044135911636589056
252,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.013072202715557068,0,0,1,0.0141050094596016
253,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.012807240731975374,1,0,1,0.013819113397080562
254,ANT3,Common Pathway of Fibrin Clot Formation,0.013072202715557068,0,0,1,0.0141050094596016
255,ANT3,Common Pathway of Fibrin Clot Formation,0.012807240731975374,1,0,1,0.013819113397080562
256,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013072202715557068,0,0,1,0.0141050094596016
257,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.012807240731975374,1,0,1,0.013819113397080562
258,ANT3,Post-translational protein phosphorylation,0.013072202715557068,0,0,1,0.0141050094596016
259,ANT3,Post-translational protein phosphorylation,0.012807240731975374,1,0,1,0.013819113397080562
260,A1AT,COPII-mediated vesicle transport,0.0010084149300382706,0,0,1,0.0010880876342642576
261,A1AT,COPII-mediated vesicle transport,0.0010640412687280333,1,0,1,0.0011481088908569471
262,A1AT,Cargo concentration in the ER,0.0010084149300382706,0,0,1,0.0010880876342642576
263,A1AT,Cargo concentration in the ER,0.0010640412687280333,1,0,1,0.0011481088908569471
264,A1AT,Platelet degranulation ,0.0010084149300382706,0,0,1,0.0010880876342642576
265,A1AT,Platelet degranulation ,0.0010640412687280333,1,0,1,0.0011481088908569471
266,A1AT,Neutrophil degranulation,0.0010084149300382706,0,0,1,0.0010880876342642576
267,A1AT,Neutrophil degranulation,0.0010640412687280333,1,0,1,0.0011481088908569471
268,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010084149300382706,0,0,1,0.0010880876342642576
269,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010640412687280333,1,0,1,0.0011481088908569471
270,A1AT,Post-translational protein phosphorylation,0.0010084149300382706,0,0,1,0.0010880876342642576
271,A1AT,Post-translational protein phosphorylation,0.0010640412687280333,1,0,1,0.0011481088908569471
272,AACT,Platelet degranulation ,0.0033697554561664825,0,0,1,0.0036359926188420377
273,AACT,Platelet degranulation ,0.0036735694674158974,1,0,1,0.003963810324539994
274,AACT,Neutrophil degranulation,0.0033697554561664825,0,0,1,0.0036359926188420377
275,AACT,Neutrophil degranulation,0.0036735694674158974,1,0,1,0.003963810324539994
276,ANGT,Class A/1 (Rhodopsin-like receptors),0.00479308467838564,0,0,1,0.005171776035024555
277,ANGT,Class A/1 (Rhodopsin-like receptors),0.0043997728822432695,1,0,1,0.004747389516097731
278,ANGT,G alpha (q) signalling events,0.00479308467838564,0,0,1,0.005171776035024555
279,ANGT,G alpha (q) signalling events,0.0043997728822432695,1,0,1,0.004747389516097731
280,ANGT,G alpha (i) signalling events,0.00479308467838564,0,0,1,0.005171776035024555
281,ANGT,G alpha (i) signalling events,0.0043997728822432695,1,0,1,0.004747389516097731
282,ANGT,PPARA activates gene expression,0.00479308467838564,0,0,1,0.005171776035024555
283,ANGT,PPARA activates gene expression,0.0043997728822432695,1,0,1,0.004747389516097731
284,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.00479308467838564,0,0,1,0.005171776035024555
285,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.0043997728822432695,1,0,1,0.004747389516097731
286,A2MG,Platelet degranulation ,0.005592711276040063,0,0,1,0.006034579417857808
287,A2MG,Platelet degranulation ,0.005876526590509456,1,0,1,0.006340818372567897
288,A2MG,HDL assembly,0.005592711276040063,0,0,1,0.006034579417857808
289,A2MG,HDL assembly,0.005876526590509456,1,0,1,0.006340818372567897
290,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.005592711276040063,0,0,1,0.006034579417857808
291,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.005876526590509456,1,0,1,0.006340818372567897
292,CO3,Initial triggering of complement,0.003513034034616188,0,0,1,0.0037905913309616303
293,CO3,Initial triggering of complement,0.0036382442575510748,1,0,1,0.003925694145488336
294,CO3,Activation of C3 and C5,0.003513034034616188,0,0,1,0.0037905913309616303
295,CO3,Activation of C3 and C5,0.0036382442575510748,1,0,1,0.003925694145488336
296,CO3,Regulation of Complement cascade,0.003513034034616188,0,0,1,0.0037905913309616303
297,CO3,Regulation of Complement cascade,0.0036382442575510748,1,0,1,0.003925694145488336
298,CO3,Class A/1 (Rhodopsin-like receptors),0.003513034034616188,0,0,1,0.0037905913309616303
299,CO3,Class A/1 (Rhodopsin-like receptors),0.0036382442575510748,1,0,1,0.003925694145488336
300,CO3,G alpha (i) signalling events,0.003513034034616188,0,0,1,0.0037905913309616303
301,CO3,G alpha (i) signalling events,0.0036382442575510748,1,0,1,0.003925694145488336
302,CO3,Cell recruitment (pro-inflammatory response),0.003513034034616188,0,0,1,0.0037905913309616303
303,CO3,Cell recruitment (pro-inflammatory response),0.0036382442575510748,1,0,1,0.003925694145488336
304,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003513034034616188,0,0,1,0.0037905913309616303
305,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0036382442575510748,1,0,1,0.003925694145488336
306,CO3,Neutrophil degranulation,0.003513034034616188,0,0,1,0.0037905913309616303
307,CO3,Neutrophil degranulation,0.0036382442575510748,1,0,1,0.003925694145488336
308,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003513034034616188,0,0,1,0.0037905913309616303
309,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0036382442575510748,1,0,1,0.003925694145488336
310,CO3,Post-translational protein phosphorylation,0.003513034034616188,0,0,1,0.0037905913309616303
311,CO3,Post-translational protein phosphorylation,0.0036382442575510748,1,0,1,0.003925694145488336
312,CO5,Terminal pathway of complement,0.003917514131838592,0,0,1,0.0042270285345212795
313,CO5,Terminal pathway of complement,0.003741425915207704,1,0,1,0.004037027964965608
314,CO5,Activation of C3 and C5,0.003917514131838592,0,0,1,0.0042270285345212795
315,CO5,Activation of C3 and C5,0.003741425915207704,1,0,1,0.004037027964965608
316,CO5,Regulation of Complement cascade,0.003917514131838592,0,0,1,0.0042270285345212795
317,CO5,Regulation of Complement cascade,0.003741425915207704,1,0,1,0.004037027964965608
318,CO5,Class A/1 (Rhodopsin-like receptors),0.003917514131838592,0,0,1,0.0042270285345212795
319,CO5,Class A/1 (Rhodopsin-like receptors),0.003741425915207704,1,0,1,0.004037027964965608
320,CO5,G alpha (i) signalling events,0.003917514131838592,0,0,1,0.0042270285345212795
321,CO5,G alpha (i) signalling events,0.003741425915207704,1,0,1,0.004037027964965608
322,TIMP1,Interleukin-10 signaling,0.004114942441204524,0,0,1,0.004440055231841813
323,TIMP1,Interleukin-10 signaling,0.0038294426377736574,1,0,1,0.004131998700304529
324,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.004114942441204524,0,0,1,0.004440055231841813
325,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0038294426377736574,1,0,1,0.004131998700304529
326,TIMP1,Platelet degranulation ,0.004114942441204524,0,0,1,0.004440055231841813
327,TIMP1,Platelet degranulation ,0.0038294426377736574,1,0,1,0.004131998700304529
328,TIMP1,Activation of Matrix Metalloproteinases,0.004114942441204524,0,0,1,0.004440055231841813
329,TIMP1,Activation of Matrix Metalloproteinases,0.0038294426377736574,1,0,1,0.004131998700304529
330,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004114942441204524,0,0,1,0.004440055231841813
331,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038294426377736574,1,0,1,0.004131998700304529
332,TIMP1,Post-translational protein phosphorylation,0.004114942441204524,0,0,1,0.004440055231841813
333,TIMP1,Post-translational protein phosphorylation,0.0038294426377736574,1,0,1,0.004131998700304529
334,CYTC,Neutrophil degranulation,0.004191400342824636,0,0,1,0.004522553908543754
335,CYTC,Neutrophil degranulation,0.003963854035282566,1,0,1,0.004277029654505168
336,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004191400342824636,0,0,1,0.004522553908543754
337,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003963854035282566,1,0,1,0.004277029654505168
338,CYTC,Amyloid fiber formation,0.004191400342824636,0,0,1,0.004522553908543754
339,CYTC,Amyloid fiber formation,0.003963854035282566,1,0,1,0.004277029654505168
340,CYTC,Post-translational protein phosphorylation,0.004191400342824636,0,0,1,0.004522553908543754
341,CYTC,Post-translational protein phosphorylation,0.003963854035282566,1,0,1,0.004277029654505168
342,KNG1,Class A/1 (Rhodopsin-like receptors),0.018545344692150443,0,0,1,0.02001057266370636
343,KNG1,Class A/1 (Rhodopsin-like receptors),0.017860746539857548,1,0,1,0.019271885877383405
344,KNG1,G alpha (q) signalling events,0.018545344692150443,0,0,1,0.02001057266370636
345,KNG1,G alpha (q) signalling events,0.017860746539857548,1,0,1,0.019271885877383405
346,KNG1,G alpha (i) signalling events,0.018545344692150443,0,0,1,0.02001057266370636
347,KNG1,G alpha (i) signalling events,0.017860746539857548,1,0,1,0.019271885877383405
348,KNG1,Platelet degranulation ,0.018545344692150443,0,0,1,0.02001057266370636
349,KNG1,Platelet degranulation ,0.017860746539857548,1,0,1,0.019271885877383405
350,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.018545344692150443,0,0,1,0.02001057266370636
351,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.017860746539857548,1,0,1,0.019271885877383405
352,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.018545344692150443,0,0,1,0.02001057266370636
353,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.017860746539857548,1,0,1,0.019271885877383405
354,KNG1,Post-translational protein phosphorylation,0.018545344692150443,0,0,1,0.02001057266370636
355,KNG1,Post-translational protein phosphorylation,0.017860746539857548,1,0,1,0.019271885877383405
356,IGF2,IGF1R signaling cascade,0.002000942927012754,0,0,1,0.0021590331429032677
357,IGF2,IGF1R signaling cascade,0.0020516311069513904,1,0,1,0.002213726087396363
358,IGF2,Platelet degranulation ,0.002000942927012754,0,0,1,0.0021590331429032677
359,IGF2,Platelet degranulation ,0.0020516311069513904,1,0,1,0.002213726087396363
360,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002000942927012754,0,0,1,0.0021590331429032677
361,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0020516311069513904,1,0,1,0.002213726087396363
362,IGJ,Scavenging of heme from plasma,0.0027457314643697826,0,0,1,0.0029626658277239802
363,IGJ,Scavenging of heme from plasma,0.002942790806658498,1,0,1,0.003175294406668623
364,KVD33,Initial triggering of complement,0.0014988108814577572,0,0,1,0.001617228719682884
365,KVD33,Initial triggering of complement,0.001765012153312758,1,0,1,0.0019044619839899207
366,KVD33,Regulation of Complement cascade,0.0014988108814577572,0,0,1,0.001617228719682884
367,KVD33,Regulation of Complement cascade,0.001765012153312758,1,0,1,0.0019044619839899207
368,KVD33,FCGR activation,0.0014988108814577572,0,0,1,0.001617228719682884
369,KVD33,FCGR activation,0.001765012153312758,1,0,1,0.0019044619839899207
370,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0014988108814577572,0,0,1,0.001617228719682884
371,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.001765012153312758,1,0,1,0.0019044619839899207
372,KVD33,Role of phospholipids in phagocytosis,0.0014988108814577572,0,0,1,0.001617228719682884
373,KVD33,Role of phospholipids in phagocytosis,0.001765012153312758,1,0,1,0.0019044619839899207
374,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0014988108814577572,0,0,1,0.001617228719682884
375,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.001765012153312758,1,0,1,0.0019044619839899207
376,KVD33,FCERI mediated MAPK activation,0.0014988108814577572,0,0,1,0.001617228719682884
377,KVD33,FCERI mediated MAPK activation,0.001765012153312758,1,0,1,0.0019044619839899207
378,KVD33,FCERI mediated Ca+2 mobilization,0.0014988108814577572,0,0,1,0.001617228719682884
379,KVD33,FCERI mediated Ca+2 mobilization,0.001765012153312758,1,0,1,0.0019044619839899207
380,KVD33,FCERI mediated NF-kB activation,0.0014988108814577572,0,0,1,0.001617228719682884
381,KVD33,FCERI mediated NF-kB activation,0.001765012153312758,1,0,1,0.0019044619839899207
382,KVD33,Parasite infection,0.0014988108814577572,0,0,1,0.001617228719682884
383,KVD33,Parasite infection,0.001765012153312758,1,0,1,0.0019044619839899207
384,KVD33,Leishmania parasite growth and survival,0.0014988108814577572,0,0,1,0.001617228719682884
385,KVD33,Leishmania parasite growth and survival,0.001765012153312758,1,0,1,0.0019044619839899207
386,KVD33,Potential therapeutics for SARS,0.0014988108814577572,0,0,1,0.001617228719682884
387,KVD33,Potential therapeutics for SARS,0.001765012153312758,1,0,1,0.0019044619839899207
388,KVD33,CD22 mediated BCR regulation,0.0014988108814577572,0,0,1,0.001617228719682884
389,KVD33,CD22 mediated BCR regulation,0.001765012153312758,1,0,1,0.0019044619839899207
390,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0014988108814577572,0,0,1,0.001617228719682884
391,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001765012153312758,1,0,1,0.0019044619839899207
392,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0014988108814577572,0,0,1,0.001617228719682884
393,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001765012153312758,1,0,1,0.0019044619839899207
394,KVD33,Scavenging of heme from plasma,0.0014988108814577572,0,0,1,0.001617228719682884
395,KVD33,Scavenging of heme from plasma,0.001765012153312758,1,0,1,0.0019044619839899207
396,KVD16,Initial triggering of complement,0.010381321938863645,0,0,1,0.0112015279549313
397,KVD16,Initial triggering of complement,0.010200742158728342,1,0,1,0.011006680953056857
398,KVD16,Regulation of Complement cascade,0.010381321938863645,0,0,1,0.0112015279549313
399,KVD16,Regulation of Complement cascade,0.010200742158728342,1,0,1,0.011006680953056857
400,KVD16,FCGR activation,0.010381321938863645,0,0,1,0.0112015279549313
401,KVD16,FCGR activation,0.010200742158728342,1,0,1,0.011006680953056857
402,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.010381321938863645,0,0,1,0.0112015279549313
403,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.010200742158728342,1,0,1,0.011006680953056857
404,KVD16,Role of phospholipids in phagocytosis,0.010381321938863645,0,0,1,0.0112015279549313
405,KVD16,Role of phospholipids in phagocytosis,0.010200742158728342,1,0,1,0.011006680953056857
406,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.010381321938863645,0,0,1,0.0112015279549313
407,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.010200742158728342,1,0,1,0.011006680953056857
408,KVD16,FCERI mediated MAPK activation,0.010381321938863645,0,0,1,0.0112015279549313
409,KVD16,FCERI mediated MAPK activation,0.010200742158728342,1,0,1,0.011006680953056857
410,KVD16,FCERI mediated Ca+2 mobilization,0.010381321938863645,0,0,1,0.0112015279549313
411,KVD16,FCERI mediated Ca+2 mobilization,0.010200742158728342,1,0,1,0.011006680953056857
412,KVD16,FCERI mediated NF-kB activation,0.010381321938863645,0,0,1,0.0112015279549313
413,KVD16,FCERI mediated NF-kB activation,0.010200742158728342,1,0,1,0.011006680953056857
414,KVD16,Parasite infection,0.010381321938863645,0,0,1,0.0112015279549313
415,KVD16,Parasite infection,0.010200742158728342,1,0,1,0.011006680953056857
416,KVD16,Leishmania parasite growth and survival,0.010381321938863645,0,0,1,0.0112015279549313
417,KVD16,Leishmania parasite growth and survival,0.010200742158728342,1,0,1,0.011006680953056857
418,KVD16,Potential therapeutics for SARS,0.010381321938863645,0,0,1,0.0112015279549313
419,KVD16,Potential therapeutics for SARS,0.010200742158728342,1,0,1,0.011006680953056857
420,KVD16,CD22 mediated BCR regulation,0.010381321938863645,0,0,1,0.0112015279549313
421,KVD16,CD22 mediated BCR regulation,0.010200742158728342,1,0,1,0.011006680953056857
422,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010381321938863645,0,0,1,0.0112015279549313
423,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010200742158728342,1,0,1,0.011006680953056857
424,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010381321938863645,0,0,1,0.0112015279549313
425,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010200742158728342,1,0,1,0.011006680953056857
426,KVD16,Scavenging of heme from plasma,0.010381321938863645,0,0,1,0.0112015279549313
427,KVD16,Scavenging of heme from plasma,0.010200742158728342,1,0,1,0.011006680953056857
428,KV105,Initial triggering of complement,0.009286133292092321,0,0,1,0.010019810798390134
429,KV105,Initial triggering of complement,0.009141753299627454,1,0,1,0.009864023651892583
430,KV105,Regulation of Complement cascade,0.009286133292092321,0,0,1,0.010019810798390134
431,KV105,Regulation of Complement cascade,0.009141753299627454,1,0,1,0.009864023651892583
432,KV105,FCGR activation,0.009286133292092321,0,0,1,0.010019810798390134
433,KV105,FCGR activation,0.009141753299627454,1,0,1,0.009864023651892583
434,KV105,Regulation of actin dynamics for phagocytic cup formation,0.009286133292092321,0,0,1,0.010019810798390134
435,KV105,Regulation of actin dynamics for phagocytic cup formation,0.009141753299627454,1,0,1,0.009864023651892583
436,KV105,Role of phospholipids in phagocytosis,0.009286133292092321,0,0,1,0.010019810798390134
437,KV105,Role of phospholipids in phagocytosis,0.009141753299627454,1,0,1,0.009864023651892583
438,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.009286133292092321,0,0,1,0.010019810798390134
439,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.009141753299627454,1,0,1,0.009864023651892583
440,KV105,FCERI mediated MAPK activation,0.009286133292092321,0,0,1,0.010019810798390134
441,KV105,FCERI mediated MAPK activation,0.009141753299627454,1,0,1,0.009864023651892583
442,KV105,FCERI mediated Ca+2 mobilization,0.009286133292092321,0,0,1,0.010019810798390134
443,KV105,FCERI mediated Ca+2 mobilization,0.009141753299627454,1,0,1,0.009864023651892583
444,KV105,FCERI mediated NF-kB activation,0.009286133292092321,0,0,1,0.010019810798390134
445,KV105,FCERI mediated NF-kB activation,0.009141753299627454,1,0,1,0.009864023651892583
446,KV105,Parasite infection,0.009286133292092321,0,0,1,0.010019810798390134
447,KV105,Parasite infection,0.009141753299627454,1,0,1,0.009864023651892583
448,KV105,Leishmania parasite growth and survival,0.009286133292092321,0,0,1,0.010019810798390134
449,KV105,Leishmania parasite growth and survival,0.009141753299627454,1,0,1,0.009864023651892583
450,KV105,Potential therapeutics for SARS,0.009286133292092321,0,0,1,0.010019810798390134
451,KV105,Potential therapeutics for SARS,0.009141753299627454,1,0,1,0.009864023651892583
452,KV105,CD22 mediated BCR regulation,0.009286133292092321,0,0,1,0.010019810798390134
453,KV105,CD22 mediated BCR regulation,0.009141753299627454,1,0,1,0.009864023651892583
454,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009286133292092321,0,0,1,0.010019810798390134
455,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009141753299627454,1,0,1,0.009864023651892583
456,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009286133292092321,0,0,1,0.010019810798390134
457,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009141753299627454,1,0,1,0.009864023651892583
458,KV105,Scavenging of heme from plasma,0.009286133292092321,0,0,1,0.010019810798390134
459,KV105,Scavenging of heme from plasma,0.009141753299627454,1,0,1,0.009864023651892583
460,KVD12,Initial triggering of complement,0.001222487792983884,0,0,1,0.0013190739357005414
461,KVD12,Initial triggering of complement,0.0011128656792910381,1,0,1,0.001200790813547075
462,KVD12,Regulation of Complement cascade,0.001222487792983884,0,0,1,0.0013190739357005414
463,KVD12,Regulation of Complement cascade,0.0011128656792910381,1,0,1,0.001200790813547075
464,KVD12,FCGR activation,0.001222487792983884,0,0,1,0.0013190739357005414
465,KVD12,FCGR activation,0.0011128656792910381,1,0,1,0.001200790813547075
466,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.001222487792983884,0,0,1,0.0013190739357005414
467,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.0011128656792910381,1,0,1,0.001200790813547075
468,KVD12,Role of phospholipids in phagocytosis,0.001222487792983884,0,0,1,0.0013190739357005414
469,KVD12,Role of phospholipids in phagocytosis,0.0011128656792910381,1,0,1,0.001200790813547075
470,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.001222487792983884,0,0,1,0.0013190739357005414
471,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.0011128656792910381,1,0,1,0.001200790813547075
472,KVD12,FCERI mediated MAPK activation,0.001222487792983884,0,0,1,0.0013190739357005414
473,KVD12,FCERI mediated MAPK activation,0.0011128656792910381,1,0,1,0.001200790813547075
474,KVD12,FCERI mediated Ca+2 mobilization,0.001222487792983884,0,0,1,0.0013190739357005414
475,KVD12,FCERI mediated Ca+2 mobilization,0.0011128656792910381,1,0,1,0.001200790813547075
476,KVD12,FCERI mediated NF-kB activation,0.001222487792983884,0,0,1,0.0013190739357005414
477,KVD12,FCERI mediated NF-kB activation,0.0011128656792910381,1,0,1,0.001200790813547075
478,KVD12,Parasite infection,0.001222487792983884,0,0,1,0.0013190739357005414
479,KVD12,Parasite infection,0.0011128656792910381,1,0,1,0.001200790813547075
480,KVD12,Leishmania parasite growth and survival,0.001222487792983884,0,0,1,0.0013190739357005414
481,KVD12,Leishmania parasite growth and survival,0.0011128656792910381,1,0,1,0.001200790813547075
482,KVD12,Potential therapeutics for SARS,0.001222487792983884,0,0,1,0.0013190739357005414
483,KVD12,Potential therapeutics for SARS,0.0011128656792910381,1,0,1,0.001200790813547075
484,KVD12,CD22 mediated BCR regulation,0.001222487792983884,0,0,1,0.0013190739357005414
485,KVD12,CD22 mediated BCR regulation,0.0011128656792910381,1,0,1,0.001200790813547075
486,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.001222487792983884,0,0,1,0.0013190739357005414
487,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0011128656792910381,1,0,1,0.001200790813547075
488,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001222487792983884,0,0,1,0.0013190739357005414
489,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011128656792910381,1,0,1,0.001200790813547075
490,KVD12,Scavenging of heme from plasma,0.001222487792983884,0,0,1,0.0013190739357005414
491,KVD12,Scavenging of heme from plasma,0.0011128656792910381,1,0,1,0.001200790813547075
492,KVD40,Initial triggering of complement,0.01569109940949905,0,0,1,0.016930819573287313
493,KVD40,Initial triggering of complement,0.015411828503177578,1,0,1,0.016629484070681624
494,KVD40,Regulation of Complement cascade,0.01569109940949905,0,0,1,0.016930819573287313
495,KVD40,Regulation of Complement cascade,0.015411828503177578,1,0,1,0.016629484070681624
496,KVD40,FCGR activation,0.01569109940949905,0,0,1,0.016930819573287313
497,KVD40,FCGR activation,0.015411828503177578,1,0,1,0.016629484070681624
498,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.01569109940949905,0,0,1,0.016930819573287313
499,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.015411828503177578,1,0,1,0.016629484070681624
500,KVD40,Role of phospholipids in phagocytosis,0.01569109940949905,0,0,1,0.016930819573287313
501,KVD40,Role of phospholipids in phagocytosis,0.015411828503177578,1,0,1,0.016629484070681624
502,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.01569109940949905,0,0,1,0.016930819573287313
503,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.015411828503177578,1,0,1,0.016629484070681624
504,KVD40,FCERI mediated MAPK activation,0.01569109940949905,0,0,1,0.016930819573287313
505,KVD40,FCERI mediated MAPK activation,0.015411828503177578,1,0,1,0.016629484070681624
506,KVD40,FCERI mediated Ca+2 mobilization,0.01569109940949905,0,0,1,0.016930819573287313
507,KVD40,FCERI mediated Ca+2 mobilization,0.015411828503177578,1,0,1,0.016629484070681624
508,KVD40,FCERI mediated NF-kB activation,0.01569109940949905,0,0,1,0.016930819573287313
509,KVD40,FCERI mediated NF-kB activation,0.015411828503177578,1,0,1,0.016629484070681624
510,KVD40,Parasite infection,0.01569109940949905,0,0,1,0.016930819573287313
511,KVD40,Parasite infection,0.015411828503177578,1,0,1,0.016629484070681624
512,KVD40,Leishmania parasite growth and survival,0.01569109940949905,0,0,1,0.016930819573287313
513,KVD40,Leishmania parasite growth and survival,0.015411828503177578,1,0,1,0.016629484070681624
514,KVD40,Potential therapeutics for SARS,0.01569109940949905,0,0,1,0.016930819573287313
515,KVD40,Potential therapeutics for SARS,0.015411828503177578,1,0,1,0.016629484070681624
516,KVD40,CD22 mediated BCR regulation,0.01569109940949905,0,0,1,0.016930819573287313
517,KVD40,CD22 mediated BCR regulation,0.015411828503177578,1,0,1,0.016629484070681624
518,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01569109940949905,0,0,1,0.016930819573287313
519,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015411828503177578,1,0,1,0.016629484070681624
520,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01569109940949905,0,0,1,0.016930819573287313
521,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015411828503177578,1,0,1,0.016629484070681624
522,KVD40,Scavenging of heme from plasma,0.01569109940949905,0,0,1,0.016930819573287313
523,KVD40,Scavenging of heme from plasma,0.015411828503177578,1,0,1,0.016629484070681624
524,KV320,Initial triggering of complement,0.01779512787858645,0,0,1,0.019201082826199558
525,KV320,Initial triggering of complement,0.01741964175210645,1,0,1,0.018795930344923654
526,KV320,Regulation of Complement cascade,0.01779512787858645,0,0,1,0.019201082826199558
527,KV320,Regulation of Complement cascade,0.01741964175210645,1,0,1,0.018795930344923654
528,KV320,FCGR activation,0.01779512787858645,0,0,1,0.019201082826199558
529,KV320,FCGR activation,0.01741964175210645,1,0,1,0.018795930344923654
530,KV320,Regulation of actin dynamics for phagocytic cup formation,0.01779512787858645,0,0,1,0.019201082826199558
531,KV320,Regulation of actin dynamics for phagocytic cup formation,0.01741964175210645,1,0,1,0.018795930344923654
532,KV320,Role of phospholipids in phagocytosis,0.01779512787858645,0,0,1,0.019201082826199558
533,KV320,Role of phospholipids in phagocytosis,0.01741964175210645,1,0,1,0.018795930344923654
534,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.01779512787858645,0,0,1,0.019201082826199558
535,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.01741964175210645,1,0,1,0.018795930344923654
536,KV320,FCERI mediated MAPK activation,0.01779512787858645,0,0,1,0.019201082826199558
537,KV320,FCERI mediated MAPK activation,0.01741964175210645,1,0,1,0.018795930344923654
538,KV320,FCERI mediated Ca+2 mobilization,0.01779512787858645,0,0,1,0.019201082826199558
539,KV320,FCERI mediated Ca+2 mobilization,0.01741964175210645,1,0,1,0.018795930344923654
540,KV320,FCERI mediated NF-kB activation,0.01779512787858645,0,0,1,0.019201082826199558
541,KV320,FCERI mediated NF-kB activation,0.01741964175210645,1,0,1,0.018795930344923654
542,KV320,Parasite infection,0.01779512787858645,0,0,1,0.019201082826199558
543,KV320,Parasite infection,0.01741964175210645,1,0,1,0.018795930344923654
544,KV320,Leishmania parasite growth and survival,0.01779512787858645,0,0,1,0.019201082826199558
545,KV320,Leishmania parasite growth and survival,0.01741964175210645,1,0,1,0.018795930344923654
546,KV320,Potential therapeutics for SARS,0.01779512787858645,0,0,1,0.019201082826199558
547,KV320,Potential therapeutics for SARS,0.01741964175210645,1,0,1,0.018795930344923654
548,KV320,CD22 mediated BCR regulation,0.01779512787858645,0,0,1,0.019201082826199558
549,KV320,CD22 mediated BCR regulation,0.01741964175210645,1,0,1,0.018795930344923654
550,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01779512787858645,0,0,1,0.019201082826199558
551,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01741964175210645,1,0,1,0.018795930344923654
552,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01779512787858645,0,0,1,0.019201082826199558
553,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01741964175210645,1,0,1,0.018795930344923654
554,KV320,Scavenging of heme from plasma,0.01779512787858645,0,0,1,0.019201082826199558
555,KV320,Scavenging of heme from plasma,0.01741964175210645,1,0,1,0.018795930344923654
556,LV147,Initial triggering of complement,0.01328261304006446,0,0,1,0.014332043853280534
557,LV147,Initial triggering of complement,0.01332455305576635,1,0,1,0.014377297459813653
558,LV147,Regulation of Complement cascade,0.01328261304006446,0,0,1,0.014332043853280534
559,LV147,Regulation of Complement cascade,0.01332455305576635,1,0,1,0.014377297459813653
560,LV147,FCGR activation,0.01328261304006446,0,0,1,0.014332043853280534
561,LV147,FCGR activation,0.01332455305576635,1,0,1,0.014377297459813653
562,LV147,Regulation of actin dynamics for phagocytic cup formation,0.01328261304006446,0,0,1,0.014332043853280534
563,LV147,Regulation of actin dynamics for phagocytic cup formation,0.01332455305576635,1,0,1,0.014377297459813653
564,LV147,Role of phospholipids in phagocytosis,0.01328261304006446,0,0,1,0.014332043853280534
565,LV147,Role of phospholipids in phagocytosis,0.01332455305576635,1,0,1,0.014377297459813653
566,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.01328261304006446,0,0,1,0.014332043853280534
567,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.01332455305576635,1,0,1,0.014377297459813653
568,LV147,FCERI mediated MAPK activation,0.01328261304006446,0,0,1,0.014332043853280534
569,LV147,FCERI mediated MAPK activation,0.01332455305576635,1,0,1,0.014377297459813653
570,LV147,FCERI mediated Ca+2 mobilization,0.01328261304006446,0,0,1,0.014332043853280534
571,LV147,FCERI mediated Ca+2 mobilization,0.01332455305576635,1,0,1,0.014377297459813653
572,LV147,FCERI mediated NF-kB activation,0.01328261304006446,0,0,1,0.014332043853280534
573,LV147,FCERI mediated NF-kB activation,0.01332455305576635,1,0,1,0.014377297459813653
574,LV147,Parasite infection,0.01328261304006446,0,0,1,0.014332043853280534
575,LV147,Parasite infection,0.01332455305576635,1,0,1,0.014377297459813653
576,LV147,Leishmania parasite growth and survival,0.01328261304006446,0,0,1,0.014332043853280534
577,LV147,Leishmania parasite growth and survival,0.01332455305576635,1,0,1,0.014377297459813653
578,LV147,Potential therapeutics for SARS,0.01328261304006446,0,0,1,0.014332043853280534
579,LV147,Potential therapeutics for SARS,0.01332455305576635,1,0,1,0.014377297459813653
580,LV147,CD22 mediated BCR regulation,0.01328261304006446,0,0,1,0.014332043853280534
581,LV147,CD22 mediated BCR regulation,0.01332455305576635,1,0,1,0.014377297459813653
582,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01328261304006446,0,0,1,0.014332043853280534
583,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01332455305576635,1,0,1,0.014377297459813653
584,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01328261304006446,0,0,1,0.014332043853280534
585,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01332455305576635,1,0,1,0.014377297459813653
586,LV147,Scavenging of heme from plasma,0.01328261304006446,0,0,1,0.014332043853280534
587,LV147,Scavenging of heme from plasma,0.01332455305576635,1,0,1,0.014377297459813653
588,LV319,Initial triggering of complement,0.013671019743196667,0,0,1,0.014751137738302113
589,LV319,Initial triggering of complement,0.01352387655885347,1,0,1,0.01459236908605296
590,LV319,Regulation of Complement cascade,0.013671019743196667,0,0,1,0.014751137738302113
591,LV319,Regulation of Complement cascade,0.01352387655885347,1,0,1,0.01459236908605296
592,LV319,FCGR activation,0.013671019743196667,0,0,1,0.014751137738302113
593,LV319,FCGR activation,0.01352387655885347,1,0,1,0.01459236908605296
594,LV319,Regulation of actin dynamics for phagocytic cup formation,0.013671019743196667,0,0,1,0.014751137738302113
595,LV319,Regulation of actin dynamics for phagocytic cup formation,0.01352387655885347,1,0,1,0.01459236908605296
596,LV319,Role of phospholipids in phagocytosis,0.013671019743196667,0,0,1,0.014751137738302113
597,LV319,Role of phospholipids in phagocytosis,0.01352387655885347,1,0,1,0.01459236908605296
598,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.013671019743196667,0,0,1,0.014751137738302113
599,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.01352387655885347,1,0,1,0.01459236908605296
600,LV319,FCERI mediated MAPK activation,0.013671019743196667,0,0,1,0.014751137738302113
601,LV319,FCERI mediated MAPK activation,0.01352387655885347,1,0,1,0.01459236908605296
602,LV319,FCERI mediated Ca+2 mobilization,0.013671019743196667,0,0,1,0.014751137738302113
603,LV319,FCERI mediated Ca+2 mobilization,0.01352387655885347,1,0,1,0.01459236908605296
604,LV319,FCERI mediated NF-kB activation,0.013671019743196667,0,0,1,0.014751137738302113
605,LV319,FCERI mediated NF-kB activation,0.01352387655885347,1,0,1,0.01459236908605296
606,LV319,Parasite infection,0.013671019743196667,0,0,1,0.014751137738302113
607,LV319,Parasite infection,0.01352387655885347,1,0,1,0.01459236908605296
608,LV319,Leishmania parasite growth and survival,0.013671019743196667,0,0,1,0.014751137738302113
609,LV319,Leishmania parasite growth and survival,0.01352387655885347,1,0,1,0.01459236908605296
610,LV319,Potential therapeutics for SARS,0.013671019743196667,0,0,1,0.014751137738302113
611,LV319,Potential therapeutics for SARS,0.01352387655885347,1,0,1,0.01459236908605296
612,LV319,CD22 mediated BCR regulation,0.013671019743196667,0,0,1,0.014751137738302113
613,LV319,CD22 mediated BCR regulation,0.01352387655885347,1,0,1,0.01459236908605296
614,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013671019743196667,0,0,1,0.014751137738302113
615,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01352387655885347,1,0,1,0.01459236908605296
616,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013671019743196667,0,0,1,0.014751137738302113
617,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01352387655885347,1,0,1,0.01459236908605296
618,LV319,Scavenging of heme from plasma,0.013671019743196667,0,0,1,0.014751137738302113
619,LV319,Scavenging of heme from plasma,0.01352387655885347,1,0,1,0.01459236908605296
620,LV325,Initial triggering of complement,0.013640001611444555,0,0,1,0.014717668930381775
621,LV325,Initial triggering of complement,0.013485413956853638,1,0,1,0.014550867636232047
622,LV325,Regulation of Complement cascade,0.013640001611444555,0,0,1,0.014717668930381775
623,LV325,Regulation of Complement cascade,0.013485413956853638,1,0,1,0.014550867636232047
624,LV325,FCGR activation,0.013640001611444555,0,0,1,0.014717668930381775
625,LV325,FCGR activation,0.013485413956853638,1,0,1,0.014550867636232047
626,LV325,Regulation of actin dynamics for phagocytic cup formation,0.013640001611444555,0,0,1,0.014717668930381775
627,LV325,Regulation of actin dynamics for phagocytic cup formation,0.013485413956853638,1,0,1,0.014550867636232047
628,LV325,Role of phospholipids in phagocytosis,0.013640001611444555,0,0,1,0.014717668930381775
629,LV325,Role of phospholipids in phagocytosis,0.013485413956853638,1,0,1,0.014550867636232047
630,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.013640001611444555,0,0,1,0.014717668930381775
631,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.013485413956853638,1,0,1,0.014550867636232047
632,LV325,FCERI mediated MAPK activation,0.013640001611444555,0,0,1,0.014717668930381775
633,LV325,FCERI mediated MAPK activation,0.013485413956853638,1,0,1,0.014550867636232047
634,LV325,FCERI mediated Ca+2 mobilization,0.013640001611444555,0,0,1,0.014717668930381775
635,LV325,FCERI mediated Ca+2 mobilization,0.013485413956853638,1,0,1,0.014550867636232047
636,LV325,FCERI mediated NF-kB activation,0.013640001611444555,0,0,1,0.014717668930381775
637,LV325,FCERI mediated NF-kB activation,0.013485413956853638,1,0,1,0.014550867636232047
638,LV325,Parasite infection,0.013640001611444555,0,0,1,0.014717668930381775
639,LV325,Parasite infection,0.013485413956853638,1,0,1,0.014550867636232047
640,LV325,Leishmania parasite growth and survival,0.013640001611444555,0,0,1,0.014717668930381775
641,LV325,Leishmania parasite growth and survival,0.013485413956853638,1,0,1,0.014550867636232047
642,LV325,Potential therapeutics for SARS,0.013640001611444555,0,0,1,0.014717668930381775
643,LV325,Potential therapeutics for SARS,0.013485413956853638,1,0,1,0.014550867636232047
644,LV325,CD22 mediated BCR regulation,0.013640001611444555,0,0,1,0.014717668930381775
645,LV325,CD22 mediated BCR regulation,0.013485413956853638,1,0,1,0.014550867636232047
646,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013640001611444555,0,0,1,0.014717668930381775
647,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013485413956853638,1,0,1,0.014550867636232047
648,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013640001611444555,0,0,1,0.014717668930381775
649,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013485413956853638,1,0,1,0.014550867636232047
650,LV325,Scavenging of heme from plasma,0.013640001611444555,0,0,1,0.014717668930381775
651,LV325,Scavenging of heme from plasma,0.013485413956853638,1,0,1,0.014550867636232047
652,HV169,Initial triggering of complement,0.0091364379824275,0,0,1,0.009858288382862757
653,HV169,Initial triggering of complement,0.009038848286824457,1,0,1,0.009752988334386429
654,HV169,Regulation of Complement cascade,0.0091364379824275,0,0,1,0.009858288382862757
655,HV169,Regulation of Complement cascade,0.009038848286824457,1,0,1,0.009752988334386429
656,HV169,FCGR activation,0.0091364379824275,0,0,1,0.009858288382862757
657,HV169,FCGR activation,0.009038848286824457,1,0,1,0.009752988334386429
658,HV169,Regulation of actin dynamics for phagocytic cup formation,0.0091364379824275,0,0,1,0.009858288382862757
659,HV169,Regulation of actin dynamics for phagocytic cup formation,0.009038848286824457,1,0,1,0.009752988334386429
660,HV169,Role of phospholipids in phagocytosis,0.0091364379824275,0,0,1,0.009858288382862757
661,HV169,Role of phospholipids in phagocytosis,0.009038848286824457,1,0,1,0.009752988334386429
662,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.0091364379824275,0,0,1,0.009858288382862757
663,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.009038848286824457,1,0,1,0.009752988334386429
664,HV169,FCERI mediated MAPK activation,0.0091364379824275,0,0,1,0.009858288382862757
665,HV169,FCERI mediated MAPK activation,0.009038848286824457,1,0,1,0.009752988334386429
666,HV169,FCERI mediated Ca+2 mobilization,0.0091364379824275,0,0,1,0.009858288382862757
667,HV169,FCERI mediated Ca+2 mobilization,0.009038848286824457,1,0,1,0.009752988334386429
668,HV169,FCERI mediated NF-kB activation,0.0091364379824275,0,0,1,0.009858288382862757
669,HV169,FCERI mediated NF-kB activation,0.009038848286824457,1,0,1,0.009752988334386429
670,HV169,Parasite infection,0.0091364379824275,0,0,1,0.009858288382862757
671,HV169,Parasite infection,0.009038848286824457,1,0,1,0.009752988334386429
672,HV169,Leishmania parasite growth and survival,0.0091364379824275,0,0,1,0.009858288382862757
673,HV169,Leishmania parasite growth and survival,0.009038848286824457,1,0,1,0.009752988334386429
674,HV169,Potential therapeutics for SARS,0.0091364379824275,0,0,1,0.009858288382862757
675,HV169,Potential therapeutics for SARS,0.009038848286824457,1,0,1,0.009752988334386429
676,HV169,CD22 mediated BCR regulation,0.0091364379824275,0,0,1,0.009858288382862757
677,HV169,CD22 mediated BCR regulation,0.009038848286824457,1,0,1,0.009752988334386429
678,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0091364379824275,0,0,1,0.009858288382862757
679,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009038848286824457,1,0,1,0.009752988334386429
680,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0091364379824275,0,0,1,0.009858288382862757
681,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009038848286824457,1,0,1,0.009752988334386429
682,HV169,Scavenging of heme from plasma,0.0091364379824275,0,0,1,0.009858288382862757
683,HV169,Scavenging of heme from plasma,0.009038848286824457,1,0,1,0.009752988334386429
684,HV146,Initial triggering of complement,0.006931889563808606,0,0,1,0.007479563314457626
685,HV146,Initial triggering of complement,0.006513462600075097,1,0,1,0.007028077332329325
686,HV146,Regulation of Complement cascade,0.006931889563808606,0,0,1,0.007479563314457626
687,HV146,Regulation of Complement cascade,0.006513462600075097,1,0,1,0.007028077332329325
688,HV146,FCGR activation,0.006931889563808606,0,0,1,0.007479563314457626
689,HV146,FCGR activation,0.006513462600075097,1,0,1,0.007028077332329325
690,HV146,Regulation of actin dynamics for phagocytic cup formation,0.006931889563808606,0,0,1,0.007479563314457626
691,HV146,Regulation of actin dynamics for phagocytic cup formation,0.006513462600075097,1,0,1,0.007028077332329325
692,HV146,Role of phospholipids in phagocytosis,0.006931889563808606,0,0,1,0.007479563314457626
693,HV146,Role of phospholipids in phagocytosis,0.006513462600075097,1,0,1,0.007028077332329325
694,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.006931889563808606,0,0,1,0.007479563314457626
695,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.006513462600075097,1,0,1,0.007028077332329325
696,HV146,FCERI mediated MAPK activation,0.006931889563808606,0,0,1,0.007479563314457626
697,HV146,FCERI mediated MAPK activation,0.006513462600075097,1,0,1,0.007028077332329325
698,HV146,FCERI mediated Ca+2 mobilization,0.006931889563808606,0,0,1,0.007479563314457626
699,HV146,FCERI mediated Ca+2 mobilization,0.006513462600075097,1,0,1,0.007028077332329325
700,HV146,FCERI mediated NF-kB activation,0.006931889563808606,0,0,1,0.007479563314457626
701,HV146,FCERI mediated NF-kB activation,0.006513462600075097,1,0,1,0.007028077332329325
702,HV146,Parasite infection,0.006931889563808606,0,0,1,0.007479563314457626
703,HV146,Parasite infection,0.006513462600075097,1,0,1,0.007028077332329325
704,HV146,Leishmania parasite growth and survival,0.006931889563808606,0,0,1,0.007479563314457626
705,HV146,Leishmania parasite growth and survival,0.006513462600075097,1,0,1,0.007028077332329325
706,HV146,Potential therapeutics for SARS,0.006931889563808606,0,0,1,0.007479563314457626
707,HV146,Potential therapeutics for SARS,0.006513462600075097,1,0,1,0.007028077332329325
708,HV146,CD22 mediated BCR regulation,0.006931889563808606,0,0,1,0.007479563314457626
709,HV146,CD22 mediated BCR regulation,0.006513462600075097,1,0,1,0.007028077332329325
710,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006931889563808606,0,0,1,0.007479563314457626
711,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006513462600075097,1,0,1,0.007028077332329325
712,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006931889563808606,0,0,1,0.007479563314457626
713,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006513462600075097,1,0,1,0.007028077332329325
714,HV146,Scavenging of heme from plasma,0.006931889563808606,0,0,1,0.007479563314457626
715,HV146,Scavenging of heme from plasma,0.006513462600075097,1,0,1,0.007028077332329325
716,HV348,Initial triggering of complement,0.009399965839111245,0,0,1,0.010142637011190647
717,HV348,Initial triggering of complement,0.009134735588546997,1,0,1,0.009856451486487224
718,HV348,Regulation of Complement cascade,0.009399965839111245,0,0,1,0.010142637011190647
719,HV348,Regulation of Complement cascade,0.009134735588546997,1,0,1,0.009856451486487224
720,HV348,FCGR activation,0.009399965839111245,0,0,1,0.010142637011190647
721,HV348,FCGR activation,0.009134735588546997,1,0,1,0.009856451486487224
722,HV348,Regulation of actin dynamics for phagocytic cup formation,0.009399965839111245,0,0,1,0.010142637011190647
723,HV348,Regulation of actin dynamics for phagocytic cup formation,0.009134735588546997,1,0,1,0.009856451486487224
724,HV348,Role of phospholipids in phagocytosis,0.009399965839111245,0,0,1,0.010142637011190647
725,HV348,Role of phospholipids in phagocytosis,0.009134735588546997,1,0,1,0.009856451486487224
726,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.009399965839111245,0,0,1,0.010142637011190647
727,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.009134735588546997,1,0,1,0.009856451486487224
728,HV348,FCERI mediated MAPK activation,0.009399965839111245,0,0,1,0.010142637011190647
729,HV348,FCERI mediated MAPK activation,0.009134735588546997,1,0,1,0.009856451486487224
730,HV348,FCERI mediated Ca+2 mobilization,0.009399965839111245,0,0,1,0.010142637011190647
731,HV348,FCERI mediated Ca+2 mobilization,0.009134735588546997,1,0,1,0.009856451486487224
732,HV348,FCERI mediated NF-kB activation,0.009399965839111245,0,0,1,0.010142637011190647
733,HV348,FCERI mediated NF-kB activation,0.009134735588546997,1,0,1,0.009856451486487224
734,HV348,Parasite infection,0.009399965839111245,0,0,1,0.010142637011190647
735,HV348,Parasite infection,0.009134735588546997,1,0,1,0.009856451486487224
736,HV348,Leishmania parasite growth and survival,0.009399965839111245,0,0,1,0.010142637011190647
737,HV348,Leishmania parasite growth and survival,0.009134735588546997,1,0,1,0.009856451486487224
738,HV348,Potential therapeutics for SARS,0.009399965839111245,0,0,1,0.010142637011190647
739,HV348,Potential therapeutics for SARS,0.009134735588546997,1,0,1,0.009856451486487224
740,HV348,CD22 mediated BCR regulation,0.009399965839111245,0,0,1,0.010142637011190647
741,HV348,CD22 mediated BCR regulation,0.009134735588546997,1,0,1,0.009856451486487224
742,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009399965839111245,0,0,1,0.010142637011190647
743,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009134735588546997,1,0,1,0.009856451486487224
744,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009399965839111245,0,0,1,0.010142637011190647
745,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009134735588546997,1,0,1,0.009856451486487224
746,HV348,Scavenging of heme from plasma,0.009399965839111245,0,0,1,0.010142637011190647
747,HV348,Scavenging of heme from plasma,0.009134735588546997,1,0,1,0.009856451486487224
748,HV323,Initial triggering of complement,0.025138525803534626,0,0,1,0.027124666896215933
749,HV323,Initial triggering of complement,0.025139481745524488,1,0,1,0.027125698365135384
750,HV323,Regulation of Complement cascade,0.025138525803534626,0,0,1,0.027124666896215933
751,HV323,Regulation of Complement cascade,0.025139481745524488,1,0,1,0.027125698365135384
752,HV323,FCGR activation,0.025138525803534626,0,0,1,0.027124666896215933
753,HV323,FCGR activation,0.025139481745524488,1,0,1,0.027125698365135384
754,HV323,Regulation of actin dynamics for phagocytic cup formation,0.025138525803534626,0,0,1,0.027124666896215933
755,HV323,Regulation of actin dynamics for phagocytic cup formation,0.025139481745524488,1,0,1,0.027125698365135384
756,HV323,Role of phospholipids in phagocytosis,0.025138525803534626,0,0,1,0.027124666896215933
757,HV323,Role of phospholipids in phagocytosis,0.025139481745524488,1,0,1,0.027125698365135384
758,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.025138525803534626,0,0,1,0.027124666896215933
759,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.025139481745524488,1,0,1,0.027125698365135384
760,HV323,FCERI mediated MAPK activation,0.025138525803534626,0,0,1,0.027124666896215933
761,HV323,FCERI mediated MAPK activation,0.025139481745524488,1,0,1,0.027125698365135384
762,HV323,FCERI mediated Ca+2 mobilization,0.025138525803534626,0,0,1,0.027124666896215933
763,HV323,FCERI mediated Ca+2 mobilization,0.025139481745524488,1,0,1,0.027125698365135384
764,HV323,FCERI mediated NF-kB activation,0.025138525803534626,0,0,1,0.027124666896215933
765,HV323,FCERI mediated NF-kB activation,0.025139481745524488,1,0,1,0.027125698365135384
766,HV323,Parasite infection,0.025138525803534626,0,0,1,0.027124666896215933
767,HV323,Parasite infection,0.025139481745524488,1,0,1,0.027125698365135384
768,HV323,Leishmania parasite growth and survival,0.025138525803534626,0,0,1,0.027124666896215933
769,HV323,Leishmania parasite growth and survival,0.025139481745524488,1,0,1,0.027125698365135384
770,HV323,Potential therapeutics for SARS,0.025138525803534626,0,0,1,0.027124666896215933
771,HV323,Potential therapeutics for SARS,0.025139481745524488,1,0,1,0.027125698365135384
772,HV323,CD22 mediated BCR regulation,0.025138525803534626,0,0,1,0.027124666896215933
773,HV323,CD22 mediated BCR regulation,0.025139481745524488,1,0,1,0.027125698365135384
774,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.025138525803534626,0,0,1,0.027124666896215933
775,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.025139481745524488,1,0,1,0.027125698365135384
776,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.025138525803534626,0,0,1,0.027124666896215933
777,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.025139481745524488,1,0,1,0.027125698365135384
778,HV323,Scavenging of heme from plasma,0.025138525803534626,0,0,1,0.027124666896215933
779,HV323,Scavenging of heme from plasma,0.025139481745524488,1,0,1,0.027125698365135384
780,HV313,Initial triggering of complement,0.00021445968632178848,0,0,1,0.00023140368689907598
781,HV313,Initial triggering of complement,0.00017822735333083983,1,0,1,0.0001923087148655898
782,HV313,Regulation of Complement cascade,0.00021445968632178848,0,0,1,0.00023140368689907598
783,HV313,Regulation of Complement cascade,0.00017822735333083983,1,0,1,0.0001923087148655898
784,HV313,FCGR activation,0.00021445968632178848,0,0,1,0.00023140368689907598
785,HV313,FCGR activation,0.00017822735333083983,1,0,1,0.0001923087148655898
786,HV313,Regulation of actin dynamics for phagocytic cup formation,0.00021445968632178848,0,0,1,0.00023140368689907598
787,HV313,Regulation of actin dynamics for phagocytic cup formation,0.00017822735333083983,1,0,1,0.0001923087148655898
788,HV313,Role of phospholipids in phagocytosis,0.00021445968632178848,0,0,1,0.00023140368689907598
789,HV313,Role of phospholipids in phagocytosis,0.00017822735333083983,1,0,1,0.0001923087148655898
790,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.00021445968632178848,0,0,1,0.00023140368689907598
791,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.00017822735333083983,1,0,1,0.0001923087148655898
792,HV313,FCERI mediated MAPK activation,0.00021445968632178848,0,0,1,0.00023140368689907598
793,HV313,FCERI mediated MAPK activation,0.00017822735333083983,1,0,1,0.0001923087148655898
794,HV313,FCERI mediated Ca+2 mobilization,0.00021445968632178848,0,0,1,0.00023140368689907598
795,HV313,FCERI mediated Ca+2 mobilization,0.00017822735333083983,1,0,1,0.0001923087148655898
796,HV313,FCERI mediated NF-kB activation,0.00021445968632178848,0,0,1,0.00023140368689907598
797,HV313,FCERI mediated NF-kB activation,0.00017822735333083983,1,0,1,0.0001923087148655898
798,HV313,Parasite infection,0.00021445968632178848,0,0,1,0.00023140368689907598
799,HV313,Parasite infection,0.00017822735333083983,1,0,1,0.0001923087148655898
800,HV313,Leishmania parasite growth and survival,0.00021445968632178848,0,0,1,0.00023140368689907598
801,HV313,Leishmania parasite growth and survival,0.00017822735333083983,1,0,1,0.0001923087148655898
802,HV313,Potential therapeutics for SARS,0.00021445968632178848,0,0,1,0.00023140368689907598
803,HV313,Potential therapeutics for SARS,0.00017822735333083983,1,0,1,0.0001923087148655898
804,HV313,CD22 mediated BCR regulation,0.00021445968632178848,0,0,1,0.00023140368689907598
805,HV313,CD22 mediated BCR regulation,0.00017822735333083983,1,0,1,0.0001923087148655898
806,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00021445968632178848,0,0,1,0.00023140368689907598
807,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00017822735333083983,1,0,1,0.0001923087148655898
808,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00021445968632178848,0,0,1,0.00023140368689907598
809,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00017822735333083983,1,0,1,0.0001923087148655898
810,HV313,Scavenging of heme from plasma,0.00021445968632178848,0,0,1,0.00023140368689907598
811,HV313,Scavenging of heme from plasma,0.00017822735333083983,1,0,1,0.0001923087148655898
812,HV353,Initial triggering of complement,0.02231184234842658,0,0,1,0.024074653234314177
813,HV353,Initial triggering of complement,0.022011510794982314,1,0,1,0.023750593127955296
814,HV353,Regulation of Complement cascade,0.02231184234842658,0,0,1,0.024074653234314177
815,HV353,Regulation of Complement cascade,0.022011510794982314,1,0,1,0.023750593127955296
816,HV353,FCGR activation,0.02231184234842658,0,0,1,0.024074653234314177
817,HV353,FCGR activation,0.022011510794982314,1,0,1,0.023750593127955296
818,HV353,Regulation of actin dynamics for phagocytic cup formation,0.02231184234842658,0,0,1,0.024074653234314177
819,HV353,Regulation of actin dynamics for phagocytic cup formation,0.022011510794982314,1,0,1,0.023750593127955296
820,HV353,Role of phospholipids in phagocytosis,0.02231184234842658,0,0,1,0.024074653234314177
821,HV353,Role of phospholipids in phagocytosis,0.022011510794982314,1,0,1,0.023750593127955296
822,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.02231184234842658,0,0,1,0.024074653234314177
823,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.022011510794982314,1,0,1,0.023750593127955296
824,HV353,FCERI mediated MAPK activation,0.02231184234842658,0,0,1,0.024074653234314177
825,HV353,FCERI mediated MAPK activation,0.022011510794982314,1,0,1,0.023750593127955296
826,HV353,FCERI mediated Ca+2 mobilization,0.02231184234842658,0,0,1,0.024074653234314177
827,HV353,FCERI mediated Ca+2 mobilization,0.022011510794982314,1,0,1,0.023750593127955296
828,HV353,FCERI mediated NF-kB activation,0.02231184234842658,0,0,1,0.024074653234314177
829,HV353,FCERI mediated NF-kB activation,0.022011510794982314,1,0,1,0.023750593127955296
830,HV353,Parasite infection,0.02231184234842658,0,0,1,0.024074653234314177
831,HV353,Parasite infection,0.022011510794982314,1,0,1,0.023750593127955296
832,HV353,Leishmania parasite growth and survival,0.02231184234842658,0,0,1,0.024074653234314177
833,HV353,Leishmania parasite growth and survival,0.022011510794982314,1,0,1,0.023750593127955296
834,HV353,Potential therapeutics for SARS,0.02231184234842658,0,0,1,0.024074653234314177
835,HV353,Potential therapeutics for SARS,0.022011510794982314,1,0,1,0.023750593127955296
836,HV353,CD22 mediated BCR regulation,0.02231184234842658,0,0,1,0.024074653234314177
837,HV353,CD22 mediated BCR regulation,0.022011510794982314,1,0,1,0.023750593127955296
838,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.02231184234842658,0,0,1,0.024074653234314177
839,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.022011510794982314,1,0,1,0.023750593127955296
840,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.02231184234842658,0,0,1,0.024074653234314177
841,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.022011510794982314,1,0,1,0.023750593127955296
842,HV353,Scavenging of heme from plasma,0.02231184234842658,0,0,1,0.024074653234314177
843,HV353,Scavenging of heme from plasma,0.022011510794982314,1,0,1,0.023750593127955296
844,HV307,Initial triggering of complement,0.015600917185656727,0,0,1,0.01683351224505333
845,HV307,Initial triggering of complement,0.015136719169095158,1,0,1,0.016332638937226095
846,HV307,Regulation of Complement cascade,0.015600917185656727,0,0,1,0.01683351224505333
847,HV307,Regulation of Complement cascade,0.015136719169095158,1,0,1,0.016332638937226095
848,HV307,FCGR activation,0.015600917185656727,0,0,1,0.01683351224505333
849,HV307,FCGR activation,0.015136719169095158,1,0,1,0.016332638937226095
850,HV307,Regulation of actin dynamics for phagocytic cup formation,0.015600917185656727,0,0,1,0.01683351224505333
851,HV307,Regulation of actin dynamics for phagocytic cup formation,0.015136719169095158,1,0,1,0.016332638937226095
852,HV307,Role of phospholipids in phagocytosis,0.015600917185656727,0,0,1,0.01683351224505333
853,HV307,Role of phospholipids in phagocytosis,0.015136719169095158,1,0,1,0.016332638937226095
854,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.015600917185656727,0,0,1,0.01683351224505333
855,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.015136719169095158,1,0,1,0.016332638937226095
856,HV307,FCERI mediated MAPK activation,0.015600917185656727,0,0,1,0.01683351224505333
857,HV307,FCERI mediated MAPK activation,0.015136719169095158,1,0,1,0.016332638937226095
858,HV307,FCERI mediated Ca+2 mobilization,0.015600917185656727,0,0,1,0.01683351224505333
859,HV307,FCERI mediated Ca+2 mobilization,0.015136719169095158,1,0,1,0.016332638937226095
860,HV307,FCERI mediated NF-kB activation,0.015600917185656727,0,0,1,0.01683351224505333
861,HV307,FCERI mediated NF-kB activation,0.015136719169095158,1,0,1,0.016332638937226095
862,HV307,Parasite infection,0.015600917185656727,0,0,1,0.01683351224505333
863,HV307,Parasite infection,0.015136719169095158,1,0,1,0.016332638937226095
864,HV307,Leishmania parasite growth and survival,0.015600917185656727,0,0,1,0.01683351224505333
865,HV307,Leishmania parasite growth and survival,0.015136719169095158,1,0,1,0.016332638937226095
866,HV307,Potential therapeutics for SARS,0.015600917185656727,0,0,1,0.01683351224505333
867,HV307,Potential therapeutics for SARS,0.015136719169095158,1,0,1,0.016332638937226095
868,HV307,CD22 mediated BCR regulation,0.015600917185656727,0,0,1,0.01683351224505333
869,HV307,CD22 mediated BCR regulation,0.015136719169095158,1,0,1,0.016332638937226095
870,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015600917185656727,0,0,1,0.01683351224505333
871,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015136719169095158,1,0,1,0.016332638937226095
872,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015600917185656727,0,0,1,0.01683351224505333
873,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015136719169095158,1,0,1,0.016332638937226095
874,HV307,Scavenging of heme from plasma,0.015600917185656727,0,0,1,0.01683351224505333
875,HV307,Scavenging of heme from plasma,0.015136719169095158,1,0,1,0.016332638937226095
876,PIGR,Neutrophil degranulation,0.0006353948564841023,0,0,1,0.0006855960434751061
877,PIGR,Neutrophil degranulation,0.0006186724715007586,1,0,1,0.0006675524586631557
878,IGKC,Initial triggering of complement,0.004292279827586754,0,0,1,0.004631403665375938
879,IGKC,Initial triggering of complement,0.004079278941139819,1,0,1,0.004401574035005987
880,IGKC,Regulation of Complement cascade,0.004292279827586754,0,0,1,0.004631403665375938
881,IGKC,Regulation of Complement cascade,0.004079278941139819,1,0,1,0.004401574035005987
882,IGKC,FCGR activation,0.004292279827586754,0,0,1,0.004631403665375938
883,IGKC,FCGR activation,0.004079278941139819,1,0,1,0.004401574035005987
884,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.004292279827586754,0,0,1,0.004631403665375938
885,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.004079278941139819,1,0,1,0.004401574035005987
886,IGKC,Role of phospholipids in phagocytosis,0.004292279827586754,0,0,1,0.004631403665375938
887,IGKC,Role of phospholipids in phagocytosis,0.004079278941139819,1,0,1,0.004401574035005987
888,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.004292279827586754,0,0,1,0.004631403665375938
889,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.004079278941139819,1,0,1,0.004401574035005987
890,IGKC,FCERI mediated MAPK activation,0.004292279827586754,0,0,1,0.004631403665375938
891,IGKC,FCERI mediated MAPK activation,0.004079278941139819,1,0,1,0.004401574035005987
892,IGKC,FCERI mediated Ca+2 mobilization,0.004292279827586754,0,0,1,0.004631403665375938
893,IGKC,FCERI mediated Ca+2 mobilization,0.004079278941139819,1,0,1,0.004401574035005987
894,IGKC,FCERI mediated NF-kB activation,0.004292279827586754,0,0,1,0.004631403665375938
895,IGKC,FCERI mediated NF-kB activation,0.004079278941139819,1,0,1,0.004401574035005987
896,IGKC,Parasite infection,0.004292279827586754,0,0,1,0.004631403665375938
897,IGKC,Parasite infection,0.004079278941139819,1,0,1,0.004401574035005987
898,IGKC,Leishmania parasite growth and survival,0.004292279827586754,0,0,1,0.004631403665375938
899,IGKC,Leishmania parasite growth and survival,0.004079278941139819,1,0,1,0.004401574035005987
900,IGKC,Potential therapeutics for SARS,0.004292279827586754,0,0,1,0.004631403665375938
901,IGKC,Potential therapeutics for SARS,0.004079278941139819,1,0,1,0.004401574035005987
902,IGKC,CD22 mediated BCR regulation,0.004292279827586754,0,0,1,0.004631403665375938
903,IGKC,CD22 mediated BCR regulation,0.004079278941139819,1,0,1,0.004401574035005987
904,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004292279827586754,0,0,1,0.004631403665375938
905,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004079278941139819,1,0,1,0.004401574035005987
906,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004292279827586754,0,0,1,0.004631403665375938
907,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004079278941139819,1,0,1,0.004401574035005987
908,IGKC,Scavenging of heme from plasma,0.004292279827586754,0,0,1,0.004631403665375938
909,IGKC,Scavenging of heme from plasma,0.004079278941139819,1,0,1,0.004401574035005987
910,IGHG1,Initial triggering of complement,0.009968499847370063,0,0,1,0.01075608967399646
911,IGHG1,Initial triggering of complement,0.009598526170278395,1,0,1,0.010356885168930829
912,IGHG1,Regulation of Complement cascade,0.009968499847370063,0,0,1,0.01075608967399646
913,IGHG1,Regulation of Complement cascade,0.009598526170278395,1,0,1,0.010356885168930829
914,IGHG1,FCGR activation,0.009968499847370063,0,0,1,0.01075608967399646
915,IGHG1,FCGR activation,0.009598526170278395,1,0,1,0.010356885168930829
916,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.009968499847370063,0,0,1,0.01075608967399646
917,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.009598526170278395,1,0,1,0.010356885168930829
918,IGHG1,Role of phospholipids in phagocytosis,0.009968499847370063,0,0,1,0.01075608967399646
919,IGHG1,Role of phospholipids in phagocytosis,0.009598526170278395,1,0,1,0.010356885168930829
920,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.009968499847370063,0,0,1,0.01075608967399646
921,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.009598526170278395,1,0,1,0.010356885168930829
922,IGHG1,Parasite infection,0.009968499847370063,0,0,1,0.01075608967399646
923,IGHG1,Parasite infection,0.009598526170278395,1,0,1,0.010356885168930829
924,IGHG1,Leishmania parasite growth and survival,0.009968499847370063,0,0,1,0.01075608967399646
925,IGHG1,Leishmania parasite growth and survival,0.009598526170278395,1,0,1,0.010356885168930829
926,IGHG2,Initial triggering of complement,0.009952704794462383,0,0,1,0.010739046687781703
927,IGHG2,Initial triggering of complement,0.009760891215652616,1,0,1,0.010532078328855323
928,IGHG2,Regulation of Complement cascade,0.009952704794462383,0,0,1,0.010739046687781703
929,IGHG2,Regulation of Complement cascade,0.009760891215652616,1,0,1,0.010532078328855323
930,IGHG2,FCGR activation,0.009952704794462383,0,0,1,0.010739046687781703
931,IGHG2,FCGR activation,0.009760891215652616,1,0,1,0.010532078328855323
932,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.009952704794462383,0,0,1,0.010739046687781703
933,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.009760891215652616,1,0,1,0.010532078328855323
934,IGHG2,Role of phospholipids in phagocytosis,0.009952704794462383,0,0,1,0.010739046687781703
935,IGHG2,Role of phospholipids in phagocytosis,0.009760891215652616,1,0,1,0.010532078328855323
936,IGHG2,Parasite infection,0.009952704794462383,0,0,1,0.010739046687781703
937,IGHG2,Parasite infection,0.009760891215652616,1,0,1,0.010532078328855323
938,IGHG2,Leishmania parasite growth and survival,0.009952704794462383,0,0,1,0.010739046687781703
939,IGHG2,Leishmania parasite growth and survival,0.009760891215652616,1,0,1,0.010532078328855323
940,IGHG3,Initial triggering of complement,0.0014780141384714322,0,0,1,0.0015947888705668727
941,IGHG3,Initial triggering of complement,0.0012990847722297379,1,0,1,0.0014017226782536158
942,IGHG3,Regulation of Complement cascade,0.0014780141384714322,0,0,1,0.0015947888705668727
943,IGHG3,Regulation of Complement cascade,0.0012990847722297379,1,0,1,0.0014017226782536158
944,IGHG3,FCGR activation,0.0014780141384714322,0,0,1,0.0015947888705668727
945,IGHG3,FCGR activation,0.0012990847722297379,1,0,1,0.0014017226782536158
946,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0014780141384714322,0,0,1,0.0015947888705668727
947,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0012990847722297379,1,0,1,0.0014017226782536158
948,IGHG3,Role of phospholipids in phagocytosis,0.0014780141384714322,0,0,1,0.0015947888705668727
949,IGHG3,Role of phospholipids in phagocytosis,0.0012990847722297379,1,0,1,0.0014017226782536158
950,IGHG3,Parasite infection,0.0014780141384714322,0,0,1,0.0015947888705668727
951,IGHG3,Parasite infection,0.0012990847722297379,1,0,1,0.0014017226782536158
952,IGHG3,Leishmania parasite growth and survival,0.0014780141384714322,0,0,1,0.0015947888705668727
953,IGHG3,Leishmania parasite growth and survival,0.0012990847722297379,1,0,1,0.0014017226782536158
954,IGHG4,Initial triggering of complement,0.005229068846286585,0,0,1,0.0056422063784249705
955,IGHG4,Initial triggering of complement,0.0051050920083071105,1,0,1,0.005508434395957862
956,IGHG4,Regulation of Complement cascade,0.005229068846286585,0,0,1,0.0056422063784249705
957,IGHG4,Regulation of Complement cascade,0.0051050920083071105,1,0,1,0.005508434395957862
958,IGHG4,FCGR activation,0.005229068846286585,0,0,1,0.0056422063784249705
959,IGHG4,FCGR activation,0.0051050920083071105,1,0,1,0.005508434395957862
960,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.005229068846286585,0,0,1,0.0056422063784249705
961,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0051050920083071105,1,0,1,0.005508434395957862
962,IGHG4,Role of phospholipids in phagocytosis,0.005229068846286585,0,0,1,0.0056422063784249705
963,IGHG4,Role of phospholipids in phagocytosis,0.0051050920083071105,1,0,1,0.005508434395957862
964,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.005229068846286585,0,0,1,0.0056422063784249705
965,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0051050920083071105,1,0,1,0.005508434395957862
966,IGHG4,Parasite infection,0.005229068846286585,0,0,1,0.0056422063784249705
967,IGHG4,Parasite infection,0.0051050920083071105,1,0,1,0.005508434395957862
968,IGHG4,Leishmania parasite growth and survival,0.005229068846286585,0,0,1,0.0056422063784249705
969,IGHG4,Leishmania parasite growth and survival,0.0051050920083071105,1,0,1,0.005508434395957862
970,IGHM,Potential therapeutics for SARS,0.006016989246563753,0,0,1,0.006492378682293572
971,IGHM,Potential therapeutics for SARS,0.0056527318027898826,1,0,1,0.006099342037899567
972,IGHM,CD22 mediated BCR regulation,0.006016989246563753,0,0,1,0.006492378682293572
973,IGHM,CD22 mediated BCR regulation,0.0056527318027898826,1,0,1,0.006099342037899567
974,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006016989246563753,0,0,1,0.006492378682293572
975,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0056527318027898826,1,0,1,0.006099342037899567
976,IGHA1,Scavenging of heme from plasma,0.005260644819160613,0,0,1,0.00567627710129972
977,IGHA1,Scavenging of heme from plasma,0.005650232844345737,1,0,1,0.006096645642099961
978,IGHA2,Scavenging of heme from plasma,0.002354312778561507,0,0,1,0.0025403219897248857
979,IGHA2,Scavenging of heme from plasma,0.002527475212794646,1,0,1,0.0027271656170807655
980,IGHD,Potential therapeutics for SARS,0.010365980668818034,0,0,1,0.011184974603990825
981,IGHD,Potential therapeutics for SARS,0.009777327486881404,1,0,1,0.010549813194677649
982,IGHD,CD22 mediated BCR regulation,0.010365980668818034,0,0,1,0.011184974603990825
983,IGHD,CD22 mediated BCR regulation,0.009777327486881404,1,0,1,0.010549813194677649
984,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010365980668818034,0,0,1,0.011184974603990825
985,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009777327486881404,1,0,1,0.010549813194677649
986,P01891,Antigen processing-Cross presentation,0.00032033837196649985,0,0,1,0.00034564762077041487
987,P01891,Antigen processing-Cross presentation,0.0002531877780711511,1,0,1,0.0002731916022461186
988,P01891,Interferon gamma signaling,0.00032033837196649985,0,0,1,0.00034564762077041487
989,P01891,Interferon gamma signaling,0.0002531877780711511,1,0,1,0.0002731916022461186
990,P01891,Interferon alpha/beta signaling,0.00032033837196649985,0,0,1,0.00034564762077041487
991,P01891,Interferon alpha/beta signaling,0.0002531877780711511,1,0,1,0.0002731916022461186
992,P01891,SARS-CoV-2 Infection,0.00032033837196649985,0,0,1,0.00034564762077041487
993,P01891,SARS-CoV-2 Infection,0.0002531877780711511,1,0,1,0.0002731916022461186
994,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00032033837196649985,0,0,1,0.00034564762077041487
995,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0002531877780711511,1,0,1,0.0002731916022461186
996,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00032033837196649985,0,0,1,0.00034564762077041487
997,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002531877780711511,1,0,1,0.0002731916022461186
998,MYG,Intracellular oxygen transport,0.00022784327872310922,0,0,1,0.00024584468827671074
999,MYG,Intracellular oxygen transport,0.00017955634187577136,1,0,1,0.0001937427039495911
1000,CO1A1,Collagen chain trimerization,0.017339572778049237,0,0,1,0.018709535292684022
1001,CO1A1,Collagen chain trimerization,0.016831454052589834,1,0,1,0.01816127119479972
1002,CO1A1,Anchoring fibril formation,0.017339572778049237,0,0,1,0.018709535292684022
1003,CO1A1,Anchoring fibril formation,0.016831454052589834,1,0,1,0.01816127119479972
1004,CO1A1,Crosslinking of collagen fibrils,0.017339572778049237,0,0,1,0.018709535292684022
1005,CO1A1,Crosslinking of collagen fibrils,0.016831454052589834,1,0,1,0.01816127119479972
1006,CO1A1,Transcriptional regulation by RUNX2,0.017339572778049237,0,0,1,0.018709535292684022
1007,CO1A1,Transcriptional regulation by RUNX2,0.016831454052589834,1,0,1,0.01816127119479972
1008,CO1A1,MET promotes cell motility,0.017339572778049237,0,0,1,0.018709535292684022
1009,CO1A1,MET promotes cell motility,0.016831454052589834,1,0,1,0.01816127119479972
1010,CO1A1,Platelet Adhesion to exposed collagen,0.017339572778049237,0,0,1,0.018709535292684022
1011,CO1A1,Platelet Adhesion to exposed collagen,0.016831454052589834,1,0,1,0.01816127119479972
1012,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.017339572778049237,0,0,1,0.018709535292684022
1013,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.016831454052589834,1,0,1,0.01816127119479972
1014,CO1A1,Collagen degradation,0.017339572778049237,0,0,1,0.018709535292684022
1015,CO1A1,Collagen degradation,0.016831454052589834,1,0,1,0.01816127119479972
1016,CO1A1,Integrin cell surface interactions,0.017339572778049237,0,0,1,0.018709535292684022
1017,CO1A1,Integrin cell surface interactions,0.016831454052589834,1,0,1,0.01816127119479972
1018,CO1A1,ECM proteoglycans,0.017339572778049237,0,0,1,0.018709535292684022
1019,CO1A1,ECM proteoglycans,0.016831454052589834,1,0,1,0.01816127119479972
1020,CO1A1,Scavenging by Class A Receptors,0.017339572778049237,0,0,1,0.018709535292684022
1021,CO1A1,Scavenging by Class A Receptors,0.016831454052589834,1,0,1,0.01816127119479972
1022,CO1A1,Syndecan interactions,0.017339572778049237,0,0,1,0.018709535292684022
1023,CO1A1,Syndecan interactions,0.016831454052589834,1,0,1,0.01816127119479972
1024,CO1A1,GPVI-mediated activation cascade,0.017339572778049237,0,0,1,0.018709535292684022
1025,CO1A1,GPVI-mediated activation cascade,0.016831454052589834,1,0,1,0.01816127119479972
1026,CO1A1,GP1b-IX-V activation signalling,0.017339572778049237,0,0,1,0.018709535292684022
1027,CO1A1,GP1b-IX-V activation signalling,0.016831454052589834,1,0,1,0.01816127119479972
1028,K1C14,Type I hemidesmosome assembly,0.0007444143307414682,0,0,1,0.0008032289129417735
1029,K1C14,Type I hemidesmosome assembly,0.00035946958984519977,1,0,1,0.0003878705123790287
1030,K1C14,Formation of the cornified envelope,0.0007444143307414682,0,0,1,0.0008032289129417735
1031,K1C14,Formation of the cornified envelope,0.00035946958984519977,1,0,1,0.0003878705123790287
1032,K2C6A,Formation of the cornified envelope,0.000287582123807321,0,0,1,0.00031030337158764916
1033,K2C6A,Formation of the cornified envelope,0.000330768675970224,1,0,1,0.00035690200075826225
1034,APOA1,PPARA activates gene expression,0.025133856397587806,0,0,1,0.027119628570504213
1035,APOA1,PPARA activates gene expression,0.025920883218835417,1,0,1,0.02796883669557762
1036,APOA1,Defective ABCA1 causes TGD,0.025133856397587806,0,0,1,0.027119628570504213
1037,APOA1,Defective ABCA1 causes TGD,0.025920883218835417,1,0,1,0.02796883669557762
1038,APOA1,Platelet degranulation ,0.025133856397587806,0,0,1,0.027119628570504213
1039,APOA1,Platelet degranulation ,0.025920883218835417,1,0,1,0.02796883669557762
1040,APOA1,Chylomicron assembly,0.025133856397587806,0,0,1,0.027119628570504213
1041,APOA1,Chylomicron assembly,0.025920883218835417,1,0,1,0.02796883669557762
1042,APOA1,HDL assembly,0.025133856397587806,0,0,1,0.027119628570504213
1043,APOA1,HDL assembly,0.025920883218835417,1,0,1,0.02796883669557762
1044,APOA1,Chylomicron remodeling,0.025133856397587806,0,0,1,0.027119628570504213
1045,APOA1,Chylomicron remodeling,0.025920883218835417,1,0,1,0.02796883669557762
1046,APOA1,HDL remodeling,0.025133856397587806,0,0,1,0.027119628570504213
1047,APOA1,HDL remodeling,0.025920883218835417,1,0,1,0.02796883669557762
1048,APOA1,HDL clearance,0.025133856397587806,0,0,1,0.027119628570504213
1049,APOA1,HDL clearance,0.025920883218835417,1,0,1,0.02796883669557762
1050,APOA1,Scavenging of heme from plasma,0.025133856397587806,0,0,1,0.027119628570504213
1051,APOA1,Scavenging of heme from plasma,0.025920883218835417,1,0,1,0.02796883669557762
1052,APOA1,Scavenging by Class B Receptors,0.025133856397587806,0,0,1,0.027119628570504213
1053,APOA1,Scavenging by Class B Receptors,0.025920883218835417,1,0,1,0.02796883669557762
1054,APOA1,Scavenging by Class A Receptors,0.025133856397587806,0,0,1,0.027119628570504213
1055,APOA1,Scavenging by Class A Receptors,0.025920883218835417,1,0,1,0.02796883669557762
1056,APOA1,Retinoid metabolism and transport,0.025133856397587806,0,0,1,0.027119628570504213
1057,APOA1,Retinoid metabolism and transport,0.025920883218835417,1,0,1,0.02796883669557762
1058,APOA1,Heme signaling,0.025133856397587806,0,0,1,0.027119628570504213
1059,APOA1,Heme signaling,0.025920883218835417,1,0,1,0.02796883669557762
1060,APOA1,ABC transporters in lipid homeostasis,0.025133856397587806,0,0,1,0.027119628570504213
1061,APOA1,ABC transporters in lipid homeostasis,0.025920883218835417,1,0,1,0.02796883669557762
1062,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.025133856397587806,0,0,1,0.027119628570504213
1063,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.025920883218835417,1,0,1,0.02796883669557762
1064,APOA1,Amyloid fiber formation,0.025133856397587806,0,0,1,0.027119628570504213
1065,APOA1,Amyloid fiber formation,0.025920883218835417,1,0,1,0.02796883669557762
1066,APOA1,Post-translational protein phosphorylation,0.025133856397587806,0,0,1,0.027119628570504213
1067,APOA1,Post-translational protein phosphorylation,0.025920883218835417,1,0,1,0.02796883669557762
1068,APOE,Nuclear signaling by ERBB4,0.0031731778058504763,0,0,1,0.0034238837893213843
1069,APOE,Nuclear signaling by ERBB4,0.0032350583363343808,1,0,1,0.0034906533680092895
1070,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0031731778058504763,0,0,1,0.0034238837893213843
1071,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0032350583363343808,1,0,1,0.0034906533680092895
1072,APOE,Chylomicron assembly,0.0031731778058504763,0,0,1,0.0034238837893213843
1073,APOE,Chylomicron assembly,0.0032350583363343808,1,0,1,0.0034906533680092895
1074,APOE,Chylomicron remodeling,0.0031731778058504763,0,0,1,0.0034238837893213843
1075,APOE,Chylomicron remodeling,0.0032350583363343808,1,0,1,0.0034906533680092895
1076,APOE,HDL remodeling,0.0031731778058504763,0,0,1,0.0034238837893213843
1077,APOE,HDL remodeling,0.0032350583363343808,1,0,1,0.0034906533680092895
1078,APOE,Chylomicron clearance,0.0031731778058504763,0,0,1,0.0034238837893213843
1079,APOE,Chylomicron clearance,0.0032350583363343808,1,0,1,0.0034906533680092895
1080,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0031731778058504763,0,0,1,0.0034238837893213843
1081,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0032350583363343808,1,0,1,0.0034906533680092895
1082,APOE,Scavenging by Class A Receptors,0.0031731778058504763,0,0,1,0.0034238837893213843
1083,APOE,Scavenging by Class A Receptors,0.0032350583363343808,1,0,1,0.0034906533680092895
1084,APOE,Retinoid metabolism and transport,0.0031731778058504763,0,0,1,0.0034238837893213843
1085,APOE,Retinoid metabolism and transport,0.0032350583363343808,1,0,1,0.0034906533680092895
1086,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0031731778058504763,0,0,1,0.0034238837893213843
1087,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0032350583363343808,1,0,1,0.0034906533680092895
1088,APOE,Amyloid fiber formation,0.0031731778058504763,0,0,1,0.0034238837893213843
1089,APOE,Amyloid fiber formation,0.0032350583363343808,1,0,1,0.0034906533680092895
1090,APOE,Post-translational protein phosphorylation,0.0031731778058504763,0,0,1,0.0034238837893213843
1091,APOE,Post-translational protein phosphorylation,0.0032350583363343808,1,0,1,0.0034906533680092895
1092,APOA2,PPARA activates gene expression,0.002081569520669291,0,0,1,0.0022460298710726906
1093,APOA2,PPARA activates gene expression,0.0025118180238375013,1,0,1,0.002710271387152058
1094,APOA2,Chylomicron assembly,0.002081569520669291,0,0,1,0.0022460298710726906
1095,APOA2,Chylomicron assembly,0.0025118180238375013,1,0,1,0.002710271387152058
1096,APOA2,Chylomicron remodeling,0.002081569520669291,0,0,1,0.0022460298710726906
1097,APOA2,Chylomicron remodeling,0.0025118180238375013,1,0,1,0.002710271387152058
1098,APOA2,Retinoid metabolism and transport,0.002081569520669291,0,0,1,0.0022460298710726906
1099,APOA2,Retinoid metabolism and transport,0.0025118180238375013,1,0,1,0.002710271387152058
1100,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002081569520669291,0,0,1,0.0022460298710726906
1101,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025118180238375013,1,0,1,0.002710271387152058
1102,APOA2,Post-translational protein phosphorylation,0.002081569520669291,0,0,1,0.0022460298710726906
1103,APOA2,Post-translational protein phosphorylation,0.0025118180238375013,1,0,1,0.002710271387152058
1104,APOC1,VLDL assembly,0.0037845421332046198,0,0,1,0.004083550703018391
1105,APOC1,VLDL assembly,0.003600121360371607,1,0,1,0.0038845592398382063
1106,APOC1,VLDL clearance,0.0037845421332046198,0,0,1,0.004083550703018391
1107,APOC1,VLDL clearance,0.003600121360371607,1,0,1,0.0038845592398382063
1108,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0037845421332046198,0,0,1,0.004083550703018391
1109,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.003600121360371607,1,0,1,0.0038845592398382063
1110,APOC2,Chylomicron assembly,0.00850091603109225,0,0,1,0.009172555203044472
1111,APOC2,Chylomicron assembly,0.008818133303793729,1,0,1,0.009514835133180388
1112,APOC2,Assembly of active LPL and LIPC lipase complexes,0.00850091603109225,0,0,1,0.009172555203044472
1113,APOC2,Assembly of active LPL and LIPC lipase complexes,0.008818133303793729,1,0,1,0.009514835133180388
1114,APOC2,Chylomicron remodeling,0.00850091603109225,0,0,1,0.009172555203044472
1115,APOC2,Chylomicron remodeling,0.008818133303793729,1,0,1,0.009514835133180388
1116,APOC2,HDL remodeling,0.00850091603109225,0,0,1,0.009172555203044472
1117,APOC2,HDL remodeling,0.008818133303793729,1,0,1,0.009514835133180388
1118,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00850091603109225,0,0,1,0.009172555203044472
1119,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.008818133303793729,1,0,1,0.009514835133180388
1120,APOC2,Retinoid metabolism and transport,0.00850091603109225,0,0,1,0.009172555203044472
1121,APOC2,Retinoid metabolism and transport,0.008818133303793729,1,0,1,0.009514835133180388
1122,APOC3,Chylomicron assembly,0.006573881746529272,0,0,1,0.007093270066164686
1123,APOC3,Chylomicron assembly,0.006930938208824955,1,0,1,0.007478536794953926
1124,APOC3,Chylomicron remodeling,0.006573881746529272,0,0,1,0.007093270066164686
1125,APOC3,Chylomicron remodeling,0.006930938208824955,1,0,1,0.007478536794953926
1126,APOC3,HDL remodeling,0.006573881746529272,0,0,1,0.007093270066164686
1127,APOC3,HDL remodeling,0.006930938208824955,1,0,1,0.007478536794953926
1128,APOC3,Retinoid metabolism and transport,0.006573881746529272,0,0,1,0.007093270066164686
1129,APOC3,Retinoid metabolism and transport,0.006930938208824955,1,0,1,0.007478536794953926
1130,FIBA,Antigen processing-Cross presentation,0.008150772612619523,0,0,1,0.008794747702867211
1131,FIBA,Antigen processing-Cross presentation,0.0077454873719640695,1,0,1,0.00835744174321598
1132,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.008150772612619523,0,0,1,0.008794747702867211
1133,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.0077454873719640695,1,0,1,0.00835744174321598
1134,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.008150772612619523,0,0,1,0.008794747702867211
1135,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.0077454873719640695,1,0,1,0.00835744174321598
1136,FIBA,Regulation of TLR by endogenous ligand,0.008150772612619523,0,0,1,0.008794747702867211
1137,FIBA,Regulation of TLR by endogenous ligand,0.0077454873719640695,1,0,1,0.00835744174321598
1138,FIBA,MyD88 deficiency (TLR2/4),0.008150772612619523,0,0,1,0.008794747702867211
1139,FIBA,MyD88 deficiency (TLR2/4),0.0077454873719640695,1,0,1,0.00835744174321598
1140,FIBA,IRAK4 deficiency (TLR2/4),0.008150772612619523,0,0,1,0.008794747702867211
1141,FIBA,IRAK4 deficiency (TLR2/4),0.0077454873719640695,1,0,1,0.00835744174321598
1142,FIBA,RAF/MAP kinase cascade,0.008150772612619523,0,0,1,0.008794747702867211
1143,FIBA,RAF/MAP kinase cascade,0.0077454873719640695,1,0,1,0.00835744174321598
1144,FIBA,Signaling by RAS mutants,0.008150772612619523,0,0,1,0.008794747702867211
1145,FIBA,Signaling by RAS mutants,0.0077454873719640695,1,0,1,0.00835744174321598
1146,FIBA,Signaling by moderate kinase activity BRAF mutants,0.008150772612619523,0,0,1,0.008794747702867211
1147,FIBA,Signaling by moderate kinase activity BRAF mutants,0.0077454873719640695,1,0,1,0.00835744174321598
1148,FIBA,Signaling by high-kinase activity BRAF mutants,0.008150772612619523,0,0,1,0.008794747702867211
1149,FIBA,Signaling by high-kinase activity BRAF mutants,0.0077454873719640695,1,0,1,0.00835744174321598
1150,FIBA,Signaling by BRAF and RAF1 fusions,0.008150772612619523,0,0,1,0.008794747702867211
1151,FIBA,Signaling by BRAF and RAF1 fusions,0.0077454873719640695,1,0,1,0.00835744174321598
1152,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008150772612619523,0,0,1,0.008794747702867211
1153,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0077454873719640695,1,0,1,0.00835744174321598
1154,FIBA,Signaling by RAF1 mutants,0.008150772612619523,0,0,1,0.008794747702867211
1155,FIBA,Signaling by RAF1 mutants,0.0077454873719640695,1,0,1,0.00835744174321598
1156,FIBA,Platelet degranulation ,0.008150772612619523,0,0,1,0.008794747702867211
1157,FIBA,Platelet degranulation ,0.0077454873719640695,1,0,1,0.00835744174321598
1158,FIBA,Common Pathway of Fibrin Clot Formation,0.008150772612619523,0,0,1,0.008794747702867211
1159,FIBA,Common Pathway of Fibrin Clot Formation,0.0077454873719640695,1,0,1,0.00835744174321598
1160,FIBA,Integrin cell surface interactions,0.008150772612619523,0,0,1,0.008794747702867211
1161,FIBA,Integrin cell surface interactions,0.0077454873719640695,1,0,1,0.00835744174321598
1162,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008150772612619523,0,0,1,0.008794747702867211
1163,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0077454873719640695,1,0,1,0.00835744174321598
1164,FIBA,p130Cas linkage to MAPK signaling for integrins,0.008150772612619523,0,0,1,0.008794747702867211
1165,FIBA,p130Cas linkage to MAPK signaling for integrins,0.0077454873719640695,1,0,1,0.00835744174321598
1166,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008150772612619523,0,0,1,0.008794747702867211
1167,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0077454873719640695,1,0,1,0.00835744174321598
1168,FIBA,Amyloid fiber formation,0.008150772612619523,0,0,1,0.008794747702867211
1169,FIBA,Amyloid fiber formation,0.0077454873719640695,1,0,1,0.00835744174321598
1170,FIBA,Post-translational protein phosphorylation,0.008150772612619523,0,0,1,0.008794747702867211
1171,FIBA,Post-translational protein phosphorylation,0.0077454873719640695,1,0,1,0.00835744174321598
1172,FIBB,Antigen processing-Cross presentation,0.0019107791023240375,0,0,1,0.0020617456675006184
1173,FIBB,Antigen processing-Cross presentation,0.001972511673269158,1,0,1,0.0021283555966834177
1174,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0019107791023240375,0,0,1,0.0020617456675006184
1175,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.001972511673269158,1,0,1,0.0021283555966834177
1176,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0019107791023240375,0,0,1,0.0020617456675006184
1177,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.001972511673269158,1,0,1,0.0021283555966834177
1178,FIBB,Regulation of TLR by endogenous ligand,0.0019107791023240375,0,0,1,0.0020617456675006184
1179,FIBB,Regulation of TLR by endogenous ligand,0.001972511673269158,1,0,1,0.0021283555966834177
1180,FIBB,MyD88 deficiency (TLR2/4),0.0019107791023240375,0,0,1,0.0020617456675006184
1181,FIBB,MyD88 deficiency (TLR2/4),0.001972511673269158,1,0,1,0.0021283555966834177
1182,FIBB,IRAK4 deficiency (TLR2/4),0.0019107791023240375,0,0,1,0.0020617456675006184
1183,FIBB,IRAK4 deficiency (TLR2/4),0.001972511673269158,1,0,1,0.0021283555966834177
1184,FIBB,RAF/MAP kinase cascade,0.0019107791023240375,0,0,1,0.0020617456675006184
1185,FIBB,RAF/MAP kinase cascade,0.001972511673269158,1,0,1,0.0021283555966834177
1186,FIBB,Signaling by RAS mutants,0.0019107791023240375,0,0,1,0.0020617456675006184
1187,FIBB,Signaling by RAS mutants,0.001972511673269158,1,0,1,0.0021283555966834177
1188,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0019107791023240375,0,0,1,0.0020617456675006184
1189,FIBB,Signaling by moderate kinase activity BRAF mutants,0.001972511673269158,1,0,1,0.0021283555966834177
1190,FIBB,Signaling by high-kinase activity BRAF mutants,0.0019107791023240375,0,0,1,0.0020617456675006184
1191,FIBB,Signaling by high-kinase activity BRAF mutants,0.001972511673269158,1,0,1,0.0021283555966834177
1192,FIBB,Signaling by BRAF and RAF1 fusions,0.0019107791023240375,0,0,1,0.0020617456675006184
1193,FIBB,Signaling by BRAF and RAF1 fusions,0.001972511673269158,1,0,1,0.0021283555966834177
1194,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0019107791023240375,0,0,1,0.0020617456675006184
1195,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.001972511673269158,1,0,1,0.0021283555966834177
1196,FIBB,Signaling by RAF1 mutants,0.0019107791023240375,0,0,1,0.0020617456675006184
1197,FIBB,Signaling by RAF1 mutants,0.001972511673269158,1,0,1,0.0021283555966834177
1198,FIBB,Platelet degranulation ,0.0019107791023240375,0,0,1,0.0020617456675006184
1199,FIBB,Platelet degranulation ,0.001972511673269158,1,0,1,0.0021283555966834177
1200,FIBB,Common Pathway of Fibrin Clot Formation,0.0019107791023240375,0,0,1,0.0020617456675006184
1201,FIBB,Common Pathway of Fibrin Clot Formation,0.001972511673269158,1,0,1,0.0021283555966834177
1202,FIBB,Integrin cell surface interactions,0.0019107791023240375,0,0,1,0.0020617456675006184
1203,FIBB,Integrin cell surface interactions,0.001972511673269158,1,0,1,0.0021283555966834177
1204,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0019107791023240375,0,0,1,0.0020617456675006184
1205,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.001972511673269158,1,0,1,0.0021283555966834177
1206,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0019107791023240375,0,0,1,0.0020617456675006184
1207,FIBB,p130Cas linkage to MAPK signaling for integrins,0.001972511673269158,1,0,1,0.0021283555966834177
1208,FIBG,Antigen processing-Cross presentation,0.0012386202462039363,0,0,1,0.001336480979503849
1209,FIBG,Antigen processing-Cross presentation,0.0013209888335950382,1,0,1,0.0014253573326025396
1210,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0012386202462039363,0,0,1,0.001336480979503849
1211,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0013209888335950382,1,0,1,0.0014253573326025396
1212,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0012386202462039363,0,0,1,0.001336480979503849
1213,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0013209888335950382,1,0,1,0.0014253573326025396
1214,FIBG,Regulation of TLR by endogenous ligand,0.0012386202462039363,0,0,1,0.001336480979503849
1215,FIBG,Regulation of TLR by endogenous ligand,0.0013209888335950382,1,0,1,0.0014253573326025396
1216,FIBG,MyD88 deficiency (TLR2/4),0.0012386202462039363,0,0,1,0.001336480979503849
1217,FIBG,MyD88 deficiency (TLR2/4),0.0013209888335950382,1,0,1,0.0014253573326025396
1218,FIBG,IRAK4 deficiency (TLR2/4),0.0012386202462039363,0,0,1,0.001336480979503849
1219,FIBG,IRAK4 deficiency (TLR2/4),0.0013209888335950382,1,0,1,0.0014253573326025396
1220,FIBG,RAF/MAP kinase cascade,0.0012386202462039363,0,0,1,0.001336480979503849
1221,FIBG,RAF/MAP kinase cascade,0.0013209888335950382,1,0,1,0.0014253573326025396
1222,FIBG,Signaling by RAS mutants,0.0012386202462039363,0,0,1,0.001336480979503849
1223,FIBG,Signaling by RAS mutants,0.0013209888335950382,1,0,1,0.0014253573326025396
1224,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0012386202462039363,0,0,1,0.001336480979503849
1225,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0013209888335950382,1,0,1,0.0014253573326025396
1226,FIBG,Signaling by high-kinase activity BRAF mutants,0.0012386202462039363,0,0,1,0.001336480979503849
1227,FIBG,Signaling by high-kinase activity BRAF mutants,0.0013209888335950382,1,0,1,0.0014253573326025396
1228,FIBG,Signaling by BRAF and RAF1 fusions,0.0012386202462039363,0,0,1,0.001336480979503849
1229,FIBG,Signaling by BRAF and RAF1 fusions,0.0013209888335950382,1,0,1,0.0014253573326025396
1230,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0012386202462039363,0,0,1,0.001336480979503849
1231,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0013209888335950382,1,0,1,0.0014253573326025396
1232,FIBG,Signaling by RAF1 mutants,0.0012386202462039363,0,0,1,0.001336480979503849
1233,FIBG,Signaling by RAF1 mutants,0.0013209888335950382,1,0,1,0.0014253573326025396
1234,FIBG,Platelet degranulation ,0.0012386202462039363,0,0,1,0.001336480979503849
1235,FIBG,Platelet degranulation ,0.0013209888335950382,1,0,1,0.0014253573326025396
1236,FIBG,Common Pathway of Fibrin Clot Formation,0.0012386202462039363,0,0,1,0.001336480979503849
1237,FIBG,Common Pathway of Fibrin Clot Formation,0.0013209888335950382,1,0,1,0.0014253573326025396
1238,FIBG,Integrin cell surface interactions,0.0012386202462039363,0,0,1,0.001336480979503849
1239,FIBG,Integrin cell surface interactions,0.0013209888335950382,1,0,1,0.0014253573326025396
1240,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0012386202462039363,0,0,1,0.001336480979503849
1241,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0013209888335950382,1,0,1,0.0014253573326025396
1242,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0012386202462039363,0,0,1,0.001336480979503849
1243,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0013209888335950382,1,0,1,0.0014253573326025396
1244,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012386202462039363,0,0,1,0.001336480979503849
1245,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0013209888335950382,1,0,1,0.0014253573326025396
1246,FIBG,Post-translational protein phosphorylation,0.0012386202462039363,0,0,1,0.001336480979503849
1247,FIBG,Post-translational protein phosphorylation,0.0013209888335950382,1,0,1,0.0014253573326025396
1248,B3AT,Bicarbonate transporters,0.0002530841801975233,0,0,1,0.0002730798193263374
1249,B3AT,Bicarbonate transporters,0.0002456012054608436,1,0,1,0.00026500563077958125
1250,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0002530841801975233,0,0,1,0.0002730798193263374
1251,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0002456012054608436,1,0,1,0.00026500563077958125
1252,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0002530841801975233,0,0,1,0.0002730798193263374
1253,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0002456012054608436,1,0,1,0.00026500563077958125
1254,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0002530841801975233,0,0,1,0.0002730798193263374
1255,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0002456012054608436,1,0,1,0.00026500563077958125
1256,CRP,Initial triggering of complement,0.0010420688687948617,0,0,1,0.0011244004986562433
1257,CRP,Initial triggering of complement,0.001118505398464246,1,0,1,0.0012068761148553942
1258,SAMP,Amyloid fiber formation,0.0003689192191359325,0,0,1,0.0003980667366448053
1259,SAMP,Amyloid fiber formation,0.00034840375634151617,1,0,1,0.0003759303910663382
1260,C1QA,Initial triggering of complement,0.0032157689987798222,0,0,1,0.0034698400212002847
1261,C1QA,Initial triggering of complement,0.0033694314556972434,1,0,1,0.0036356430197895316
1262,C1QA,Regulation of Complement cascade,0.0032157689987798222,0,0,1,0.0034698400212002847
1263,C1QA,Regulation of Complement cascade,0.0033694314556972434,1,0,1,0.0036356430197895316
1264,C1QB,Initial triggering of complement,0.00024612856268504404,0,0,1,0.0002655746533687952
1265,C1QB,Initial triggering of complement,0.00026002798301002865,1,0,1,0.00028057223712976063
1266,C1QB,Regulation of Complement cascade,0.00024612856268504404,0,0,1,0.0002655746533687952
1267,C1QB,Regulation of Complement cascade,0.00026002798301002865,1,0,1,0.00028057223712976063
1268,C1QC,Initial triggering of complement,0.0010711057746599787,0,0,1,0.0011557315482748063
1269,C1QC,Initial triggering of complement,0.0011305726561658958,1,0,1,0.0012198967807475055
1270,C1QC,Regulation of Complement cascade,0.0010711057746599787,0,0,1,0.0011557315482748063
1271,C1QC,Regulation of Complement cascade,0.0011305726561658958,1,0,1,0.0012198967807475055
1272,CO9,Terminal pathway of complement,0.00018248871538209717,0,0,1,0.00019690675800733512
1273,CO9,Terminal pathway of complement,0.00019556347841971357,1,0,1,0.00021101453007455937
1274,CO9,Regulation of Complement cascade,0.00018248871538209717,0,0,1,0.00019690675800733512
1275,CO9,Regulation of Complement cascade,0.00019556347841971357,1,0,1,0.00021101453007455937
1276,APOH,Platelet degranulation ,0.0027570049474282617,0,0,1,0.002974830004538134
1277,APOH,Platelet degranulation ,0.0031483149987858875,1,0,1,0.0033970566251112604
1278,A2GL,Neutrophil degranulation,0.0019209440190631236,0,0,1,0.002072713692544343
1279,A2GL,Neutrophil degranulation,0.0018694524448922797,1,0,1,0.002017153879361123
1280,FINC,G alpha (s) signalling events,0.006074616461652719,0,0,1,0.006554558900245136
1281,FINC,G alpha (s) signalling events,0.006407425832003355,1,0,1,0.00691366282627691
1282,FINC,Interleukin-4 and Interleukin-13 signaling,0.006074616461652719,0,0,1,0.006554558900245136
1283,FINC,Interleukin-4 and Interleukin-13 signaling,0.006407425832003355,1,0,1,0.00691366282627691
1284,FINC,RAF/MAP kinase cascade,0.006074616461652719,0,0,1,0.006554558900245136
1285,FINC,RAF/MAP kinase cascade,0.006407425832003355,1,0,1,0.00691366282627691
1286,FINC,Signaling by RAS mutants,0.006074616461652719,0,0,1,0.006554558900245136
1287,FINC,Signaling by RAS mutants,0.006407425832003355,1,0,1,0.00691366282627691
1288,FINC,Signaling by moderate kinase activity BRAF mutants,0.006074616461652719,0,0,1,0.006554558900245136
1289,FINC,Signaling by moderate kinase activity BRAF mutants,0.006407425832003355,1,0,1,0.00691366282627691
1290,FINC,Signaling by high-kinase activity BRAF mutants,0.006074616461652719,0,0,1,0.006554558900245136
1291,FINC,Signaling by high-kinase activity BRAF mutants,0.006407425832003355,1,0,1,0.00691366282627691
1292,FINC,Signaling by BRAF and RAF1 fusions,0.006074616461652719,0,0,1,0.006554558900245136
1293,FINC,Signaling by BRAF and RAF1 fusions,0.006407425832003355,1,0,1,0.00691366282627691
1294,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006074616461652719,0,0,1,0.006554558900245136
1295,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006407425832003355,1,0,1,0.00691366282627691
1296,FINC,Signaling by RAF1 mutants,0.006074616461652719,0,0,1,0.006554558900245136
1297,FINC,Signaling by RAF1 mutants,0.006407425832003355,1,0,1,0.00691366282627691
1298,FINC,MET promotes cell motility,0.006074616461652719,0,0,1,0.006554558900245136
1299,FINC,MET promotes cell motility,0.006407425832003355,1,0,1,0.00691366282627691
1300,FINC,Platelet degranulation ,0.006074616461652719,0,0,1,0.006554558900245136
1301,FINC,Platelet degranulation ,0.006407425832003355,1,0,1,0.00691366282627691
1302,FINC,ALK mutants bind TKIs,0.006074616461652719,0,0,1,0.006554558900245136
1303,FINC,ALK mutants bind TKIs,0.006407425832003355,1,0,1,0.00691366282627691
1304,FINC,Signaling by ALK fusions and activated point mutants,0.006074616461652719,0,0,1,0.006554558900245136
1305,FINC,Signaling by ALK fusions and activated point mutants,0.006407425832003355,1,0,1,0.00691366282627691
1306,FINC,Fibronectin matrix formation,0.006074616461652719,0,0,1,0.006554558900245136
1307,FINC,Fibronectin matrix formation,0.006407425832003355,1,0,1,0.00691366282627691
1308,FINC,Integrin cell surface interactions,0.006074616461652719,0,0,1,0.006554558900245136
1309,FINC,Integrin cell surface interactions,0.006407425832003355,1,0,1,0.00691366282627691
1310,FINC,ECM proteoglycans,0.006074616461652719,0,0,1,0.006554558900245136
1311,FINC,ECM proteoglycans,0.006407425832003355,1,0,1,0.00691366282627691
1312,FINC,Molecules associated with elastic fibres,0.006074616461652719,0,0,1,0.006554558900245136
1313,FINC,Molecules associated with elastic fibres,0.006407425832003355,1,0,1,0.00691366282627691
1314,FINC,Syndecan interactions,0.006074616461652719,0,0,1,0.006554558900245136
1315,FINC,Syndecan interactions,0.006407425832003355,1,0,1,0.00691366282627691
1316,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006074616461652719,0,0,1,0.006554558900245136
1317,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006407425832003355,1,0,1,0.00691366282627691
1318,FINC,p130Cas linkage to MAPK signaling for integrins,0.006074616461652719,0,0,1,0.006554558900245136
1319,FINC,p130Cas linkage to MAPK signaling for integrins,0.006407425832003355,1,0,1,0.00691366282627691
1320,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006074616461652719,0,0,1,0.006554558900245136
1321,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006407425832003355,1,0,1,0.00691366282627691
1322,FINC,Post-translational protein phosphorylation,0.006074616461652719,0,0,1,0.006554558900245136
1323,FINC,Post-translational protein phosphorylation,0.006407425832003355,1,0,1,0.00691366282627691
1324,RET4,Retinoid cycle disease events,0.003976263831524799,0,0,1,0.004290419922174451
1325,RET4,Retinoid cycle disease events,0.003991950784741978,1,0,1,0.004307346267973642
1326,RET4,Retinoid metabolism disease events,0.003976263831524799,0,0,1,0.004290419922174451
1327,RET4,Retinoid metabolism disease events,0.003991950784741978,1,0,1,0.004307346267973642
1328,RET4,The canonical retinoid cycle in rods (twilight vision),0.003976263831524799,0,0,1,0.004290419922174451
1329,RET4,The canonical retinoid cycle in rods (twilight vision),0.003991950784741978,1,0,1,0.004307346267973642
1330,RET4,Retinoid metabolism and transport,0.003976263831524799,0,0,1,0.004290419922174451
1331,RET4,Retinoid metabolism and transport,0.003991950784741978,1,0,1,0.004307346267973642
1332,AMBP,Scavenging of heme from plasma,0.001389081326245408,0,0,1,0.0014988296672855312
1333,AMBP,Scavenging of heme from plasma,0.0014916960809690258,1,0,1,0.001609551794043007
1334,A1AG1,Platelet degranulation ,0.0027960847059754694,0,0,1,0.0030169973711236682
1335,A1AG1,Platelet degranulation ,0.0029275191208095446,1,0,1,0.0031588161376231772
1336,A1AG1,Neutrophil degranulation,0.0027960847059754694,0,0,1,0.0030169973711236682
1337,A1AG1,Neutrophil degranulation,0.0029275191208095446,1,0,1,0.0031588161376231772
1338,FETUA,Platelet degranulation ,0.010009892185856491,0,0,1,0.010800752332510107
1339,FETUA,Platelet degranulation ,0.010085723778502143,1,0,1,0.010882575216906677
1340,FETUA,Neutrophil degranulation,0.010009892185856491,0,0,1,0.010800752332510107
1341,FETUA,Neutrophil degranulation,0.010085723778502143,1,0,1,0.010882575216906677
1342,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010009892185856491,0,0,1,0.010800752332510107
1343,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.010085723778502143,1,0,1,0.010882575216906677
1344,FETUA,Post-translational protein phosphorylation,0.010009892185856491,0,0,1,0.010800752332510107
1345,FETUA,Post-translational protein phosphorylation,0.010085723778502143,1,0,1,0.010882575216906677
1346,TTHY,Retinoid cycle disease events,0.0034812745157978497,0,0,1,0.003756322560570552
1347,TTHY,Retinoid cycle disease events,0.003468924304373407,1,0,1,0.0037429965853879206
1348,TTHY,Neutrophil degranulation,0.0034812745157978497,0,0,1,0.003756322560570552
1349,TTHY,Neutrophil degranulation,0.003468924304373407,1,0,1,0.0037429965853879206
1350,TTHY,The canonical retinoid cycle in rods (twilight vision),0.0034812745157978497,0,0,1,0.003756322560570552
1351,TTHY,The canonical retinoid cycle in rods (twilight vision),0.003468924304373407,1,0,1,0.0037429965853879206
1352,TTHY,Retinoid metabolism and transport,0.0034812745157978497,0,0,1,0.003756322560570552
1353,TTHY,Retinoid metabolism and transport,0.003468924304373407,1,0,1,0.0037429965853879206
1354,TTHY,Amyloid fiber formation,0.0034812745157978497,0,0,1,0.003756322560570552
1355,TTHY,Amyloid fiber formation,0.003468924304373407,1,0,1,0.0037429965853879206
1356,ALBU,Bile acid and bile salt metabolism,0.004929932889535848,0,0,1,0.005319436330294157
1357,ALBU,Bile acid and bile salt metabolism,0.005294387287419037,1,0,1,0.005712685489719902
1358,ALBU,Platelet degranulation ,0.004929932889535848,0,0,1,0.005319436330294157
1359,ALBU,Platelet degranulation ,0.005294387287419037,1,0,1,0.005712685489719902
1360,ALBU,HDL remodeling,0.004929932889535848,0,0,1,0.005319436330294157
1361,ALBU,HDL remodeling,0.005294387287419037,1,0,1,0.005712685489719902
1362,ALBU,Cytoprotection by HMOX1,0.004929932889535848,0,0,1,0.005319436330294157
1363,ALBU,Cytoprotection by HMOX1,0.005294387287419037,1,0,1,0.005712685489719902
1364,ALBU,Heme biosynthesis,0.004929932889535848,0,0,1,0.005319436330294157
1365,ALBU,Heme biosynthesis,0.005294387287419037,1,0,1,0.005712685489719902
1366,ALBU,Heme degradation,0.004929932889535848,0,0,1,0.005319436330294157
1367,ALBU,Heme degradation,0.005294387287419037,1,0,1,0.005712685489719902
1368,ALBU,Scavenging of heme from plasma,0.004929932889535848,0,0,1,0.005319436330294157
1369,ALBU,Scavenging of heme from plasma,0.005294387287419037,1,0,1,0.005712685489719902
1370,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004929932889535848,0,0,1,0.005319436330294157
1371,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005294387287419037,1,0,1,0.005712685489719902
1372,ALBU,Post-translational protein phosphorylation,0.004929932889535848,0,0,1,0.005319436330294157
1373,ALBU,Post-translational protein phosphorylation,0.005294387287419037,1,0,1,0.005712685489719902
1374,ALBU,Aspirin ADME,0.004929932889535848,0,0,1,0.005319436330294157
1375,ALBU,Aspirin ADME,0.005294387287419037,1,0,1,0.005712685489719902
1376,VTDB,Vitamin D (calciferol) metabolism,0.0007461186678938247,0,0,1,0.0008050679061229097
1377,VTDB,Vitamin D (calciferol) metabolism,0.0006680847527453201,1,0,1,0.0007208686984385373
1378,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0015736706878821374,0,0,1,0.0016980030391098018
1379,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0014232039129941161,1,0,1,0.001535648206543939
1380,CXCL7,G alpha (i) signalling events,0.0015736706878821374,0,0,1,0.0016980030391098018
1381,CXCL7,G alpha (i) signalling events,0.0014232039129941161,1,0,1,0.001535648206543939
1382,CXCL7,Platelet degranulation ,0.0015736706878821374,0,0,1,0.0016980030391098018
1383,CXCL7,Platelet degranulation ,0.0014232039129941161,1,0,1,0.001535648206543939
1384,CXCL7,Neutrophil degranulation,0.0015736706878821374,0,0,1,0.0016980030391098018
1385,CXCL7,Neutrophil degranulation,0.0014232039129941161,1,0,1,0.001535648206543939
1386,PLF4,Transcriptional regulation by RUNX1,0.005465379103164499,0,0,1,0.005897187002669506
1387,PLF4,Transcriptional regulation by RUNX1,0.005370055191451684,1,0,1,0.005794331752816675
1388,PLF4,Class A/1 (Rhodopsin-like receptors),0.005465379103164499,0,0,1,0.005897187002669506
1389,PLF4,Class A/1 (Rhodopsin-like receptors),0.005370055191451684,1,0,1,0.005794331752816675
1390,PLF4,G alpha (i) signalling events,0.005465379103164499,0,0,1,0.005897187002669506
1391,PLF4,G alpha (i) signalling events,0.005370055191451684,1,0,1,0.005794331752816675
1392,PLF4,Platelet degranulation ,0.005465379103164499,0,0,1,0.005897187002669506
1393,PLF4,Platelet degranulation ,0.005370055191451684,1,0,1,0.005794331752816675
1394,PLF4,Common Pathway of Fibrin Clot Formation,0.005465379103164499,0,0,1,0.005897187002669506
1395,PLF4,Common Pathway of Fibrin Clot Formation,0.005370055191451684,1,0,1,0.005794331752816675
1396,TFR1,RHO GTPase cycle,0.004637518310119049,0,0,1,0.005003918701127432
1397,TFR1,RHO GTPase cycle,0.004767468182035372,1,0,1,0.005144135634152223
1398,TFR1,Golgi Associated Vesicle Biogenesis,0.004637518310119049,0,0,1,0.005003918701127432
1399,TFR1,Golgi Associated Vesicle Biogenesis,0.004767468182035372,1,0,1,0.005144135634152223
1400,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.004637518310119049,0,0,1,0.005003918701127432
1401,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.004767468182035372,1,0,1,0.005144135634152223
1402,TFR1,Transferrin endocytosis and recycling,0.004637518310119049,0,0,1,0.005003918701127432
1403,TFR1,Transferrin endocytosis and recycling,0.004767468182035372,1,0,1,0.005144135634152223
1404,TRFE,Platelet degranulation ,0.0004434285164999589,0,0,1,0.0004784628540410826
1405,TRFE,Platelet degranulation ,0.0003142747231758373,1,0,1,0.0003391048960733589
1406,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0004434285164999589,0,0,1,0.0004784628540410826
1407,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0003142747231758373,1,0,1,0.0003391048960733589
1408,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004434285164999589,0,0,1,0.0004784628540410826
1409,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003142747231758373,1,0,1,0.0003391048960733589
1410,TRFE,Post-translational protein phosphorylation,0.0004434285164999589,0,0,1,0.0004784628540410826
1411,TRFE,Post-translational protein phosphorylation,0.0003142747231758373,1,0,1,0.0003391048960733589
1412,TRFE,Transferrin endocytosis and recycling,0.0004434285164999589,0,0,1,0.0004784628540410826
1413,TRFE,Transferrin endocytosis and recycling,0.0003142747231758373,1,0,1,0.0003391048960733589
1414,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.002618047286523506,0,0,1,0.0028248935964060055
1415,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.002615016232205865,1,0,1,0.002821623064977357
1416,TRFL,Metal sequestration by antimicrobial proteins,0.002618047286523506,0,0,1,0.0028248935964060055
1417,TRFL,Metal sequestration by antimicrobial proteins,0.002615016232205865,1,0,1,0.002821623064977357
1418,TRFL,Neutrophil degranulation,0.002618047286523506,0,0,1,0.0028248935964060055
1419,TRFL,Neutrophil degranulation,0.002615016232205865,1,0,1,0.002821623064977357
1420,TRFL,Amyloid fiber formation,0.002618047286523506,0,0,1,0.0028248935964060055
1421,TRFL,Amyloid fiber formation,0.002615016232205865,1,0,1,0.002821623064977357
1422,HEMO,Scavenging of heme from plasma,8.525345791857339e-05,0,0,1,9.198915106894288e-05
1423,HEMO,Scavenging of heme from plasma,9.173927246592939e-05,1,0,1,9.898739593511269e-05
1424,ANGI,Adherens junctions interactions,0.00019761898535458993,0,0,1,0.00021323243821074544
1425,ANGI,Adherens junctions interactions,0.00011957715826914258,1,0,1,0.0001290246934842349
1426,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00019761898535458993,0,0,1,0.00021323243821074544
1427,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.00011957715826914258,1,0,1,0.0001290246934842349
1428,FA11,Defective factor IX causes hemophilia B,0.0019006639421604633,0,0,1,0.0020508313301928894
1429,FA11,Defective factor IX causes hemophilia B,0.0018489446416121305,1,0,1,0.0019950257984587437
1430,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0019006639421604633,0,0,1,0.0020508313301928894
1431,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0018489446416121305,1,0,1,0.0019950257984587437
1432,KLKB1,Defective factor XII causes hereditary angioedema,0.0034089094989515917,0,0,1,0.0036782401387040397
1433,KLKB1,Defective factor XII causes hereditary angioedema,0.0033358872979685353,1,0,1,0.0035994486099893593
1434,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0034089094989515917,0,0,1,0.0036782401387040397
1435,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0033358872979685353,1,0,1,0.0035994486099893593
1436,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0034089094989515917,0,0,1,0.0036782401387040397
1437,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0033358872979685353,1,0,1,0.0035994486099893593
1438,KLKB1,Activation of Matrix Metalloproteinases,0.0034089094989515917,0,0,1,0.0036782401387040397
1439,KLKB1,Activation of Matrix Metalloproteinases,0.0033358872979685353,1,0,1,0.0035994486099893593
1440,C4BPA,Regulation of Complement cascade,0.000748856224102686,0,0,1,0.0008080217507856937
1441,C4BPA,Regulation of Complement cascade,0.0007728861357009009,1,0,1,0.0008339502142421884
1442,VTNC,Regulation of Complement cascade,0.004306522064750121,0,0,1,0.004646771151199586
1443,VTNC,Regulation of Complement cascade,0.004043497406382812,1,0,1,0.004362965477809577
1444,VTNC,Integrin cell surface interactions,0.004306522064750121,0,0,1,0.004646771151199586
1445,VTNC,Integrin cell surface interactions,0.004043497406382812,1,0,1,0.004362965477809577
1446,VTNC,ECM proteoglycans,0.004306522064750121,0,0,1,0.004646771151199586
1447,VTNC,ECM proteoglycans,0.004043497406382812,1,0,1,0.004362965477809577
1448,VTNC,Molecules associated with elastic fibres,0.004306522064750121,0,0,1,0.004646771151199586
1449,VTNC,Molecules associated with elastic fibres,0.004043497406382812,1,0,1,0.004362965477809577
1450,VTNC,Syndecan interactions,0.004306522064750121,0,0,1,0.004646771151199586
1451,VTNC,Syndecan interactions,0.004043497406382812,1,0,1,0.004362965477809577
1452,CATA,FOXO-mediated transcription,0.004505254561081529,0,0,1,0.0048612050765049816
1453,CATA,FOXO-mediated transcription,0.004464337055105716,1,0,1,0.004817054766001817
1454,CATA,Detoxification of Reactive Oxygen Species,0.004505254561081529,0,0,1,0.0048612050765049816
1455,CATA,Detoxification of Reactive Oxygen Species,0.004464337055105716,1,0,1,0.004817054766001817
1456,CATA,Neutrophil degranulation,0.004505254561081529,0,0,1,0.0048612050765049816
1457,CATA,Neutrophil degranulation,0.004464337055105716,1,0,1,0.004817054766001817
1458,FUCO,Neutrophil degranulation,0.0027629262952056405,0,0,1,0.0029812191853235675
1459,FUCO,Neutrophil degranulation,0.002690097040613182,1,0,1,0.0029026358472806343
1460,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00375340687642165,0,0,1,0.0040499555162693155
1461,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.003653186284403394,1,0,1,0.003941816709885747
1462,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.00375340687642165,0,0,1,0.0040499555162693155
1463,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.003653186284403394,1,0,1,0.003941816709885747
1464,PROC,Common Pathway of Fibrin Clot Formation,0.00375340687642165,0,0,1,0.0040499555162693155
1465,PROC,Common Pathway of Fibrin Clot Formation,0.003653186284403394,1,0,1,0.003941816709885747
1466,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00375340687642165,0,0,1,0.0040499555162693155
1467,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003653186284403394,1,0,1,0.003941816709885747
1468,PROC,Post-translational protein phosphorylation,0.00375340687642165,0,0,1,0.0040499555162693155
1469,PROC,Post-translational protein phosphorylation,0.003653186284403394,1,0,1,0.003941816709885747
1470,ALDOA,Glycolysis,0.004469068417771875,0,0,1,0.0048221599435006
1471,ALDOA,Glycolysis,0.004796798600485393,1,0,1,0.005175783386156502
1472,ALDOA,Gluconeogenesis,0.004469068417771875,0,0,1,0.0048221599435006
1473,ALDOA,Gluconeogenesis,0.004796798600485393,1,0,1,0.005175783386156502
1474,ALDOA,Platelet degranulation ,0.004469068417771875,0,0,1,0.0048221599435006
1475,ALDOA,Platelet degranulation ,0.004796798600485393,1,0,1,0.005175783386156502
1476,ALDOA,Neutrophil degranulation,0.004469068417771875,0,0,1,0.0048221599435006
1477,ALDOA,Neutrophil degranulation,0.004796798600485393,1,0,1,0.005175783386156502
1478,APOB,Regulation of TLR by endogenous ligand,0.0372446843306534,0,0,1,0.040187307084715344
1479,APOB,Regulation of TLR by endogenous ligand,0.03867989667148019,1,0,1,0.041735912479260444
1480,APOB,Cargo recognition for clathrin-mediated endocytosis,0.0372446843306534,0,0,1,0.040187307084715344
1481,APOB,Cargo recognition for clathrin-mediated endocytosis,0.03867989667148019,1,0,1,0.041735912479260444
1482,APOB,VLDL assembly,0.0372446843306534,0,0,1,0.040187307084715344
1483,APOB,VLDL assembly,0.03867989667148019,1,0,1,0.041735912479260444
1484,APOB,Chylomicron assembly,0.0372446843306534,0,0,1,0.040187307084715344
1485,APOB,Chylomicron assembly,0.03867989667148019,1,0,1,0.041735912479260444
1486,APOB,Chylomicron remodeling,0.0372446843306534,0,0,1,0.040187307084715344
1487,APOB,Chylomicron remodeling,0.03867989667148019,1,0,1,0.041735912479260444
1488,APOB,LDL remodeling,0.0372446843306534,0,0,1,0.040187307084715344
1489,APOB,LDL remodeling,0.03867989667148019,1,0,1,0.041735912479260444
1490,APOB,Chylomicron clearance,0.0372446843306534,0,0,1,0.040187307084715344
1491,APOB,Chylomicron clearance,0.03867989667148019,1,0,1,0.041735912479260444
1492,APOB,LDL clearance,0.0372446843306534,0,0,1,0.040187307084715344
1493,APOB,LDL clearance,0.03867989667148019,1,0,1,0.041735912479260444
1494,APOB,VLDL clearance,0.0372446843306534,0,0,1,0.040187307084715344
1495,APOB,VLDL clearance,0.03867989667148019,1,0,1,0.041735912479260444
1496,APOB,Scavenging by Class B Receptors,0.0372446843306534,0,0,1,0.040187307084715344
1497,APOB,Scavenging by Class B Receptors,0.03867989667148019,1,0,1,0.041735912479260444
1498,APOB,Scavenging by Class A Receptors,0.0372446843306534,0,0,1,0.040187307084715344
1499,APOB,Scavenging by Class A Receptors,0.03867989667148019,1,0,1,0.041735912479260444
1500,APOB,Scavenging by Class F Receptors,0.0372446843306534,0,0,1,0.040187307084715344
1501,APOB,Scavenging by Class F Receptors,0.03867989667148019,1,0,1,0.041735912479260444
1502,APOB,Scavenging by Class H Receptors,0.0372446843306534,0,0,1,0.040187307084715344
1503,APOB,Scavenging by Class H Receptors,0.03867989667148019,1,0,1,0.041735912479260444
1504,APOB,Retinoid metabolism and transport,0.0372446843306534,0,0,1,0.040187307084715344
1505,APOB,Retinoid metabolism and transport,0.03867989667148019,1,0,1,0.041735912479260444
1506,APOB,Heme signaling,0.0372446843306534,0,0,1,0.040187307084715344
1507,APOB,Heme signaling,0.03867989667148019,1,0,1,0.041735912479260444
1508,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0372446843306534,0,0,1,0.040187307084715344
1509,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.03867989667148019,1,0,1,0.041735912479260444
1510,APOB,Platelet sensitization by LDL,0.0372446843306534,0,0,1,0.040187307084715344
1511,APOB,Platelet sensitization by LDL,0.03867989667148019,1,0,1,0.041735912479260444
1512,APOB,Post-translational protein phosphorylation,0.0372446843306534,0,0,1,0.040187307084715344
1513,APOB,Post-translational protein phosphorylation,0.03867989667148019,1,0,1,0.041735912479260444
1514,SODM,FOXO-mediated transcription,0.0001456930647085149,0,0,1,0.00015720396176738586
1515,SODM,FOXO-mediated transcription,0.00011508410061651375,1,0,1,0.0001241766489678013
1516,SODM,Interleukin-12 family signaling,0.0001456930647085149,0,0,1,0.00015720396176738586
1517,SODM,Interleukin-12 family signaling,0.00011508410061651375,1,0,1,0.0001241766489678013
1518,SODM,Neurodegenerative Diseases,0.0001456930647085149,0,0,1,0.00015720396176738586
1519,SODM,Neurodegenerative Diseases,0.00011508410061651375,1,0,1,0.0001241766489678013
1520,SODM,Detoxification of Reactive Oxygen Species,0.0001456930647085149,0,0,1,0.00015720396176738586
1521,SODM,Detoxification of Reactive Oxygen Species,0.00011508410061651375,1,0,1,0.0001241766489678013
1522,SODM,Transcriptional activation of mitochondrial biogenesis,0.0001456930647085149,0,0,1,0.00015720396176738586
1523,SODM,Transcriptional activation of mitochondrial biogenesis,0.00011508410061651375,1,0,1,0.0001241766489678013
1524,LCAT,HDL remodeling,3.704511664371542e-05,0,0,1,3.997197198218201e-05
1525,LCAT,HDL remodeling,3.980213227047595e-05,1,0,1,4.294681350980358e-05
1526,HRG,Platelet degranulation ,0.002053714681460406,0,0,1,0.0022159742806656182
1527,HRG,Platelet degranulation ,0.002318051223172309,1,0,1,0.0025011954864940407
1528,HRG,Dissolution of Fibrin Clot,0.002053714681460406,0,0,1,0.0022159742806656182
1529,HRG,Dissolution of Fibrin Clot,0.002318051223172309,1,0,1,0.0025011954864940407
1530,LV743,Initial triggering of complement,0.012926500045189944,0,0,1,0.01394779513325309
1531,LV743,Initial triggering of complement,0.012667494544924314,1,0,1,0.01366832616303984
1532,LV743,Regulation of Complement cascade,0.012926500045189944,0,0,1,0.01394779513325309
1533,LV743,Regulation of Complement cascade,0.012667494544924314,1,0,1,0.01366832616303984
1534,LV743,FCGR activation,0.012926500045189944,0,0,1,0.01394779513325309
1535,LV743,FCGR activation,0.012667494544924314,1,0,1,0.01366832616303984
1536,LV743,Regulation of actin dynamics for phagocytic cup formation,0.012926500045189944,0,0,1,0.01394779513325309
1537,LV743,Regulation of actin dynamics for phagocytic cup formation,0.012667494544924314,1,0,1,0.01366832616303984
1538,LV743,Role of phospholipids in phagocytosis,0.012926500045189944,0,0,1,0.01394779513325309
1539,LV743,Role of phospholipids in phagocytosis,0.012667494544924314,1,0,1,0.01366832616303984
1540,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.012926500045189944,0,0,1,0.01394779513325309
1541,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.012667494544924314,1,0,1,0.01366832616303984
1542,LV743,FCERI mediated MAPK activation,0.012926500045189944,0,0,1,0.01394779513325309
1543,LV743,FCERI mediated MAPK activation,0.012667494544924314,1,0,1,0.01366832616303984
1544,LV743,FCERI mediated Ca+2 mobilization,0.012926500045189944,0,0,1,0.01394779513325309
1545,LV743,FCERI mediated Ca+2 mobilization,0.012667494544924314,1,0,1,0.01366832616303984
1546,LV743,FCERI mediated NF-kB activation,0.012926500045189944,0,0,1,0.01394779513325309
1547,LV743,FCERI mediated NF-kB activation,0.012667494544924314,1,0,1,0.01366832616303984
1548,LV743,Parasite infection,0.012926500045189944,0,0,1,0.01394779513325309
1549,LV743,Parasite infection,0.012667494544924314,1,0,1,0.01366832616303984
1550,LV743,Leishmania parasite growth and survival,0.012926500045189944,0,0,1,0.01394779513325309
1551,LV743,Leishmania parasite growth and survival,0.012667494544924314,1,0,1,0.01366832616303984
1552,LV743,Potential therapeutics for SARS,0.012926500045189944,0,0,1,0.01394779513325309
1553,LV743,Potential therapeutics for SARS,0.012667494544924314,1,0,1,0.01366832616303984
1554,LV743,CD22 mediated BCR regulation,0.012926500045189944,0,0,1,0.01394779513325309
1555,LV743,CD22 mediated BCR regulation,0.012667494544924314,1,0,1,0.01366832616303984
1556,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012926500045189944,0,0,1,0.01394779513325309
1557,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012667494544924314,1,0,1,0.01366832616303984
1558,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012926500045189944,0,0,1,0.01394779513325309
1559,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012667494544924314,1,0,1,0.01366832616303984
1560,LV743,Scavenging of heme from plasma,0.012926500045189944,0,0,1,0.01394779513325309
1561,LV743,Scavenging of heme from plasma,0.012667494544924314,1,0,1,0.01366832616303984
1562,A1BG,Platelet degranulation ,0.005155734132616393,0,0,1,0.005563077646064951
1563,A1BG,Platelet degranulation ,0.005380088265519589,1,0,1,0.005805157518582093
1564,A1BG,Neutrophil degranulation,0.005155734132616393,0,0,1,0.005563077646064951
1565,A1BG,Neutrophil degranulation,0.005380088265519589,1,0,1,0.005805157518582093
1566,K2C6B,Formation of the cornified envelope,0.00014434404050310453,0,0,1,0.00015574835404827514
1567,K2C6B,Formation of the cornified envelope,0.00016738714669675876,1,0,1,0.00018061204671831698
1568,K2C1,Neutrophil degranulation,0.0011353089341923806,0,0,1,0.001225007261958707
1569,K2C1,Neutrophil degranulation,0.0011605804280255445,1,0,1,0.0012522754024038385
1570,K2C1,Formation of the cornified envelope,0.0011353089341923806,0,0,1,0.001225007261958707
1571,K2C1,Formation of the cornified envelope,0.0011605804280255445,1,0,1,0.0012522754024038385
1572,VWF,RAF/MAP kinase cascade,0.006431337114493848,0,0,1,0.006939463287993912
1573,VWF,RAF/MAP kinase cascade,0.005912606539914123,1,0,1,0.00637974892151426
1574,VWF,Signaling by RAS mutants,0.006431337114493848,0,0,1,0.006939463287993912
1575,VWF,Signaling by RAS mutants,0.005912606539914123,1,0,1,0.00637974892151426
1576,VWF,Signaling by moderate kinase activity BRAF mutants,0.006431337114493848,0,0,1,0.006939463287993912
1577,VWF,Signaling by moderate kinase activity BRAF mutants,0.005912606539914123,1,0,1,0.00637974892151426
1578,VWF,Signaling by high-kinase activity BRAF mutants,0.006431337114493848,0,0,1,0.006939463287993912
1579,VWF,Signaling by high-kinase activity BRAF mutants,0.005912606539914123,1,0,1,0.00637974892151426
1580,VWF,Signaling by BRAF and RAF1 fusions,0.006431337114493848,0,0,1,0.006939463287993912
1581,VWF,Signaling by BRAF and RAF1 fusions,0.005912606539914123,1,0,1,0.00637974892151426
1582,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006431337114493848,0,0,1,0.006939463287993912
1583,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005912606539914123,1,0,1,0.00637974892151426
1584,VWF,Signaling by RAF1 mutants,0.006431337114493848,0,0,1,0.006939463287993912
1585,VWF,Signaling by RAF1 mutants,0.005912606539914123,1,0,1,0.00637974892151426
1586,VWF,Platelet degranulation ,0.006431337114493848,0,0,1,0.006939463287993912
1587,VWF,Platelet degranulation ,0.005912606539914123,1,0,1,0.00637974892151426
1588,VWF,Defective factor VIII causes hemophilia A,0.006431337114493848,0,0,1,0.006939463287993912
1589,VWF,Defective factor VIII causes hemophilia A,0.005912606539914123,1,0,1,0.00637974892151426
1590,VWF,Platelet Adhesion to exposed collagen,0.006431337114493848,0,0,1,0.006939463287993912
1591,VWF,Platelet Adhesion to exposed collagen,0.005912606539914123,1,0,1,0.00637974892151426
1592,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.006431337114493848,0,0,1,0.006939463287993912
1593,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.005912606539914123,1,0,1,0.00637974892151426
1594,VWF,Integrin cell surface interactions,0.006431337114493848,0,0,1,0.006939463287993912
1595,VWF,Integrin cell surface interactions,0.005912606539914123,1,0,1,0.00637974892151426
1596,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006431337114493848,0,0,1,0.006939463287993912
1597,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005912606539914123,1,0,1,0.00637974892151426
1598,VWF,p130Cas linkage to MAPK signaling for integrins,0.006431337114493848,0,0,1,0.006939463287993912
1599,VWF,p130Cas linkage to MAPK signaling for integrins,0.005912606539914123,1,0,1,0.00637974892151426
1600,VWF,GP1b-IX-V activation signalling,0.006431337114493848,0,0,1,0.006939463287993912
1601,VWF,GP1b-IX-V activation signalling,0.005912606539914123,1,0,1,0.00637974892151426
1602,G3P,Glycolysis,0.00036771512022824024,0,0,1,0.0003967675044608457
1603,G3P,Glycolysis,0.0004891332738528338,1,0,1,0.0005277786464013011
1604,G3P,Gluconeogenesis,0.00036771512022824024,0,0,1,0.0003967675044608457
1605,G3P,Gluconeogenesis,0.0004891332738528338,1,0,1,0.0005277786464013011
1606,ARLY,Urea cycle,0.0005343028067727573,0,0,1,0.0005765169273922378
1607,ARLY,Urea cycle,0.0004915810294429927,1,0,1,0.0005304197939190713
1608,KV116,Initial triggering of complement,0.004161515064091266,0,0,1,0.004490307457933302
1609,KV116,Initial triggering of complement,0.004011309686696525,1,0,1,0.004328234675316914
1610,KV116,Regulation of Complement cascade,0.004161515064091266,0,0,1,0.004490307457933302
1611,KV116,Regulation of Complement cascade,0.004011309686696525,1,0,1,0.004328234675316914
1612,KV116,FCGR activation,0.004161515064091266,0,0,1,0.004490307457933302
1613,KV116,FCGR activation,0.004011309686696525,1,0,1,0.004328234675316914
1614,KV116,Regulation of actin dynamics for phagocytic cup formation,0.004161515064091266,0,0,1,0.004490307457933302
1615,KV116,Regulation of actin dynamics for phagocytic cup formation,0.004011309686696525,1,0,1,0.004328234675316914
1616,KV116,Role of phospholipids in phagocytosis,0.004161515064091266,0,0,1,0.004490307457933302
1617,KV116,Role of phospholipids in phagocytosis,0.004011309686696525,1,0,1,0.004328234675316914
1618,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.004161515064091266,0,0,1,0.004490307457933302
1619,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.004011309686696525,1,0,1,0.004328234675316914
1620,KV116,FCERI mediated MAPK activation,0.004161515064091266,0,0,1,0.004490307457933302
1621,KV116,FCERI mediated MAPK activation,0.004011309686696525,1,0,1,0.004328234675316914
1622,KV116,FCERI mediated Ca+2 mobilization,0.004161515064091266,0,0,1,0.004490307457933302
1623,KV116,FCERI mediated Ca+2 mobilization,0.004011309686696525,1,0,1,0.004328234675316914
1624,KV116,FCERI mediated NF-kB activation,0.004161515064091266,0,0,1,0.004490307457933302
1625,KV116,FCERI mediated NF-kB activation,0.004011309686696525,1,0,1,0.004328234675316914
1626,KV116,Parasite infection,0.004161515064091266,0,0,1,0.004490307457933302
1627,KV116,Parasite infection,0.004011309686696525,1,0,1,0.004328234675316914
1628,KV116,Leishmania parasite growth and survival,0.004161515064091266,0,0,1,0.004490307457933302
1629,KV116,Leishmania parasite growth and survival,0.004011309686696525,1,0,1,0.004328234675316914
1630,KV116,Potential therapeutics for SARS,0.004161515064091266,0,0,1,0.004490307457933302
1631,KV116,Potential therapeutics for SARS,0.004011309686696525,1,0,1,0.004328234675316914
1632,KV116,CD22 mediated BCR regulation,0.004161515064091266,0,0,1,0.004490307457933302
1633,KV116,CD22 mediated BCR regulation,0.004011309686696525,1,0,1,0.004328234675316914
1634,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004161515064091266,0,0,1,0.004490307457933302
1635,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004011309686696525,1,0,1,0.004328234675316914
1636,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004161515064091266,0,0,1,0.004490307457933302
1637,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004011309686696525,1,0,1,0.004328234675316914
1638,KV116,Scavenging of heme from plasma,0.004161515064091266,0,0,1,0.004490307457933302
1639,KV116,Scavenging of heme from plasma,0.004011309686696525,1,0,1,0.004328234675316914
1640,KV311,Initial triggering of complement,0.010304187859098117,0,0,1,0.011118299676696626
1641,KV311,Initial triggering of complement,0.00985484776829253,1,0,1,0.010633458187522935
1642,KV311,Regulation of Complement cascade,0.010304187859098117,0,0,1,0.011118299676696626
1643,KV311,Regulation of Complement cascade,0.00985484776829253,1,0,1,0.010633458187522935
1644,KV311,FCGR activation,0.010304187859098117,0,0,1,0.011118299676696626
1645,KV311,FCGR activation,0.00985484776829253,1,0,1,0.010633458187522935
1646,KV311,Regulation of actin dynamics for phagocytic cup formation,0.010304187859098117,0,0,1,0.011118299676696626
1647,KV311,Regulation of actin dynamics for phagocytic cup formation,0.00985484776829253,1,0,1,0.010633458187522935
1648,KV311,Role of phospholipids in phagocytosis,0.010304187859098117,0,0,1,0.011118299676696626
1649,KV311,Role of phospholipids in phagocytosis,0.00985484776829253,1,0,1,0.010633458187522935
1650,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.010304187859098117,0,0,1,0.011118299676696626
1651,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.00985484776829253,1,0,1,0.010633458187522935
1652,KV311,FCERI mediated MAPK activation,0.010304187859098117,0,0,1,0.011118299676696626
1653,KV311,FCERI mediated MAPK activation,0.00985484776829253,1,0,1,0.010633458187522935
1654,KV311,FCERI mediated Ca+2 mobilization,0.010304187859098117,0,0,1,0.011118299676696626
1655,KV311,FCERI mediated Ca+2 mobilization,0.00985484776829253,1,0,1,0.010633458187522935
1656,KV311,FCERI mediated NF-kB activation,0.010304187859098117,0,0,1,0.011118299676696626
1657,KV311,FCERI mediated NF-kB activation,0.00985484776829253,1,0,1,0.010633458187522935
1658,KV311,Parasite infection,0.010304187859098117,0,0,1,0.011118299676696626
1659,KV311,Parasite infection,0.00985484776829253,1,0,1,0.010633458187522935
1660,KV311,Leishmania parasite growth and survival,0.010304187859098117,0,0,1,0.011118299676696626
1661,KV311,Leishmania parasite growth and survival,0.00985484776829253,1,0,1,0.010633458187522935
1662,KV311,Potential therapeutics for SARS,0.010304187859098117,0,0,1,0.011118299676696626
1663,KV311,Potential therapeutics for SARS,0.00985484776829253,1,0,1,0.010633458187522935
1664,KV311,CD22 mediated BCR regulation,0.010304187859098117,0,0,1,0.011118299676696626
1665,KV311,CD22 mediated BCR regulation,0.00985484776829253,1,0,1,0.010633458187522935
1666,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010304187859098117,0,0,1,0.011118299676696626
1667,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00985484776829253,1,0,1,0.010633458187522935
1668,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010304187859098117,0,0,1,0.011118299676696626
1669,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00985484776829253,1,0,1,0.010633458187522935
1670,KV311,Scavenging of heme from plasma,0.010304187859098117,0,0,1,0.011118299676696626
1671,KV311,Scavenging of heme from plasma,0.00985484776829253,1,0,1,0.010633458187522935
1672,MT1A,Metallothioneins bind metals,4.991823313199954e-05,0,0,1,5.386216583801245e-05
1673,MT1A,Metallothioneins bind metals,3.751610092119033e-05,1,0,1,4.0480167718865406e-05
1674,MT1E,Metallothioneins bind metals,0.0017578650469658897,0,0,1,0.001896750200075234
1675,MT1E,Metallothioneins bind metals,0.0013261139334645121,1,0,1,0.0014308873556379308
1676,H2A1B,Packaging Of Telomere Ends,0.005956951559831699,0,0,1,0.006427597546496127
1677,H2A1B,Packaging Of Telomere Ends,0.005485829097839693,1,0,1,0.005919252707632844
1678,H2A1B,Inhibition of DNA recombination at telomere,0.005956951559831699,0,0,1,0.006427597546496127
1679,H2A1B,Inhibition of DNA recombination at telomere,0.005485829097839693,1,0,1,0.005919252707632844
1680,H2A1B,Pre-NOTCH Transcription and Translation,0.005956951559831699,0,0,1,0.006427597546496127
1681,H2A1B,Pre-NOTCH Transcription and Translation,0.005485829097839693,1,0,1,0.005919252707632844
1682,H2A1B,RHO GTPase Effectors,0.005956951559831699,0,0,1,0.006427597546496127
1683,H2A1B,RHO GTPase Effectors,0.005485829097839693,1,0,1,0.005919252707632844
1684,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.005956951559831699,0,0,1,0.006427597546496127
1685,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.005485829097839693,1,0,1,0.005919252707632844
1686,H2A1B,Transcriptional regulation by RUNX1,0.005956951559831699,0,0,1,0.006427597546496127
1687,H2A1B,Transcriptional regulation by RUNX1,0.005485829097839693,1,0,1,0.005919252707632844
1688,H2A1B,Oxidative Stress Induced Senescence,0.005956951559831699,0,0,1,0.006427597546496127
1689,H2A1B,Oxidative Stress Induced Senescence,0.005485829097839693,1,0,1,0.005919252707632844
1690,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.005956951559831699,0,0,1,0.006427597546496127
1691,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.005485829097839693,1,0,1,0.005919252707632844
1692,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.005956951559831699,0,0,1,0.006427597546496127
1693,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.005485829097839693,1,0,1,0.005919252707632844
1694,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.005956951559831699,0,0,1,0.006427597546496127
1695,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.005485829097839693,1,0,1,0.005919252707632844
1696,H2A1B,B-WICH complex positively regulates rRNA expression,0.005956951559831699,0,0,1,0.006427597546496127
1697,H2A1B,B-WICH complex positively regulates rRNA expression,0.005485829097839693,1,0,1,0.005919252707632844
1698,H2A1B,SIRT1 negatively regulates rRNA expression,0.005956951559831699,0,0,1,0.006427597546496127
1699,H2A1B,SIRT1 negatively regulates rRNA expression,0.005485829097839693,1,0,1,0.005919252707632844
1700,H2A1B,NoRC negatively regulates rRNA expression,0.005956951559831699,0,0,1,0.006427597546496127
1701,H2A1B,NoRC negatively regulates rRNA expression,0.005485829097839693,1,0,1,0.005919252707632844
1702,H2A1B,UCH proteinases,0.005956951559831699,0,0,1,0.006427597546496127
1703,H2A1B,UCH proteinases,0.005485829097839693,1,0,1,0.005919252707632844
1704,H2A1B,Ub-specific processing proteases,0.005956951559831699,0,0,1,0.006427597546496127
1705,H2A1B,Ub-specific processing proteases,0.005485829097839693,1,0,1,0.005919252707632844
1706,H2A1B,Metalloprotease DUBs,0.005956951559831699,0,0,1,0.006427597546496127
1707,H2A1B,Metalloprotease DUBs,0.005485829097839693,1,0,1,0.005919252707632844
1708,H2A1B,Assembly of the ORC complex at the origin of replication,0.005956951559831699,0,0,1,0.006427597546496127
1709,H2A1B,Assembly of the ORC complex at the origin of replication,0.005485829097839693,1,0,1,0.005919252707632844
1710,H2A1B,Mitotic Prophase,0.005956951559831699,0,0,1,0.006427597546496127
1711,H2A1B,Mitotic Prophase,0.005485829097839693,1,0,1,0.005919252707632844
1712,H2A1B,RNA Polymerase I Promoter Opening,0.005956951559831699,0,0,1,0.006427597546496127
1713,H2A1B,RNA Polymerase I Promoter Opening,0.005485829097839693,1,0,1,0.005919252707632844
1714,H2A1B,RNA Polymerase I Promoter Escape,0.005956951559831699,0,0,1,0.006427597546496127
1715,H2A1B,RNA Polymerase I Promoter Escape,0.005485829097839693,1,0,1,0.005919252707632844
1716,H2A1B,Depurination,0.005956951559831699,0,0,1,0.006427597546496127
1717,H2A1B,Depurination,0.005485829097839693,1,0,1,0.005919252707632844
1718,H2A1B,Depyrimidination,0.005956951559831699,0,0,1,0.006427597546496127
1719,H2A1B,Depyrimidination,0.005485829097839693,1,0,1,0.005919252707632844
1720,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.005956951559831699,0,0,1,0.006427597546496127
1721,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.005485829097839693,1,0,1,0.005919252707632844
1722,H2A1B,Estrogen-dependent gene expression,0.005956951559831699,0,0,1,0.006427597546496127
1723,H2A1B,Estrogen-dependent gene expression,0.005485829097839693,1,0,1,0.005919252707632844
1724,H2A1B,HCMV Early Events,0.005956951559831699,0,0,1,0.006427597546496127
1725,H2A1B,HCMV Early Events,0.005485829097839693,1,0,1,0.005919252707632844
1726,H2A1B,HCMV Late Events,0.005956951559831699,0,0,1,0.006427597546496127
1727,H2A1B,HCMV Late Events,0.005485829097839693,1,0,1,0.005919252707632844
1728,H2A1B,Transcriptional regulation of granulopoiesis,0.005956951559831699,0,0,1,0.006427597546496127
1729,H2A1B,Transcriptional regulation of granulopoiesis,0.005485829097839693,1,0,1,0.005919252707632844
1730,H2A1B,Meiotic synapsis,0.005956951559831699,0,0,1,0.006427597546496127
1731,H2A1B,Meiotic synapsis,0.005485829097839693,1,0,1,0.005919252707632844
1732,H2A1B,Meiotic recombination,0.005956951559831699,0,0,1,0.006427597546496127
1733,H2A1B,Meiotic recombination,0.005485829097839693,1,0,1,0.005919252707632844
1734,H2A1B,Transcriptional regulation by small RNAs,0.005956951559831699,0,0,1,0.006427597546496127
1735,H2A1B,Transcriptional regulation by small RNAs,0.005485829097839693,1,0,1,0.005919252707632844
1736,H2A1B,PRC2 methylates histones and DNA,0.005956951559831699,0,0,1,0.006427597546496127
1737,H2A1B,PRC2 methylates histones and DNA,0.005485829097839693,1,0,1,0.005919252707632844
1738,H2A1B,DNA methylation,0.005956951559831699,0,0,1,0.006427597546496127
1739,H2A1B,DNA methylation,0.005485829097839693,1,0,1,0.005919252707632844
1740,H2A1B,HDACs deacetylate histones,0.005956951559831699,0,0,1,0.006427597546496127
1741,H2A1B,HDACs deacetylate histones,0.005485829097839693,1,0,1,0.005919252707632844
1742,H2A1B,HATs acetylate histones,0.005956951559831699,0,0,1,0.006427597546496127
1743,H2A1B,HATs acetylate histones,0.005485829097839693,1,0,1,0.005919252707632844
1744,H2A1B,RMTs methylate histone arginines,0.005956951559831699,0,0,1,0.006427597546496127
1745,H2A1B,RMTs methylate histone arginines,0.005485829097839693,1,0,1,0.005919252707632844
1746,H2A1B,Amyloid fiber formation,0.005956951559831699,0,0,1,0.006427597546496127
1747,H2A1B,Amyloid fiber formation,0.005485829097839693,1,0,1,0.005919252707632844
1748,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.005956951559831699,0,0,1,0.006427597546496127
1749,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.005485829097839693,1,0,1,0.005919252707632844
1750,H2A1B,Defective pyroptosis,0.005956951559831699,0,0,1,0.006427597546496127
1751,H2A1B,Defective pyroptosis,0.005485829097839693,1,0,1,0.005919252707632844
1752,IGF1,IGF1R signaling cascade,0.0004830841935472563,0,0,1,0.0005212516412141401
1753,IGF1,IGF1R signaling cascade,0.0006914542483476301,1,0,1,0.0007460845678454901
1754,IGF1,Platelet degranulation ,0.0004830841935472563,0,0,1,0.0005212516412141401
1755,IGF1,Platelet degranulation ,0.0006914542483476301,1,0,1,0.0007460845678454901
1756,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0004830841935472563,0,0,1,0.0005212516412141401
1757,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0006914542483476301,1,0,1,0.0007460845678454901
1758,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004830841935472563,0,0,1,0.0005212516412141401
1759,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006914542483476301,1,0,1,0.0007460845678454901
1760,ALDOB,Fructose catabolism,0.0035665681066651207,0,0,1,0.0038483550154065297
1761,ALDOB,Fructose catabolism,0.0038763088416696218,1,0,1,0.004182567702612112
1762,ALDOB,Hereditary fructose intolerance,0.0035665681066651207,0,0,1,0.0038483550154065297
1763,ALDOB,Hereditary fructose intolerance,0.0038763088416696218,1,0,1,0.004182567702612112
1764,ALDOB,Glycolysis,0.0035665681066651207,0,0,1,0.0038483550154065297
1765,ALDOB,Glycolysis,0.0038763088416696218,1,0,1,0.004182567702612112
1766,ALDOB,Gluconeogenesis,0.0035665681066651207,0,0,1,0.0038483550154065297
1767,ALDOB,Gluconeogenesis,0.0038763088416696218,1,0,1,0.004182567702612112
1768,APOD,Transport of fatty acids,0.0003833489315676767,0,0,1,0.0004136365097563302
1769,APOD,Transport of fatty acids,0.00019748098209599146,1,0,1,0.00021308353161020207
1770,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0003833489315676767,0,0,1,0.0004136365097563302
1771,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00019748098209599146,1,0,1,0.00021308353161020207
1772,ALDH2,Serotonin clearance from the synaptic cleft,0.00042997350562169837,0,0,1,0.0004639447915655788
1773,ALDH2,Serotonin clearance from the synaptic cleft,0.0005448500696123422,1,0,1,0.0005878975068831144
1774,ALDH2,Ethanol oxidation,0.00042997350562169837,0,0,1,0.0004639447915655788
1775,ALDH2,Ethanol oxidation,0.0005448500696123422,1,0,1,0.0005878975068831144
1776,ALDH2,Smooth Muscle Contraction,0.00042997350562169837,0,0,1,0.0004639447915655788
1777,ALDH2,Smooth Muscle Contraction,0.0005448500696123422,1,0,1,0.0005878975068831144
1778,ITB3,TGF-beta receptor signaling activates SMADs,0.003933824591028193,0,0,1,0.004244627648164613
1779,ITB3,TGF-beta receptor signaling activates SMADs,0.003617406345438212,1,0,1,0.0039032098745612575
1780,ITB3,VEGFA-VEGFR2 Pathway,0.003933824591028193,0,0,1,0.004244627648164613
1781,ITB3,VEGFA-VEGFR2 Pathway,0.003617406345438212,1,0,1,0.0039032098745612575
1782,ITB3,L1CAM interactions,0.003933824591028193,0,0,1,0.004244627648164613
1783,ITB3,L1CAM interactions,0.003617406345438212,1,0,1,0.0039032098745612575
1784,ITB3,RAF/MAP kinase cascade,0.003933824591028193,0,0,1,0.004244627648164613
1785,ITB3,RAF/MAP kinase cascade,0.003617406345438212,1,0,1,0.0039032098745612575
1786,ITB3,Signaling by RAS mutants,0.003933824591028193,0,0,1,0.004244627648164613
1787,ITB3,Signaling by RAS mutants,0.003617406345438212,1,0,1,0.0039032098745612575
1788,ITB3,Signaling by moderate kinase activity BRAF mutants,0.003933824591028193,0,0,1,0.004244627648164613
1789,ITB3,Signaling by moderate kinase activity BRAF mutants,0.003617406345438212,1,0,1,0.0039032098745612575
1790,ITB3,Signaling by high-kinase activity BRAF mutants,0.003933824591028193,0,0,1,0.004244627648164613
1791,ITB3,Signaling by high-kinase activity BRAF mutants,0.003617406345438212,1,0,1,0.0039032098745612575
1792,ITB3,Signaling by BRAF and RAF1 fusions,0.003933824591028193,0,0,1,0.004244627648164613
1793,ITB3,Signaling by BRAF and RAF1 fusions,0.003617406345438212,1,0,1,0.0039032098745612575
1794,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.003933824591028193,0,0,1,0.004244627648164613
1795,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.003617406345438212,1,0,1,0.0039032098745612575
1796,ITB3,Signaling by RAF1 mutants,0.003933824591028193,0,0,1,0.004244627648164613
1797,ITB3,Signaling by RAF1 mutants,0.003617406345438212,1,0,1,0.0039032098745612575
1798,ITB3,Platelet degranulation ,0.003933824591028193,0,0,1,0.004244627648164613
1799,ITB3,Platelet degranulation ,0.003617406345438212,1,0,1,0.0039032098745612575
1800,ITB3,Integrin cell surface interactions,0.003933824591028193,0,0,1,0.004244627648164613
1801,ITB3,Integrin cell surface interactions,0.003617406345438212,1,0,1,0.0039032098745612575
1802,ITB3,ECM proteoglycans,0.003933824591028193,0,0,1,0.004244627648164613
1803,ITB3,ECM proteoglycans,0.003617406345438212,1,0,1,0.0039032098745612575
1804,ITB3,Molecules associated with elastic fibres,0.003933824591028193,0,0,1,0.004244627648164613
1805,ITB3,Molecules associated with elastic fibres,0.003617406345438212,1,0,1,0.0039032098745612575
1806,ITB3,PECAM1 interactions,0.003933824591028193,0,0,1,0.004244627648164613
1807,ITB3,PECAM1 interactions,0.003617406345438212,1,0,1,0.0039032098745612575
1808,ITB3,Syndecan interactions,0.003933824591028193,0,0,1,0.004244627648164613
1809,ITB3,Syndecan interactions,0.003617406345438212,1,0,1,0.0039032098745612575
1810,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.003933824591028193,0,0,1,0.004244627648164613
1811,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.003617406345438212,1,0,1,0.0039032098745612575
1812,ITB3,p130Cas linkage to MAPK signaling for integrins,0.003933824591028193,0,0,1,0.004244627648164613
1813,ITB3,p130Cas linkage to MAPK signaling for integrins,0.003617406345438212,1,0,1,0.0039032098745612575
1814,S10A8,Antigen processing-Cross presentation,0.006622125961196919,0,0,1,0.007145325952924182
1815,S10A8,Antigen processing-Cross presentation,0.006563663886724195,1,0,1,0.007082244915136698
1816,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.006622125961196919,0,0,1,0.007145325952924182
1817,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.006563663886724195,1,0,1,0.007082244915136698
1818,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.006622125961196919,0,0,1,0.007145325952924182
1819,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.006563663886724195,1,0,1,0.007082244915136698
1820,S10A8,Regulation of TLR by endogenous ligand,0.006622125961196919,0,0,1,0.007145325952924182
1821,S10A8,Regulation of TLR by endogenous ligand,0.006563663886724195,1,0,1,0.007082244915136698
1822,S10A8,RHO GTPase Effectors,0.006622125961196919,0,0,1,0.007145325952924182
1823,S10A8,RHO GTPase Effectors,0.006563663886724195,1,0,1,0.007082244915136698
1824,S10A8,MyD88 deficiency (TLR2/4),0.006622125961196919,0,0,1,0.007145325952924182
1825,S10A8,MyD88 deficiency (TLR2/4),0.006563663886724195,1,0,1,0.007082244915136698
1826,S10A8,IRAK4 deficiency (TLR2/4),0.006622125961196919,0,0,1,0.007145325952924182
1827,S10A8,IRAK4 deficiency (TLR2/4),0.006563663886724195,1,0,1,0.007082244915136698
1828,S10A8,Metal sequestration by antimicrobial proteins,0.006622125961196919,0,0,1,0.007145325952924182
1829,S10A8,Metal sequestration by antimicrobial proteins,0.006563663886724195,1,0,1,0.007082244915136698
1830,S10A8,Neutrophil degranulation,0.006622125961196919,0,0,1,0.007145325952924182
1831,S10A8,Neutrophil degranulation,0.006563663886724195,1,0,1,0.007082244915136698
1832,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.004099759964932067,0,0,1,0.004423673220630472
1833,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.004354545024883313,1,0,1,0.00469858830257765
1834,PAI1,Platelet degranulation ,0.004099759964932067,0,0,1,0.004423673220630472
1835,PAI1,Platelet degranulation ,0.004354545024883313,1,0,1,0.00469858830257765
1836,PAI1,Dissolution of Fibrin Clot,0.004099759964932067,0,0,1,0.004423673220630472
1837,PAI1,Dissolution of Fibrin Clot,0.004354545024883313,1,0,1,0.00469858830257765
1838,PAI1,ECM proteoglycans,0.004099759964932067,0,0,1,0.004423673220630472
1839,PAI1,ECM proteoglycans,0.004354545024883313,1,0,1,0.00469858830257765
1840,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.004099759964932067,0,0,1,0.004423673220630472
1841,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.004354545024883313,1,0,1,0.00469858830257765
1842,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0003768656925482598,0,0,1,0.0004066410439050467
1843,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.0003765385910810437,1,0,1,0.00040628809885135336
1844,IPSP,Common Pathway of Fibrin Clot Formation,0.0003768656925482598,0,0,1,0.0004066410439050467
1845,IPSP,Common Pathway of Fibrin Clot Formation,0.0003765385910810437,1,0,1,0.00040628809885135336
1846,IC1,Regulation of Complement cascade,0.0026877778001410963,0,0,1,0.0029001333685852175
1847,IC1,Regulation of Complement cascade,0.0028802489603549477,1,0,1,0.0031078112630142877
1848,IC1,Platelet degranulation ,0.0026877778001410963,0,0,1,0.0029001333685852175
1849,IC1,Platelet degranulation ,0.0028802489603549477,1,0,1,0.0031078112630142877
1850,IC1,Defective SERPING1 causes hereditary angioedema,0.0026877778001410963,0,0,1,0.0029001333685852175
1851,IC1,Defective SERPING1 causes hereditary angioedema,0.0028802489603549477,1,0,1,0.0031078112630142877
1852,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.0026877778001410963,0,0,1,0.0029001333685852175
1853,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.0028802489603549477,1,0,1,0.0031078112630142877
1854,CFAI,Regulation of Complement cascade,0.0006890870577990427,0,0,1,0.0007435303506407057
1855,CFAI,Regulation of Complement cascade,0.0007113676718896992,1,0,1,0.0007675713083394748
1856,F13B,Common Pathway of Fibrin Clot Formation,0.00019431458138114978,0,0,1,0.00020966696035533777
1857,F13B,Common Pathway of Fibrin Clot Formation,0.00020460718010326673,1,0,1,0.0002207727552621571
1858,PERM,Events associated with phagocytolytic activity of PMN cells,0.0004541330597930937,0,0,1,0.0004900131403773473
1859,PERM,Events associated with phagocytolytic activity of PMN cells,0.00015976001928568923,1,0,1,0.00017238231630305255
1860,PERM,Neutrophil degranulation,0.0004541330597930937,0,0,1,0.0004900131403773473
1861,PERM,Neutrophil degranulation,0.00015976001928568923,1,0,1,0.00017238231630305255
1862,ICAM1,Interleukin-10 signaling,0.0036391341761676205,0,0,1,0.003926654374669124
1863,ICAM1,Interleukin-10 signaling,0.0032908842232548825,1,0,1,0.0035508899387111208
1864,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.0036391341761676205,0,0,1,0.003926654374669124
1865,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.0032908842232548825,1,0,1,0.0035508899387111208
1866,ICAM1,Interferon gamma signaling,0.0036391341761676205,0,0,1,0.003926654374669124
1867,ICAM1,Interferon gamma signaling,0.0032908842232548825,1,0,1,0.0035508899387111208
1868,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0036391341761676205,0,0,1,0.003926654374669124
1869,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0032908842232548825,1,0,1,0.0035508899387111208
1870,ICAM1,Integrin cell surface interactions,0.0036391341761676205,0,0,1,0.003926654374669124
1871,ICAM1,Integrin cell surface interactions,0.0032908842232548825,1,0,1,0.0035508899387111208
1872,TETN,Platelet degranulation ,0.0018003158580540911,0,0,1,0.0019425549588443323
1873,TETN,Platelet degranulation ,0.0020499069089661742,1,0,1,0.0022118656642204928
1874,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.005398567208855335,0,0,1,0.005825096443660416
1875,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0052975053264769185,1,0,1,0.005716049878366851
1876,HEP2,Common Pathway of Fibrin Clot Formation,0.005398567208855335,0,0,1,0.005825096443660416
1877,HEP2,Common Pathway of Fibrin Clot Formation,0.0052975053264769185,1,0,1,0.005716049878366851
1878,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005398567208855335,0,0,1,0.005825096443660416
1879,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0052975053264769185,1,0,1,0.005716049878366851
1880,HEP2,Post-translational protein phosphorylation,0.005398567208855335,0,0,1,0.005825096443660416
1881,HEP2,Post-translational protein phosphorylation,0.0052975053264769185,1,0,1,0.005716049878366851
1882,K2C8,Formation of the cornified envelope,6.278333157752058e-05,0,0,1,6.774370816269077e-05
1883,K2C8,Formation of the cornified envelope,7.184815397825635e-05,1,0,1,7.752472277010827e-05
1884,CHLE,Glycerophospholipid biosynthesis,0.0001655486052792791,0,0,1,0.00017862824608045217
1885,CHLE,Glycerophospholipid biosynthesis,0.00012414408405637308,1,0,1,0.00013395244229840554
1886,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.0001655486052792791,0,0,1,0.00017862824608045217
1887,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.00012414408405637308,1,0,1,0.00013395244229840554
1888,CHLE,Aspirin ADME,0.0001655486052792791,0,0,1,0.00017862824608045217
1889,CHLE,Aspirin ADME,0.00012414408405637308,1,0,1,0.00013395244229840554
1890,KV230,Initial triggering of complement,0.00268097805189124,0,0,1,0.002892796386786963
1891,KV230,Initial triggering of complement,0.0027284493737776455,1,0,1,0.002944018316161626
1892,KV230,Regulation of Complement cascade,0.00268097805189124,0,0,1,0.002892796386786963
1893,KV230,Regulation of Complement cascade,0.0027284493737776455,1,0,1,0.002944018316161626
1894,KV230,FCGR activation,0.00268097805189124,0,0,1,0.002892796386786963
1895,KV230,FCGR activation,0.0027284493737776455,1,0,1,0.002944018316161626
1896,KV230,Regulation of actin dynamics for phagocytic cup formation,0.00268097805189124,0,0,1,0.002892796386786963
1897,KV230,Regulation of actin dynamics for phagocytic cup formation,0.0027284493737776455,1,0,1,0.002944018316161626
1898,KV230,Role of phospholipids in phagocytosis,0.00268097805189124,0,0,1,0.002892796386786963
1899,KV230,Role of phospholipids in phagocytosis,0.0027284493737776455,1,0,1,0.002944018316161626
1900,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.00268097805189124,0,0,1,0.002892796386786963
1901,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.0027284493737776455,1,0,1,0.002944018316161626
1902,KV230,FCERI mediated MAPK activation,0.00268097805189124,0,0,1,0.002892796386786963
1903,KV230,FCERI mediated MAPK activation,0.0027284493737776455,1,0,1,0.002944018316161626
1904,KV230,FCERI mediated Ca+2 mobilization,0.00268097805189124,0,0,1,0.002892796386786963
1905,KV230,FCERI mediated Ca+2 mobilization,0.0027284493737776455,1,0,1,0.002944018316161626
1906,KV230,FCERI mediated NF-kB activation,0.00268097805189124,0,0,1,0.002892796386786963
1907,KV230,FCERI mediated NF-kB activation,0.0027284493737776455,1,0,1,0.002944018316161626
1908,KV230,Parasite infection,0.00268097805189124,0,0,1,0.002892796386786963
1909,KV230,Parasite infection,0.0027284493737776455,1,0,1,0.002944018316161626
1910,KV230,Leishmania parasite growth and survival,0.00268097805189124,0,0,1,0.002892796386786963
1911,KV230,Leishmania parasite growth and survival,0.0027284493737776455,1,0,1,0.002944018316161626
1912,KV230,Potential therapeutics for SARS,0.00268097805189124,0,0,1,0.002892796386786963
1913,KV230,Potential therapeutics for SARS,0.0027284493737776455,1,0,1,0.002944018316161626
1914,KV230,CD22 mediated BCR regulation,0.00268097805189124,0,0,1,0.002892796386786963
1915,KV230,CD22 mediated BCR regulation,0.0027284493737776455,1,0,1,0.002944018316161626
1916,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00268097805189124,0,0,1,0.002892796386786963
1917,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0027284493737776455,1,0,1,0.002944018316161626
1918,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00268097805189124,0,0,1,0.002892796386786963
1919,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0027284493737776455,1,0,1,0.002944018316161626
1920,KV230,Scavenging of heme from plasma,0.00268097805189124,0,0,1,0.002892796386786963
1921,KV230,Scavenging of heme from plasma,0.0027284493737776455,1,0,1,0.002944018316161626
1922,KV401,Initial triggering of complement,0.003451354812750651,0,0,1,0.0037240389658549523
1923,KV401,Initial triggering of complement,0.003302091251741028,1,0,1,0.0035629824105194857
1924,KV401,Regulation of Complement cascade,0.003451354812750651,0,0,1,0.0037240389658549523
1925,KV401,Regulation of Complement cascade,0.003302091251741028,1,0,1,0.0035629824105194857
1926,KV401,FCGR activation,0.003451354812750651,0,0,1,0.0037240389658549523
1927,KV401,FCGR activation,0.003302091251741028,1,0,1,0.0035629824105194857
1928,KV401,Regulation of actin dynamics for phagocytic cup formation,0.003451354812750651,0,0,1,0.0037240389658549523
1929,KV401,Regulation of actin dynamics for phagocytic cup formation,0.003302091251741028,1,0,1,0.0035629824105194857
1930,KV401,Role of phospholipids in phagocytosis,0.003451354812750651,0,0,1,0.0037240389658549523
1931,KV401,Role of phospholipids in phagocytosis,0.003302091251741028,1,0,1,0.0035629824105194857
1932,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.003451354812750651,0,0,1,0.0037240389658549523
1933,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.003302091251741028,1,0,1,0.0035629824105194857
1934,KV401,FCERI mediated MAPK activation,0.003451354812750651,0,0,1,0.0037240389658549523
1935,KV401,FCERI mediated MAPK activation,0.003302091251741028,1,0,1,0.0035629824105194857
1936,KV401,FCERI mediated Ca+2 mobilization,0.003451354812750651,0,0,1,0.0037240389658549523
1937,KV401,FCERI mediated Ca+2 mobilization,0.003302091251741028,1,0,1,0.0035629824105194857
1938,KV401,FCERI mediated NF-kB activation,0.003451354812750651,0,0,1,0.0037240389658549523
1939,KV401,FCERI mediated NF-kB activation,0.003302091251741028,1,0,1,0.0035629824105194857
1940,KV401,Parasite infection,0.003451354812750651,0,0,1,0.0037240389658549523
1941,KV401,Parasite infection,0.003302091251741028,1,0,1,0.0035629824105194857
1942,KV401,Leishmania parasite growth and survival,0.003451354812750651,0,0,1,0.0037240389658549523
1943,KV401,Leishmania parasite growth and survival,0.003302091251741028,1,0,1,0.0035629824105194857
1944,KV401,Potential therapeutics for SARS,0.003451354812750651,0,0,1,0.0037240389658549523
1945,KV401,Potential therapeutics for SARS,0.003302091251741028,1,0,1,0.0035629824105194857
1946,KV401,CD22 mediated BCR regulation,0.003451354812750651,0,0,1,0.0037240389658549523
1947,KV401,CD22 mediated BCR regulation,0.003302091251741028,1,0,1,0.0035629824105194857
1948,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003451354812750651,0,0,1,0.0037240389658549523
1949,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003302091251741028,1,0,1,0.0035629824105194857
1950,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003451354812750651,0,0,1,0.0037240389658549523
1951,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003302091251741028,1,0,1,0.0035629824105194857
1952,KV401,Scavenging of heme from plasma,0.003451354812750651,0,0,1,0.0037240389658549523
1953,KV401,Scavenging of heme from plasma,0.003302091251741028,1,0,1,0.0035629824105194857
1954,HV434,Initial triggering of complement,0.012569038203218951,0,0,1,0.013562090996608463
1955,HV434,Initial triggering of complement,0.012181809187556307,1,0,1,0.013144267845621544
1956,HV434,Regulation of Complement cascade,0.012569038203218951,0,0,1,0.013562090996608463
1957,HV434,Regulation of Complement cascade,0.012181809187556307,1,0,1,0.013144267845621544
1958,HV434,FCGR activation,0.012569038203218951,0,0,1,0.013562090996608463
1959,HV434,FCGR activation,0.012181809187556307,1,0,1,0.013144267845621544
1960,HV434,Regulation of actin dynamics for phagocytic cup formation,0.012569038203218951,0,0,1,0.013562090996608463
1961,HV434,Regulation of actin dynamics for phagocytic cup formation,0.012181809187556307,1,0,1,0.013144267845621544
1962,HV434,Role of phospholipids in phagocytosis,0.012569038203218951,0,0,1,0.013562090996608463
1963,HV434,Role of phospholipids in phagocytosis,0.012181809187556307,1,0,1,0.013144267845621544
1964,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.012569038203218951,0,0,1,0.013562090996608463
1965,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.012181809187556307,1,0,1,0.013144267845621544
1966,HV434,FCERI mediated MAPK activation,0.012569038203218951,0,0,1,0.013562090996608463
1967,HV434,FCERI mediated MAPK activation,0.012181809187556307,1,0,1,0.013144267845621544
1968,HV434,FCERI mediated Ca+2 mobilization,0.012569038203218951,0,0,1,0.013562090996608463
1969,HV434,FCERI mediated Ca+2 mobilization,0.012181809187556307,1,0,1,0.013144267845621544
1970,HV434,FCERI mediated NF-kB activation,0.012569038203218951,0,0,1,0.013562090996608463
1971,HV434,FCERI mediated NF-kB activation,0.012181809187556307,1,0,1,0.013144267845621544
1972,HV434,Parasite infection,0.012569038203218951,0,0,1,0.013562090996608463
1973,HV434,Parasite infection,0.012181809187556307,1,0,1,0.013144267845621544
1974,HV434,Leishmania parasite growth and survival,0.012569038203218951,0,0,1,0.013562090996608463
1975,HV434,Leishmania parasite growth and survival,0.012181809187556307,1,0,1,0.013144267845621544
1976,HV434,Potential therapeutics for SARS,0.012569038203218951,0,0,1,0.013562090996608463
1977,HV434,Potential therapeutics for SARS,0.012181809187556307,1,0,1,0.013144267845621544
1978,HV434,CD22 mediated BCR regulation,0.012569038203218951,0,0,1,0.013562090996608463
1979,HV434,CD22 mediated BCR regulation,0.012181809187556307,1,0,1,0.013144267845621544
1980,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012569038203218951,0,0,1,0.013562090996608463
1981,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012181809187556307,1,0,1,0.013144267845621544
1982,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012569038203218951,0,0,1,0.013562090996608463
1983,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012181809187556307,1,0,1,0.013144267845621544
1984,HV434,Scavenging of heme from plasma,0.012569038203218951,0,0,1,0.013562090996608463
1985,HV434,Scavenging of heme from plasma,0.012181809187556307,1,0,1,0.013144267845621544
1986,GELS,Apoptotic cleavage of cellular proteins,0.0024576153284821584,0,0,1,0.002651786252905084
1987,GELS,Apoptotic cleavage of cellular proteins,0.002334867535379696,1,0,1,0.0025193404195188725
1988,GELS,Neutrophil degranulation,0.0024576153284821584,0,0,1,0.002651786252905084
1989,GELS,Neutrophil degranulation,0.002334867535379696,1,0,1,0.0025193404195188725
1990,GELS,Amyloid fiber formation,0.0024576153284821584,0,0,1,0.002651786252905084
1991,GELS,Amyloid fiber formation,0.002334867535379696,1,0,1,0.0025193404195188725
1992,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0024576153284821584,0,0,1,0.002651786252905084
1993,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.002334867535379696,1,0,1,0.0025193404195188725
1994,CO2,Initial triggering of complement,0.0002731302477210799,0,0,1,0.00029470968371874627
1995,CO2,Initial triggering of complement,0.00027753863450925565,1,0,1,0.0002994663677070386
1996,CO2,Activation of C3 and C5,0.0002731302477210799,0,0,1,0.00029470968371874627
1997,CO2,Activation of C3 and C5,0.00027753863450925565,1,0,1,0.0002994663677070386
1998,CO2,Regulation of Complement cascade,0.0002731302477210799,0,0,1,0.00029470968371874627
1999,CO2,Regulation of Complement cascade,0.00027753863450925565,1,0,1,0.0002994663677070386
2000,S10A9,Antigen processing-Cross presentation,0.0036836121641196464,0,0,1,0.003974646473205108
2001,S10A9,Antigen processing-Cross presentation,0.003883509703882737,1,0,1,0.004190337489528926
2002,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0036836121641196464,0,0,1,0.003974646473205108
2003,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.003883509703882737,1,0,1,0.004190337489528926
2004,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0036836121641196464,0,0,1,0.003974646473205108
2005,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.003883509703882737,1,0,1,0.004190337489528926
2006,S10A9,Regulation of TLR by endogenous ligand,0.0036836121641196464,0,0,1,0.003974646473205108
2007,S10A9,Regulation of TLR by endogenous ligand,0.003883509703882737,1,0,1,0.004190337489528926
2008,S10A9,RHO GTPase Effectors,0.0036836121641196464,0,0,1,0.003974646473205108
2009,S10A9,RHO GTPase Effectors,0.003883509703882737,1,0,1,0.004190337489528926
2010,S10A9,MyD88 deficiency (TLR2/4),0.0036836121641196464,0,0,1,0.003974646473205108
2011,S10A9,MyD88 deficiency (TLR2/4),0.003883509703882737,1,0,1,0.004190337489528926
2012,S10A9,IRAK4 deficiency (TLR2/4),0.0036836121641196464,0,0,1,0.003974646473205108
2013,S10A9,IRAK4 deficiency (TLR2/4),0.003883509703882737,1,0,1,0.004190337489528926
2014,S10A9,Metal sequestration by antimicrobial proteins,0.0036836121641196464,0,0,1,0.003974646473205108
2015,S10A9,Metal sequestration by antimicrobial proteins,0.003883509703882737,1,0,1,0.004190337489528926
2016,S10A9,Neutrophil degranulation,0.0036836121641196464,0,0,1,0.003974646473205108
2017,S10A9,Neutrophil degranulation,0.003883509703882737,1,0,1,0.004190337489528926
2018,APOA4,Chylomicron assembly,0.01912712835376927,0,0,1,0.020638321806611657
2019,APOA4,Chylomicron assembly,0.019653537872363812,1,0,1,0.021206321814029223
2020,APOA4,Assembly of active LPL and LIPC lipase complexes,0.01912712835376927,0,0,1,0.020638321806611657
2021,APOA4,Assembly of active LPL and LIPC lipase complexes,0.019653537872363812,1,0,1,0.021206321814029223
2022,APOA4,Chylomicron remodeling,0.01912712835376927,0,0,1,0.020638321806611657
2023,APOA4,Chylomicron remodeling,0.019653537872363812,1,0,1,0.021206321814029223
2024,APOA4,Retinoid metabolism and transport,0.01912712835376927,0,0,1,0.020638321806611657
2025,APOA4,Retinoid metabolism and transport,0.019653537872363812,1,0,1,0.021206321814029223
2026,APOA4,Amyloid fiber formation,0.01912712835376927,0,0,1,0.020638321806611657
2027,APOA4,Amyloid fiber formation,0.019653537872363812,1,0,1,0.021206321814029223
2028,ENOA,Glycolysis,0.0010504225045830631,0,0,1,0.0011334141373197885
2029,ENOA,Glycolysis,0.0013317196406812096,1,0,1,0.0014369359577778881
2030,ENOA,Gluconeogenesis,0.0010504225045830631,0,0,1,0.0011334141373197885
2031,ENOA,Gluconeogenesis,0.0013317196406812096,1,0,1,0.0014369359577778881
2032,ENOA,Response of Mtb to phagocytosis,0.0010504225045830631,0,0,1,0.0011334141373197885
2033,ENOA,Response of Mtb to phagocytosis,0.0013317196406812096,1,0,1,0.0014369359577778881
2034,PYGL,Glycogen breakdown (glycogenolysis),0.0006563126014953013,0,0,1,0.0007081664547268661
2035,PYGL,Glycogen breakdown (glycogenolysis),0.000752713772332451,1,0,1,0.0008121840756406283
2036,PYGL,Neutrophil degranulation,0.0006563126014953013,0,0,1,0.0007081664547268661
2037,PYGL,Neutrophil degranulation,0.000752713772332451,1,0,1,0.0008121840756406283
2038,G6PI,Transcriptional Regulation by TP53,0.0018868280065362341,0,0,1,0.0020359022469229413
2039,G6PI,Transcriptional Regulation by TP53,0.001967088559467811,1,0,1,0.0021225040142735566
2040,G6PI,Glycolysis,0.0018868280065362341,0,0,1,0.0020359022469229413
2041,G6PI,Glycolysis,0.001967088559467811,1,0,1,0.0021225040142735566
2042,G6PI,Gluconeogenesis,0.0018868280065362341,0,0,1,0.0020359022469229413
2043,G6PI,Gluconeogenesis,0.001967088559467811,1,0,1,0.0021225040142735566
2044,G6PI,Neutrophil degranulation,0.0018868280065362341,0,0,1,0.0020359022469229413
2045,G6PI,Neutrophil degranulation,0.001967088559467811,1,0,1,0.0021225040142735566
2046,TPM3,RHO GTPase cycle,0.0071376266695248585,0,0,1,0.007701555268335854
2047,TPM3,RHO GTPase cycle,0.00649879383854568,1,0,1,0.007012249623362814
2048,TPM3,Signaling by ALK fusions and activated point mutants,0.0071376266695248585,0,0,1,0.007701555268335854
2049,TPM3,Signaling by ALK fusions and activated point mutants,0.00649879383854568,1,0,1,0.007012249623362814
2050,TPM3,Striated Muscle Contraction,0.0071376266695248585,0,0,1,0.007701555268335854
2051,TPM3,Striated Muscle Contraction,0.00649879383854568,1,0,1,0.007012249623362814
2052,TPM3,Smooth Muscle Contraction,0.0071376266695248585,0,0,1,0.007701555268335854
2053,TPM3,Smooth Muscle Contraction,0.00649879383854568,1,0,1,0.007012249623362814
2054,FABPL,PPARA activates gene expression,0.005417223105905577,0,0,1,0.005845226303187292
2055,FABPL,PPARA activates gene expression,0.005780233951130261,1,0,1,0.006236917857950177
2056,FABPL,Triglyceride catabolism,0.005417223105905577,0,0,1,0.005845226303187292
2057,FABPL,Triglyceride catabolism,0.005780233951130261,1,0,1,0.006236917857950177
2058,FABPL,Cytoprotection by HMOX1,0.005417223105905577,0,0,1,0.005845226303187292
2059,FABPL,Cytoprotection by HMOX1,0.005780233951130261,1,0,1,0.006236917857950177
2060,FABPL,Heme degradation,0.005417223105905577,0,0,1,0.005845226303187292
2061,FABPL,Heme degradation,0.005780233951130261,1,0,1,0.006236917857950177
2062,LDHB,Pyruvate metabolism,0.0004210861542560451,0,0,1,0.00045435526959969336
2063,LDHB,Pyruvate metabolism,0.00043695659993924586,1,0,1,0.00047147960521171957
2064,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0003551794498397006,0,0,1,0.00038324141759850134
2065,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00024670115400340367,1,0,1,0.0002661924839010846
2066,PROS,Regulation of Complement cascade,0.0003551794498397006,0,0,1,0.00038324141759850134
2067,PROS,Regulation of Complement cascade,0.00024670115400340367,1,0,1,0.0002661924839010846
2068,PROS,Platelet degranulation ,0.0003551794498397006,0,0,1,0.00038324141759850134
2069,PROS,Platelet degranulation ,0.00024670115400340367,1,0,1,0.0002661924839010846
2070,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.0003551794498397006,0,0,1,0.00038324141759850134
2071,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.00024670115400340367,1,0,1,0.0002661924839010846
2072,PROS,Common Pathway of Fibrin Clot Formation,0.0003551794498397006,0,0,1,0.00038324141759850134
2073,PROS,Common Pathway of Fibrin Clot Formation,0.00024670115400340367,1,0,1,0.0002661924839010846
2074,PDIA1,Interleukin-12 family signaling,0.0037901678530033677,0,0,1,0.0040896208988916525
2075,PDIA1,Interleukin-12 family signaling,0.0035003335409176848,1,0,1,0.003776887398452551
2076,PDIA1,VLDL assembly,0.0037901678530033677,0,0,1,0.0040896208988916525
2077,PDIA1,VLDL assembly,0.0035003335409176848,1,0,1,0.003776887398452551
2078,PDIA1,Chylomicron assembly,0.0037901678530033677,0,0,1,0.0040896208988916525
2079,PDIA1,Chylomicron assembly,0.0035003335409176848,1,0,1,0.003776887398452551
2080,PDIA1,LDL remodeling,0.0037901678530033677,0,0,1,0.0040896208988916525
2081,PDIA1,LDL remodeling,0.0035003335409176848,1,0,1,0.003776887398452551
2082,PDIA1,Detoxification of Reactive Oxygen Species,0.0037901678530033677,0,0,1,0.0040896208988916525
2083,PDIA1,Detoxification of Reactive Oxygen Species,0.0035003335409176848,1,0,1,0.003776887398452551
2084,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037901678530033677,0,0,1,0.0040896208988916525
2085,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0035003335409176848,1,0,1,0.003776887398452551
2086,PDIA1,Hedgehog ligand biogenesis,0.0037901678530033677,0,0,1,0.0040896208988916525
2087,PDIA1,Hedgehog ligand biogenesis,0.0035003335409176848,1,0,1,0.003776887398452551
2088,PDIA1,Post-translational protein phosphorylation,0.0037901678530033677,0,0,1,0.0040896208988916525
2089,PDIA1,Post-translational protein phosphorylation,0.0035003335409176848,1,0,1,0.003776887398452551
2090,ADH1A,Ethanol oxidation,0.00365461826537891,0,0,1,0.003943361828611728
2091,ADH1A,Ethanol oxidation,0.003516000941939031,1,0,1,0.003793792647278785
2092,ADH1A,RA biosynthesis pathway,0.00365461826537891,0,0,1,0.003943361828611728
2093,ADH1A,RA biosynthesis pathway,0.003516000941939031,1,0,1,0.003793792647278785
2094,ADH1A,Abacavir metabolism,0.00365461826537891,0,0,1,0.003943361828611728
2095,ADH1A,Abacavir metabolism,0.003516000941939031,1,0,1,0.003793792647278785
2096,CSF1R,Transcriptional Regulation by VENTX,0.0005865863369156917,0,0,1,0.0006329312672930269
2097,CSF1R,Transcriptional Regulation by VENTX,0.0006693898945134909,1,0,1,0.000722276956663011
2098,CSF1R,Other interleukin signaling,0.0005865863369156917,0,0,1,0.0006329312672930269
2099,CSF1R,Other interleukin signaling,0.0006693898945134909,1,0,1,0.000722276956663011
2100,CATD,Estrogen-dependent gene expression,0.0009465234380816886,0,0,1,0.001021306228061191
2101,CATD,Estrogen-dependent gene expression,0.0009297170113616933,1,0,1,0.0010031719615549413
2102,CATD,MHC class II antigen presentation,0.0009465234380816886,0,0,1,0.001021306228061191
2103,CATD,MHC class II antigen presentation,0.0009297170113616933,1,0,1,0.0010031719615549413
2104,CATD,Collagen degradation,0.0009465234380816886,0,0,1,0.001021306228061191
2105,CATD,Collagen degradation,0.0009297170113616933,1,0,1,0.0010031719615549413
2106,CATD,Neutrophil degranulation,0.0009465234380816886,0,0,1,0.001021306228061191
2107,CATD,Neutrophil degranulation,0.0009297170113616933,1,0,1,0.0010031719615549413
2108,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0009465234380816886,0,0,1,0.001021306228061191
2109,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0009297170113616933,1,0,1,0.0010031719615549413
2110,CO8A,Terminal pathway of complement,0.0012778598601774624,0,0,1,0.0013788208313506242
2111,CO8A,Terminal pathway of complement,0.0013437691814033315,1,0,1,0.001449937506909858
2112,CO8A,Regulation of Complement cascade,0.0012778598601774624,0,0,1,0.0013788208313506242
2113,CO8A,Regulation of Complement cascade,0.0013437691814033315,1,0,1,0.001449937506909858
2114,CO8B,Terminal pathway of complement,0.0005858167971685665,0,0,1,0.0006321009278583559
2115,CO8B,Terminal pathway of complement,0.000645372889812279,1,0,1,0.0006963624198498131
2116,CO8B,Regulation of Complement cascade,0.0005858167971685665,0,0,1,0.0006321009278583559
2117,CO8B,Regulation of Complement cascade,0.000645372889812279,1,0,1,0.0006963624198498131
2118,GP1BA,Transcriptional regulation by RUNX1,0.0003729643495489654,0,0,1,0.00040243146414962344
2119,GP1BA,Transcriptional regulation by RUNX1,0.0003888965430528894,1,0,1,0.00041962242614546297
2120,GP1BA,Defective factor IX causes hemophilia B,0.0003729643495489654,0,0,1,0.00040243146414962344
2121,GP1BA,Defective factor IX causes hemophilia B,0.0003888965430528894,1,0,1,0.00041962242614546297
2122,GP1BA,Platelet Adhesion to exposed collagen,0.0003729643495489654,0,0,1,0.00040243146414962344
2123,GP1BA,Platelet Adhesion to exposed collagen,0.0003888965430528894,1,0,1,0.00041962242614546297
2124,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.0003729643495489654,0,0,1,0.00040243146414962344
2125,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.0003888965430528894,1,0,1,0.00041962242614546297
2126,GP1BA,GP1b-IX-V activation signalling,0.0003729643495489654,0,0,1,0.00040243146414962344
2127,GP1BA,GP1b-IX-V activation signalling,0.0003888965430528894,1,0,1,0.00041962242614546297
2128,CO8G,Terminal pathway of complement,0.0013720893340102218,0,0,1,0.0014804951741301008
2129,CO8G,Terminal pathway of complement,0.0014907179603975843,1,0,1,0.0016084963942597404
2130,CO8G,Regulation of Complement cascade,0.0013720893340102218,0,0,1,0.0014804951741301008
2131,CO8G,Regulation of Complement cascade,0.0014907179603975843,1,0,1,0.0016084963942597404
2132,TBB5,G2/M Transition,0.0007739915471271767,0,0,1,0.0008351429618581519
2133,TBB5,G2/M Transition,0.0006794767005582496,1,0,1,0.0007331606996537136
2134,TBB5,Mitotic Prometaphase,0.0007739915471271767,0,0,1,0.0008351429618581519
2135,TBB5,Mitotic Prometaphase,0.0006794767005582496,1,0,1,0.0007331606996537136
2136,TBB5,Potential therapeutics for SARS,0.0007739915471271767,0,0,1,0.0008351429618581519
2137,TBB5,Potential therapeutics for SARS,0.0006794767005582496,1,0,1,0.0007331606996537136
2138,TBB5,Neutrophil degranulation,0.0007739915471271767,0,0,1,0.0008351429618581519
2139,TBB5,Neutrophil degranulation,0.0006794767005582496,1,0,1,0.0007331606996537136
2140,TBB5,Anchoring of the basal body to the plasma membrane,0.0007739915471271767,0,0,1,0.0008351429618581519
2141,TBB5,Anchoring of the basal body to the plasma membrane,0.0006794767005582496,1,0,1,0.0007331606996537136
2142,CAH3,Reversible hydration of carbon dioxide,0.0031229863035453793,0,0,1,0.0033697267638980797
2143,CAH3,Reversible hydration of carbon dioxide,0.003137300555439045,1,0,1,0.003385171954181657
2144,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0014386667956083935,0,0,1,0.0015523327784017125
2145,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0013100354173123682,1,0,1,0.0014135385103547676
2146,TRY1,Activation of Matrix Metalloproteinases,0.0014386667956083935,0,0,1,0.0015523327784017125
2147,TRY1,Activation of Matrix Metalloproteinases,0.0013100354173123682,1,0,1,0.0014135385103547676
2148,TRY2,Defensins,0.005246401923553397,0,0,1,0.005660908905009984
2149,TRY2,Defensins,0.004751960030989722,1,0,1,0.00512740221730125
2150,TRY2,Collagen degradation,0.005246401923553397,0,0,1,0.005660908905009984
2151,TRY2,Collagen degradation,0.004751960030989722,1,0,1,0.00512740221730125
2152,TRY2,Activation of Matrix Metalloproteinases,0.005246401923553397,0,0,1,0.005660908905009984
2153,TRY2,Activation of Matrix Metalloproteinases,0.004751960030989722,1,0,1,0.00512740221730125
2154,TRY2,Neutrophil degranulation,0.005246401923553397,0,0,1,0.005660908905009984
2155,TRY2,Neutrophil degranulation,0.004751960030989722,1,0,1,0.00512740221730125
2156,SAP,Class A/1 (Rhodopsin-like receptors),0.005519004655070603,0,0,1,0.005955049394599199
2157,SAP,Class A/1 (Rhodopsin-like receptors),0.005951788815824936,1,0,1,0.0064220269051407704
2158,SAP,G alpha (i) signalling events,0.005519004655070603,0,0,1,0.005955049394599199
2159,SAP,G alpha (i) signalling events,0.005951788815824936,1,0,1,0.0064220269051407704
2160,SAP,Glycosphingolipid metabolism,0.005519004655070603,0,0,1,0.005955049394599199
2161,SAP,Glycosphingolipid metabolism,0.005951788815824936,1,0,1,0.0064220269051407704
2162,SAP,Platelet degranulation ,0.005519004655070603,0,0,1,0.005955049394599199
2163,SAP,Platelet degranulation ,0.005951788815824936,1,0,1,0.0064220269051407704
2164,SAP,Neutrophil degranulation,0.005519004655070603,0,0,1,0.005955049394599199
2165,SAP,Neutrophil degranulation,0.005951788815824936,1,0,1,0.0064220269051407704
2166,PROF1,RHO GTPase Effectors,0.003374178811403302,0,0,1,0.0036407654539040483
2167,PROF1,RHO GTPase Effectors,0.0036755265478859655,1,0,1,0.0039659220297471555
2168,PROF1,Signaling by ROBO receptors,0.003374178811403302,0,0,1,0.0036407654539040483
2169,PROF1,Signaling by ROBO receptors,0.0036755265478859655,1,0,1,0.0039659220297471555
2170,PROF1,PCP/CE pathway,0.003374178811403302,0,0,1,0.0036407654539040483
2171,PROF1,PCP/CE pathway,0.0036755265478859655,1,0,1,0.0039659220297471555
2172,PROF1,Platelet degranulation ,0.003374178811403302,0,0,1,0.0036407654539040483
2173,PROF1,Platelet degranulation ,0.0036755265478859655,1,0,1,0.0039659220297471555
2174,CATB,Trafficking and processing of endosomal TLR,0.001629749841231387,0,0,1,0.0017585128862785777
2175,CATB,Trafficking and processing of endosomal TLR,0.001367189594990729,1,0,1,0.0014752083172228654
2176,CATB,MHC class II antigen presentation,0.001629749841231387,0,0,1,0.0017585128862785777
2177,CATB,MHC class II antigen presentation,0.001367189594990729,1,0,1,0.0014752083172228654
2178,CATB,Collagen degradation,0.001629749841231387,0,0,1,0.0017585128862785777
2179,CATB,Collagen degradation,0.001367189594990729,1,0,1,0.0014752083172228654
2180,CATB,Neutrophil degranulation,0.001629749841231387,0,0,1,0.0017585128862785777
2181,CATB,Neutrophil degranulation,0.001367189594990729,1,0,1,0.0014752083172228654
2182,HS90A,Downregulation of ERBB2 signaling,0.009820783724232266,0,0,1,0.010596702816285424
2183,HS90A,Downregulation of ERBB2 signaling,0.010570268255348007,1,0,1,0.011405402515275833
2184,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.009820783724232266,0,0,1,0.010596702816285424
2185,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.010570268255348007,1,0,1,0.011405402515275833
2186,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.009820783724232266,0,0,1,0.010596702816285424
2187,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.010570268255348007,1,0,1,0.011405402515275833
2188,HS90A,Signaling by ERBB2 KD Mutants,0.009820783724232266,0,0,1,0.010596702816285424
2189,HS90A,Signaling by ERBB2 KD Mutants,0.010570268255348007,1,0,1,0.011405402515275833
2190,HS90A,Drug resistance in ERBB2 KD mutants,0.009820783724232266,0,0,1,0.010596702816285424
2191,HS90A,Drug resistance in ERBB2 KD mutants,0.010570268255348007,1,0,1,0.011405402515275833
2192,HS90A,Signaling by ERBB2 ECD mutants,0.009820783724232266,0,0,1,0.010596702816285424
2193,HS90A,Signaling by ERBB2 ECD mutants,0.010570268255348007,1,0,1,0.011405402515275833
2194,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.009820783724232266,0,0,1,0.010596702816285424
2195,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.010570268255348007,1,0,1,0.011405402515275833
2196,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.009820783724232266,0,0,1,0.010596702816285424
2197,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.010570268255348007,1,0,1,0.011405402515275833
2198,HS90A,Signaling by EGFRvIII in Cancer,0.009820783724232266,0,0,1,0.010596702816285424
2199,HS90A,Signaling by EGFRvIII in Cancer,0.010570268255348007,1,0,1,0.011405402515275833
2200,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.009820783724232266,0,0,1,0.010596702816285424
2201,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.010570268255348007,1,0,1,0.011405402515275833
2202,HS90A,Influenza Viral RNA Transcription and Replication,0.009820783724232266,0,0,1,0.010596702816285424
2203,HS90A,Influenza Viral RNA Transcription and Replication,0.010570268255348007,1,0,1,0.011405402515275833
2204,HS90A,VEGFA-VEGFR2 Pathway,0.009820783724232266,0,0,1,0.010596702816285424
2205,HS90A,VEGFA-VEGFR2 Pathway,0.010570268255348007,1,0,1,0.011405402515275833
2206,HS90A,RHO GTPase cycle,0.009820783724232266,0,0,1,0.010596702816285424
2207,HS90A,RHO GTPase cycle,0.010570268255348007,1,0,1,0.011405402515275833
2208,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.009820783724232266,0,0,1,0.010596702816285424
2209,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.010570268255348007,1,0,1,0.011405402515275833
2210,HS90A,HSF1 activation,0.009820783724232266,0,0,1,0.010596702816285424
2211,HS90A,HSF1 activation,0.010570268255348007,1,0,1,0.011405402515275833
2212,HS90A,HSF1-dependent transactivation,0.009820783724232266,0,0,1,0.010596702816285424
2213,HS90A,HSF1-dependent transactivation,0.010570268255348007,1,0,1,0.011405402515275833
2214,HS90A,Semaphorin interactions,0.009820783724232266,0,0,1,0.010596702816285424
2215,HS90A,Semaphorin interactions,0.010570268255348007,1,0,1,0.011405402515275833
2216,HS90A,Interleukin-4 and Interleukin-13 signaling,0.009820783724232266,0,0,1,0.010596702816285424
2217,HS90A,Interleukin-4 and Interleukin-13 signaling,0.010570268255348007,1,0,1,0.011405402515275833
2218,HS90A,G2/M Transition,0.009820783724232266,0,0,1,0.010596702816285424
2219,HS90A,G2/M Transition,0.010570268255348007,1,0,1,0.011405402515275833
2220,HS90A,Regulation of necroptotic cell death,0.009820783724232266,0,0,1,0.010596702816285424
2221,HS90A,Regulation of necroptotic cell death,0.010570268255348007,1,0,1,0.011405402515275833
2222,HS90A,Uptake and function of diphtheria toxin,0.009820783724232266,0,0,1,0.010596702816285424
2223,HS90A,Uptake and function of diphtheria toxin,0.010570268255348007,1,0,1,0.011405402515275833
2224,HS90A,Mitotic Prometaphase,0.009820783724232266,0,0,1,0.010596702816285424
2225,HS90A,Mitotic Prometaphase,0.010570268255348007,1,0,1,0.011405402515275833
2226,HS90A,Extra-nuclear estrogen signaling,0.009820783724232266,0,0,1,0.010596702816285424
2227,HS90A,Extra-nuclear estrogen signaling,0.010570268255348007,1,0,1,0.011405402515275833
2228,HS90A,Estrogen-dependent gene expression,0.009820783724232266,0,0,1,0.010596702816285424
2229,HS90A,Estrogen-dependent gene expression,0.010570268255348007,1,0,1,0.011405402515275833
2230,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.009820783724232266,0,0,1,0.010596702816285424
2231,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.010570268255348007,1,0,1,0.011405402515275833
2232,HS90A,Aggrephagy,0.009820783724232266,0,0,1,0.010596702816285424
2233,HS90A,Aggrephagy,0.010570268255348007,1,0,1,0.011405402515275833
2234,HS90A,Potential therapeutics for SARS,0.009820783724232266,0,0,1,0.010596702816285424
2235,HS90A,Potential therapeutics for SARS,0.010570268255348007,1,0,1,0.011405402515275833
2236,HS90A,SARS-CoV-2 Infection,0.009820783724232266,0,0,1,0.010596702816285424
2237,HS90A,SARS-CoV-2 Infection,0.010570268255348007,1,0,1,0.011405402515275833
2238,HS90A,Neutrophil degranulation,0.009820783724232266,0,0,1,0.010596702816285424
2239,HS90A,Neutrophil degranulation,0.010570268255348007,1,0,1,0.011405402515275833
2240,HS90A,eNOS activation,0.009820783724232266,0,0,1,0.010596702816285424
2241,HS90A,eNOS activation,0.010570268255348007,1,0,1,0.011405402515275833
2242,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.009820783724232266,0,0,1,0.010596702816285424
2243,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.010570268255348007,1,0,1,0.011405402515275833
2244,HS90A,Scavenging by Class F Receptors,0.009820783724232266,0,0,1,0.010596702816285424
2245,HS90A,Scavenging by Class F Receptors,0.010570268255348007,1,0,1,0.011405402515275833
2246,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.009820783724232266,0,0,1,0.010596702816285424
2247,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.010570268255348007,1,0,1,0.011405402515275833
2248,HS90A,Anchoring of the basal body to the plasma membrane,0.009820783724232266,0,0,1,0.010596702816285424
2249,HS90A,Anchoring of the basal body to the plasma membrane,0.010570268255348007,1,0,1,0.011405402515275833
2250,HS90A,Chaperone Mediated Autophagy,0.009820783724232266,0,0,1,0.010596702816285424
2251,HS90A,Chaperone Mediated Autophagy,0.010570268255348007,1,0,1,0.011405402515275833
2252,FUMH,Citric acid cycle (TCA cycle),0.0001248504973470214,0,0,1,0.00013471466779045097
2253,FUMH,Citric acid cycle (TCA cycle),9.029454325476157e-05,1,0,1,9.74285217626801e-05
2254,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.0013124014978529886,0,0,1,0.0014160915298522321
2255,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.0014666431399139887,1,0,1,0.0015825194737629981
2256,PSPB,Defective CSF2RB causes SMDP5,0.0013124014978529886,0,0,1,0.0014160915298522321
2257,PSPB,Defective CSF2RB causes SMDP5,0.0014666431399139887,1,0,1,0.0015825194737629981
2258,PSPB,Defective CSF2RA causes SMDP4,0.0013124014978529886,0,0,1,0.0014160915298522321
2259,PSPB,Defective CSF2RA causes SMDP4,0.0014666431399139887,1,0,1,0.0015825194737629981
2260,PSPB,Surfactant metabolism,0.0013124014978529886,0,0,1,0.0014160915298522321
2261,PSPB,Surfactant metabolism,0.0014666431399139887,1,0,1,0.0015825194737629981
2262,TSP1,Transcriptional regulation by RUNX1,0.002473617261906232,0,0,1,0.0026690524648228246
2263,TSP1,Transcriptional regulation by RUNX1,0.002666381386370631,1,0,1,0.0028770464699805318
2264,TSP1,Diseases associated with O-glycosylation of proteins,0.002473617261906232,0,0,1,0.0026690524648228246
2265,TSP1,Diseases associated with O-glycosylation of proteins,0.002666381386370631,1,0,1,0.0028770464699805318
2266,TSP1,O-glycosylation of TSR domain-containing proteins,0.002473617261906232,0,0,1,0.0026690524648228246
2267,TSP1,O-glycosylation of TSR domain-containing proteins,0.002666381386370631,1,0,1,0.0028770464699805318
2268,TSP1,Platelet degranulation ,0.002473617261906232,0,0,1,0.0026690524648228246
2269,TSP1,Platelet degranulation ,0.002666381386370631,1,0,1,0.0028770464699805318
2270,TSP1,Integrin cell surface interactions,0.002473617261906232,0,0,1,0.0026690524648228246
2271,TSP1,Integrin cell surface interactions,0.002666381386370631,1,0,1,0.0028770464699805318
2272,TSP1,Syndecan interactions,0.002473617261906232,0,0,1,0.0026690524648228246
2273,TSP1,Syndecan interactions,0.002666381386370631,1,0,1,0.0028770464699805318
2274,TSP1,Signaling by PDGF,0.002473617261906232,0,0,1,0.0026690524648228246
2275,TSP1,Signaling by PDGF,0.002666381386370631,1,0,1,0.0028770464699805318
2276,RNAS1,Chaperone Mediated Autophagy,0.007858314701297785,0,0,1,0.008479183318234529
2277,RNAS1,Chaperone Mediated Autophagy,0.007568769388308283,1,0,1,0.00816676165009134
2278,RNAS1,Late endosomal microautophagy,0.007858314701297785,0,0,1,0.008479183318234529
2279,RNAS1,Late endosomal microautophagy,0.007568769388308283,1,0,1,0.00816676165009134
2280,CO1A2,Collagen chain trimerization,0.007158560313594838,0,0,1,0.007724142834796983
2281,CO1A2,Collagen chain trimerization,0.0068050559028051795,1,0,1,0.007342708797496977
2282,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.007158560313594838,0,0,1,0.007724142834796983
2283,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.0068050559028051795,1,0,1,0.007342708797496977
2284,CO1A2,Anchoring fibril formation,0.007158560313594838,0,0,1,0.007724142834796983
2285,CO1A2,Anchoring fibril formation,0.0068050559028051795,1,0,1,0.007342708797496977
2286,CO1A2,Crosslinking of collagen fibrils,0.007158560313594838,0,0,1,0.007724142834796983
2287,CO1A2,Crosslinking of collagen fibrils,0.0068050559028051795,1,0,1,0.007342708797496977
2288,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.007158560313594838,0,0,1,0.007724142834796983
2289,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.0068050559028051795,1,0,1,0.007342708797496977
2290,CO1A2,MET promotes cell motility,0.007158560313594838,0,0,1,0.007724142834796983
2291,CO1A2,MET promotes cell motility,0.0068050559028051795,1,0,1,0.007342708797496977
2292,CO1A2,Platelet Adhesion to exposed collagen,0.007158560313594838,0,0,1,0.007724142834796983
2293,CO1A2,Platelet Adhesion to exposed collagen,0.0068050559028051795,1,0,1,0.007342708797496977
2294,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007158560313594838,0,0,1,0.007724142834796983
2295,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0068050559028051795,1,0,1,0.007342708797496977
2296,CO1A2,Collagen degradation,0.007158560313594838,0,0,1,0.007724142834796983
2297,CO1A2,Collagen degradation,0.0068050559028051795,1,0,1,0.007342708797496977
2298,CO1A2,Integrin cell surface interactions,0.007158560313594838,0,0,1,0.007724142834796983
2299,CO1A2,Integrin cell surface interactions,0.0068050559028051795,1,0,1,0.007342708797496977
2300,CO1A2,ECM proteoglycans,0.007158560313594838,0,0,1,0.007724142834796983
2301,CO1A2,ECM proteoglycans,0.0068050559028051795,1,0,1,0.007342708797496977
2302,CO1A2,Scavenging by Class A Receptors,0.007158560313594838,0,0,1,0.007724142834796983
2303,CO1A2,Scavenging by Class A Receptors,0.0068050559028051795,1,0,1,0.007342708797496977
2304,CO1A2,Syndecan interactions,0.007158560313594838,0,0,1,0.007724142834796983
2305,CO1A2,Syndecan interactions,0.0068050559028051795,1,0,1,0.007342708797496977
2306,CO1A2,GPVI-mediated activation cascade,0.007158560313594838,0,0,1,0.007724142834796983
2307,CO1A2,GPVI-mediated activation cascade,0.0068050559028051795,1,0,1,0.007342708797496977
2308,CO1A2,GP1b-IX-V activation signalling,0.007158560313594838,0,0,1,0.007724142834796983
2309,CO1A2,GP1b-IX-V activation signalling,0.0068050559028051795,1,0,1,0.007342708797496977
2310,CBG,Metabolism of steroid hormones,0.0018772658023711605,0,0,1,0.0020255845534830675
2311,CBG,Metabolism of steroid hormones,0.0017435137284337542,1,0,1,0.001881265014597455
2312,4F2,Amino acid transport across the plasma membrane,0.002626797749932545,0,0,1,0.002834335415190953
2313,4F2,Amino acid transport across the plasma membrane,0.0025596058432711287,1,0,1,0.0027618348198674082
2314,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.002626797749932545,0,0,1,0.002834335415190953
2315,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0025596058432711287,1,0,1,0.0027618348198674082
2316,4F2,Basigin interactions,0.002626797749932545,0,0,1,0.002834335415190953
2317,4F2,Basigin interactions,0.0025596058432711287,1,0,1,0.0027618348198674082
2318,4F2,Tryptophan catabolism,0.002626797749932545,0,0,1,0.002834335415190953
2319,4F2,Tryptophan catabolism,0.0025596058432711287,1,0,1,0.0027618348198674082
2320,HS90B,Inflammasomes,0.0018196179478157622,0,0,1,0.0019633820653850256
2321,HS90B,Inflammasomes,0.0017740054667228834,1,0,1,0.0019141658398345073
2322,HS90B,RHO GTPase cycle,0.0018196179478157622,0,0,1,0.0019633820653850256
2323,HS90B,RHO GTPase cycle,0.0017740054667228834,1,0,1,0.0019141658398345073
2324,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.0018196179478157622,0,0,1,0.0019633820653850256
2325,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.0017740054667228834,1,0,1,0.0019141658398345073
2326,HS90B,Aryl hydrocarbon receptor signalling,0.0018196179478157622,0,0,1,0.0019633820653850256
2327,HS90B,Aryl hydrocarbon receptor signalling,0.0017740054667228834,1,0,1,0.0019141658398345073
2328,HS90B,HSF1 activation,0.0018196179478157622,0,0,1,0.0019633820653850256
2329,HS90B,HSF1 activation,0.0017740054667228834,1,0,1,0.0019141658398345073
2330,HS90B,HSF1-dependent transactivation,0.0018196179478157622,0,0,1,0.0019633820653850256
2331,HS90B,HSF1-dependent transactivation,0.0017740054667228834,1,0,1,0.0019141658398345073
2332,HS90B,Semaphorin interactions,0.0018196179478157622,0,0,1,0.0019633820653850256
2333,HS90B,Semaphorin interactions,0.0017740054667228834,1,0,1,0.0019141658398345073
2334,HS90B,G2/M Transition,0.0018196179478157622,0,0,1,0.0019633820653850256
2335,HS90B,G2/M Transition,0.0017740054667228834,1,0,1,0.0019141658398345073
2336,HS90B,Uptake and function of diphtheria toxin,0.0018196179478157622,0,0,1,0.0019633820653850256
2337,HS90B,Uptake and function of diphtheria toxin,0.0017740054667228834,1,0,1,0.0019141658398345073
2338,HS90B,Estrogen-dependent gene expression,0.0018196179478157622,0,0,1,0.0019633820653850256
2339,HS90B,Estrogen-dependent gene expression,0.0017740054667228834,1,0,1,0.0019141658398345073
2340,HS90B,Cell recruitment (pro-inflammatory response),0.0018196179478157622,0,0,1,0.0019633820653850256
2341,HS90B,Cell recruitment (pro-inflammatory response),0.0017740054667228834,1,0,1,0.0019141658398345073
2342,HS90B,Potential therapeutics for SARS,0.0018196179478157622,0,0,1,0.0019633820653850256
2343,HS90B,Potential therapeutics for SARS,0.0017740054667228834,1,0,1,0.0019141658398345073
2344,HS90B,SARS-CoV-2 Infection,0.0018196179478157622,0,0,1,0.0019633820653850256
2345,HS90B,SARS-CoV-2 Infection,0.0017740054667228834,1,0,1,0.0019141658398345073
2346,HS90B,Neutrophil degranulation,0.0018196179478157622,0,0,1,0.0019633820653850256
2347,HS90B,Neutrophil degranulation,0.0017740054667228834,1,0,1,0.0019141658398345073
2348,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0018196179478157622,0,0,1,0.0019633820653850256
2349,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0017740054667228834,1,0,1,0.0019141658398345073
2350,HS90B,Chaperone Mediated Autophagy,0.0018196179478157622,0,0,1,0.0019633820653850256
2351,HS90B,Chaperone Mediated Autophagy,0.0017740054667228834,1,0,1,0.0019141658398345073
2352,SODE,Detoxification of Reactive Oxygen Species,2.6585102129198884e-05,0,0,1,2.868553411970594e-05
2353,SODE,Detoxification of Reactive Oxygen Species,2.106057922380463e-05,1,0,1,2.272453048964167e-05
2354,ITA2B,Transcriptional regulation by RUNX1,0.0015847055765334517,0,0,1,0.001709909770683602
2355,ITA2B,Transcriptional regulation by RUNX1,0.0013849475450115277,1,0,1,0.0014943692848483454
2356,ITA2B,L1CAM interactions,0.0015847055765334517,0,0,1,0.001709909770683602
2357,ITA2B,L1CAM interactions,0.0013849475450115277,1,0,1,0.0014943692848483454
2358,ITA2B,RAF/MAP kinase cascade,0.0015847055765334517,0,0,1,0.001709909770683602
2359,ITA2B,RAF/MAP kinase cascade,0.0013849475450115277,1,0,1,0.0014943692848483454
2360,ITA2B,Signaling by RAS mutants,0.0015847055765334517,0,0,1,0.001709909770683602
2361,ITA2B,Signaling by RAS mutants,0.0013849475450115277,1,0,1,0.0014943692848483454
2362,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0015847055765334517,0,0,1,0.001709909770683602
2363,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0013849475450115277,1,0,1,0.0014943692848483454
2364,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0015847055765334517,0,0,1,0.001709909770683602
2365,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0013849475450115277,1,0,1,0.0014943692848483454
2366,ITA2B,Signaling by BRAF and RAF1 fusions,0.0015847055765334517,0,0,1,0.001709909770683602
2367,ITA2B,Signaling by BRAF and RAF1 fusions,0.0013849475450115277,1,0,1,0.0014943692848483454
2368,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0015847055765334517,0,0,1,0.001709909770683602
2369,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0013849475450115277,1,0,1,0.0014943692848483454
2370,ITA2B,Signaling by RAF1 mutants,0.0015847055765334517,0,0,1,0.001709909770683602
2371,ITA2B,Signaling by RAF1 mutants,0.0013849475450115277,1,0,1,0.0014943692848483454
2372,ITA2B,Platelet degranulation ,0.0015847055765334517,0,0,1,0.001709909770683602
2373,ITA2B,Platelet degranulation ,0.0013849475450115277,1,0,1,0.0014943692848483454
2374,ITA2B,Integrin cell surface interactions,0.0015847055765334517,0,0,1,0.001709909770683602
2375,ITA2B,Integrin cell surface interactions,0.0013849475450115277,1,0,1,0.0014943692848483454
2376,ITA2B,ECM proteoglycans,0.0015847055765334517,0,0,1,0.001709909770683602
2377,ITA2B,ECM proteoglycans,0.0013849475450115277,1,0,1,0.0014943692848483454
2378,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0015847055765334517,0,0,1,0.001709909770683602
2379,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0013849475450115277,1,0,1,0.0014943692848483454
2380,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0015847055765334517,0,0,1,0.001709909770683602
2381,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0013849475450115277,1,0,1,0.0014943692848483454
2382,APOA,LDL remodeling,0.0002678319697627292,0,0,1,0.0002889928001645159
2383,APOA,LDL remodeling,0.00026239300682699235,1,0,1,0.00028312411641409554
2384,PLEK,Platelet degranulation ,0.0003265037151625923,0,0,1,0.00035230007453010767
2385,PLEK,Platelet degranulation ,0.00037304937128889527,1,0,1,0.0004025232032751616
2386,CD14,Antigen processing-Cross presentation,0.02814890808504297,0,0,1,0.03037289303542347
2387,CD14,Antigen processing-Cross presentation,0.028073055439745077,1,0,1,0.030291047435049685
2388,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.02814890808504297,0,0,1,0.03037289303542347
2389,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.028073055439745077,1,0,1,0.030291047435049685
2390,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.02814890808504297,0,0,1,0.03037289303542347
2391,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.028073055439745077,1,0,1,0.030291047435049685
2392,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.02814890808504297,0,0,1,0.03037289303542347
2393,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.028073055439745077,1,0,1,0.030291047435049685
2394,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.02814890808504297,0,0,1,0.03037289303542347
2395,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.028073055439745077,1,0,1,0.030291047435049685
2396,CD14,Regulation of TLR by endogenous ligand,0.02814890808504297,0,0,1,0.03037289303542347
2397,CD14,Regulation of TLR by endogenous ligand,0.028073055439745077,1,0,1,0.030291047435049685
2398,CD14,Caspase activation via Death Receptors in the presence of ligand,0.02814890808504297,0,0,1,0.03037289303542347
2399,CD14,Caspase activation via Death Receptors in the presence of ligand,0.028073055439745077,1,0,1,0.030291047435049685
2400,CD14,MyD88 deficiency (TLR2/4),0.02814890808504297,0,0,1,0.03037289303542347
2401,CD14,MyD88 deficiency (TLR2/4),0.028073055439745077,1,0,1,0.030291047435049685
2402,CD14,IRAK4 deficiency (TLR2/4),0.02814890808504297,0,0,1,0.03037289303542347
2403,CD14,IRAK4 deficiency (TLR2/4),0.028073055439745077,1,0,1,0.030291047435049685
2404,CD14,Neutrophil degranulation,0.02814890808504297,0,0,1,0.03037289303542347
2405,CD14,Neutrophil degranulation,0.028073055439745077,1,0,1,0.030291047435049685
2406,CFAH,Regulation of Complement cascade,0.0006226317522077807,0,0,1,0.0006718245536605278
2407,CFAH,Regulation of Complement cascade,0.0006435476915721476,1,0,1,0.000694393016605166
2408,FCG3A,FCGR activation,0.001808844012824314,0,0,1,0.0019517569048609577
2409,FCG3A,FCGR activation,0.0016144213112662933,1,0,1,0.0017419732819851004
2410,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.001808844012824314,0,0,1,0.0019517569048609577
2411,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0016144213112662933,1,0,1,0.0017419732819851004
2412,FCG3A,Role of phospholipids in phagocytosis,0.001808844012824314,0,0,1,0.0019517569048609577
2413,FCG3A,Role of phospholipids in phagocytosis,0.0016144213112662933,1,0,1,0.0017419732819851004
2414,FCG3A,Parasite infection,0.001808844012824314,0,0,1,0.0019517569048609577
2415,FCG3A,Parasite infection,0.0016144213112662933,1,0,1,0.0017419732819851004
2416,FCG3A,Leishmania parasite growth and survival,0.001808844012824314,0,0,1,0.0019517569048609577
2417,FCG3A,Leishmania parasite growth and survival,0.0016144213112662933,1,0,1,0.0017419732819851004
2418,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001808844012824314,0,0,1,0.0019517569048609577
2419,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016144213112662933,1,0,1,0.0017419732819851004
2420,A2AP,Platelet degranulation ,0.004000618492773356,0,0,1,0.004316698793055749
2421,A2AP,Platelet degranulation ,0.00453412555924236,1,0,1,0.004892357110406814
2422,A2AP,Dissolution of Fibrin Clot,0.004000618492773356,0,0,1,0.004316698793055749
2423,A2AP,Dissolution of Fibrin Clot,0.00453412555924236,1,0,1,0.004892357110406814
2424,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002680803766512933,0,0,1,0.002892608331494126
2425,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.002521348346878464,1,0,1,0.0027205546806084746
2426,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.002680803766512933,0,0,1,0.002892608331494126
2427,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.002521348346878464,1,0,1,0.0027205546806084746
2428,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.002680803766512933,0,0,1,0.002892608331494126
2429,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.002521348346878464,1,0,1,0.0027205546806084746
2430,K1C16,Formation of the cornified envelope,2.4966137639618563e-06,0,0,1,2.6938658712616876e-06
2431,K1C16,Formation of the cornified envelope,2.8584144880975753e-06,1,0,1,3.0842516958596928e-06
2432,ENOG,Glycolysis,1.1336208823801522e-05,0,0,1,1.2231858407875496e-05
2433,ENOG,Glycolysis,1.7588572836757523e-05,1,0,1,1.8978208312827898e-05
2434,ENOG,Gluconeogenesis,1.1336208823801522e-05,0,0,1,1.2231858407875496e-05
2435,ENOG,Gluconeogenesis,1.7588572836757523e-05,1,0,1,1.8978208312827898e-05
2436,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.000377763841728059,0,0,1,0.000407610153928266
2437,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0005223945265849276,1,0,1,0.0005636677994868825
2438,THIK,Peroxisomal lipid metabolism,0.000377763841728059,0,0,1,0.000407610153928266
2439,THIK,Peroxisomal lipid metabolism,0.0005223945265849276,1,0,1,0.0005636677994868825
2440,THIK,Neutrophil degranulation,0.000377763841728059,0,0,1,0.000407610153928266
2441,THIK,Neutrophil degranulation,0.0005223945265849276,1,0,1,0.0005636677994868825
2442,THIK,TYSND1 cleaves peroxisomal proteins,0.000377763841728059,0,0,1,0.000407610153928266
2443,THIK,TYSND1 cleaves peroxisomal proteins,0.0005223945265849276,1,0,1,0.0005636677994868825
2444,DOPO,Catecholamine biosynthesis,0.0005054108990104093,0,0,1,0.0005453423318660478
2445,DOPO,Catecholamine biosynthesis,0.00023119417631581503,1,0,1,0.00024946033311268193
2446,F16P1,Gluconeogenesis,2.975875437793244e-05,0,0,1,3.2109929836626634e-05
2447,F16P1,Gluconeogenesis,4.1030379482738986e-05,1,0,1,4.4272101904167436e-05
2448,C1S,Initial triggering of complement,0.003178170101818978,0,0,1,0.00342927051590397
2449,C1S,Initial triggering of complement,0.003334022913016573,1,0,1,0.0035974369239746926
2450,C1S,Regulation of Complement cascade,0.003178170101818978,0,0,1,0.00342927051590397
2451,C1S,Regulation of Complement cascade,0.003334022913016573,1,0,1,0.0035974369239746926
2452,LKHA4,Arachidonic acid metabolism,0.0005993037476097622,0,0,1,0.0006466534533732678
2453,LKHA4,Arachidonic acid metabolism,0.0005849329882039456,1,0,1,0.0006311472910400083
2454,LKHA4,Biosynthesis of DHA-derived SPMs,0.0005993037476097622,0,0,1,0.0006466534533732678
2455,LKHA4,Biosynthesis of DHA-derived SPMs,0.0005849329882039456,1,0,1,0.0006311472910400083
2456,LKHA4,Biosynthesis of EPA-derived SPMs,0.0005993037476097622,0,0,1,0.0006466534533732678
2457,LKHA4,Biosynthesis of EPA-derived SPMs,0.0005849329882039456,1,0,1,0.0006311472910400083
2458,LKHA4,Neutrophil degranulation,0.0005993037476097622,0,0,1,0.0006466534533732678
2459,LKHA4,Neutrophil degranulation,0.0005849329882039456,1,0,1,0.0006311472910400083
2460,CO4A,Initial triggering of complement,0.0033108499847912753,0,0,1,0.0035724331523122855
2461,CO4A,Initial triggering of complement,0.0033073425298122553,1,0,1,0.0035686485808261556
2462,CO4A,Activation of C3 and C5,0.0033108499847912753,0,0,1,0.0035724331523122855
2463,CO4A,Activation of C3 and C5,0.0033073425298122553,1,0,1,0.0035686485808261556
2464,CO4A,Regulation of Complement cascade,0.0033108499847912753,0,0,1,0.0035724331523122855
2465,CO4A,Regulation of Complement cascade,0.0033073425298122553,1,0,1,0.0035686485808261556
2466,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0033108499847912753,0,0,1,0.0035724331523122855
2467,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0033073425298122553,1,0,1,0.0035686485808261556
2468,CO4A,Post-translational protein phosphorylation,0.0033108499847912753,0,0,1,0.0035724331523122855
2469,CO4A,Post-translational protein phosphorylation,0.0033073425298122553,1,0,1,0.0035686485808261556
2470,CO4B,Initial triggering of complement,0.0011657695245351836,0,0,1,0.0012578744783168934
2471,CO4B,Initial triggering of complement,0.0012013986244104066,1,0,1,0.0012963185570779299
2472,CO4B,Activation of C3 and C5,0.0011657695245351836,0,0,1,0.0012578744783168934
2473,CO4B,Activation of C3 and C5,0.0012013986244104066,1,0,1,0.0012963185570779299
2474,CO4B,Regulation of Complement cascade,0.0011657695245351836,0,0,1,0.0012578744783168934
2475,CO4B,Regulation of Complement cascade,0.0012013986244104066,1,0,1,0.0012963185570779299
2476,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2477,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2478,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2479,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2480,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2481,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2482,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2483,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2484,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2485,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2486,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2487,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2488,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.003940734575341291,0,0,1,0.004252083575541408
2489,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0038682652172004357,1,0,1,0.004173888568598047
2490,SAA1,TRAF6 mediated NF-kB activation,0.003940734575341291,0,0,1,0.004252083575541408
2491,SAA1,TRAF6 mediated NF-kB activation,0.0038682652172004357,1,0,1,0.004173888568598047
2492,SAA1,Class A/1 (Rhodopsin-like receptors),0.003940734575341291,0,0,1,0.004252083575541408
2493,SAA1,Class A/1 (Rhodopsin-like receptors),0.0038682652172004357,1,0,1,0.004173888568598047
2494,SAA1,G alpha (q) signalling events,0.003940734575341291,0,0,1,0.004252083575541408
2495,SAA1,G alpha (q) signalling events,0.0038682652172004357,1,0,1,0.004173888568598047
2496,SAA1,G alpha (i) signalling events,0.003940734575341291,0,0,1,0.004252083575541408
2497,SAA1,G alpha (i) signalling events,0.0038682652172004357,1,0,1,0.004173888568598047
2498,SAA1,Interleukin-1 family signaling,0.003940734575341291,0,0,1,0.004252083575541408
2499,SAA1,Interleukin-1 family signaling,0.0038682652172004357,1,0,1,0.004173888568598047
2500,SAA1,Interleukin-4 and Interleukin-13 signaling,0.003940734575341291,0,0,1,0.004252083575541408
2501,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0038682652172004357,1,0,1,0.004173888568598047
2502,SAA1,Advanced glycosylation endproduct receptor signaling,0.003940734575341291,0,0,1,0.004252083575541408
2503,SAA1,Advanced glycosylation endproduct receptor signaling,0.0038682652172004357,1,0,1,0.004173888568598047
2504,SAA1,Scavenging by Class B Receptors,0.003940734575341291,0,0,1,0.004252083575541408
2505,SAA1,Scavenging by Class B Receptors,0.0038682652172004357,1,0,1,0.004173888568598047
2506,SAA1,Amyloid fiber formation,0.003940734575341291,0,0,1,0.004252083575541408
2507,SAA1,Amyloid fiber formation,0.0038682652172004357,1,0,1,0.004173888568598047
2508,OSTP,Transcriptional regulation by RUNX3,0.01284116650543486,0,0,1,0.013855719573253218
2509,OSTP,Transcriptional regulation by RUNX3,0.011962514091283082,1,0,1,0.012907646713385203
2510,OSTP,Integrin cell surface interactions,0.01284116650543486,0,0,1,0.013855719573253218
2511,OSTP,Integrin cell surface interactions,0.011962514091283082,1,0,1,0.012907646713385203
2512,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01284116650543486,0,0,1,0.013855719573253218
2513,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011962514091283082,1,0,1,0.012907646713385203
2514,OSTP,Post-translational protein phosphorylation,0.01284116650543486,0,0,1,0.013855719573253218
2515,OSTP,Post-translational protein phosphorylation,0.011962514091283082,1,0,1,0.012907646713385203
2516,OSTP,Signaling by PDGF,0.01284116650543486,0,0,1,0.013855719573253218
2517,OSTP,Signaling by PDGF,0.011962514091283082,1,0,1,0.012907646713385203
2518,CO7,Terminal pathway of complement,0.001427747051464697,0,0,1,0.0015405502886565092
2519,CO7,Terminal pathway of complement,0.0014717837807287045,1,0,1,0.0015880662656004355
2520,CO7,Regulation of Complement cascade,0.001427747051464697,0,0,1,0.0015405502886565092
2521,CO7,Regulation of Complement cascade,0.0014717837807287045,1,0,1,0.0015880662656004355
2522,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,4.732991734002212e-06,0,0,1,5.106935275787029e-06
2523,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,1.2224041057606883e-05,1,0,1,1.3189836365290469e-05
2524,CH60,Mitochondrial protein import,4.732991734002212e-06,0,0,1,5.106935275787029e-06
2525,CH60,Mitochondrial protein import,1.2224041057606883e-05,1,0,1,1.3189836365290469e-05
2526,CLUS,Terminal pathway of complement,0.00411236903413131,0,0,1,0.004437278505386379
2527,CLUS,Terminal pathway of complement,0.004552580154510603,1,0,1,0.004912269763728959
2528,CLUS,Regulation of Complement cascade,0.00411236903413131,0,0,1,0.004437278505386379
2529,CLUS,Regulation of Complement cascade,0.004552580154510603,1,0,1,0.004912269763728959
2530,CLUS,Platelet degranulation ,0.00411236903413131,0,0,1,0.004437278505386379
2531,CLUS,Platelet degranulation ,0.004552580154510603,1,0,1,0.004912269763728959
2532,BIP,Regulation of HSF1-mediated heat shock response,0.0030066153292561165,0,0,1,0.0032441615681243273
2533,BIP,Regulation of HSF1-mediated heat shock response,0.0029904761679063084,1,0,1,0.0032267472861962966
2534,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0030066153292561165,0,0,1,0.0032441615681243273
2535,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0029904761679063084,1,0,1,0.0032267472861962966
2536,BIP,IRE1alpha activates chaperones,0.0030066153292561165,0,0,1,0.0032441615681243273
2537,BIP,IRE1alpha activates chaperones,0.0029904761679063084,1,0,1,0.0032267472861962966
2538,BIP,PERK regulates gene expression,0.0030066153292561165,0,0,1,0.0032441615681243273
2539,BIP,PERK regulates gene expression,0.0029904761679063084,1,0,1,0.0032267472861962966
2540,BIP,Platelet degranulation ,0.0030066153292561165,0,0,1,0.0032441615681243273
2541,BIP,Platelet degranulation ,0.0029904761679063084,1,0,1,0.0032267472861962966
2542,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0030066153292561165,0,0,1,0.0032441615681243273
2543,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0029904761679063084,1,0,1,0.0032267472861962966
2544,LAMC1,L1CAM interactions,0.004699709778651595,0,0,1,0.005071023784413367
2545,LAMC1,L1CAM interactions,0.005047546819938967,1,0,1,0.0054463426854826835
2546,LAMC1,MET promotes cell motility,0.004699709778651595,0,0,1,0.005071023784413367
2547,LAMC1,MET promotes cell motility,0.005047546819938967,1,0,1,0.0054463426854826835
2548,LAMC1,Laminin interactions,0.004699709778651595,0,0,1,0.005071023784413367
2549,LAMC1,Laminin interactions,0.005047546819938967,1,0,1,0.0054463426854826835
2550,LAMC1,ECM proteoglycans,0.004699709778651595,0,0,1,0.005071023784413367
2551,LAMC1,ECM proteoglycans,0.005047546819938967,1,0,1,0.0054463426854826835
2552,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004699709778651595,0,0,1,0.005071023784413367
2553,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005047546819938967,1,0,1,0.0054463426854826835
2554,LAMC1,Post-translational protein phosphorylation,0.004699709778651595,0,0,1,0.005071023784413367
2555,LAMC1,Post-translational protein phosphorylation,0.005047546819938967,1,0,1,0.0054463426854826835
2556,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.004699709778651595,0,0,1,0.005071023784413367
2557,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.005047546819938967,1,0,1,0.0054463426854826835
2558,HSP7C,"GABA synthesis, release, reuptake and degradation",0.00864252650256579,0,0,1,0.00932535401462776
2559,HSP7C,"GABA synthesis, release, reuptake and degradation",0.009107740723993629,1,0,1,0.009827323815491671
2560,HSP7C,Lysosome Vesicle Biogenesis,0.00864252650256579,0,0,1,0.00932535401462776
2561,HSP7C,Lysosome Vesicle Biogenesis,0.009107740723993629,1,0,1,0.009827323815491671
2562,HSP7C,Golgi Associated Vesicle Biogenesis,0.00864252650256579,0,0,1,0.00932535401462776
2563,HSP7C,Golgi Associated Vesicle Biogenesis,0.009107740723993629,1,0,1,0.009827323815491671
2564,HSP7C,Regulation of HSF1-mediated heat shock response,0.00864252650256579,0,0,1,0.00932535401462776
2565,HSP7C,Regulation of HSF1-mediated heat shock response,0.009107740723993629,1,0,1,0.009827323815491671
2566,HSP7C,HSF1-dependent transactivation,0.00864252650256579,0,0,1,0.00932535401462776
2567,HSP7C,HSF1-dependent transactivation,0.009107740723993629,1,0,1,0.009827323815491671
2568,HSP7C,L1CAM interactions,0.00864252650256579,0,0,1,0.00932535401462776
2569,HSP7C,L1CAM interactions,0.009107740723993629,1,0,1,0.009827323815491671
2570,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.00864252650256579,0,0,1,0.00932535401462776
2571,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.009107740723993629,1,0,1,0.009827323815491671
2572,HSP7C,mRNA Splicing - Major Pathway,0.00864252650256579,0,0,1,0.00932535401462776
2573,HSP7C,mRNA Splicing - Major Pathway,0.009107740723993629,1,0,1,0.009827323815491671
2574,HSP7C,Lipophagy,0.00864252650256579,0,0,1,0.00932535401462776
2575,HSP7C,Lipophagy,0.009107740723993629,1,0,1,0.009827323815491671
2576,HSP7C,Neutrophil degranulation,0.00864252650256579,0,0,1,0.00932535401462776
2577,HSP7C,Neutrophil degranulation,0.009107740723993629,1,0,1,0.009827323815491671
2578,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00864252650256579,0,0,1,0.00932535401462776
2579,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.009107740723993629,1,0,1,0.009827323815491671
2580,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00864252650256579,0,0,1,0.00932535401462776
2581,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.009107740723993629,1,0,1,0.009827323815491671
2582,HSP7C,Protein methylation,0.00864252650256579,0,0,1,0.00932535401462776
2583,HSP7C,Protein methylation,0.009107740723993629,1,0,1,0.009827323815491671
2584,HSP7C,Chaperone Mediated Autophagy,0.00864252650256579,0,0,1,0.00932535401462776
2585,HSP7C,Chaperone Mediated Autophagy,0.009107740723993629,1,0,1,0.009827323815491671
2586,HSP7C,Late endosomal microautophagy,0.00864252650256579,0,0,1,0.00932535401462776
2587,HSP7C,Late endosomal microautophagy,0.009107740723993629,1,0,1,0.009827323815491671
2588,PYGB,Glycogen breakdown (glycogenolysis),8.134732385466729e-05,0,0,1,8.777440171715244e-05
2589,PYGB,Glycogen breakdown (glycogenolysis),6.754630733970164e-05,1,0,1,7.288299644051595e-05
2590,PYGB,Neutrophil degranulation,8.134732385466729e-05,0,0,1,8.777440171715244e-05
2591,PYGB,Neutrophil degranulation,6.754630733970164e-05,1,0,1,7.288299644051595e-05
2592,C1TC,Metabolism of folate and pterines,0.00023593156480880377,0,0,1,0.0002545720125259679
2593,C1TC,Metabolism of folate and pterines,0.0002099474518521068,1,0,1,0.00022653495044633895
2594,CO6A1,Collagen chain trimerization,0.007663747300102841,0,0,1,0.008269243563313291
2595,CO6A1,Collagen chain trimerization,0.007742445690867802,1,0,1,0.008354159745409684
2596,CO6A1,NCAM signaling for neurite out-growth,0.007663747300102841,0,0,1,0.008269243563313291
2597,CO6A1,NCAM signaling for neurite out-growth,0.007742445690867802,1,0,1,0.008354159745409684
2598,CO6A1,Collagen degradation,0.007663747300102841,0,0,1,0.008269243563313291
2599,CO6A1,Collagen degradation,0.007742445690867802,1,0,1,0.008354159745409684
2600,CO6A1,Integrin cell surface interactions,0.007663747300102841,0,0,1,0.008269243563313291
2601,CO6A1,Integrin cell surface interactions,0.007742445690867802,1,0,1,0.008354159745409684
2602,CO6A1,ECM proteoglycans,0.007663747300102841,0,0,1,0.008269243563313291
2603,CO6A1,ECM proteoglycans,0.007742445690867802,1,0,1,0.008354159745409684
2604,CO6A1,Signaling by PDGF,0.007663747300102841,0,0,1,0.008269243563313291
2605,CO6A1,Signaling by PDGF,0.007742445690867802,1,0,1,0.008354159745409684
2606,CO6A3,Collagen chain trimerization,0.006659205242370566,0,0,1,0.007185334788702646
2607,CO6A3,Collagen chain trimerization,0.006743155287889143,1,0,1,0.007275917547548966
2608,CO6A3,NCAM signaling for neurite out-growth,0.006659205242370566,0,0,1,0.007185334788702646
2609,CO6A3,NCAM signaling for neurite out-growth,0.006743155287889143,1,0,1,0.007275917547548966
2610,CO6A3,Collagen degradation,0.006659205242370566,0,0,1,0.007185334788702646
2611,CO6A3,Collagen degradation,0.006743155287889143,1,0,1,0.007275917547548966
2612,CO6A3,Integrin cell surface interactions,0.006659205242370566,0,0,1,0.007185334788702646
2613,CO6A3,Integrin cell surface interactions,0.006743155287889143,1,0,1,0.007275917547548966
2614,CO6A3,ECM proteoglycans,0.006659205242370566,0,0,1,0.007185334788702646
2615,CO6A3,ECM proteoglycans,0.006743155287889143,1,0,1,0.007275917547548966
2616,CO6A3,Signaling by PDGF,0.006659205242370566,0,0,1,0.007185334788702646
2617,CO6A3,Signaling by PDGF,0.006743155287889143,1,0,1,0.007275917547548966
2618,FA5,COPII-mediated vesicle transport,0.00016401551900978954,0,0,1,0.00017697403394772564
2619,FA5,COPII-mediated vesicle transport,0.0003398628530400553,1,0,1,0.00036671468928432105
2620,FA5,Cargo concentration in the ER,0.00016401551900978954,0,0,1,0.00017697403394772564
2621,FA5,Cargo concentration in the ER,0.0003398628530400553,1,0,1,0.00036671468928432105
2622,FA5,Platelet degranulation ,0.00016401551900978954,0,0,1,0.00017697403394772564
2623,FA5,Platelet degranulation ,0.0003398628530400553,1,0,1,0.00036671468928432105
2624,FA5,Common Pathway of Fibrin Clot Formation,0.00016401551900978954,0,0,1,0.00017697403394772564
2625,FA5,Common Pathway of Fibrin Clot Formation,0.0003398628530400553,1,0,1,0.00036671468928432105
2626,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00016401551900978954,0,0,1,0.00017697403394772564
2627,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0003398628530400553,1,0,1,0.00036671468928432105
2628,FA5,Post-translational protein phosphorylation,0.00016401551900978954,0,0,1,0.00017697403394772564
2629,FA5,Post-translational protein phosphorylation,0.0003398628530400553,1,0,1,0.00036671468928432105
2630,ACTN1,RHO GTPase cycle,0.0013052245223661885,0,0,1,0.001408347516900829
2631,ACTN1,RHO GTPase cycle,0.0012231419609937196,1,0,1,0.0013197797881240138
2632,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0013052245223661885,0,0,1,0.001408347516900829
2633,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0012231419609937196,1,0,1,0.0013197797881240138
2634,ACTN1,Platelet degranulation ,0.0013052245223661885,0,0,1,0.001408347516900829
2635,ACTN1,Platelet degranulation ,0.0012231419609937196,1,0,1,0.0013197797881240138
2636,ACTN1,Nephrin family interactions,0.0013052245223661885,0,0,1,0.001408347516900829
2637,ACTN1,Nephrin family interactions,0.0012231419609937196,1,0,1,0.0013197797881240138
2638,ACTN1,Syndecan interactions,0.0013052245223661885,0,0,1,0.001408347516900829
2639,ACTN1,Syndecan interactions,0.0012231419609937196,1,0,1,0.0013197797881240138
2640,ICAM2,CD209 (DC-SIGN) signaling,0.0004620436642047328,0,0,1,0.0004985487447039652
2641,ICAM2,CD209 (DC-SIGN) signaling,0.0004207482482039874,1,0,1,0.0004539906663140467
2642,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004620436642047328,0,0,1,0.0004985487447039652
2643,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0004207482482039874,1,0,1,0.0004539906663140467
2644,ICAM2,Integrin cell surface interactions,0.0004620436642047328,0,0,1,0.0004985487447039652
2645,ICAM2,Integrin cell surface interactions,0.0004207482482039874,1,0,1,0.0004539906663140467
2646,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.007316829623111213,0,0,1,0.00789491666354402
2647,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.007161673608546456,1,0,1,0.00772750210451599
2648,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.007316829623111213,0,0,1,0.00789491666354402
2649,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.007161673608546456,1,0,1,0.00772750210451599
2650,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.007316829623111213,0,0,1,0.00789491666354402
2651,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.007161673608546456,1,0,1,0.00772750210451599
2652,CSPG2,ECM proteoglycans,0.007316829623111213,0,0,1,0.00789491666354402
2653,CSPG2,ECM proteoglycans,0.007161673608546456,1,0,1,0.00772750210451599
2654,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007316829623111213,0,0,1,0.00789491666354402
2655,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007161673608546456,1,0,1,0.00772750210451599
2656,CSPG2,Post-translational protein phosphorylation,0.007316829623111213,0,0,1,0.00789491666354402
2657,CSPG2,Post-translational protein phosphorylation,0.007161673608546456,1,0,1,0.00772750210451599
2658,K1C10,Formation of the cornified envelope,9.146922330576975e-05,0,0,1,9.869601076908584e-05
2659,K1C10,Formation of the cornified envelope,0.00010614304821198554,1,0,1,0.0001145291831589535
2660,K2C5,Type I hemidesmosome assembly,0.0012553832852669681,0,0,1,0.001354568430387268
2661,K2C5,Type I hemidesmosome assembly,0.0006846510693624926,1,0,1,0.0007387438842569065
2662,K2C5,Formation of the cornified envelope,0.0012553832852669681,0,0,1,0.001354568430387268
2663,K2C5,Formation of the cornified envelope,0.0006846510693624926,1,0,1,0.0007387438842569065
2664,CO6,Terminal pathway of complement,0.0011084911659660671,0,0,1,0.0011960706792917795
2665,CO6,Terminal pathway of complement,0.001137715282766294,1,0,1,0.0012276037309805463
2666,CO6,Regulation of Complement cascade,0.0011084911659660671,0,0,1,0.0011960706792917795
2667,CO6,Regulation of Complement cascade,0.001137715282766294,1,0,1,0.0012276037309805463
2668,PRG2,Neutrophil degranulation,0.0011122019330893332,0,0,1,0.001200074626179304
2669,PRG2,Neutrophil degranulation,0.0010838911373866722,1,0,1,0.001169527055132257
2670,PLSL,Interleukin-12 family signaling,0.0004632129112602949,0,0,1,0.0004998103714655887
2671,PLSL,Interleukin-12 family signaling,0.0005142419764069927,1,0,1,0.000554871133777071
2672,CD59,Regulation of Complement cascade,0.0013656887087563519,0,0,1,0.0014735888491810732
2673,CD59,Regulation of Complement cascade,0.001548815731924454,1,0,1,0.001671184346305728
2674,CD59,COPII-mediated vesicle transport,0.0013656887087563519,0,0,1,0.0014735888491810732
2675,CD59,COPII-mediated vesicle transport,0.001548815731924454,1,0,1,0.001671184346305728
2676,CD59,Cargo concentration in the ER,0.0013656887087563519,0,0,1,0.0014735888491810732
2677,CD59,Cargo concentration in the ER,0.001548815731924454,1,0,1,0.001671184346305728
2678,CD59,COPI-mediated anterograde transport,0.0013656887087563519,0,0,1,0.0014735888491810732
2679,CD59,COPI-mediated anterograde transport,0.001548815731924454,1,0,1,0.001671184346305728
2680,CD59,Neutrophil degranulation,0.0013656887087563519,0,0,1,0.0014735888491810732
2681,CD59,Neutrophil degranulation,0.001548815731924454,1,0,1,0.001671184346305728
2682,GFAP,Nuclear signaling by ERBB4,0.0001236064867953246,0,0,1,0.00013337237062895993
2683,GFAP,Nuclear signaling by ERBB4,9.969765421071012e-05,1,0,1,0.00010757455237965449
2684,GFAP,Chaperone Mediated Autophagy,0.0001236064867953246,0,0,1,0.00013337237062895993
2685,GFAP,Chaperone Mediated Autophagy,9.969765421071012e-05,1,0,1,0.00010757455237965449
2686,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006183671375220001,0,0,1,0.006672230009005706
2687,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005700717693859284,1,0,1,0.0061511191914664885
2688,LYAM1,Neutrophil degranulation,0.006183671375220001,0,0,1,0.006672230009005706
2689,LYAM1,Neutrophil degranulation,0.005700717693859284,1,0,1,0.0061511191914664885
2690,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.00823805780382827,0,0,1,0.008888929110122876
2691,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.007653288450092078,1,0,1,0.008257958381959515
2692,GLU2B,SARS-CoV-1 Infection,0.00823805780382827,0,0,1,0.008888929110122876
2693,GLU2B,SARS-CoV-1 Infection,0.007653288450092078,1,0,1,0.008257958381959515
2694,GLU2B,SARS-CoV-2 Infection,0.00823805780382827,0,0,1,0.008888929110122876
2695,GLU2B,SARS-CoV-2 Infection,0.007653288450092078,1,0,1,0.008257958381959515
2696,GLU2B,Advanced glycosylation endproduct receptor signaling,0.00823805780382827,0,0,1,0.008888929110122876
2697,GLU2B,Advanced glycosylation endproduct receptor signaling,0.007653288450092078,1,0,1,0.008257958381959515
2698,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00823805780382827,0,0,1,0.008888929110122876
2699,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007653288450092078,1,0,1,0.008257958381959515
2700,GLU2B,Post-translational protein phosphorylation,0.00823805780382827,0,0,1,0.008888929110122876
2701,GLU2B,Post-translational protein phosphorylation,0.007653288450092078,1,0,1,0.008257958381959515
2702,NID1,Laminin interactions,0.0008476437196198579,0,0,1,0.0009146142347824263
2703,NID1,Laminin interactions,0.0006603554758839892,1,0,1,0.0007125287479636867
2704,PA2GA,Glycerophospholipid biosynthesis,0.00043444622400177954,0,0,1,0.0004687708898470948
2705,PA2GA,Glycerophospholipid biosynthesis,0.00029815183843311387,1,0,1,0.0003217081767322842
2706,KPYM,Neutrophil degranulation,0.0002902474664248681,0,0,1,0.0003131792972179058
2707,KPYM,Neutrophil degranulation,0.00028288025059737266,1,0,1,0.00030523001344386503
2708,ENPL,Trafficking and processing of endosomal TLR,0.0027288866528882255,0,0,1,0.0029444901437583534
2709,ENPL,Trafficking and processing of endosomal TLR,0.0025350712014793925,1,0,1,0.00273536174856562
2710,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0027288866528882255,0,0,1,0.0029444901437583534
2711,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0025350712014793925,1,0,1,0.00273536174856562
2712,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0027288866528882255,0,0,1,0.0029444901437583534
2713,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0025350712014793925,1,0,1,0.00273536174856562
2714,ENPL,Scavenging by Class A Receptors,0.0027288866528882255,0,0,1,0.0029444901437583534
2715,ENPL,Scavenging by Class A Receptors,0.0025350712014793925,1,0,1,0.00273536174856562
2716,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0027288866528882255,0,0,1,0.0029444901437583534
2717,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025350712014793925,1,0,1,0.00273536174856562
2718,ENPL,Post-translational protein phosphorylation,0.0027288866528882255,0,0,1,0.0029444901437583534
2719,ENPL,Post-translational protein phosphorylation,0.0025350712014793925,1,0,1,0.00273536174856562
2720,GPIX,Defective factor IX causes hemophilia B,4.3339458578846764e-05,0,0,1,4.676361639505029e-05
2721,GPIX,Defective factor IX causes hemophilia B,3.638188946323654e-05,1,0,1,3.9256344642392795e-05
2722,GPIX,Platelet Adhesion to exposed collagen,4.3339458578846764e-05,0,0,1,4.676361639505029e-05
2723,GPIX,Platelet Adhesion to exposed collagen,3.638188946323654e-05,1,0,1,3.9256344642392795e-05
2724,GPIX,Intrinsic Pathway of Fibrin Clot Formation,4.3339458578846764e-05,0,0,1,4.676361639505029e-05
2725,GPIX,Intrinsic Pathway of Fibrin Clot Formation,3.638188946323654e-05,1,0,1,3.9256344642392795e-05
2726,GPIX,GP1b-IX-V activation signalling,4.3339458578846764e-05,0,0,1,4.676361639505029e-05
2727,GPIX,GP1b-IX-V activation signalling,3.638188946323654e-05,1,0,1,3.9256344642392795e-05
2728,MMP9,EPH-Ephrin signaling,0.012574289653760692,0,0,1,0.013567757353012173
2729,MMP9,EPH-Ephrin signaling,0.012480569623100261,1,0,1,0.01346663270341916
2730,MMP9,Interleukin-4 and Interleukin-13 signaling,0.012574289653760692,0,0,1,0.013567757353012173
2731,MMP9,Interleukin-4 and Interleukin-13 signaling,0.012480569623100261,1,0,1,0.01346663270341916
2732,MMP9,Extra-nuclear estrogen signaling,0.012574289653760692,0,0,1,0.013567757353012173
2733,MMP9,Extra-nuclear estrogen signaling,0.012480569623100261,1,0,1,0.01346663270341916
2734,MMP9,Collagen degradation,0.012574289653760692,0,0,1,0.013567757353012173
2735,MMP9,Collagen degradation,0.012480569623100261,1,0,1,0.01346663270341916
2736,MMP9,Activation of Matrix Metalloproteinases,0.012574289653760692,0,0,1,0.013567757353012173
2737,MMP9,Activation of Matrix Metalloproteinases,0.012480569623100261,1,0,1,0.01346663270341916
2738,MMP9,Neutrophil degranulation,0.012574289653760692,0,0,1,0.013567757353012173
2739,MMP9,Neutrophil degranulation,0.012480569623100261,1,0,1,0.01346663270341916
2740,MMP9,Signaling by SCF-KIT,0.012574289653760692,0,0,1,0.013567757353012173
2741,MMP9,Signaling by SCF-KIT,0.012480569623100261,1,0,1,0.01346663270341916
2742,AMPN,Neutrophil degranulation,0.003345931616665136,0,0,1,0.003610286508797507
2743,AMPN,Neutrophil degranulation,0.003134784466116495,1,0,1,0.003382457074029628
2744,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.003345931616665136,0,0,1,0.003610286508797507
2745,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.003134784466116495,1,0,1,0.003382457074029628
2746,PVR,Adherens junctions interactions,0.0011618903413060859,0,0,1,0.0012536888091276579
2747,PVR,Adherens junctions interactions,0.0010538175921434836,1,0,1,0.0011370774634781962
2748,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0011618903413060859,0,0,1,0.0012536888091276579
2749,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0010538175921434836,1,0,1,0.0011370774634781962
2750,CBPN,Regulation of Complement cascade,0.0020943233882159498,0,0,1,0.0022597913943833746
2751,CBPN,Regulation of Complement cascade,0.0021653229389812624,1,0,1,0.002336400467617864
2752,B4GT1,Keratan sulfate/keratin metabolism,0.007812038141370673,0,0,1,0.008429250546403127
2753,B4GT1,Keratan sulfate/keratin metabolism,0.008172944844894421,1,0,1,0.008818671715735044
2754,B4GT1,Pre-NOTCH Processing in Golgi,0.007812038141370673,0,0,1,0.008429250546403127
2755,B4GT1,Pre-NOTCH Processing in Golgi,0.008172944844894421,1,0,1,0.008818671715735044
2756,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.007812038141370673,0,0,1,0.008429250546403127
2757,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.008172944844894421,1,0,1,0.008818671715735044
2758,B4GT1,Diseases associated with N-glycosylation of proteins,0.007812038141370673,0,0,1,0.008429250546403127
2759,B4GT1,Diseases associated with N-glycosylation of proteins,0.008172944844894421,1,0,1,0.008818671715735044
2760,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.007812038141370673,0,0,1,0.008429250546403127
2761,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.008172944844894421,1,0,1,0.008818671715735044
2762,B4GT1,Neutrophil degranulation,0.007812038141370673,0,0,1,0.008429250546403127
2763,B4GT1,Neutrophil degranulation,0.008172944844894421,1,0,1,0.008818671715735044
2764,B4GT1,Lactose synthesis,0.007812038141370673,0,0,1,0.008429250546403127
2765,B4GT1,Lactose synthesis,0.008172944844894421,1,0,1,0.008818671715735044
2766,EZRI,L1CAM interactions,0.003369672728391985,0,0,1,0.0036359033549232286
2767,EZRI,L1CAM interactions,0.0040044895800141,1,0,1,0.0043208757266099285
2768,EZRI,Netrin-1 signaling,0.003369672728391985,0,0,1,0.0036359033549232286
2769,EZRI,Netrin-1 signaling,0.0040044895800141,1,0,1,0.0043208757266099285
2770,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.003369672728391985,0,0,1,0.0036359033549232286
2771,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.0040044895800141,1,0,1,0.0043208757266099285
2772,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.003369672728391985,0,0,1,0.0036359033549232286
2773,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.0040044895800141,1,0,1,0.0043208757266099285
2774,TIMP2,Activation of Matrix Metalloproteinases,0.0002572304536139806,0,0,1,0.00027755368092669534
2775,TIMP2,Activation of Matrix Metalloproteinases,0.00020934056571301576,1,0,1,0.00022588011553297023
2776,TIMP2,Neutrophil degranulation,0.0002572304536139806,0,0,1,0.00027755368092669534
2777,TIMP2,Neutrophil degranulation,0.00020934056571301576,1,0,1,0.00022588011553297023
2778,CD44,Hyaluronan metabolism,0.010619018744121907,0,0,1,0.011458004675774593
2779,CD44,Hyaluronan metabolism,0.01086451593325061,1,0,1,0.011722898072114369
2780,CD44,Interferon gamma signaling,0.010619018744121907,0,0,1,0.011458004675774593
2781,CD44,Interferon gamma signaling,0.01086451593325061,1,0,1,0.011722898072114369
2782,CD44,Integrin cell surface interactions,0.010619018744121907,0,0,1,0.011458004675774593
2783,CD44,Integrin cell surface interactions,0.01086451593325061,1,0,1,0.011722898072114369
2784,CD44,Neutrophil degranulation,0.010619018744121907,0,0,1,0.011458004675774593
2785,CD44,Neutrophil degranulation,0.01086451593325061,1,0,1,0.011722898072114369
2786,CD36,Antigen processing-Cross presentation,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2787,CD36,Antigen processing-Cross presentation,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2788,CD36,Toll Like Receptor 4 (TLR4) Cascade,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2789,CD36,Toll Like Receptor 4 (TLR4) Cascade,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2790,CD36,Toll Like Receptor 2 (TLR2) Cascade,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2791,CD36,Toll Like Receptor 2 (TLR2) Cascade,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2792,CD36,Regulation of TLR by endogenous ligand,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2793,CD36,Regulation of TLR by endogenous ligand,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2794,CD36,PPARA activates gene expression,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2795,CD36,PPARA activates gene expression,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2796,CD36,Free fatty acids regulate insulin secretion,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2797,CD36,Free fatty acids regulate insulin secretion,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2798,CD36,Interleukin-4 and Interleukin-13 signaling,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2799,CD36,Interleukin-4 and Interleukin-13 signaling,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2800,CD36,MyD88 deficiency (TLR2/4),3.951625520386415e-05,0,0,1,4.263834990832931e-05
2801,CD36,MyD88 deficiency (TLR2/4),3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2802,CD36,IRAK4 deficiency (TLR2/4),3.951625520386415e-05,0,0,1,4.263834990832931e-05
2803,CD36,IRAK4 deficiency (TLR2/4),3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2804,CD36,Platelet degranulation ,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2805,CD36,Platelet degranulation ,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2806,CD36,Transcriptional regulation of white adipocyte differentiation,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2807,CD36,Transcriptional regulation of white adipocyte differentiation,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2808,CD36,Neutrophil degranulation,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2809,CD36,Neutrophil degranulation,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2810,CD36,Scavenging by Class B Receptors,3.951625520386415e-05,0,0,1,4.263834990832931e-05
2811,CD36,Scavenging by Class B Receptors,3.667424063252452e-05,1,0,1,3.9571793851532204e-05
2812,FAAA,Tyrosine catabolism,0.00010494540905104562,0,0,1,0.00011323692109250443
2813,FAAA,Tyrosine catabolism,0.00010984095100260068,1,0,1,0.0001185192493304519
2814,HSP76,Regulation of HSF1-mediated heat shock response,0.00021510402062669225,0,0,1,0.00023209892867764767
2815,HSP76,Regulation of HSF1-mediated heat shock response,0.00018963945742574614,1,0,1,0.00020462246486741968
2816,HSP76,Neutrophil degranulation,0.00021510402062669225,0,0,1,0.00023209892867764767
2817,HSP76,Neutrophil degranulation,0.00018963945742574614,1,0,1,0.00020462246486741968
2818,AATC,Methionine salvage pathway,0.0008602430478883131,0,0,1,0.0009282090089974629
2819,AATC,Methionine salvage pathway,0.001035634774355761,1,0,1,0.00111745806019333
2820,AATC,Gluconeogenesis,0.0008602430478883131,0,0,1,0.0009282090089974629
2821,AATC,Gluconeogenesis,0.001035634774355761,1,0,1,0.00111745806019333
2822,AATC,Aspartate and asparagine metabolism,0.0008602430478883131,0,0,1,0.0009282090089974629
2823,AATC,Aspartate and asparagine metabolism,0.001035634774355761,1,0,1,0.00111745806019333
2824,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",2.2006555802060272e-05,0,0,1,2.3745246651652994e-05
2825,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",1.861631593177056e-05,1,0,1,2.00871511889927e-05
2826,CTRB1,Activation of Matrix Metalloproteinases,2.2006555802060272e-05,0,0,1,2.3745246651652994e-05
2827,CTRB1,Activation of Matrix Metalloproteinases,1.861631593177056e-05,1,0,1,2.00871511889927e-05
2828,IBP3,Transcriptional Regulation by TP53,0.0025040679317802034,0,0,1,0.0027019089769171802
2829,IBP3,Transcriptional Regulation by TP53,0.002387636506803877,1,0,1,0.0025762785543770265
2830,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025040679317802034,0,0,1,0.0027019089769171802
2831,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002387636506803877,1,0,1,0.0025762785543770265
2832,IBP3,Post-translational protein phosphorylation,0.0025040679317802034,0,0,1,0.0027019089769171802
2833,IBP3,Post-translational protein phosphorylation,0.002387636506803877,1,0,1,0.0025762785543770265
2834,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0011423568218863996,0,0,1,0.0012326119881672475
2835,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0010833194401432896,1,0,1,0.0011689101893138938
2836,VINC,RAF/MAP kinase cascade,0.01128341065486893,0,0,1,0.012174888768676314
2837,VINC,RAF/MAP kinase cascade,0.011126813963831713,1,0,1,0.012005919708412768
2838,VINC,Signaling by RAS mutants,0.01128341065486893,0,0,1,0.012174888768676314
2839,VINC,Signaling by RAS mutants,0.011126813963831713,1,0,1,0.012005919708412768
2840,VINC,Signaling by moderate kinase activity BRAF mutants,0.01128341065486893,0,0,1,0.012174888768676314
2841,VINC,Signaling by moderate kinase activity BRAF mutants,0.011126813963831713,1,0,1,0.012005919708412768
2842,VINC,Signaling by high-kinase activity BRAF mutants,0.01128341065486893,0,0,1,0.012174888768676314
2843,VINC,Signaling by high-kinase activity BRAF mutants,0.011126813963831713,1,0,1,0.012005919708412768
2844,VINC,Signaling by BRAF and RAF1 fusions,0.01128341065486893,0,0,1,0.012174888768676314
2845,VINC,Signaling by BRAF and RAF1 fusions,0.011126813963831713,1,0,1,0.012005919708412768
2846,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.01128341065486893,0,0,1,0.012174888768676314
2847,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.011126813963831713,1,0,1,0.012005919708412768
2848,VINC,Signaling by RAF1 mutants,0.01128341065486893,0,0,1,0.012174888768676314
2849,VINC,Signaling by RAF1 mutants,0.011126813963831713,1,0,1,0.012005919708412768
2850,VINC,Platelet degranulation ,0.01128341065486893,0,0,1,0.012174888768676314
2851,VINC,Platelet degranulation ,0.011126813963831713,1,0,1,0.012005919708412768
2852,VINC,Signaling by ALK fusions and activated point mutants,0.01128341065486893,0,0,1,0.012174888768676314
2853,VINC,Signaling by ALK fusions and activated point mutants,0.011126813963831713,1,0,1,0.012005919708412768
2854,VINC,Neutrophil degranulation,0.01128341065486893,0,0,1,0.012174888768676314
2855,VINC,Neutrophil degranulation,0.011126813963831713,1,0,1,0.012005919708412768
2856,VINC,Smooth Muscle Contraction,0.01128341065486893,0,0,1,0.012174888768676314
2857,VINC,Smooth Muscle Contraction,0.011126813963831713,1,0,1,0.012005919708412768
2858,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0036265635120950415,0,0,1,0.003913090529346699
2859,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0037870577521819846,1,0,1,0.004086265075664269
2860,LBP,Regulation of TLR by endogenous ligand,0.0036265635120950415,0,0,1,0.003913090529346699
2861,LBP,Regulation of TLR by endogenous ligand,0.0037870577521819846,1,0,1,0.004086265075664269
2862,LBP,Interleukin-4 and Interleukin-13 signaling,0.0036265635120950415,0,0,1,0.003913090529346699
2863,LBP,Interleukin-4 and Interleukin-13 signaling,0.0037870577521819846,1,0,1,0.004086265075664269
2864,ML12A,EPH-Ephrin signaling,0.0030925719474907964,0,0,1,0.0033369094347002206
2865,ML12A,EPH-Ephrin signaling,0.003248986761900596,1,0,1,0.003505682248653484
2866,ML12A,Smooth Muscle Contraction,0.0030925719474907964,0,0,1,0.0033369094347002206
2867,ML12A,Smooth Muscle Contraction,0.003248986761900596,1,0,1,0.003505682248653484
2868,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.00627698208312116,0,0,1,0.00677291299612475
2869,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.00593390937622947,1,0,1,0.006402734849309483
2870,VCAM1,Interferon gamma signaling,0.00627698208312116,0,0,1,0.00677291299612475
2871,VCAM1,Interferon gamma signaling,0.00593390937622947,1,0,1,0.006402734849309483
2872,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00627698208312116,0,0,1,0.00677291299612475
2873,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00593390937622947,1,0,1,0.006402734849309483
2874,VCAM1,Integrin cell surface interactions,0.00627698208312116,0,0,1,0.00677291299612475
2875,VCAM1,Integrin cell surface interactions,0.00593390937622947,1,0,1,0.006402734849309483
2876,A1AG2,Platelet degranulation ,0.005452395120209985,0,0,1,0.005883177183025356
2877,A1AG2,Platelet degranulation ,0.005973222799851404,1,0,1,0.006445154342346934
2878,A1AG2,Neutrophil degranulation,0.005452395120209985,0,0,1,0.005883177183025356
2879,A1AG2,Neutrophil degranulation,0.005973222799851404,1,0,1,0.006445154342346934
2880,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00773629097614806,0,0,1,0.008347518759859496
2881,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007154820612534725,1,0,1,0.00772010766796422
2882,ITIH2,Post-translational protein phosphorylation,0.00773629097614806,0,0,1,0.008347518759859496
2883,ITIH2,Post-translational protein phosphorylation,0.007154820612534725,1,0,1,0.00772010766796422
2884,TYPH,Pyrimidine catabolism,0.0006202999223508717,0,0,1,0.0006693084909199508
2885,TYPH,Pyrimidine catabolism,0.0006333765292462582,1,0,1,0.000683418252524199
2886,TYPH,Pyrimidine salvage,0.0006202999223508717,0,0,1,0.0006693084909199508
2887,TYPH,Pyrimidine salvage,0.0006333765292462582,1,0,1,0.000683418252524199
2888,C4BPB,Regulation of Complement cascade,0.00156229789987871,0,0,1,0.001685731711479648
2889,C4BPB,Regulation of Complement cascade,0.0016143155383967192,1,0,1,0.0017418591522276009
2890,FLNA,Antiviral mechanism by IFN-stimulated genes,0.0028270845243241636,0,0,1,0.0030504464187378014
2891,FLNA,Antiviral mechanism by IFN-stimulated genes,0.0030473485356196763,1,0,1,0.0032881130178975286
2892,FLNA,RHO GTPase Effectors,0.0028270845243241636,0,0,1,0.0030504464187378014
2893,FLNA,RHO GTPase Effectors,0.0030473485356196763,1,0,1,0.0032881130178975286
2894,FLNA,Platelet degranulation ,0.0028270845243241636,0,0,1,0.0030504464187378014
2895,FLNA,Platelet degranulation ,0.0030473485356196763,1,0,1,0.0032881130178975286
2896,FLNA,GP1b-IX-V activation signalling,0.0028270845243241636,0,0,1,0.0030504464187378014
2897,FLNA,GP1b-IX-V activation signalling,0.0030473485356196763,1,0,1,0.0032881130178975286
2898,TENX,ECM proteoglycans,0.0004590366870009651,0,0,1,0.0004953041926703991
2899,TENX,ECM proteoglycans,0.00045681951645140846,1,0,1,0.0004929118482235196
2900,GPX3,Detoxification of Reactive Oxygen Species,1.845622636362047e-05,0,0,1,1.9914413286875157e-05
2901,GPX3,Detoxification of Reactive Oxygen Species,1.4393645062208785e-05,1,0,1,1.5530856136356286e-05
2902,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0014433910828302032,0,0,1,0.0015574303214404383
2903,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0013414818580107142,1,0,1,0.001447469466994011
2904,IBP4,Post-translational protein phosphorylation,0.0014433910828302032,0,0,1,0.0015574303214404383
2905,IBP4,Post-translational protein phosphorylation,0.0013414818580107142,1,0,1,0.001447469466994011
2906,CPN2,Regulation of Complement cascade,0.0006694738510759635,0,0,1,0.0007223675464537019
2907,CPN2,Regulation of Complement cascade,0.0006925789011802408,1,0,1,0.0007472980770900999
2908,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0007380621884825208,0,0,1,0.0007963749015252767
2909,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0006903957054343361,1,0,1,0.000744942391723356
2910,MMP8,Collagen degradation,0.0002048291359566671,0,0,1,0.0002210122473722435
2911,MMP8,Collagen degradation,0.00020952480501819083,1,0,1,0.00022607891119112142
2912,MMP8,Activation of Matrix Metalloproteinases,0.0002048291359566671,0,0,1,0.0002210122473722435
2913,MMP8,Activation of Matrix Metalloproteinases,0.00020952480501819083,1,0,1,0.00022607891119112142
2914,MMP8,Neutrophil degranulation,0.0002048291359566671,0,0,1,0.0002210122473722435
2915,MMP8,Neutrophil degranulation,0.00020952480501819083,1,0,1,0.00022607891119112142
2916,MRC1,Antigen processing-Cross presentation,0.0027333434903994203,0,0,1,0.0029492991064575397
2917,MRC1,Antigen processing-Cross presentation,0.0027761473960708828,1,0,1,0.0029954848570568136
2918,MRC1,Modulation by Mtb of host immune system,0.0027333434903994203,0,0,1,0.0029492991064575397
2919,MRC1,Modulation by Mtb of host immune system,0.0027761473960708828,1,0,1,0.0029954848570568136
2920,HV102,Initial triggering of complement,0.0023014941575335494,0,0,1,0.002483330282554079
2921,HV102,Initial triggering of complement,0.0021814391135800784,1,0,1,0.00235378994666093
2922,HV102,Regulation of Complement cascade,0.0023014941575335494,0,0,1,0.002483330282554079
2923,HV102,Regulation of Complement cascade,0.0021814391135800784,1,0,1,0.00235378994666093
2924,HV102,FCGR activation,0.0023014941575335494,0,0,1,0.002483330282554079
2925,HV102,FCGR activation,0.0021814391135800784,1,0,1,0.00235378994666093
2926,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0023014941575335494,0,0,1,0.002483330282554079
2927,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0021814391135800784,1,0,1,0.00235378994666093
2928,HV102,Role of phospholipids in phagocytosis,0.0023014941575335494,0,0,1,0.002483330282554079
2929,HV102,Role of phospholipids in phagocytosis,0.0021814391135800784,1,0,1,0.00235378994666093
2930,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023014941575335494,0,0,1,0.002483330282554079
2931,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0021814391135800784,1,0,1,0.00235378994666093
2932,HV102,FCERI mediated MAPK activation,0.0023014941575335494,0,0,1,0.002483330282554079
2933,HV102,FCERI mediated MAPK activation,0.0021814391135800784,1,0,1,0.00235378994666093
2934,HV102,FCERI mediated Ca+2 mobilization,0.0023014941575335494,0,0,1,0.002483330282554079
2935,HV102,FCERI mediated Ca+2 mobilization,0.0021814391135800784,1,0,1,0.00235378994666093
2936,HV102,FCERI mediated NF-kB activation,0.0023014941575335494,0,0,1,0.002483330282554079
2937,HV102,FCERI mediated NF-kB activation,0.0021814391135800784,1,0,1,0.00235378994666093
2938,HV102,Parasite infection,0.0023014941575335494,0,0,1,0.002483330282554079
2939,HV102,Parasite infection,0.0021814391135800784,1,0,1,0.00235378994666093
2940,HV102,Leishmania parasite growth and survival,0.0023014941575335494,0,0,1,0.002483330282554079
2941,HV102,Leishmania parasite growth and survival,0.0021814391135800784,1,0,1,0.00235378994666093
2942,HV102,Potential therapeutics for SARS,0.0023014941575335494,0,0,1,0.002483330282554079
2943,HV102,Potential therapeutics for SARS,0.0021814391135800784,1,0,1,0.00235378994666093
2944,HV102,CD22 mediated BCR regulation,0.0023014941575335494,0,0,1,0.002483330282554079
2945,HV102,CD22 mediated BCR regulation,0.0021814391135800784,1,0,1,0.00235378994666093
2946,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023014941575335494,0,0,1,0.002483330282554079
2947,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0021814391135800784,1,0,1,0.00235378994666093
2948,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023014941575335494,0,0,1,0.002483330282554079
2949,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0021814391135800784,1,0,1,0.00235378994666093
2950,HV102,Scavenging of heme from plasma,0.0023014941575335494,0,0,1,0.002483330282554079
2951,HV102,Scavenging of heme from plasma,0.0021814391135800784,1,0,1,0.00235378994666093
2952,EST1,Metabolism of Angiotensinogen to Angiotensins,0.004732596226191769,0,0,1,0.005106508519751414
2953,EST1,Metabolism of Angiotensinogen to Angiotensins,0.0044113448316541815,1,0,1,0.004759875740451695
2954,EST1,Physiological factors,0.004732596226191769,0,0,1,0.005106508519751414
2955,EST1,Physiological factors,0.0044113448316541815,1,0,1,0.004759875740451695
2956,EST1,Aspirin ADME,0.004732596226191769,0,0,1,0.005106508519751414
2957,EST1,Aspirin ADME,0.0044113448316541815,1,0,1,0.004759875740451695
2958,FBLN1,Molecules associated with elastic fibres,0.00022254709087121682,0,0,1,0.00024013005996377417
2959,FBLN1,Molecules associated with elastic fibres,0.0002019653712068248,1,0,1,0.00021792222270191553
2960,SAHH,Methylation,7.177816190354255e-05,0,0,1,7.744920077145074e-05
2961,SAHH,Methylation,0.0001460221810702933,1,0,1,0.00015755908090814624
2962,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",7.177816190354255e-05,0,0,1,7.744920077145074e-05
2963,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0001460221810702933,1,0,1,0.00015755908090814624
2964,SAHH,Defective AHCY causes HMAHCHD,7.177816190354255e-05,0,0,1,7.744920077145074e-05
2965,SAHH,Defective AHCY causes HMAHCHD,0.0001460221810702933,1,0,1,0.00015755908090814624
2966,PRTN3,Other interleukin signaling,0.0003237262885591008,0,0,1,0.00034930320939819125
2967,PRTN3,Other interleukin signaling,0.00028956677871671367,1,0,1,0.000312444829831539
2968,PRTN3,Common Pathway of Fibrin Clot Formation,0.0003237262885591008,0,0,1,0.00034930320939819125
2969,PRTN3,Common Pathway of Fibrin Clot Formation,0.00028956677871671367,1,0,1,0.000312444829831539
2970,PRTN3,Neutrophil degranulation,0.0003237262885591008,0,0,1,0.00034930320939819125
2971,PRTN3,Neutrophil degranulation,0.00028956677871671367,1,0,1,0.000312444829831539
2972,ALAT1,Alanine metabolism,7.753432397900421e-05,0,0,1,8.366014488638269e-05
2973,ALAT1,Alanine metabolism,7.637186054125778e-05,1,0,1,8.240583770169216e-05
2974,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002850540449799155,0,0,1,0.0003075755546656597
2975,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0002699220860146549,1,0,1,0.00029124805202577976
2976,THIL,Utilization of Ketone Bodies,0.0007821019384815979,0,0,1,0.0008438941378660819
2977,THIL,Utilization of Ketone Bodies,0.0007740662969202579,1,0,1,0.0008352236174723169
2978,THIL,Synthesis of Ketone Bodies,0.0007821019384815979,0,0,1,0.0008438941378660819
2979,THIL,Synthesis of Ketone Bodies,0.0007740662969202579,1,0,1,0.0008352236174723169
2980,THIL,Branched-chain amino acid catabolism,0.0007821019384815979,0,0,1,0.0008438941378660819
2981,THIL,Branched-chain amino acid catabolism,0.0007740662969202579,1,0,1,0.0008352236174723169
2982,TENA,Integrin cell surface interactions,0.006242034281603992,0,0,1,0.006735204043646122
2983,TENA,Integrin cell surface interactions,0.005741634155856446,1,0,1,0.006195268375508483
2984,TENA,ECM proteoglycans,0.006242034281603992,0,0,1,0.006735204043646122
2985,TENA,ECM proteoglycans,0.005741634155856446,1,0,1,0.006195268375508483
2986,TENA,Syndecan interactions,0.006242034281603992,0,0,1,0.006735204043646122
2987,TENA,Syndecan interactions,0.005741634155856446,1,0,1,0.006195268375508483
2988,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006242034281603992,0,0,1,0.006735204043646122
2989,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005741634155856446,1,0,1,0.006195268375508483
2990,TENA,Post-translational protein phosphorylation,0.006242034281603992,0,0,1,0.006735204043646122
2991,TENA,Post-translational protein phosphorylation,0.005741634155856446,1,0,1,0.006195268375508483
2992,ZA2G,Miscellaneous transport and binding events,0.0008547512796212686,0,0,1,0.0009222833478795843
2993,ZA2G,Miscellaneous transport and binding events,0.001043570038746111,1,0,1,0.0011260202728307703
2994,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.0063111296816108125,0,0,1,0.006809758523248196
2995,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.0064360942846784985,1,0,1,0.006944596312007958
2996,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0063111296816108125,0,0,1,0.006809758523248196
2997,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0064360942846784985,1,0,1,0.006944596312007958
2998,PSA1,Antigen processing-Cross presentation,0.0063111296816108125,0,0,1,0.006809758523248196
2999,PSA1,Antigen processing-Cross presentation,0.0064360942846784985,1,0,1,0.006944596312007958
3000,PSA1,PTEN Regulation,0.0063111296816108125,0,0,1,0.006809758523248196
3001,PSA1,PTEN Regulation,0.0064360942846784985,1,0,1,0.006944596312007958
3002,PSA1,Host Interactions of HIV factors,0.0063111296816108125,0,0,1,0.006809758523248196
3003,PSA1,Host Interactions of HIV factors,0.0064360942846784985,1,0,1,0.006944596312007958
3004,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0063111296816108125,0,0,1,0.006809758523248196
3005,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0064360942846784985,1,0,1,0.006944596312007958
3006,PSA1,APC/C-mediated degradation of cell cycle proteins,0.0063111296816108125,0,0,1,0.006809758523248196
3007,PSA1,APC/C-mediated degradation of cell cycle proteins,0.0064360942846784985,1,0,1,0.006944596312007958
3008,PSA1,Degradation of AXIN,0.0063111296816108125,0,0,1,0.006809758523248196
3009,PSA1,Degradation of AXIN,0.0064360942846784985,1,0,1,0.006944596312007958
3010,PSA1,Degradation of DVL,0.0063111296816108125,0,0,1,0.006809758523248196
3011,PSA1,Degradation of DVL,0.0064360942846784985,1,0,1,0.006944596312007958
3012,PSA1,Downstream TCR signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3013,PSA1,Downstream TCR signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3014,PSA1,Transcriptional regulation by RUNX3,0.0063111296816108125,0,0,1,0.006809758523248196
3015,PSA1,Transcriptional regulation by RUNX3,0.0064360942846784985,1,0,1,0.006944596312007958
3016,PSA1,Transcriptional regulation by RUNX2,0.0063111296816108125,0,0,1,0.006809758523248196
3017,PSA1,Transcriptional regulation by RUNX2,0.0064360942846784985,1,0,1,0.006944596312007958
3018,PSA1,Transcriptional regulation by RUNX1,0.0063111296816108125,0,0,1,0.006809758523248196
3019,PSA1,Transcriptional regulation by RUNX1,0.0064360942846784985,1,0,1,0.006944596312007958
3020,PSA1,FCERI mediated NF-kB activation,0.0063111296816108125,0,0,1,0.006809758523248196
3021,PSA1,FCERI mediated NF-kB activation,0.0064360942846784985,1,0,1,0.006944596312007958
3022,PSA1,Mitotic Metaphase and Anaphase,0.0063111296816108125,0,0,1,0.006809758523248196
3023,PSA1,Mitotic Metaphase and Anaphase,0.0064360942846784985,1,0,1,0.006944596312007958
3024,PSA1,Regulation of ornithine decarboxylase (ODC),0.0063111296816108125,0,0,1,0.006809758523248196
3025,PSA1,Regulation of ornithine decarboxylase (ODC),0.0064360942846784985,1,0,1,0.006944596312007958
3026,PSA1,Signaling by ROBO receptors,0.0063111296816108125,0,0,1,0.006809758523248196
3027,PSA1,Signaling by ROBO receptors,0.0064360942846784985,1,0,1,0.006944596312007958
3028,PSA1,PCP/CE pathway,0.0063111296816108125,0,0,1,0.006809758523248196
3029,PSA1,PCP/CE pathway,0.0064360942846784985,1,0,1,0.006944596312007958
3030,PSA1,Interleukin-1 family signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3031,PSA1,Interleukin-1 family signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3032,PSA1,G2/M Transition,0.0063111296816108125,0,0,1,0.006809758523248196
3033,PSA1,G2/M Transition,0.0064360942846784985,1,0,1,0.006944596312007958
3034,PSA1,G1/S Transition,0.0063111296816108125,0,0,1,0.006809758523248196
3035,PSA1,G1/S Transition,0.0064360942846784985,1,0,1,0.006944596312007958
3036,PSA1,Hh mutants are degraded by ERAD,0.0063111296816108125,0,0,1,0.006809758523248196
3037,PSA1,Hh mutants are degraded by ERAD,0.0064360942846784985,1,0,1,0.006944596312007958
3038,PSA1,CLEC7A (Dectin-1) signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3039,PSA1,CLEC7A (Dectin-1) signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3040,PSA1,Degradation of GLI1 by the proteasome,0.0063111296816108125,0,0,1,0.006809758523248196
3041,PSA1,Degradation of GLI1 by the proteasome,0.0064360942846784985,1,0,1,0.006944596312007958
3042,PSA1,Degradation of GLI2 by the proteasome,0.0063111296816108125,0,0,1,0.006809758523248196
3043,PSA1,Degradation of GLI2 by the proteasome,0.0064360942846784985,1,0,1,0.006944596312007958
3044,PSA1,GLI3 is processed to GLI3R by the proteasome,0.0063111296816108125,0,0,1,0.006809758523248196
3045,PSA1,GLI3 is processed to GLI3R by the proteasome,0.0064360942846784985,1,0,1,0.006944596312007958
3046,PSA1,Defective CFTR causes cystic fibrosis,0.0063111296816108125,0,0,1,0.006809758523248196
3047,PSA1,Defective CFTR causes cystic fibrosis,0.0064360942846784985,1,0,1,0.006944596312007958
3048,PSA1,NIK-->noncanonical NF-kB signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3049,PSA1,NIK-->noncanonical NF-kB signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3050,PSA1,RAF/MAP kinase cascade,0.0063111296816108125,0,0,1,0.006809758523248196
3051,PSA1,RAF/MAP kinase cascade,0.0064360942846784985,1,0,1,0.006944596312007958
3052,PSA1,UCH proteinases,0.0063111296816108125,0,0,1,0.006809758523248196
3053,PSA1,UCH proteinases,0.0064360942846784985,1,0,1,0.006944596312007958
3054,PSA1,Ub-specific processing proteases,0.0063111296816108125,0,0,1,0.006809758523248196
3055,PSA1,Ub-specific processing proteases,0.0064360942846784985,1,0,1,0.006944596312007958
3056,PSA1,Orc1 removal from chromatin,0.0063111296816108125,0,0,1,0.006809758523248196
3057,PSA1,Orc1 removal from chromatin,0.0064360942846784985,1,0,1,0.006944596312007958
3058,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.0063111296816108125,0,0,1,0.006809758523248196
3059,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.0064360942846784985,1,0,1,0.006944596312007958
3060,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.0063111296816108125,0,0,1,0.006809758523248196
3061,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.0064360942846784985,1,0,1,0.006944596312007958
3062,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.0063111296816108125,0,0,1,0.006809758523248196
3063,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.0064360942846784985,1,0,1,0.006944596312007958
3064,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.0063111296816108125,0,0,1,0.006809758523248196
3065,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.0064360942846784985,1,0,1,0.006944596312007958
3066,PSA1,p53-Independent G1/S DNA damage checkpoint,0.0063111296816108125,0,0,1,0.006809758523248196
3067,PSA1,p53-Independent G1/S DNA damage checkpoint,0.0064360942846784985,1,0,1,0.006944596312007958
3068,PSA1,Negative regulation of NOTCH4 signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3069,PSA1,Negative regulation of NOTCH4 signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3070,PSA1,KEAP1-NFE2L2 pathway,0.0063111296816108125,0,0,1,0.006809758523248196
3071,PSA1,KEAP1-NFE2L2 pathway,0.0064360942846784985,1,0,1,0.006944596312007958
3072,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.0063111296816108125,0,0,1,0.006809758523248196
3073,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.0064360942846784985,1,0,1,0.006944596312007958
3074,PSA1,Degradation of beta-catenin by the destruction complex,0.0063111296816108125,0,0,1,0.006809758523248196
3075,PSA1,Degradation of beta-catenin by the destruction complex,0.0064360942846784985,1,0,1,0.006944596312007958
3076,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0063111296816108125,0,0,1,0.006809758523248196
3077,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0064360942846784985,1,0,1,0.006944596312007958
3078,PSA1,Hedgehog ligand biogenesis,0.0063111296816108125,0,0,1,0.006809758523248196
3079,PSA1,Hedgehog ligand biogenesis,0.0064360942846784985,1,0,1,0.006944596312007958
3080,PSA1,Hedgehog 'on' state,0.0063111296816108125,0,0,1,0.006809758523248196
3081,PSA1,Hedgehog 'on' state,0.0064360942846784985,1,0,1,0.006944596312007958
3082,PSA1,MAPK6/MAPK4 signaling,0.0063111296816108125,0,0,1,0.006809758523248196
3083,PSA1,MAPK6/MAPK4 signaling,0.0064360942846784985,1,0,1,0.006944596312007958
3084,PSA1,Neddylation,0.0063111296816108125,0,0,1,0.006809758523248196
3085,PSA1,Neddylation,0.0064360942846784985,1,0,1,0.006944596312007958
3086,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.003576995022012852,0,0,1,0.0038596057390079303
3087,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.0036138324949812764,1,0,1,0.00389935366183268
3088,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.003576995022012852,0,0,1,0.0038596057390079303
3089,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0036138324949812764,1,0,1,0.00389935366183268
3090,PSA3,Antigen processing-Cross presentation,0.003576995022012852,0,0,1,0.0038596057390079303
3091,PSA3,Antigen processing-Cross presentation,0.0036138324949812764,1,0,1,0.00389935366183268
3092,PSA3,PTEN Regulation,0.003576995022012852,0,0,1,0.0038596057390079303
3093,PSA3,PTEN Regulation,0.0036138324949812764,1,0,1,0.00389935366183268
3094,PSA3,Host Interactions of HIV factors,0.003576995022012852,0,0,1,0.0038596057390079303
3095,PSA3,Host Interactions of HIV factors,0.0036138324949812764,1,0,1,0.00389935366183268
3096,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.003576995022012852,0,0,1,0.0038596057390079303
3097,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0036138324949812764,1,0,1,0.00389935366183268
3098,PSA3,APC/C-mediated degradation of cell cycle proteins,0.003576995022012852,0,0,1,0.0038596057390079303
3099,PSA3,APC/C-mediated degradation of cell cycle proteins,0.0036138324949812764,1,0,1,0.00389935366183268
3100,PSA3,Degradation of AXIN,0.003576995022012852,0,0,1,0.0038596057390079303
3101,PSA3,Degradation of AXIN,0.0036138324949812764,1,0,1,0.00389935366183268
3102,PSA3,Degradation of DVL,0.003576995022012852,0,0,1,0.0038596057390079303
3103,PSA3,Degradation of DVL,0.0036138324949812764,1,0,1,0.00389935366183268
3104,PSA3,Downstream TCR signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3105,PSA3,Downstream TCR signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3106,PSA3,Transcriptional regulation by RUNX3,0.003576995022012852,0,0,1,0.0038596057390079303
3107,PSA3,Transcriptional regulation by RUNX3,0.0036138324949812764,1,0,1,0.00389935366183268
3108,PSA3,Transcriptional regulation by RUNX2,0.003576995022012852,0,0,1,0.0038596057390079303
3109,PSA3,Transcriptional regulation by RUNX2,0.0036138324949812764,1,0,1,0.00389935366183268
3110,PSA3,Transcriptional regulation by RUNX1,0.003576995022012852,0,0,1,0.0038596057390079303
3111,PSA3,Transcriptional regulation by RUNX1,0.0036138324949812764,1,0,1,0.00389935366183268
3112,PSA3,FCERI mediated NF-kB activation,0.003576995022012852,0,0,1,0.0038596057390079303
3113,PSA3,FCERI mediated NF-kB activation,0.0036138324949812764,1,0,1,0.00389935366183268
3114,PSA3,Mitotic Metaphase and Anaphase,0.003576995022012852,0,0,1,0.0038596057390079303
3115,PSA3,Mitotic Metaphase and Anaphase,0.0036138324949812764,1,0,1,0.00389935366183268
3116,PSA3,Regulation of ornithine decarboxylase (ODC),0.003576995022012852,0,0,1,0.0038596057390079303
3117,PSA3,Regulation of ornithine decarboxylase (ODC),0.0036138324949812764,1,0,1,0.00389935366183268
3118,PSA3,Signaling by ROBO receptors,0.003576995022012852,0,0,1,0.0038596057390079303
3119,PSA3,Signaling by ROBO receptors,0.0036138324949812764,1,0,1,0.00389935366183268
3120,PSA3,PCP/CE pathway,0.003576995022012852,0,0,1,0.0038596057390079303
3121,PSA3,PCP/CE pathway,0.0036138324949812764,1,0,1,0.00389935366183268
3122,PSA3,Interleukin-1 family signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3123,PSA3,Interleukin-1 family signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3124,PSA3,G2/M Transition,0.003576995022012852,0,0,1,0.0038596057390079303
3125,PSA3,G2/M Transition,0.0036138324949812764,1,0,1,0.00389935366183268
3126,PSA3,G1/S Transition,0.003576995022012852,0,0,1,0.0038596057390079303
3127,PSA3,G1/S Transition,0.0036138324949812764,1,0,1,0.00389935366183268
3128,PSA3,Hh mutants are degraded by ERAD,0.003576995022012852,0,0,1,0.0038596057390079303
3129,PSA3,Hh mutants are degraded by ERAD,0.0036138324949812764,1,0,1,0.00389935366183268
3130,PSA3,CLEC7A (Dectin-1) signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3131,PSA3,CLEC7A (Dectin-1) signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3132,PSA3,Degradation of GLI1 by the proteasome,0.003576995022012852,0,0,1,0.0038596057390079303
3133,PSA3,Degradation of GLI1 by the proteasome,0.0036138324949812764,1,0,1,0.00389935366183268
3134,PSA3,Degradation of GLI2 by the proteasome,0.003576995022012852,0,0,1,0.0038596057390079303
3135,PSA3,Degradation of GLI2 by the proteasome,0.0036138324949812764,1,0,1,0.00389935366183268
3136,PSA3,GLI3 is processed to GLI3R by the proteasome,0.003576995022012852,0,0,1,0.0038596057390079303
3137,PSA3,GLI3 is processed to GLI3R by the proteasome,0.0036138324949812764,1,0,1,0.00389935366183268
3138,PSA3,Defective CFTR causes cystic fibrosis,0.003576995022012852,0,0,1,0.0038596057390079303
3139,PSA3,Defective CFTR causes cystic fibrosis,0.0036138324949812764,1,0,1,0.00389935366183268
3140,PSA3,NIK-->noncanonical NF-kB signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3141,PSA3,NIK-->noncanonical NF-kB signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3142,PSA3,RAF/MAP kinase cascade,0.003576995022012852,0,0,1,0.0038596057390079303
3143,PSA3,RAF/MAP kinase cascade,0.0036138324949812764,1,0,1,0.00389935366183268
3144,PSA3,UCH proteinases,0.003576995022012852,0,0,1,0.0038596057390079303
3145,PSA3,UCH proteinases,0.0036138324949812764,1,0,1,0.00389935366183268
3146,PSA3,Ub-specific processing proteases,0.003576995022012852,0,0,1,0.0038596057390079303
3147,PSA3,Ub-specific processing proteases,0.0036138324949812764,1,0,1,0.00389935366183268
3148,PSA3,Orc1 removal from chromatin,0.003576995022012852,0,0,1,0.0038596057390079303
3149,PSA3,Orc1 removal from chromatin,0.0036138324949812764,1,0,1,0.00389935366183268
3150,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.003576995022012852,0,0,1,0.0038596057390079303
3151,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.0036138324949812764,1,0,1,0.00389935366183268
3152,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.003576995022012852,0,0,1,0.0038596057390079303
3153,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.0036138324949812764,1,0,1,0.00389935366183268
3154,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.003576995022012852,0,0,1,0.0038596057390079303
3155,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.0036138324949812764,1,0,1,0.00389935366183268
3156,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.003576995022012852,0,0,1,0.0038596057390079303
3157,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.0036138324949812764,1,0,1,0.00389935366183268
3158,PSA3,p53-Independent G1/S DNA damage checkpoint,0.003576995022012852,0,0,1,0.0038596057390079303
3159,PSA3,p53-Independent G1/S DNA damage checkpoint,0.0036138324949812764,1,0,1,0.00389935366183268
3160,PSA3,Negative regulation of NOTCH4 signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3161,PSA3,Negative regulation of NOTCH4 signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3162,PSA3,KEAP1-NFE2L2 pathway,0.003576995022012852,0,0,1,0.0038596057390079303
3163,PSA3,KEAP1-NFE2L2 pathway,0.0036138324949812764,1,0,1,0.00389935366183268
3164,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.003576995022012852,0,0,1,0.0038596057390079303
3165,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.0036138324949812764,1,0,1,0.00389935366183268
3166,PSA3,Degradation of beta-catenin by the destruction complex,0.003576995022012852,0,0,1,0.0038596057390079303
3167,PSA3,Degradation of beta-catenin by the destruction complex,0.0036138324949812764,1,0,1,0.00389935366183268
3168,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.003576995022012852,0,0,1,0.0038596057390079303
3169,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0036138324949812764,1,0,1,0.00389935366183268
3170,PSA3,Hedgehog ligand biogenesis,0.003576995022012852,0,0,1,0.0038596057390079303
3171,PSA3,Hedgehog ligand biogenesis,0.0036138324949812764,1,0,1,0.00389935366183268
3172,PSA3,Hedgehog 'on' state,0.003576995022012852,0,0,1,0.0038596057390079303
3173,PSA3,Hedgehog 'on' state,0.0036138324949812764,1,0,1,0.00389935366183268
3174,PSA3,MAPK6/MAPK4 signaling,0.003576995022012852,0,0,1,0.0038596057390079303
3175,PSA3,MAPK6/MAPK4 signaling,0.0036138324949812764,1,0,1,0.00389935366183268
3176,PSA3,Neddylation,0.003576995022012852,0,0,1,0.0038596057390079303
3177,PSA3,Neddylation,0.0036138324949812764,1,0,1,0.00389935366183268
3178,PTX3,Neutrophil degranulation,0.0007116243393587259,0,0,1,0.0007678482545556076
3179,PTX3,Neutrophil degranulation,0.0006933670413369934,1,0,1,0.0007481484865129324
3180,HGFL,Signaling by MST1,0.00015391505982051968,0,0,1,0.00016607555910680053
3181,HGFL,Signaling by MST1,0.00018191566247196533,1,0,1,0.00019628842941389596
3182,STOM,RHO GTPase cycle,0.0008975113518924142,0,0,1,0.0009684218018954464
3183,STOM,RHO GTPase cycle,0.0008006516754297384,1,0,1,0.0008639094498085186
3184,STOM,Neutrophil degranulation,0.0008975113518924142,0,0,1,0.0009684218018954464
3185,STOM,Neutrophil degranulation,0.0008006516754297384,1,0,1,0.0008639094498085186
3186,STOM,Stimuli-sensing channels,0.0008975113518924142,0,0,1,0.0009684218018954464
3187,STOM,Stimuli-sensing channels,0.0008006516754297384,1,0,1,0.0008639094498085186
3188,PON1,Arachidonic acid metabolism,0.00449627984125982,0,0,1,0.004851521283288416
3189,PON1,Arachidonic acid metabolism,0.004238940590100052,1,0,1,0.004573850208954818
3190,PON1,Atorvastatin ADME,0.00449627984125982,0,0,1,0.004851521283288416
3191,PON1,Atorvastatin ADME,0.004238940590100052,1,0,1,0.004573850208954818
3192,1433T,Activation of BH3-only proteins,0.0014293891052754284,0,0,1,0.0015423220776225705
3193,1433T,Activation of BH3-only proteins,0.0014045523241899597,1,0,1,0.001515522995648446
3194,1433T,RHO GTPase Effectors,0.0014293891052754284,0,0,1,0.0015423220776225705
3195,1433T,RHO GTPase Effectors,0.0014045523241899597,1,0,1,0.001515522995648446
3196,1433T,Transcriptional Regulation by TP53,0.0014293891052754284,0,0,1,0.0015423220776225705
3197,1433T,Transcriptional Regulation by TP53,0.0014045523241899597,1,0,1,0.001515522995648446
3198,1433T,FOXO-mediated transcription,0.0014293891052754284,0,0,1,0.0015423220776225705
3199,1433T,FOXO-mediated transcription,0.0014045523241899597,1,0,1,0.001515522995648446
3200,1433T,G2/M DNA damage checkpoint,0.0014293891052754284,0,0,1,0.0015423220776225705
3201,1433T,G2/M DNA damage checkpoint,0.0014045523241899597,1,0,1,0.001515522995648446
3202,1433T,SARS-CoV-2 Infection,0.0014293891052754284,0,0,1,0.0015423220776225705
3203,1433T,SARS-CoV-2 Infection,0.0014045523241899597,1,0,1,0.001515522995648446
3204,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0014293891052754284,0,0,1,0.0015423220776225705
3205,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0014045523241899597,1,0,1,0.001515522995648446
3206,CALR,Antigen processing-Cross presentation,0.026422958526139458,0,0,1,0.028510579897779338
3207,CALR,Antigen processing-Cross presentation,0.02613977442185084,1,0,1,0.02820502202381475
3208,CALR,Virus Assembly and Release,0.026422958526139458,0,0,1,0.028510579897779338
3209,CALR,Virus Assembly and Release,0.02613977442185084,1,0,1,0.02820502202381475
3210,CALR,ATF6 (ATF6-alpha) activates chaperones,0.026422958526139458,0,0,1,0.028510579897779338
3211,CALR,ATF6 (ATF6-alpha) activates chaperones,0.02613977442185084,1,0,1,0.02820502202381475
3212,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.026422958526139458,0,0,1,0.028510579897779338
3213,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.02613977442185084,1,0,1,0.02820502202381475
3214,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.026422958526139458,0,0,1,0.028510579897779338
3215,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.02613977442185084,1,0,1,0.02820502202381475
3216,CALR,Scavenging by Class A Receptors,0.026422958526139458,0,0,1,0.028510579897779338
3217,CALR,Scavenging by Class A Receptors,0.02613977442185084,1,0,1,0.02820502202381475
3218,CALR,Scavenging by Class F Receptors,0.026422958526139458,0,0,1,0.028510579897779338
3219,CALR,Scavenging by Class F Receptors,0.02613977442185084,1,0,1,0.02820502202381475
3220,PROP,Initial triggering of complement,0.0008132218911062713,0,0,1,0.0008774728113080862
3221,PROP,Initial triggering of complement,0.0008865311324314007,1,0,1,0.0009565740588076055
3222,PROP,Activation of C3 and C5,0.0008132218911062713,0,0,1,0.0008774728113080862
3223,PROP,Activation of C3 and C5,0.0008865311324314007,1,0,1,0.0009565740588076055
3224,PROP,Regulation of Complement cascade,0.0008132218911062713,0,0,1,0.0008774728113080862
3225,PROP,Regulation of Complement cascade,0.0008865311324314007,1,0,1,0.0009565740588076055
3226,PROP,Diseases associated with O-glycosylation of proteins,0.0008132218911062713,0,0,1,0.0008774728113080862
3227,PROP,Diseases associated with O-glycosylation of proteins,0.0008865311324314007,1,0,1,0.0009565740588076055
3228,PROP,O-glycosylation of TSR domain-containing proteins,0.0008132218911062713,0,0,1,0.0008774728113080862
3229,PROP,O-glycosylation of TSR domain-containing proteins,0.0008865311324314007,1,0,1,0.0009565740588076055
3230,PROP,Neutrophil degranulation,0.0008132218911062713,0,0,1,0.0008774728113080862
3231,PROP,Neutrophil degranulation,0.0008865311324314007,1,0,1,0.0009565740588076055
3232,IL1R2,Interleukin-1 family signaling,0.00024476745844973874,0,0,1,0.00026410601120249543
3233,IL1R2,Interleukin-1 family signaling,0.00025516341447655576,1,0,1,0.00027532332945333224
3234,IL1R2,Interleukin-10 signaling,0.00024476745844973874,0,0,1,0.00026410601120249543
3235,IL1R2,Interleukin-10 signaling,0.00025516341447655576,1,0,1,0.00027532332945333224
3236,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.008170040180751433,0,0,1,0.0088155375602981
3237,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.008399628011587387,1,0,1,0.009063264634014346
3238,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.008170040180751433,0,0,1,0.0088155375602981
3239,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.008399628011587387,1,0,1,0.009063264634014346
3240,PSA5,Antigen processing-Cross presentation,0.008170040180751433,0,0,1,0.0088155375602981
3241,PSA5,Antigen processing-Cross presentation,0.008399628011587387,1,0,1,0.009063264634014346
3242,PSA5,PTEN Regulation,0.008170040180751433,0,0,1,0.0088155375602981
3243,PSA5,PTEN Regulation,0.008399628011587387,1,0,1,0.009063264634014346
3244,PSA5,Host Interactions of HIV factors,0.008170040180751433,0,0,1,0.0088155375602981
3245,PSA5,Host Interactions of HIV factors,0.008399628011587387,1,0,1,0.009063264634014346
3246,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.008170040180751433,0,0,1,0.0088155375602981
3247,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.008399628011587387,1,0,1,0.009063264634014346
3248,PSA5,APC/C-mediated degradation of cell cycle proteins,0.008170040180751433,0,0,1,0.0088155375602981
3249,PSA5,APC/C-mediated degradation of cell cycle proteins,0.008399628011587387,1,0,1,0.009063264634014346
3250,PSA5,Degradation of AXIN,0.008170040180751433,0,0,1,0.0088155375602981
3251,PSA5,Degradation of AXIN,0.008399628011587387,1,0,1,0.009063264634014346
3252,PSA5,Degradation of DVL,0.008170040180751433,0,0,1,0.0088155375602981
3253,PSA5,Degradation of DVL,0.008399628011587387,1,0,1,0.009063264634014346
3254,PSA5,Downstream TCR signaling,0.008170040180751433,0,0,1,0.0088155375602981
3255,PSA5,Downstream TCR signaling,0.008399628011587387,1,0,1,0.009063264634014346
3256,PSA5,Transcriptional regulation by RUNX3,0.008170040180751433,0,0,1,0.0088155375602981
3257,PSA5,Transcriptional regulation by RUNX3,0.008399628011587387,1,0,1,0.009063264634014346
3258,PSA5,Transcriptional regulation by RUNX2,0.008170040180751433,0,0,1,0.0088155375602981
3259,PSA5,Transcriptional regulation by RUNX2,0.008399628011587387,1,0,1,0.009063264634014346
3260,PSA5,Transcriptional regulation by RUNX1,0.008170040180751433,0,0,1,0.0088155375602981
3261,PSA5,Transcriptional regulation by RUNX1,0.008399628011587387,1,0,1,0.009063264634014346
3262,PSA5,FCERI mediated NF-kB activation,0.008170040180751433,0,0,1,0.0088155375602981
3263,PSA5,FCERI mediated NF-kB activation,0.008399628011587387,1,0,1,0.009063264634014346
3264,PSA5,Mitotic Metaphase and Anaphase,0.008170040180751433,0,0,1,0.0088155375602981
3265,PSA5,Mitotic Metaphase and Anaphase,0.008399628011587387,1,0,1,0.009063264634014346
3266,PSA5,Regulation of ornithine decarboxylase (ODC),0.008170040180751433,0,0,1,0.0088155375602981
3267,PSA5,Regulation of ornithine decarboxylase (ODC),0.008399628011587387,1,0,1,0.009063264634014346
3268,PSA5,Signaling by ROBO receptors,0.008170040180751433,0,0,1,0.0088155375602981
3269,PSA5,Signaling by ROBO receptors,0.008399628011587387,1,0,1,0.009063264634014346
3270,PSA5,PCP/CE pathway,0.008170040180751433,0,0,1,0.0088155375602981
3271,PSA5,PCP/CE pathway,0.008399628011587387,1,0,1,0.009063264634014346
3272,PSA5,Interleukin-1 family signaling,0.008170040180751433,0,0,1,0.0088155375602981
3273,PSA5,Interleukin-1 family signaling,0.008399628011587387,1,0,1,0.009063264634014346
3274,PSA5,G2/M Transition,0.008170040180751433,0,0,1,0.0088155375602981
3275,PSA5,G2/M Transition,0.008399628011587387,1,0,1,0.009063264634014346
3276,PSA5,G1/S Transition,0.008170040180751433,0,0,1,0.0088155375602981
3277,PSA5,G1/S Transition,0.008399628011587387,1,0,1,0.009063264634014346
3278,PSA5,Hh mutants are degraded by ERAD,0.008170040180751433,0,0,1,0.0088155375602981
3279,PSA5,Hh mutants are degraded by ERAD,0.008399628011587387,1,0,1,0.009063264634014346
3280,PSA5,CLEC7A (Dectin-1) signaling,0.008170040180751433,0,0,1,0.0088155375602981
3281,PSA5,CLEC7A (Dectin-1) signaling,0.008399628011587387,1,0,1,0.009063264634014346
3282,PSA5,Degradation of GLI1 by the proteasome,0.008170040180751433,0,0,1,0.0088155375602981
3283,PSA5,Degradation of GLI1 by the proteasome,0.008399628011587387,1,0,1,0.009063264634014346
3284,PSA5,Degradation of GLI2 by the proteasome,0.008170040180751433,0,0,1,0.0088155375602981
3285,PSA5,Degradation of GLI2 by the proteasome,0.008399628011587387,1,0,1,0.009063264634014346
3286,PSA5,GLI3 is processed to GLI3R by the proteasome,0.008170040180751433,0,0,1,0.0088155375602981
3287,PSA5,GLI3 is processed to GLI3R by the proteasome,0.008399628011587387,1,0,1,0.009063264634014346
3288,PSA5,Defective CFTR causes cystic fibrosis,0.008170040180751433,0,0,1,0.0088155375602981
3289,PSA5,Defective CFTR causes cystic fibrosis,0.008399628011587387,1,0,1,0.009063264634014346
3290,PSA5,NIK-->noncanonical NF-kB signaling,0.008170040180751433,0,0,1,0.0088155375602981
3291,PSA5,NIK-->noncanonical NF-kB signaling,0.008399628011587387,1,0,1,0.009063264634014346
3292,PSA5,RAF/MAP kinase cascade,0.008170040180751433,0,0,1,0.0088155375602981
3293,PSA5,RAF/MAP kinase cascade,0.008399628011587387,1,0,1,0.009063264634014346
3294,PSA5,UCH proteinases,0.008170040180751433,0,0,1,0.0088155375602981
3295,PSA5,UCH proteinases,0.008399628011587387,1,0,1,0.009063264634014346
3296,PSA5,Ub-specific processing proteases,0.008170040180751433,0,0,1,0.0088155375602981
3297,PSA5,Ub-specific processing proteases,0.008399628011587387,1,0,1,0.009063264634014346
3298,PSA5,Orc1 removal from chromatin,0.008170040180751433,0,0,1,0.0088155375602981
3299,PSA5,Orc1 removal from chromatin,0.008399628011587387,1,0,1,0.009063264634014346
3300,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.008170040180751433,0,0,1,0.0088155375602981
3301,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.008399628011587387,1,0,1,0.009063264634014346
3302,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.008170040180751433,0,0,1,0.0088155375602981
3303,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.008399628011587387,1,0,1,0.009063264634014346
3304,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.008170040180751433,0,0,1,0.0088155375602981
3305,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.008399628011587387,1,0,1,0.009063264634014346
3306,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.008170040180751433,0,0,1,0.0088155375602981
3307,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.008399628011587387,1,0,1,0.009063264634014346
3308,PSA5,p53-Independent G1/S DNA damage checkpoint,0.008170040180751433,0,0,1,0.0088155375602981
3309,PSA5,p53-Independent G1/S DNA damage checkpoint,0.008399628011587387,1,0,1,0.009063264634014346
3310,PSA5,Negative regulation of NOTCH4 signaling,0.008170040180751433,0,0,1,0.0088155375602981
3311,PSA5,Negative regulation of NOTCH4 signaling,0.008399628011587387,1,0,1,0.009063264634014346
3312,PSA5,KEAP1-NFE2L2 pathway,0.008170040180751433,0,0,1,0.0088155375602981
3313,PSA5,KEAP1-NFE2L2 pathway,0.008399628011587387,1,0,1,0.009063264634014346
3314,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.008170040180751433,0,0,1,0.0088155375602981
3315,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.008399628011587387,1,0,1,0.009063264634014346
3316,PSA5,Neutrophil degranulation,0.008170040180751433,0,0,1,0.0088155375602981
3317,PSA5,Neutrophil degranulation,0.008399628011587387,1,0,1,0.009063264634014346
3318,PSA5,Degradation of beta-catenin by the destruction complex,0.008170040180751433,0,0,1,0.0088155375602981
3319,PSA5,Degradation of beta-catenin by the destruction complex,0.008399628011587387,1,0,1,0.009063264634014346
3320,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.008170040180751433,0,0,1,0.0088155375602981
3321,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.008399628011587387,1,0,1,0.009063264634014346
3322,PSA5,Hedgehog ligand biogenesis,0.008170040180751433,0,0,1,0.0088155375602981
3323,PSA5,Hedgehog ligand biogenesis,0.008399628011587387,1,0,1,0.009063264634014346
3324,PSA5,Hedgehog 'on' state,0.008170040180751433,0,0,1,0.0088155375602981
3325,PSA5,Hedgehog 'on' state,0.008399628011587387,1,0,1,0.009063264634014346
3326,PSA5,MAPK6/MAPK4 signaling,0.008170040180751433,0,0,1,0.0088155375602981
3327,PSA5,MAPK6/MAPK4 signaling,0.008399628011587387,1,0,1,0.009063264634014346
3328,PSA5,Neddylation,0.008170040180751433,0,0,1,0.0088155375602981
3329,PSA5,Neddylation,0.008399628011587387,1,0,1,0.009063264634014346
3330,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.005457652532883609,0,0,1,0.005888849972616222
3331,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.005243388720555231,1,0,1,0.005657657635295335
3332,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005457652532883609,0,0,1,0.005888849972616222
3333,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005243388720555231,1,0,1,0.005657657635295335
3334,PSB6,Antigen processing-Cross presentation,0.005457652532883609,0,0,1,0.005888849972616222
3335,PSB6,Antigen processing-Cross presentation,0.005243388720555231,1,0,1,0.005657657635295335
3336,PSB6,PTEN Regulation,0.005457652532883609,0,0,1,0.005888849972616222
3337,PSB6,PTEN Regulation,0.005243388720555231,1,0,1,0.005657657635295335
3338,PSB6,Host Interactions of HIV factors,0.005457652532883609,0,0,1,0.005888849972616222
3339,PSB6,Host Interactions of HIV factors,0.005243388720555231,1,0,1,0.005657657635295335
3340,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005457652532883609,0,0,1,0.005888849972616222
3341,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005243388720555231,1,0,1,0.005657657635295335
3342,PSB6,APC/C-mediated degradation of cell cycle proteins,0.005457652532883609,0,0,1,0.005888849972616222
3343,PSB6,APC/C-mediated degradation of cell cycle proteins,0.005243388720555231,1,0,1,0.005657657635295335
3344,PSB6,Degradation of AXIN,0.005457652532883609,0,0,1,0.005888849972616222
3345,PSB6,Degradation of AXIN,0.005243388720555231,1,0,1,0.005657657635295335
3346,PSB6,Degradation of DVL,0.005457652532883609,0,0,1,0.005888849972616222
3347,PSB6,Degradation of DVL,0.005243388720555231,1,0,1,0.005657657635295335
3348,PSB6,Downstream TCR signaling,0.005457652532883609,0,0,1,0.005888849972616222
3349,PSB6,Downstream TCR signaling,0.005243388720555231,1,0,1,0.005657657635295335
3350,PSB6,Transcriptional regulation by RUNX3,0.005457652532883609,0,0,1,0.005888849972616222
3351,PSB6,Transcriptional regulation by RUNX3,0.005243388720555231,1,0,1,0.005657657635295335
3352,PSB6,Transcriptional regulation by RUNX2,0.005457652532883609,0,0,1,0.005888849972616222
3353,PSB6,Transcriptional regulation by RUNX2,0.005243388720555231,1,0,1,0.005657657635295335
3354,PSB6,Transcriptional regulation by RUNX1,0.005457652532883609,0,0,1,0.005888849972616222
3355,PSB6,Transcriptional regulation by RUNX1,0.005243388720555231,1,0,1,0.005657657635295335
3356,PSB6,FCERI mediated NF-kB activation,0.005457652532883609,0,0,1,0.005888849972616222
3357,PSB6,FCERI mediated NF-kB activation,0.005243388720555231,1,0,1,0.005657657635295335
3358,PSB6,Mitotic Metaphase and Anaphase,0.005457652532883609,0,0,1,0.005888849972616222
3359,PSB6,Mitotic Metaphase and Anaphase,0.005243388720555231,1,0,1,0.005657657635295335
3360,PSB6,Regulation of ornithine decarboxylase (ODC),0.005457652532883609,0,0,1,0.005888849972616222
3361,PSB6,Regulation of ornithine decarboxylase (ODC),0.005243388720555231,1,0,1,0.005657657635295335
3362,PSB6,Signaling by ROBO receptors,0.005457652532883609,0,0,1,0.005888849972616222
3363,PSB6,Signaling by ROBO receptors,0.005243388720555231,1,0,1,0.005657657635295335
3364,PSB6,PCP/CE pathway,0.005457652532883609,0,0,1,0.005888849972616222
3365,PSB6,PCP/CE pathway,0.005243388720555231,1,0,1,0.005657657635295335
3366,PSB6,Interleukin-1 family signaling,0.005457652532883609,0,0,1,0.005888849972616222
3367,PSB6,Interleukin-1 family signaling,0.005243388720555231,1,0,1,0.005657657635295335
3368,PSB6,G2/M Transition,0.005457652532883609,0,0,1,0.005888849972616222
3369,PSB6,G2/M Transition,0.005243388720555231,1,0,1,0.005657657635295335
3370,PSB6,G1/S Transition,0.005457652532883609,0,0,1,0.005888849972616222
3371,PSB6,G1/S Transition,0.005243388720555231,1,0,1,0.005657657635295335
3372,PSB6,Hh mutants are degraded by ERAD,0.005457652532883609,0,0,1,0.005888849972616222
3373,PSB6,Hh mutants are degraded by ERAD,0.005243388720555231,1,0,1,0.005657657635295335
3374,PSB6,CLEC7A (Dectin-1) signaling,0.005457652532883609,0,0,1,0.005888849972616222
3375,PSB6,CLEC7A (Dectin-1) signaling,0.005243388720555231,1,0,1,0.005657657635295335
3376,PSB6,Degradation of GLI1 by the proteasome,0.005457652532883609,0,0,1,0.005888849972616222
3377,PSB6,Degradation of GLI1 by the proteasome,0.005243388720555231,1,0,1,0.005657657635295335
3378,PSB6,Degradation of GLI2 by the proteasome,0.005457652532883609,0,0,1,0.005888849972616222
3379,PSB6,Degradation of GLI2 by the proteasome,0.005243388720555231,1,0,1,0.005657657635295335
3380,PSB6,GLI3 is processed to GLI3R by the proteasome,0.005457652532883609,0,0,1,0.005888849972616222
3381,PSB6,GLI3 is processed to GLI3R by the proteasome,0.005243388720555231,1,0,1,0.005657657635295335
3382,PSB6,Defective CFTR causes cystic fibrosis,0.005457652532883609,0,0,1,0.005888849972616222
3383,PSB6,Defective CFTR causes cystic fibrosis,0.005243388720555231,1,0,1,0.005657657635295335
3384,PSB6,NIK-->noncanonical NF-kB signaling,0.005457652532883609,0,0,1,0.005888849972616222
3385,PSB6,NIK-->noncanonical NF-kB signaling,0.005243388720555231,1,0,1,0.005657657635295335
3386,PSB6,RAF/MAP kinase cascade,0.005457652532883609,0,0,1,0.005888849972616222
3387,PSB6,RAF/MAP kinase cascade,0.005243388720555231,1,0,1,0.005657657635295335
3388,PSB6,UCH proteinases,0.005457652532883609,0,0,1,0.005888849972616222
3389,PSB6,UCH proteinases,0.005243388720555231,1,0,1,0.005657657635295335
3390,PSB6,Ub-specific processing proteases,0.005457652532883609,0,0,1,0.005888849972616222
3391,PSB6,Ub-specific processing proteases,0.005243388720555231,1,0,1,0.005657657635295335
3392,PSB6,Orc1 removal from chromatin,0.005457652532883609,0,0,1,0.005888849972616222
3393,PSB6,Orc1 removal from chromatin,0.005243388720555231,1,0,1,0.005657657635295335
3394,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.005457652532883609,0,0,1,0.005888849972616222
3395,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.005243388720555231,1,0,1,0.005657657635295335
3396,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.005457652532883609,0,0,1,0.005888849972616222
3397,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.005243388720555231,1,0,1,0.005657657635295335
3398,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.005457652532883609,0,0,1,0.005888849972616222
3399,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.005243388720555231,1,0,1,0.005657657635295335
3400,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.005457652532883609,0,0,1,0.005888849972616222
3401,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.005243388720555231,1,0,1,0.005657657635295335
3402,PSB6,p53-Independent G1/S DNA damage checkpoint,0.005457652532883609,0,0,1,0.005888849972616222
3403,PSB6,p53-Independent G1/S DNA damage checkpoint,0.005243388720555231,1,0,1,0.005657657635295335
3404,PSB6,Negative regulation of NOTCH4 signaling,0.005457652532883609,0,0,1,0.005888849972616222
3405,PSB6,Negative regulation of NOTCH4 signaling,0.005243388720555231,1,0,1,0.005657657635295335
3406,PSB6,KEAP1-NFE2L2 pathway,0.005457652532883609,0,0,1,0.005888849972616222
3407,PSB6,KEAP1-NFE2L2 pathway,0.005243388720555231,1,0,1,0.005657657635295335
3408,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.005457652532883609,0,0,1,0.005888849972616222
3409,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.005243388720555231,1,0,1,0.005657657635295335
3410,PSB6,Degradation of beta-catenin by the destruction complex,0.005457652532883609,0,0,1,0.005888849972616222
3411,PSB6,Degradation of beta-catenin by the destruction complex,0.005243388720555231,1,0,1,0.005657657635295335
3412,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005457652532883609,0,0,1,0.005888849972616222
3413,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005243388720555231,1,0,1,0.005657657635295335
3414,PSB6,Hedgehog ligand biogenesis,0.005457652532883609,0,0,1,0.005888849972616222
3415,PSB6,Hedgehog ligand biogenesis,0.005243388720555231,1,0,1,0.005657657635295335
3416,PSB6,Hedgehog 'on' state,0.005457652532883609,0,0,1,0.005888849972616222
3417,PSB6,Hedgehog 'on' state,0.005243388720555231,1,0,1,0.005657657635295335
3418,PSB6,MAPK6/MAPK4 signaling,0.005457652532883609,0,0,1,0.005888849972616222
3419,PSB6,MAPK6/MAPK4 signaling,0.005243388720555231,1,0,1,0.005657657635295335
3420,PSB6,Neddylation,0.005457652532883609,0,0,1,0.005888849972616222
3421,PSB6,Neddylation,0.005243388720555231,1,0,1,0.005657657635295335
3422,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.001673630282554465,0,0,1,0.0018058602273060332
3423,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.0018659455633799856,1,0,1,0.002013369926650097
3424,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.001673630282554465,0,0,1,0.0018058602273060332
3425,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0018659455633799856,1,0,1,0.002013369926650097
3426,PSB5,Antigen processing-Cross presentation,0.001673630282554465,0,0,1,0.0018058602273060332
3427,PSB5,Antigen processing-Cross presentation,0.0018659455633799856,1,0,1,0.002013369926650097
3428,PSB5,PTEN Regulation,0.001673630282554465,0,0,1,0.0018058602273060332
3429,PSB5,PTEN Regulation,0.0018659455633799856,1,0,1,0.002013369926650097
3430,PSB5,Host Interactions of HIV factors,0.001673630282554465,0,0,1,0.0018058602273060332
3431,PSB5,Host Interactions of HIV factors,0.0018659455633799856,1,0,1,0.002013369926650097
3432,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.001673630282554465,0,0,1,0.0018058602273060332
3433,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0018659455633799856,1,0,1,0.002013369926650097
3434,PSB5,APC/C-mediated degradation of cell cycle proteins,0.001673630282554465,0,0,1,0.0018058602273060332
3435,PSB5,APC/C-mediated degradation of cell cycle proteins,0.0018659455633799856,1,0,1,0.002013369926650097
3436,PSB5,Degradation of AXIN,0.001673630282554465,0,0,1,0.0018058602273060332
3437,PSB5,Degradation of AXIN,0.0018659455633799856,1,0,1,0.002013369926650097
3438,PSB5,Degradation of DVL,0.001673630282554465,0,0,1,0.0018058602273060332
3439,PSB5,Degradation of DVL,0.0018659455633799856,1,0,1,0.002013369926650097
3440,PSB5,Downstream TCR signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3441,PSB5,Downstream TCR signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3442,PSB5,Transcriptional regulation by RUNX3,0.001673630282554465,0,0,1,0.0018058602273060332
3443,PSB5,Transcriptional regulation by RUNX3,0.0018659455633799856,1,0,1,0.002013369926650097
3444,PSB5,Transcriptional regulation by RUNX2,0.001673630282554465,0,0,1,0.0018058602273060332
3445,PSB5,Transcriptional regulation by RUNX2,0.0018659455633799856,1,0,1,0.002013369926650097
3446,PSB5,Transcriptional regulation by RUNX1,0.001673630282554465,0,0,1,0.0018058602273060332
3447,PSB5,Transcriptional regulation by RUNX1,0.0018659455633799856,1,0,1,0.002013369926650097
3448,PSB5,FCERI mediated NF-kB activation,0.001673630282554465,0,0,1,0.0018058602273060332
3449,PSB5,FCERI mediated NF-kB activation,0.0018659455633799856,1,0,1,0.002013369926650097
3450,PSB5,Mitotic Metaphase and Anaphase,0.001673630282554465,0,0,1,0.0018058602273060332
3451,PSB5,Mitotic Metaphase and Anaphase,0.0018659455633799856,1,0,1,0.002013369926650097
3452,PSB5,Regulation of ornithine decarboxylase (ODC),0.001673630282554465,0,0,1,0.0018058602273060332
3453,PSB5,Regulation of ornithine decarboxylase (ODC),0.0018659455633799856,1,0,1,0.002013369926650097
3454,PSB5,Signaling by ROBO receptors,0.001673630282554465,0,0,1,0.0018058602273060332
3455,PSB5,Signaling by ROBO receptors,0.0018659455633799856,1,0,1,0.002013369926650097
3456,PSB5,PCP/CE pathway,0.001673630282554465,0,0,1,0.0018058602273060332
3457,PSB5,PCP/CE pathway,0.0018659455633799856,1,0,1,0.002013369926650097
3458,PSB5,Interleukin-1 family signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3459,PSB5,Interleukin-1 family signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3460,PSB5,G2/M Transition,0.001673630282554465,0,0,1,0.0018058602273060332
3461,PSB5,G2/M Transition,0.0018659455633799856,1,0,1,0.002013369926650097
3462,PSB5,G1/S Transition,0.001673630282554465,0,0,1,0.0018058602273060332
3463,PSB5,G1/S Transition,0.0018659455633799856,1,0,1,0.002013369926650097
3464,PSB5,Hh mutants are degraded by ERAD,0.001673630282554465,0,0,1,0.0018058602273060332
3465,PSB5,Hh mutants are degraded by ERAD,0.0018659455633799856,1,0,1,0.002013369926650097
3466,PSB5,CLEC7A (Dectin-1) signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3467,PSB5,CLEC7A (Dectin-1) signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3468,PSB5,Degradation of GLI1 by the proteasome,0.001673630282554465,0,0,1,0.0018058602273060332
3469,PSB5,Degradation of GLI1 by the proteasome,0.0018659455633799856,1,0,1,0.002013369926650097
3470,PSB5,Degradation of GLI2 by the proteasome,0.001673630282554465,0,0,1,0.0018058602273060332
3471,PSB5,Degradation of GLI2 by the proteasome,0.0018659455633799856,1,0,1,0.002013369926650097
3472,PSB5,GLI3 is processed to GLI3R by the proteasome,0.001673630282554465,0,0,1,0.0018058602273060332
3473,PSB5,GLI3 is processed to GLI3R by the proteasome,0.0018659455633799856,1,0,1,0.002013369926650097
3474,PSB5,Defective CFTR causes cystic fibrosis,0.001673630282554465,0,0,1,0.0018058602273060332
3475,PSB5,Defective CFTR causes cystic fibrosis,0.0018659455633799856,1,0,1,0.002013369926650097
3476,PSB5,NIK-->noncanonical NF-kB signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3477,PSB5,NIK-->noncanonical NF-kB signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3478,PSB5,RAF/MAP kinase cascade,0.001673630282554465,0,0,1,0.0018058602273060332
3479,PSB5,RAF/MAP kinase cascade,0.0018659455633799856,1,0,1,0.002013369926650097
3480,PSB5,UCH proteinases,0.001673630282554465,0,0,1,0.0018058602273060332
3481,PSB5,UCH proteinases,0.0018659455633799856,1,0,1,0.002013369926650097
3482,PSB5,Ub-specific processing proteases,0.001673630282554465,0,0,1,0.0018058602273060332
3483,PSB5,Ub-specific processing proteases,0.0018659455633799856,1,0,1,0.002013369926650097
3484,PSB5,Orc1 removal from chromatin,0.001673630282554465,0,0,1,0.0018058602273060332
3485,PSB5,Orc1 removal from chromatin,0.0018659455633799856,1,0,1,0.002013369926650097
3486,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.001673630282554465,0,0,1,0.0018058602273060332
3487,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.0018659455633799856,1,0,1,0.002013369926650097
3488,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.001673630282554465,0,0,1,0.0018058602273060332
3489,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.0018659455633799856,1,0,1,0.002013369926650097
3490,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.001673630282554465,0,0,1,0.0018058602273060332
3491,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.0018659455633799856,1,0,1,0.002013369926650097
3492,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.001673630282554465,0,0,1,0.0018058602273060332
3493,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.0018659455633799856,1,0,1,0.002013369926650097
3494,PSB5,p53-Independent G1/S DNA damage checkpoint,0.001673630282554465,0,0,1,0.0018058602273060332
3495,PSB5,p53-Independent G1/S DNA damage checkpoint,0.0018659455633799856,1,0,1,0.002013369926650097
3496,PSB5,Negative regulation of NOTCH4 signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3497,PSB5,Negative regulation of NOTCH4 signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3498,PSB5,KEAP1-NFE2L2 pathway,0.001673630282554465,0,0,1,0.0018058602273060332
3499,PSB5,KEAP1-NFE2L2 pathway,0.0018659455633799856,1,0,1,0.002013369926650097
3500,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.001673630282554465,0,0,1,0.0018058602273060332
3501,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.0018659455633799856,1,0,1,0.002013369926650097
3502,PSB5,Degradation of beta-catenin by the destruction complex,0.001673630282554465,0,0,1,0.0018058602273060332
3503,PSB5,Degradation of beta-catenin by the destruction complex,0.0018659455633799856,1,0,1,0.002013369926650097
3504,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.001673630282554465,0,0,1,0.0018058602273060332
3505,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0018659455633799856,1,0,1,0.002013369926650097
3506,PSB5,Hedgehog ligand biogenesis,0.001673630282554465,0,0,1,0.0018058602273060332
3507,PSB5,Hedgehog ligand biogenesis,0.0018659455633799856,1,0,1,0.002013369926650097
3508,PSB5,Hedgehog 'on' state,0.001673630282554465,0,0,1,0.0018058602273060332
3509,PSB5,Hedgehog 'on' state,0.0018659455633799856,1,0,1,0.002013369926650097
3510,PSB5,MAPK6/MAPK4 signaling,0.001673630282554465,0,0,1,0.0018058602273060332
3511,PSB5,MAPK6/MAPK4 signaling,0.0018659455633799856,1,0,1,0.002013369926650097
3512,PSB5,Neddylation,0.001673630282554465,0,0,1,0.0018058602273060332
3513,PSB5,Neddylation,0.0018659455633799856,1,0,1,0.002013369926650097
3514,GRN,Neutrophil degranulation,0.00018295851951582637,0,0,1,0.00019741368035964258
3515,GRN,Neutrophil degranulation,0.00017859414331269363,1,0,1,0.0001927044841384743
3516,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.000298082567981813,0,0,1,0.0003216334333709602
3517,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.00026004129819436154,1,0,1,0.00028058660431829483
3518,CCN2,Transcriptional regulation by RUNX3,0.000298082567981813,0,0,1,0.0003216334333709602
3519,CCN2,Transcriptional regulation by RUNX3,0.00026004129819436154,1,0,1,0.00028058660431829483
3520,TKT,KEAP1-NFE2L2 pathway,0.002408800470099474,0,0,1,0.0025991146370925888
3521,TKT,KEAP1-NFE2L2 pathway,0.002722982535973036,1,0,1,0.0029381195552086337
3522,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.002408800470099474,0,0,1,0.0025991146370925888
3523,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.002722982535973036,1,0,1,0.0029381195552086337
3524,TKT,Pentose phosphate pathway,0.002408800470099474,0,0,1,0.0025991146370925888
3525,TKT,Pentose phosphate pathway,0.002722982535973036,1,0,1,0.0029381195552086337
3526,KAIN,Platelet degranulation ,0.0008438017223549347,0,0,1,0.0009104686895407653
3527,KAIN,Platelet degranulation ,0.000963606228409238,1,0,1,0.0010397386930718292
3528,PRDX6,Detoxification of Reactive Oxygen Species,0.0004226777103516118,0,0,1,0.00045607257113424945
3529,PRDX6,Detoxification of Reactive Oxygen Species,0.0004168596123539222,1,0,1,0.0004497947976725025
3530,PRDX6,Neutrophil degranulation,0.0004226777103516118,0,0,1,0.00045607257113424945
3531,PRDX6,Neutrophil degranulation,0.0004168596123539222,1,0,1,0.0004497947976725025
3532,BLVRB,Cytoprotection by HMOX1,0.002785767122016599,0,0,1,0.0030058646169500427
3533,BLVRB,Cytoprotection by HMOX1,0.002896546539462482,1,0,1,0.0031253964789478505
3534,BLVRB,Heme degradation,0.002785767122016599,0,0,1,0.0030058646169500427
3535,BLVRB,Heme degradation,0.002896546539462482,1,0,1,0.0031253964789478505
3536,PEBP1,RAF/MAP kinase cascade,0.0017763919114562063,0,0,1,0.0019167408324559329
3537,PEBP1,RAF/MAP kinase cascade,0.00167456843216011,1,0,1,0.0018068724981030882
3538,PEBP1,Signaling by RAS mutants,0.0017763919114562063,0,0,1,0.0019167408324559329
3539,PEBP1,Signaling by RAS mutants,0.00167456843216011,1,0,1,0.0018068724981030882
3540,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0017763919114562063,0,0,1,0.0019167408324559329
3541,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.00167456843216011,1,0,1,0.0018068724981030882
3542,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0017763919114562063,0,0,1,0.0019167408324559329
3543,PEBP1,Signaling by high-kinase activity BRAF mutants,0.00167456843216011,1,0,1,0.0018068724981030882
3544,PEBP1,Signaling by BRAF and RAF1 fusions,0.0017763919114562063,0,0,1,0.0019167408324559329
3545,PEBP1,Signaling by BRAF and RAF1 fusions,0.00167456843216011,1,0,1,0.0018068724981030882
3546,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0017763919114562063,0,0,1,0.0019167408324559329
3547,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00167456843216011,1,0,1,0.0018068724981030882
3548,PDIA3,Antigen processing-Cross presentation,0.00286795046122279,0,0,1,0.003094541085801419
3549,PDIA3,Antigen processing-Cross presentation,0.002767143855453469,1,0,1,0.002985769965975191
3550,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.00286795046122279,0,0,1,0.003094541085801419
3551,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.002767143855453469,1,0,1,0.002985769965975191
3552,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00286795046122279,0,0,1,0.003094541085801419
3553,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.002767143855453469,1,0,1,0.002985769965975191
3554,P30443,Antigen processing-Cross presentation,0.003388805433254068,0,0,1,0.0036565476938261346
3555,P30443,Antigen processing-Cross presentation,0.0032788297743536533,1,0,1,0.0035378830936153224
3556,P30443,Interferon gamma signaling,0.003388805433254068,0,0,1,0.0036565476938261346
3557,P30443,Interferon gamma signaling,0.0032788297743536533,1,0,1,0.0035378830936153224
3558,P30443,Interferon alpha/beta signaling,0.003388805433254068,0,0,1,0.0036565476938261346
3559,P30443,Interferon alpha/beta signaling,0.0032788297743536533,1,0,1,0.0035378830936153224
3560,P30443,SARS-CoV-2 Infection,0.003388805433254068,0,0,1,0.0036565476938261346
3561,P30443,SARS-CoV-2 Infection,0.0032788297743536533,1,0,1,0.0035378830936153224
3562,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.003388805433254068,0,0,1,0.0036565476938261346
3563,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0032788297743536533,1,0,1,0.0035378830936153224
3564,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003388805433254068,0,0,1,0.0036565476938261346
3565,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0032788297743536533,1,0,1,0.0035378830936153224
3566,ILEU,Neutrophil degranulation,0.0006363559259625617,0,0,1,0.0006866330449950468
3567,ILEU,Neutrophil degranulation,0.0006213155601775118,1,0,1,0.0006704043721164104
3568,CPSM,Urea cycle,0.00038896858095540667,0,0,1,0.00041970015560839787
3569,CPSM,Urea cycle,0.00035671301223677196,1,0,1,0.00038489614347663034
3570,1433B,Activation of BH3-only proteins,0.0004758989210434568,0,0,1,0.0005134986757161913
3571,1433B,Activation of BH3-only proteins,0.0004072590196907792,1,0,1,0.00043943568274153096
3572,1433B,Signaling by NTRK1 (TRKA),0.0004758989210434568,0,0,1,0.0005134986757161913
3573,1433B,Signaling by NTRK1 (TRKA),0.0004072590196907792,1,0,1,0.00043943568274153096
3574,1433B,RHO GTPase Effectors,0.0004758989210434568,0,0,1,0.0005134986757161913
3575,1433B,RHO GTPase Effectors,0.0004072590196907792,1,0,1,0.00043943568274153096
3576,1433B,Transcriptional Regulation by TP53,0.0004758989210434568,0,0,1,0.0005134986757161913
3577,1433B,Transcriptional Regulation by TP53,0.0004072590196907792,1,0,1,0.00043943568274153096
3578,1433B,FOXO-mediated transcription,0.0004758989210434568,0,0,1,0.0005134986757161913
3579,1433B,FOXO-mediated transcription,0.0004072590196907792,1,0,1,0.00043943568274153096
3580,1433B,RAF/MAP kinase cascade,0.0004758989210434568,0,0,1,0.0005134986757161913
3581,1433B,RAF/MAP kinase cascade,0.0004072590196907792,1,0,1,0.00043943568274153096
3582,1433B,Signaling by RAS mutants,0.0004758989210434568,0,0,1,0.0005134986757161913
3583,1433B,Signaling by RAS mutants,0.0004072590196907792,1,0,1,0.00043943568274153096
3584,1433B,Signaling by moderate kinase activity BRAF mutants,0.0004758989210434568,0,0,1,0.0005134986757161913
3585,1433B,Signaling by moderate kinase activity BRAF mutants,0.0004072590196907792,1,0,1,0.00043943568274153096
3586,1433B,Signaling by high-kinase activity BRAF mutants,0.0004758989210434568,0,0,1,0.0005134986757161913
3587,1433B,Signaling by high-kinase activity BRAF mutants,0.0004072590196907792,1,0,1,0.00043943568274153096
3588,1433B,Signaling by BRAF and RAF1 fusions,0.0004758989210434568,0,0,1,0.0005134986757161913
3589,1433B,Signaling by BRAF and RAF1 fusions,0.0004072590196907792,1,0,1,0.00043943568274153096
3590,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0004758989210434568,0,0,1,0.0005134986757161913
3591,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0004072590196907792,1,0,1,0.00043943568274153096
3592,1433B,Signaling by RAF1 mutants,0.0004758989210434568,0,0,1,0.0005134986757161913
3593,1433B,Signaling by RAF1 mutants,0.0004072590196907792,1,0,1,0.00043943568274153096
3594,1433B,Signaling by MRAS-complex mutants,0.0004758989210434568,0,0,1,0.0005134986757161913
3595,1433B,Signaling by MRAS-complex mutants,0.0004072590196907792,1,0,1,0.00043943568274153096
3596,1433B,G2/M DNA damage checkpoint,0.0004758989210434568,0,0,1,0.0005134986757161913
3597,1433B,G2/M DNA damage checkpoint,0.0004072590196907792,1,0,1,0.00043943568274153096
3598,1433B,SARS-CoV-2 Infection,0.0004758989210434568,0,0,1,0.0005134986757161913
3599,1433B,SARS-CoV-2 Infection,0.0004072590196907792,1,0,1,0.00043943568274153096
3600,1433B,Rap1 signalling,0.0004758989210434568,0,0,1,0.0005134986757161913
3601,1433B,Rap1 signalling,0.0004072590196907792,1,0,1,0.00043943568274153096
3602,1433B,Signaling by Hippo,0.0004758989210434568,0,0,1,0.0005134986757161913
3603,1433B,Signaling by Hippo,0.0004072590196907792,1,0,1,0.00043943568274153096
3604,1433B,mTORC1-mediated signalling,0.0004758989210434568,0,0,1,0.0005134986757161913
3605,1433B,mTORC1-mediated signalling,0.0004072590196907792,1,0,1,0.00043943568274153096
3606,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0004758989210434568,0,0,1,0.0005134986757161913
3607,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0004072590196907792,1,0,1,0.00043943568274153096
3608,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0004758989210434568,0,0,1,0.0005134986757161913
3609,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0004072590196907792,1,0,1,0.00043943568274153096
3610,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0004758989210434568,0,0,1,0.0005134986757161913
3611,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0004072590196907792,1,0,1,0.00043943568274153096
3612,PRDX2,Transcriptional Regulation by TP53,0.0004955387536237292,0,0,1,0.0005346902094123491
3613,PRDX2,Transcriptional Regulation by TP53,0.00041996099514184,1,0,1,0.0004531412140732645
3614,PRDX2,Neurodegenerative Diseases,0.0004955387536237292,0,0,1,0.0005346902094123491
3615,PRDX2,Neurodegenerative Diseases,0.00041996099514184,1,0,1,0.0004531412140732645
3616,PRDX2,Detoxification of Reactive Oxygen Species,0.0004955387536237292,0,0,1,0.0005346902094123491
3617,PRDX2,Detoxification of Reactive Oxygen Species,0.00041996099514184,1,0,1,0.0004531412140732645
3618,HPPD,Tyrosine catabolism,0.0009237307172346239,0,0,1,0.0009967127031478033
3619,HPPD,Tyrosine catabolism,0.0009686871851348163,1,0,1,0.0010452210853080525
3620,CADH5,VEGFA-VEGFR2 Pathway,0.0015471251521375962,0,0,1,0.001669360197430079
3621,CADH5,VEGFA-VEGFR2 Pathway,0.001194804899811667,1,0,1,0.0012892038764182928
3622,CADH5,Adherens junctions interactions,0.0015471251521375962,0,0,1,0.001669360197430079
3623,CADH5,Adherens junctions interactions,0.001194804899811667,1,0,1,0.0012892038764182928
3624,MA1A1,Intra-Golgi traffic,0.0005277473222425518,0,0,1,0.0005694435080670633
3625,MA1A1,Intra-Golgi traffic,0.0005512648664686518,1,0,1,0.0005948191231025438
3626,HS71L,Regulation of HSF1-mediated heat shock response,0.0009812546350682775,0,0,1,0.0010587814625491107
3627,HS71L,Regulation of HSF1-mediated heat shock response,0.001072492632859697,1,0,1,0.0011572279791710984
3628,HS71L,HSF1-dependent transactivation,0.0009812546350682775,0,0,1,0.0010587814625491107
3629,HS71L,HSF1-dependent transactivation,0.001072492632859697,1,0,1,0.0011572279791710984
3630,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0009812546350682775,0,0,1,0.0010587814625491107
3631,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.001072492632859697,1,0,1,0.0011572279791710984
3632,TRY3,Defensins,0.0008600802970856118,0,0,1,0.0009280333996023509
3633,TRY3,Defensins,0.000833907869188503,1,0,1,0.0008997931442221215
3634,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0008600802970856118,0,0,1,0.0009280333996023509
3635,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.000833907869188503,1,0,1,0.0008997931442221215
3636,TRY3,Neutrophil degranulation,0.0008600802970856118,0,0,1,0.0009280333996023509
3637,TRY3,Neutrophil degranulation,0.000833907869188503,1,0,1,0.0008997931442221215
3638,CBS,Cysteine formation from homocysteine,6.973188698111699e-06,0,0,1,7.524125404924998e-06
3639,CBS,Cysteine formation from homocysteine,9.38749908622564e-06,1,0,1,1.0129185286855567e-05
3640,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",6.973188698111699e-06,0,0,1,7.524125404924998e-06
3641,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",9.38749908622564e-06,1,0,1,1.0129185286855567e-05
3642,K1C9,Formation of the cornified envelope,2.419409748218489e-05,0,0,1,2.610562131557325e-05
3643,K1C9,Formation of the cornified envelope,2.8066554534689203e-05,1,0,1,3.0284032907406235e-05
3644,FBN1,TGF-beta receptor signaling activates SMADs,0.002791797867879116,0,0,1,0.003012371839129058
3645,FBN1,TGF-beta receptor signaling activates SMADs,0.00244971342132582,1,0,1,0.0026432600329852843
3646,FBN1,Integrin cell surface interactions,0.002791797867879116,0,0,1,0.003012371839129058
3647,FBN1,Integrin cell surface interactions,0.00244971342132582,1,0,1,0.0026432600329852843
3648,FBN1,Molecules associated with elastic fibres,0.002791797867879116,0,0,1,0.003012371839129058
3649,FBN1,Molecules associated with elastic fibres,0.00244971342132582,1,0,1,0.0026432600329852843
3650,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002791797867879116,0,0,1,0.003012371839129058
3651,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00244971342132582,1,0,1,0.0026432600329852843
3652,FBN1,Post-translational protein phosphorylation,0.002791797867879116,0,0,1,0.003012371839129058
3653,FBN1,Post-translational protein phosphorylation,0.00244971342132582,1,0,1,0.0026432600329852843
3654,MYH9,RHO GTPase Effectors,0.0015375917302056527,0,0,1,0.001659073560245941
3655,MYH9,RHO GTPase Effectors,0.0021124474578148996,1,0,1,0.002279347407910876
3656,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.0015375917302056527,0,0,1,0.001659073560245941
3657,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.0021124474578148996,1,0,1,0.002279347407910876
3658,MYH9,EPH-Ephrin signaling,0.0015375917302056527,0,0,1,0.001659073560245941
3659,MYH9,EPH-Ephrin signaling,0.0021124474578148996,1,0,1,0.002279347407910876
3660,MYH9,Semaphorin interactions,0.0015375917302056527,0,0,1,0.001659073560245941
3661,MYH9,Semaphorin interactions,0.0021124474578148996,1,0,1,0.002279347407910876
3662,MYH9,Parasite infection,0.0015375917302056527,0,0,1,0.001659073560245941
3663,MYH9,Parasite infection,0.0021124474578148996,1,0,1,0.002279347407910876
3664,MYH9,Leishmania parasite growth and survival,0.0015375917302056527,0,0,1,0.001659073560245941
3665,MYH9,Leishmania parasite growth and survival,0.0021124474578148996,1,0,1,0.002279347407910876
3666,MYH9,Signaling by ALK fusions and activated point mutants,0.0015375917302056527,0,0,1,0.001659073560245941
3667,MYH9,Signaling by ALK fusions and activated point mutants,0.0021124474578148996,1,0,1,0.002279347407910876
3668,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0015375917302056527,0,0,1,0.001659073560245941
3669,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0021124474578148996,1,0,1,0.002279347407910876
3670,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.0015375917302056527,0,0,1,0.001659073560245941
3671,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.0021124474578148996,1,0,1,0.002279347407910876
3672,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.0015375917302056527,0,0,1,0.001659073560245941
3673,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.0021124474578148996,1,0,1,0.002279347407910876
3674,MYH10,RHO GTPase Effectors,1.5585589842714853e-05,0,0,1,1.6816973921567237e-05
3675,MYH10,RHO GTPase Effectors,1.599446133442479e-05,1,0,1,1.725814947428925e-05
3676,MYH10,EPH-Ephrin signaling,1.5585589842714853e-05,0,0,1,1.6816973921567237e-05
3677,MYH10,EPH-Ephrin signaling,1.599446133442479e-05,1,0,1,1.725814947428925e-05
3678,MYH10,Semaphorin interactions,1.5585589842714853e-05,0,0,1,1.6816973921567237e-05
3679,MYH10,Semaphorin interactions,1.599446133442479e-05,1,0,1,1.725814947428925e-05
3680,MYH11,RHO GTPase Effectors,0.00022761075233574958,0,0,1,0.0002455937904774125
3681,MYH11,RHO GTPase Effectors,0.00023865678692042518,1,0,1,0.0002575125486009011
3682,MYH11,EPH-Ephrin signaling,0.00022761075233574958,0,0,1,0.0002455937904774125
3683,MYH11,EPH-Ephrin signaling,0.00023865678692042518,1,0,1,0.0002575125486009011
3684,MYH11,Semaphorin interactions,0.00022761075233574958,0,0,1,0.0002455937904774125
3685,MYH11,Semaphorin interactions,0.00023865678692042518,1,0,1,0.0002575125486009011
3686,MYH11,Smooth Muscle Contraction,0.00022761075233574958,0,0,1,0.0002455937904774125
3687,MYH11,Smooth Muscle Contraction,0.00023865678692042518,1,0,1,0.0002575125486009011
3688,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0007012462965424978,0,0,1,0.0007566502647997694
3689,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0006619767046458947,1,0,1,0.0007142780665384088
3690,K1C20,Formation of the cornified envelope,3.7858209414783537e-06,0,0,1,4.084930547195422e-06
3691,K1C20,Formation of the cornified envelope,4.385575992197725e-06,1,0,1,4.7320709601705785e-06
3692,K22E,Formation of the cornified envelope,0.0003865667897722839,0,0,1,0.0004171086040470365
3693,K22E,Formation of the cornified envelope,0.00044842736388091,1,0,1,0.00048385664964918683
3694,CH3L1,Neutrophil degranulation,0.002772299641704497,0,0,1,0.0029913330998574315
3695,CH3L1,Neutrophil degranulation,0.0026988727011485027,1,0,1,0.002912104853962855
3696,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0006902515210337394,0,0,1,0.0007447868156220212
3697,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0006543639099011974,1,0,1,0.0007060638011827951
3698,PGM1,Glycogen synthesis,0.0006902515210337394,0,0,1,0.0007447868156220212
3699,PGM1,Glycogen synthesis,0.0006543639099011974,1,0,1,0.0007060638011827951
3700,PGM1,Glycogen breakdown (glycogenolysis),0.0006902515210337394,0,0,1,0.0007447868156220212
3701,PGM1,Glycogen breakdown (glycogenolysis),0.0006543639099011974,1,0,1,0.0007060638011827951
3702,PGM1,Neutrophil degranulation,0.0006902515210337394,0,0,1,0.0007447868156220212
3703,PGM1,Neutrophil degranulation,0.0006543639099011974,1,0,1,0.0007060638011827951
3704,PGM1,Galactose catabolism,0.0006902515210337394,0,0,1,0.0007447868156220212
3705,PGM1,Galactose catabolism,0.0006543639099011974,1,0,1,0.0007060638011827951
3706,FHR2,Regulation of Complement cascade,5.831308232847239e-06,0,0,1,6.292027409296332e-06
3707,FHR2,Regulation of Complement cascade,6.017418889747716e-06,1,0,1,6.4928422706654716e-06
3708,TAGL2,Platelet degranulation ,0.001174145151647584,0,0,1,0.001266911845792071
3709,TAGL2,Platelet degranulation ,0.0013381215069481792,1,0,1,0.0014438436217898032
3710,TALDO,Interleukin-12 family signaling,0.001725998561596498,0,0,1,0.001862366011934959
3711,TALDO,Interleukin-12 family signaling,0.0020250603488724058,1,0,1,0.002185056030619563
3712,TALDO,Pentose phosphate pathway disease,0.001725998561596498,0,0,1,0.001862366011934959
3713,TALDO,Pentose phosphate pathway disease,0.0020250603488724058,1,0,1,0.002185056030619563
3714,TALDO,KEAP1-NFE2L2 pathway,0.001725998561596498,0,0,1,0.001862366011934959
3715,TALDO,KEAP1-NFE2L2 pathway,0.0020250603488724058,1,0,1,0.002185056030619563
3716,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.001725998561596498,0,0,1,0.001862366011934959
3717,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0020250603488724058,1,0,1,0.002185056030619563
3718,TALDO,Pentose phosphate pathway,0.001725998561596498,0,0,1,0.001862366011934959
3719,TALDO,Pentose phosphate pathway,0.0020250603488724058,1,0,1,0.002185056030619563
3720,GRP75,Regulation of HSF1-mediated heat shock response,0.0004679597018063456,0,0,1,0.0005049321957680158
3721,GRP75,Regulation of HSF1-mediated heat shock response,0.00048258658571285193,1,0,1,0.0005207147184503054
3722,GRP75,Interleukin-12 family signaling,0.0004679597018063456,0,0,1,0.0005049321957680158
3723,GRP75,Interleukin-12 family signaling,0.00048258658571285193,1,0,1,0.0005207147184503054
3724,GRP75,Cristae formation,0.0004679597018063456,0,0,1,0.0005049321957680158
3725,GRP75,Cristae formation,0.00048258658571285193,1,0,1,0.0005207147184503054
3726,GRP75,Mitochondrial protein import,0.0004679597018063456,0,0,1,0.0005049321957680158
3727,GRP75,Mitochondrial protein import,0.00048258658571285193,1,0,1,0.0005207147184503054
3728,COIA1,Collagen chain trimerization,0.006226354168029502,0,0,1,0.006718285077875143
3729,COIA1,Collagen chain trimerization,0.00590212758203658,1,0,1,0.00636844204361421
3730,COIA1,Collagen degradation,0.006226354168029502,0,0,1,0.006718285077875143
3731,COIA1,Collagen degradation,0.00590212758203658,1,0,1,0.00636844204361421
3732,COIA1,Activation of Matrix Metalloproteinases,0.006226354168029502,0,0,1,0.006718285077875143
3733,COIA1,Activation of Matrix Metalloproteinases,0.00590212758203658,1,0,1,0.00636844204361421
3734,COIA1,Integrin cell surface interactions,0.006226354168029502,0,0,1,0.006718285077875143
3735,COIA1,Integrin cell surface interactions,0.00590212758203658,1,0,1,0.00636844204361421
3736,COIA1,Laminin interactions,0.006226354168029502,0,0,1,0.006718285077875143
3737,COIA1,Laminin interactions,0.00590212758203658,1,0,1,0.00636844204361421
3738,MDHC,Gluconeogenesis,7.569942387514554e-05,0,0,1,8.168027325453066e-05
3739,MDHC,Gluconeogenesis,0.00010433785419081688,1,0,1,0.0001125813646237729
3740,MDHM,Gluconeogenesis,0.0005685389199546383,0,0,1,0.0006134579625642007
3741,MDHM,Gluconeogenesis,0.0006229303010816997,1,0,1,0.0006721466902416695
3742,MDHM,Citric acid cycle (TCA cycle),0.0005685389199546383,0,0,1,0.0006134579625642007
3743,MDHM,Citric acid cycle (TCA cycle),0.0006229303010816997,1,0,1,0.0006721466902416695
3744,PTGDS,Arachidonic acid metabolism,0.0012040487749648795,0,0,1,0.001299178090352741
3745,PTGDS,Arachidonic acid metabolism,0.0014336335636471631,1,0,1,0.0015469018815612713
3746,PTGDS,Transcriptional regulation of testis differentiation,0.0012040487749648795,0,0,1,0.001299178090352741
3747,PTGDS,Transcriptional regulation of testis differentiation,0.0014336335636471631,1,0,1,0.0015469018815612713
3748,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.0012719827236044997,0,0,1,0.0013724793548021959
3749,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.001393548414732019,1,0,1,0.0015036496908677496
3750,MUC18,RHO GTPase cycle,0.00045777144381039153,0,0,1,0.0004939389853247007
3751,MUC18,RHO GTPase cycle,0.0004041861398339582,1,0,1,0.00043612002122741617
3752,BTD,Biotin transport and metabolism,0.003028854801717292,0,0,1,0.0032681581336815695
3753,BTD,Biotin transport and metabolism,0.0029529468891269063,1,0,1,0.0031862528994648603
3754,BTD,Defects in biotin (Btn) metabolism,0.003028854801717292,0,0,1,0.0032681581336815695
3755,BTD,Defects in biotin (Btn) metabolism,0.0029529468891269063,1,0,1,0.0031862528994648603
3756,GSHB,Glutathione conjugation,6.674347914668033e-05,0,0,1,7.201673851112169e-05
3757,GSHB,Glutathione conjugation,7.385347265274808e-05,1,0,1,7.968847737892869e-05
3758,GSHB,Defective GSS causes GSS deficiency,6.674347914668033e-05,0,0,1,7.201673851112169e-05
3759,GSHB,Defective GSS causes GSS deficiency,7.385347265274808e-05,1,0,1,7.968847737892869e-05
3760,MASP1,Initial triggering of complement,0.001824018396049117,0,0,1,0.00196813018361028
3761,MASP1,Initial triggering of complement,0.0018935931981104658,1,0,1,0.002043201941796629
3762,MASP1,SARS-CoV-2 Infection,0.001824018396049117,0,0,1,0.00196813018361028
3763,MASP1,SARS-CoV-2 Infection,0.0018935931981104658,1,0,1,0.002043201941796629
3764,MASP1,Scavenging by Class A Receptors,0.001824018396049117,0,0,1,0.00196813018361028
3765,MASP1,Scavenging by Class A Receptors,0.0018935931981104658,1,0,1,0.002043201941796629
3766,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.0056423790306629,0,0,1,0.006088171315416018
3767,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.0054298175925699375,1,0,1,0.005858815853273462
3768,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0056423790306629,0,0,1,0.006088171315416018
3769,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0054298175925699375,1,0,1,0.005858815853273462
3770,PSB2,Antigen processing-Cross presentation,0.0056423790306629,0,0,1,0.006088171315416018
3771,PSB2,Antigen processing-Cross presentation,0.0054298175925699375,1,0,1,0.005858815853273462
3772,PSB2,PTEN Regulation,0.0056423790306629,0,0,1,0.006088171315416018
3773,PSB2,PTEN Regulation,0.0054298175925699375,1,0,1,0.005858815853273462
3774,PSB2,Host Interactions of HIV factors,0.0056423790306629,0,0,1,0.006088171315416018
3775,PSB2,Host Interactions of HIV factors,0.0054298175925699375,1,0,1,0.005858815853273462
3776,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0056423790306629,0,0,1,0.006088171315416018
3777,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0054298175925699375,1,0,1,0.005858815853273462
3778,PSB2,APC/C-mediated degradation of cell cycle proteins,0.0056423790306629,0,0,1,0.006088171315416018
3779,PSB2,APC/C-mediated degradation of cell cycle proteins,0.0054298175925699375,1,0,1,0.005858815853273462
3780,PSB2,Degradation of AXIN,0.0056423790306629,0,0,1,0.006088171315416018
3781,PSB2,Degradation of AXIN,0.0054298175925699375,1,0,1,0.005858815853273462
3782,PSB2,Degradation of DVL,0.0056423790306629,0,0,1,0.006088171315416018
3783,PSB2,Degradation of DVL,0.0054298175925699375,1,0,1,0.005858815853273462
3784,PSB2,Downstream TCR signaling,0.0056423790306629,0,0,1,0.006088171315416018
3785,PSB2,Downstream TCR signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3786,PSB2,Transcriptional regulation by RUNX3,0.0056423790306629,0,0,1,0.006088171315416018
3787,PSB2,Transcriptional regulation by RUNX3,0.0054298175925699375,1,0,1,0.005858815853273462
3788,PSB2,Transcriptional regulation by RUNX2,0.0056423790306629,0,0,1,0.006088171315416018
3789,PSB2,Transcriptional regulation by RUNX2,0.0054298175925699375,1,0,1,0.005858815853273462
3790,PSB2,Transcriptional regulation by RUNX1,0.0056423790306629,0,0,1,0.006088171315416018
3791,PSB2,Transcriptional regulation by RUNX1,0.0054298175925699375,1,0,1,0.005858815853273462
3792,PSB2,FCERI mediated NF-kB activation,0.0056423790306629,0,0,1,0.006088171315416018
3793,PSB2,FCERI mediated NF-kB activation,0.0054298175925699375,1,0,1,0.005858815853273462
3794,PSB2,Mitotic Metaphase and Anaphase,0.0056423790306629,0,0,1,0.006088171315416018
3795,PSB2,Mitotic Metaphase and Anaphase,0.0054298175925699375,1,0,1,0.005858815853273462
3796,PSB2,Regulation of ornithine decarboxylase (ODC),0.0056423790306629,0,0,1,0.006088171315416018
3797,PSB2,Regulation of ornithine decarboxylase (ODC),0.0054298175925699375,1,0,1,0.005858815853273462
3798,PSB2,Signaling by ROBO receptors,0.0056423790306629,0,0,1,0.006088171315416018
3799,PSB2,Signaling by ROBO receptors,0.0054298175925699375,1,0,1,0.005858815853273462
3800,PSB2,PCP/CE pathway,0.0056423790306629,0,0,1,0.006088171315416018
3801,PSB2,PCP/CE pathway,0.0054298175925699375,1,0,1,0.005858815853273462
3802,PSB2,Interleukin-1 family signaling,0.0056423790306629,0,0,1,0.006088171315416018
3803,PSB2,Interleukin-1 family signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3804,PSB2,G2/M Transition,0.0056423790306629,0,0,1,0.006088171315416018
3805,PSB2,G2/M Transition,0.0054298175925699375,1,0,1,0.005858815853273462
3806,PSB2,G1/S Transition,0.0056423790306629,0,0,1,0.006088171315416018
3807,PSB2,G1/S Transition,0.0054298175925699375,1,0,1,0.005858815853273462
3808,PSB2,Hh mutants are degraded by ERAD,0.0056423790306629,0,0,1,0.006088171315416018
3809,PSB2,Hh mutants are degraded by ERAD,0.0054298175925699375,1,0,1,0.005858815853273462
3810,PSB2,CLEC7A (Dectin-1) signaling,0.0056423790306629,0,0,1,0.006088171315416018
3811,PSB2,CLEC7A (Dectin-1) signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3812,PSB2,Degradation of GLI1 by the proteasome,0.0056423790306629,0,0,1,0.006088171315416018
3813,PSB2,Degradation of GLI1 by the proteasome,0.0054298175925699375,1,0,1,0.005858815853273462
3814,PSB2,Degradation of GLI2 by the proteasome,0.0056423790306629,0,0,1,0.006088171315416018
3815,PSB2,Degradation of GLI2 by the proteasome,0.0054298175925699375,1,0,1,0.005858815853273462
3816,PSB2,GLI3 is processed to GLI3R by the proteasome,0.0056423790306629,0,0,1,0.006088171315416018
3817,PSB2,GLI3 is processed to GLI3R by the proteasome,0.0054298175925699375,1,0,1,0.005858815853273462
3818,PSB2,Defective CFTR causes cystic fibrosis,0.0056423790306629,0,0,1,0.006088171315416018
3819,PSB2,Defective CFTR causes cystic fibrosis,0.0054298175925699375,1,0,1,0.005858815853273462
3820,PSB2,NIK-->noncanonical NF-kB signaling,0.0056423790306629,0,0,1,0.006088171315416018
3821,PSB2,NIK-->noncanonical NF-kB signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3822,PSB2,RAF/MAP kinase cascade,0.0056423790306629,0,0,1,0.006088171315416018
3823,PSB2,RAF/MAP kinase cascade,0.0054298175925699375,1,0,1,0.005858815853273462
3824,PSB2,UCH proteinases,0.0056423790306629,0,0,1,0.006088171315416018
3825,PSB2,UCH proteinases,0.0054298175925699375,1,0,1,0.005858815853273462
3826,PSB2,Ub-specific processing proteases,0.0056423790306629,0,0,1,0.006088171315416018
3827,PSB2,Ub-specific processing proteases,0.0054298175925699375,1,0,1,0.005858815853273462
3828,PSB2,Orc1 removal from chromatin,0.0056423790306629,0,0,1,0.006088171315416018
3829,PSB2,Orc1 removal from chromatin,0.0054298175925699375,1,0,1,0.005858815853273462
3830,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.0056423790306629,0,0,1,0.006088171315416018
3831,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.0054298175925699375,1,0,1,0.005858815853273462
3832,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.0056423790306629,0,0,1,0.006088171315416018
3833,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.0054298175925699375,1,0,1,0.005858815853273462
3834,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.0056423790306629,0,0,1,0.006088171315416018
3835,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.0054298175925699375,1,0,1,0.005858815853273462
3836,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.0056423790306629,0,0,1,0.006088171315416018
3837,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.0054298175925699375,1,0,1,0.005858815853273462
3838,PSB2,p53-Independent G1/S DNA damage checkpoint,0.0056423790306629,0,0,1,0.006088171315416018
3839,PSB2,p53-Independent G1/S DNA damage checkpoint,0.0054298175925699375,1,0,1,0.005858815853273462
3840,PSB2,Negative regulation of NOTCH4 signaling,0.0056423790306629,0,0,1,0.006088171315416018
3841,PSB2,Negative regulation of NOTCH4 signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3842,PSB2,KEAP1-NFE2L2 pathway,0.0056423790306629,0,0,1,0.006088171315416018
3843,PSB2,KEAP1-NFE2L2 pathway,0.0054298175925699375,1,0,1,0.005858815853273462
3844,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.0056423790306629,0,0,1,0.006088171315416018
3845,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.0054298175925699375,1,0,1,0.005858815853273462
3846,PSB2,Degradation of beta-catenin by the destruction complex,0.0056423790306629,0,0,1,0.006088171315416018
3847,PSB2,Degradation of beta-catenin by the destruction complex,0.0054298175925699375,1,0,1,0.005858815853273462
3848,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0056423790306629,0,0,1,0.006088171315416018
3849,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0054298175925699375,1,0,1,0.005858815853273462
3850,PSB2,Hedgehog ligand biogenesis,0.0056423790306629,0,0,1,0.006088171315416018
3851,PSB2,Hedgehog ligand biogenesis,0.0054298175925699375,1,0,1,0.005858815853273462
3852,PSB2,Hedgehog 'on' state,0.0056423790306629,0,0,1,0.006088171315416018
3853,PSB2,Hedgehog 'on' state,0.0054298175925699375,1,0,1,0.005858815853273462
3854,PSB2,MAPK6/MAPK4 signaling,0.0056423790306629,0,0,1,0.006088171315416018
3855,PSB2,MAPK6/MAPK4 signaling,0.0054298175925699375,1,0,1,0.005858815853273462
3856,PSB2,Neddylation,0.0056423790306629,0,0,1,0.006088171315416018
3857,PSB2,Neddylation,0.0054298175925699375,1,0,1,0.005858815853273462
3858,COMP,Integrin cell surface interactions,0.0018474459585074024,0,0,1,0.0019934087076111558
3859,COMP,Integrin cell surface interactions,0.001688616308941467,1,0,1,0.0018220302675471427
3860,COMP,ECM proteoglycans,0.0018474459585074024,0,0,1,0.0019934087076111558
3861,COMP,ECM proteoglycans,0.001688616308941467,1,0,1,0.0018220302675471427
3862,SEPP1,Platelet degranulation ,0.0012218730635747002,0,0,1,0.0013184106378371053
3863,SEPP1,Platelet degranulation ,0.001402402121554284,1,0,1,0.0015132029101069195
3864,CAMP,Neutrophil degranulation,0.00394554139735798,0,0,1,0.004257270174272419
3865,CAMP,Neutrophil degranulation,0.0038449928261494884,1,0,1,0.004148777475765122
3866,MMP14,Collagen degradation,0.0006429109695697358,0,0,1,0.0006937059885608055
3867,MMP14,Collagen degradation,0.0005866683990461752,1,0,1,0.0006330198129767139
3868,MMP14,Activation of Matrix Metalloproteinases,0.0006429109695697358,0,0,1,0.0006937059885608055
3869,MMP14,Activation of Matrix Metalloproteinases,0.0005866683990461752,1,0,1,0.0006330198129767139
3870,LUM,Keratan sulfate/keratin metabolism,0.005702858039148851,0,0,1,0.006153428640854098
3871,LUM,Keratan sulfate/keratin metabolism,0.005341947505439748,1,0,1,0.005764003338722083
3872,LUM,Diseases associated with glycosaminoglycan metabolism,0.005702858039148851,0,0,1,0.006153428640854098
3873,LUM,Diseases associated with glycosaminoglycan metabolism,0.005341947505439748,1,0,1,0.005764003338722083
3874,LUM,Integrin cell surface interactions,0.005702858039148851,0,0,1,0.006153428640854098
3875,LUM,Integrin cell surface interactions,0.005341947505439748,1,0,1,0.005764003338722083
3876,LUM,ECM proteoglycans,0.005702858039148851,0,0,1,0.006153428640854098
3877,LUM,ECM proteoglycans,0.005341947505439748,1,0,1,0.005764003338722083
3878,RIDA,Threonine catabolism,0.00015710038472510252,0,0,1,0.00016951254971111362
3879,RIDA,Threonine catabolism,0.0001106725714635104,1,0,1,0.00011941657434316532
3880,CRIS3,Neutrophil degranulation,0.0007500087000456309,0,0,1,0.0008092652813850054
3881,CRIS3,Neutrophil degranulation,0.000732084942592337,1,0,1,0.0007899254062368452
3882,HSP72,Regulation of HSF1-mediated heat shock response,0.0017873078943618263,0,0,1,0.0019285192637956933
3883,HSP72,Regulation of HSF1-mediated heat shock response,0.0016134552124033993,1,0,1,0.0017409308537198308
3884,HSP72,HSF1-dependent transactivation,0.0017873078943618263,0,0,1,0.0019285192637956933
3885,HSP72,HSF1-dependent transactivation,0.0016134552124033993,1,0,1,0.0017409308537198308
3886,HSP72,Meiotic synapsis,0.0017873078943618263,0,0,1,0.0019285192637956933
3887,HSP72,Meiotic synapsis,0.0016134552124033993,1,0,1,0.0017409308537198308
3888,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0017873078943618263,0,0,1,0.0019285192637956933
3889,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0016134552124033993,1,0,1,0.0017409308537198308
3890,MFAP4,Molecules associated with elastic fibres,0.0006196601076226216,0,0,1,0.0006686181258001061
3891,MFAP4,Molecules associated with elastic fibres,0.0005617677027961084,1,0,1,0.0006061517660377028
3892,CAD13,Adherens junctions interactions,6.906891943193235e-05,0,0,1,7.452590685366758e-05
3893,CAD13,Adherens junctions interactions,2.0003565752328237e-05,1,0,1,2.1584004647248056e-05
3894,DEF1,Defensins,0.002588656275474932,0,0,1,0.0027931804645117127
3895,DEF1,Defensins,0.00254159128817264,1,0,1,0.0027423969733465386
3896,DEF1,Neutrophil degranulation,0.002588656275474932,0,0,1,0.0027931804645117127
3897,DEF1,Neutrophil degranulation,0.00254159128817264,1,0,1,0.0027423969733465386
3898,TPIS,Glycolysis,0.0002448338773319847,0,0,1,0.00026417767769839983
3899,TPIS,Glycolysis,0.00032593563446425833,1,0,1,0.00035168711099227315
3900,TPIS,Gluconeogenesis,0.0002448338773319847,0,0,1,0.00026417767769839983
3901,TPIS,Gluconeogenesis,0.00032593563446425833,1,0,1,0.00035168711099227315
3902,MYL6,RHO GTPase Effectors,8.748056207726525e-05,0,0,1,9.439221395814382e-05
3903,MYL6,RHO GTPase Effectors,8.848722648811721e-05,1,0,1,9.547841276844938e-05
3904,MYL6,EPH-Ephrin signaling,8.748056207726525e-05,0,0,1,9.439221395814382e-05
3905,MYL6,EPH-Ephrin signaling,8.848722648811721e-05,1,0,1,9.547841276844938e-05
3906,MYL6,Semaphorin interactions,8.748056207726525e-05,0,0,1,9.439221395814382e-05
3907,MYL6,Semaphorin interactions,8.848722648811721e-05,1,0,1,9.547841276844938e-05
3908,MYL6,Smooth Muscle Contraction,8.748056207726525e-05,0,0,1,9.439221395814382e-05
3909,MYL6,Smooth Muscle Contraction,8.848722648811721e-05,1,0,1,9.547841276844938e-05
3910,ACTB,Gap junction trafficking,0.02756909077288583,0,0,1,0.029747265599040135
3911,ACTB,Gap junction trafficking,0.02806666735947753,1,0,1,0.03028415464623949
3912,ACTB,VEGFA-VEGFR2 Pathway,0.02756909077288583,0,0,1,0.029747265599040135
3913,ACTB,VEGFA-VEGFR2 Pathway,0.02806666735947753,1,0,1,0.03028415464623949
3914,ACTB,RHO GTPase Effectors,0.02756909077288583,0,0,1,0.029747265599040135
3915,ACTB,RHO GTPase Effectors,0.02806666735947753,1,0,1,0.03028415464623949
3916,ACTB,RHO GTPase cycle,0.02756909077288583,0,0,1,0.029747265599040135
3917,ACTB,RHO GTPase cycle,0.02806666735947753,1,0,1,0.03028415464623949
3918,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.02756909077288583,0,0,1,0.029747265599040135
3919,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.02806666735947753,1,0,1,0.03028415464623949
3920,ACTB,EPH-Ephrin signaling,0.02756909077288583,0,0,1,0.029747265599040135
3921,ACTB,EPH-Ephrin signaling,0.02806666735947753,1,0,1,0.03028415464623949
3922,ACTB,L1CAM interactions,0.02756909077288583,0,0,1,0.029747265599040135
3923,ACTB,L1CAM interactions,0.02806666735947753,1,0,1,0.03028415464623949
3924,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.02756909077288583,0,0,1,0.029747265599040135
3925,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.02806666735947753,1,0,1,0.03028415464623949
3926,ACTB,Adherens junctions interactions,0.02756909077288583,0,0,1,0.029747265599040135
3927,ACTB,Adherens junctions interactions,0.02806666735947753,1,0,1,0.03028415464623949
3928,ACTB,B-WICH complex positively regulates rRNA expression,0.02756909077288583,0,0,1,0.029747265599040135
3929,ACTB,B-WICH complex positively regulates rRNA expression,0.02806666735947753,1,0,1,0.03028415464623949
3930,ACTB,RAF/MAP kinase cascade,0.02756909077288583,0,0,1,0.029747265599040135
3931,ACTB,RAF/MAP kinase cascade,0.02806666735947753,1,0,1,0.03028415464623949
3932,ACTB,UCH proteinases,0.02756909077288583,0,0,1,0.029747265599040135
3933,ACTB,UCH proteinases,0.02806666735947753,1,0,1,0.03028415464623949
3934,ACTB,DNA Damage Recognition in GG-NER,0.02756909077288583,0,0,1,0.029747265599040135
3935,ACTB,DNA Damage Recognition in GG-NER,0.02806666735947753,1,0,1,0.03028415464623949
3936,ACTB,Signaling by RAS mutants,0.02756909077288583,0,0,1,0.029747265599040135
3937,ACTB,Signaling by RAS mutants,0.02806666735947753,1,0,1,0.03028415464623949
3938,ACTB,Signaling by moderate kinase activity BRAF mutants,0.02756909077288583,0,0,1,0.029747265599040135
3939,ACTB,Signaling by moderate kinase activity BRAF mutants,0.02806666735947753,1,0,1,0.03028415464623949
3940,ACTB,Signaling by high-kinase activity BRAF mutants,0.02756909077288583,0,0,1,0.029747265599040135
3941,ACTB,Signaling by high-kinase activity BRAF mutants,0.02806666735947753,1,0,1,0.03028415464623949
3942,ACTB,Signaling by BRAF and RAF1 fusions,0.02756909077288583,0,0,1,0.029747265599040135
3943,ACTB,Signaling by BRAF and RAF1 fusions,0.02806666735947753,1,0,1,0.03028415464623949
3944,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.02756909077288583,0,0,1,0.029747265599040135
3945,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.02806666735947753,1,0,1,0.03028415464623949
3946,ACTB,Signaling by RAF1 mutants,0.02756909077288583,0,0,1,0.029747265599040135
3947,ACTB,Signaling by RAF1 mutants,0.02806666735947753,1,0,1,0.03028415464623949
3948,ACTB,Parasite infection,0.02756909077288583,0,0,1,0.029747265599040135
3949,ACTB,Parasite infection,0.02806666735947753,1,0,1,0.03028415464623949
3950,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.02756909077288583,0,0,1,0.029747265599040135
3951,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.02806666735947753,1,0,1,0.03028415464623949
3952,ACTB,HATs acetylate histones,0.02756909077288583,0,0,1,0.029747265599040135
3953,ACTB,HATs acetylate histones,0.02806666735947753,1,0,1,0.03028415464623949
3954,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.02756909077288583,0,0,1,0.029747265599040135
3955,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.02806666735947753,1,0,1,0.03028415464623949
3956,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.02756909077288583,0,0,1,0.029747265599040135
3957,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.02806666735947753,1,0,1,0.03028415464623949
3958,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0009371194102034982,0,0,1,0.0010111592080779119
3959,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.0012449116208396542,1,0,1,0.0013432694221773313
3960,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0009371194102034982,0,0,1,0.0010111592080779119
3961,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0012449116208396542,1,0,1,0.0013432694221773313
3962,PSA6,Antigen processing-Cross presentation,0.0009371194102034982,0,0,1,0.0010111592080779119
3963,PSA6,Antigen processing-Cross presentation,0.0012449116208396542,1,0,1,0.0013432694221773313
3964,PSA6,PTEN Regulation,0.0009371194102034982,0,0,1,0.0010111592080779119
3965,PSA6,PTEN Regulation,0.0012449116208396542,1,0,1,0.0013432694221773313
3966,PSA6,Host Interactions of HIV factors,0.0009371194102034982,0,0,1,0.0010111592080779119
3967,PSA6,Host Interactions of HIV factors,0.0012449116208396542,1,0,1,0.0013432694221773313
3968,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0009371194102034982,0,0,1,0.0010111592080779119
3969,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0012449116208396542,1,0,1,0.0013432694221773313
3970,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0009371194102034982,0,0,1,0.0010111592080779119
3971,PSA6,APC/C-mediated degradation of cell cycle proteins,0.0012449116208396542,1,0,1,0.0013432694221773313
3972,PSA6,Degradation of AXIN,0.0009371194102034982,0,0,1,0.0010111592080779119
3973,PSA6,Degradation of AXIN,0.0012449116208396542,1,0,1,0.0013432694221773313
3974,PSA6,Degradation of DVL,0.0009371194102034982,0,0,1,0.0010111592080779119
3975,PSA6,Degradation of DVL,0.0012449116208396542,1,0,1,0.0013432694221773313
3976,PSA6,Downstream TCR signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
3977,PSA6,Downstream TCR signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
3978,PSA6,Transcriptional regulation by RUNX3,0.0009371194102034982,0,0,1,0.0010111592080779119
3979,PSA6,Transcriptional regulation by RUNX3,0.0012449116208396542,1,0,1,0.0013432694221773313
3980,PSA6,Transcriptional regulation by RUNX2,0.0009371194102034982,0,0,1,0.0010111592080779119
3981,PSA6,Transcriptional regulation by RUNX2,0.0012449116208396542,1,0,1,0.0013432694221773313
3982,PSA6,Transcriptional regulation by RUNX1,0.0009371194102034982,0,0,1,0.0010111592080779119
3983,PSA6,Transcriptional regulation by RUNX1,0.0012449116208396542,1,0,1,0.0013432694221773313
3984,PSA6,FCERI mediated NF-kB activation,0.0009371194102034982,0,0,1,0.0010111592080779119
3985,PSA6,FCERI mediated NF-kB activation,0.0012449116208396542,1,0,1,0.0013432694221773313
3986,PSA6,Mitotic Metaphase and Anaphase,0.0009371194102034982,0,0,1,0.0010111592080779119
3987,PSA6,Mitotic Metaphase and Anaphase,0.0012449116208396542,1,0,1,0.0013432694221773313
3988,PSA6,Regulation of ornithine decarboxylase (ODC),0.0009371194102034982,0,0,1,0.0010111592080779119
3989,PSA6,Regulation of ornithine decarboxylase (ODC),0.0012449116208396542,1,0,1,0.0013432694221773313
3990,PSA6,Signaling by ROBO receptors,0.0009371194102034982,0,0,1,0.0010111592080779119
3991,PSA6,Signaling by ROBO receptors,0.0012449116208396542,1,0,1,0.0013432694221773313
3992,PSA6,PCP/CE pathway,0.0009371194102034982,0,0,1,0.0010111592080779119
3993,PSA6,PCP/CE pathway,0.0012449116208396542,1,0,1,0.0013432694221773313
3994,PSA6,Interleukin-1 family signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
3995,PSA6,Interleukin-1 family signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
3996,PSA6,G2/M Transition,0.0009371194102034982,0,0,1,0.0010111592080779119
3997,PSA6,G2/M Transition,0.0012449116208396542,1,0,1,0.0013432694221773313
3998,PSA6,G1/S Transition,0.0009371194102034982,0,0,1,0.0010111592080779119
3999,PSA6,G1/S Transition,0.0012449116208396542,1,0,1,0.0013432694221773313
4000,PSA6,Hh mutants are degraded by ERAD,0.0009371194102034982,0,0,1,0.0010111592080779119
4001,PSA6,Hh mutants are degraded by ERAD,0.0012449116208396542,1,0,1,0.0013432694221773313
4002,PSA6,CLEC7A (Dectin-1) signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
4003,PSA6,CLEC7A (Dectin-1) signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
4004,PSA6,Degradation of GLI1 by the proteasome,0.0009371194102034982,0,0,1,0.0010111592080779119
4005,PSA6,Degradation of GLI1 by the proteasome,0.0012449116208396542,1,0,1,0.0013432694221773313
4006,PSA6,Degradation of GLI2 by the proteasome,0.0009371194102034982,0,0,1,0.0010111592080779119
4007,PSA6,Degradation of GLI2 by the proteasome,0.0012449116208396542,1,0,1,0.0013432694221773313
4008,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0009371194102034982,0,0,1,0.0010111592080779119
4009,PSA6,GLI3 is processed to GLI3R by the proteasome,0.0012449116208396542,1,0,1,0.0013432694221773313
4010,PSA6,Defective CFTR causes cystic fibrosis,0.0009371194102034982,0,0,1,0.0010111592080779119
4011,PSA6,Defective CFTR causes cystic fibrosis,0.0012449116208396542,1,0,1,0.0013432694221773313
4012,PSA6,NIK-->noncanonical NF-kB signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
4013,PSA6,NIK-->noncanonical NF-kB signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
4014,PSA6,RAF/MAP kinase cascade,0.0009371194102034982,0,0,1,0.0010111592080779119
4015,PSA6,RAF/MAP kinase cascade,0.0012449116208396542,1,0,1,0.0013432694221773313
4016,PSA6,UCH proteinases,0.0009371194102034982,0,0,1,0.0010111592080779119
4017,PSA6,UCH proteinases,0.0012449116208396542,1,0,1,0.0013432694221773313
4018,PSA6,Ub-specific processing proteases,0.0009371194102034982,0,0,1,0.0010111592080779119
4019,PSA6,Ub-specific processing proteases,0.0012449116208396542,1,0,1,0.0013432694221773313
4020,PSA6,Orc1 removal from chromatin,0.0009371194102034982,0,0,1,0.0010111592080779119
4021,PSA6,Orc1 removal from chromatin,0.0012449116208396542,1,0,1,0.0013432694221773313
4022,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0009371194102034982,0,0,1,0.0010111592080779119
4023,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.0012449116208396542,1,0,1,0.0013432694221773313
4024,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0009371194102034982,0,0,1,0.0010111592080779119
4025,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.0012449116208396542,1,0,1,0.0013432694221773313
4026,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0009371194102034982,0,0,1,0.0010111592080779119
4027,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.0012449116208396542,1,0,1,0.0013432694221773313
4028,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0009371194102034982,0,0,1,0.0010111592080779119
4029,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.0012449116208396542,1,0,1,0.0013432694221773313
4030,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0009371194102034982,0,0,1,0.0010111592080779119
4031,PSA6,p53-Independent G1/S DNA damage checkpoint,0.0012449116208396542,1,0,1,0.0013432694221773313
4032,PSA6,Negative regulation of NOTCH4 signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
4033,PSA6,Negative regulation of NOTCH4 signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
4034,PSA6,KEAP1-NFE2L2 pathway,0.0009371194102034982,0,0,1,0.0010111592080779119
4035,PSA6,KEAP1-NFE2L2 pathway,0.0012449116208396542,1,0,1,0.0013432694221773313
4036,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0009371194102034982,0,0,1,0.0010111592080779119
4037,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.0012449116208396542,1,0,1,0.0013432694221773313
4038,PSA6,Degradation of beta-catenin by the destruction complex,0.0009371194102034982,0,0,1,0.0010111592080779119
4039,PSA6,Degradation of beta-catenin by the destruction complex,0.0012449116208396542,1,0,1,0.0013432694221773313
4040,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0009371194102034982,0,0,1,0.0010111592080779119
4041,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0012449116208396542,1,0,1,0.0013432694221773313
4042,PSA6,Hedgehog ligand biogenesis,0.0009371194102034982,0,0,1,0.0010111592080779119
4043,PSA6,Hedgehog ligand biogenesis,0.0012449116208396542,1,0,1,0.0013432694221773313
4044,PSA6,Hedgehog 'on' state,0.0009371194102034982,0,0,1,0.0010111592080779119
4045,PSA6,Hedgehog 'on' state,0.0012449116208396542,1,0,1,0.0013432694221773313
4046,PSA6,MAPK6/MAPK4 signaling,0.0009371194102034982,0,0,1,0.0010111592080779119
4047,PSA6,MAPK6/MAPK4 signaling,0.0012449116208396542,1,0,1,0.0013432694221773313
4048,PSA6,Neddylation,0.0009371194102034982,0,0,1,0.0010111592080779119
4049,PSA6,Neddylation,0.0012449116208396542,1,0,1,0.0013432694221773313
4050,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0004771724394231569,0,0,1,0.0005148728120559887
4051,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.0005038251787482295,1,0,1,0.0005436313272415776
4052,RAB10,Neutrophil degranulation,0.0004771724394231569,0,0,1,0.0005148728120559887
4053,RAB10,Neutrophil degranulation,0.0005038251787482295,1,0,1,0.0005436313272415776
4054,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0004771724394231569,0,0,1,0.0005148728120559887
4055,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0005038251787482295,1,0,1,0.0005436313272415776
4056,RAB10,RAB geranylgeranylation,0.0004771724394231569,0,0,1,0.0005148728120559887
4057,RAB10,RAB geranylgeranylation,0.0005038251787482295,1,0,1,0.0005436313272415776
4058,LYSC,Neutrophil degranulation,0.006369768127357626,0,0,1,0.006873029867026458
4059,LYSC,Neutrophil degranulation,0.006090135823645444,1,0,1,0.006571304413796103
4060,LYSC,Amyloid fiber formation,0.006369768127357626,0,0,1,0.006873029867026458
4061,LYSC,Amyloid fiber formation,0.006090135823645444,1,0,1,0.006571304413796103
4062,B2MG,Antigen processing-Cross presentation,0.009639103852047507,0,0,1,0.01040066880644441
4063,B2MG,Antigen processing-Cross presentation,0.009340150664502288,1,0,1,0.010078095967722665
4064,B2MG,Host Interactions of HIV factors,0.009639103852047507,0,0,1,0.01040066880644441
4065,B2MG,Host Interactions of HIV factors,0.009340150664502288,1,0,1,0.010078095967722665
4066,B2MG,DAP12 signaling,0.009639103852047507,0,0,1,0.01040066880644441
4067,B2MG,DAP12 signaling,0.009340150664502288,1,0,1,0.010078095967722665
4068,B2MG,Interferon gamma signaling,0.009639103852047507,0,0,1,0.01040066880644441
4069,B2MG,Interferon gamma signaling,0.009340150664502288,1,0,1,0.010078095967722665
4070,B2MG,Modulation by Mtb of host immune system,0.009639103852047507,0,0,1,0.01040066880644441
4071,B2MG,Modulation by Mtb of host immune system,0.009340150664502288,1,0,1,0.010078095967722665
4072,B2MG,SARS-CoV-2 Infection,0.009639103852047507,0,0,1,0.01040066880644441
4073,B2MG,SARS-CoV-2 Infection,0.009340150664502288,1,0,1,0.010078095967722665
4074,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.009639103852047507,0,0,1,0.01040066880644441
4075,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.009340150664502288,1,0,1,0.010078095967722665
4076,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009639103852047507,0,0,1,0.01040066880644441
4077,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009340150664502288,1,0,1,0.010078095967722665
4078,B2MG,Neutrophil degranulation,0.009639103852047507,0,0,1,0.01040066880644441
4079,B2MG,Neutrophil degranulation,0.009340150664502288,1,0,1,0.010078095967722665
4080,B2MG,Amyloid fiber formation,0.009639103852047507,0,0,1,0.01040066880644441
4081,B2MG,Amyloid fiber formation,0.009340150664502288,1,0,1,0.010078095967722665
4082,NPC2,LDL clearance,0.002153395211401706,0,0,1,0.002323530355824006
4083,NPC2,LDL clearance,0.0021670276570754745,1,0,1,0.002338239871838256
4084,NPC2,Neutrophil degranulation,0.002153395211401706,0,0,1,0.002323530355824006
4085,NPC2,Neutrophil degranulation,0.0021670276570754745,1,0,1,0.002338239871838256
4086,1433G,Activation of BH3-only proteins,0.005079225433291867,0,0,1,0.005480524158240749
4087,1433G,Activation of BH3-only proteins,0.005562187775891895,1,0,1,0.006001644321325247
4088,1433G,RHO GTPase Effectors,0.005079225433291867,0,0,1,0.005480524158240749
4089,1433G,RHO GTPase Effectors,0.005562187775891895,1,0,1,0.006001644321325247
4090,1433G,Transcriptional Regulation by TP53,0.005079225433291867,0,0,1,0.005480524158240749
4091,1433G,Transcriptional Regulation by TP53,0.005562187775891895,1,0,1,0.006001644321325247
4092,1433G,FOXO-mediated transcription,0.005079225433291867,0,0,1,0.005480524158240749
4093,1433G,FOXO-mediated transcription,0.005562187775891895,1,0,1,0.006001644321325247
4094,1433G,G2/M Transition,0.005079225433291867,0,0,1,0.005480524158240749
4095,1433G,G2/M Transition,0.005562187775891895,1,0,1,0.006001644321325247
4096,1433G,Mitotic Prometaphase,0.005079225433291867,0,0,1,0.005480524158240749
4097,1433G,Mitotic Prometaphase,0.005562187775891895,1,0,1,0.006001644321325247
4098,1433G,G2/M DNA damage checkpoint,0.005079225433291867,0,0,1,0.005480524158240749
4099,1433G,G2/M DNA damage checkpoint,0.005562187775891895,1,0,1,0.006001644321325247
4100,1433G,SARS-CoV-2 Infection,0.005079225433291867,0,0,1,0.005480524158240749
4101,1433G,SARS-CoV-2 Infection,0.005562187775891895,1,0,1,0.006001644321325247
4102,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005079225433291867,0,0,1,0.005480524158240749
4103,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005562187775891895,1,0,1,0.006001644321325247
4104,1433G,Anchoring of the basal body to the plasma membrane,0.005079225433291867,0,0,1,0.005480524158240749
4105,1433G,Anchoring of the basal body to the plasma membrane,0.005562187775891895,1,0,1,0.006001644321325247
4106,1433E,Activation of BH3-only proteins,0.0029460732475854456,0,0,1,0.0031788361862242656
4107,1433E,Activation of BH3-only proteins,0.002811324183130637,1,0,1,0.003033440886735403
4108,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.0029460732475854456,0,0,1,0.0031788361862242656
4109,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.002811324183130637,1,0,1,0.003033440886735403
4110,1433E,RHO GTPase Effectors,0.0029460732475854456,0,0,1,0.0031788361862242656
4111,1433E,RHO GTPase Effectors,0.002811324183130637,1,0,1,0.003033440886735403
4112,1433E,Transcriptional Regulation by TP53,0.0029460732475854456,0,0,1,0.0031788361862242656
4113,1433E,Transcriptional Regulation by TP53,0.002811324183130637,1,0,1,0.003033440886735403
4114,1433E,Regulation of HSF1-mediated heat shock response,0.0029460732475854456,0,0,1,0.0031788361862242656
4115,1433E,Regulation of HSF1-mediated heat shock response,0.002811324183130637,1,0,1,0.003033440886735403
4116,1433E,HSF1 activation,0.0029460732475854456,0,0,1,0.0031788361862242656
4117,1433E,HSF1 activation,0.002811324183130637,1,0,1,0.003033440886735403
4118,1433E,G2/M Transition,0.0029460732475854456,0,0,1,0.0031788361862242656
4119,1433E,G2/M Transition,0.002811324183130637,1,0,1,0.003033440886735403
4120,1433E,Mitotic Prometaphase,0.0029460732475854456,0,0,1,0.0031788361862242656
4121,1433E,Mitotic Prometaphase,0.002811324183130637,1,0,1,0.003033440886735403
4122,1433E,G2/M DNA damage checkpoint,0.0029460732475854456,0,0,1,0.0031788361862242656
4123,1433E,G2/M DNA damage checkpoint,0.002811324183130637,1,0,1,0.003033440886735403
4124,1433E,Neurodegenerative Diseases,0.0029460732475854456,0,0,1,0.0031788361862242656
4125,1433E,Neurodegenerative Diseases,0.002811324183130637,1,0,1,0.003033440886735403
4126,1433E,RAB GEFs exchange GTP for GDP on RABs,0.0029460732475854456,0,0,1,0.0031788361862242656
4127,1433E,RAB GEFs exchange GTP for GDP on RABs,0.002811324183130637,1,0,1,0.003033440886735403
4128,1433E,SARS-CoV-2 Infection,0.0029460732475854456,0,0,1,0.0031788361862242656
4129,1433E,SARS-CoV-2 Infection,0.002811324183130637,1,0,1,0.003033440886735403
4130,1433E,Signaling by Hippo,0.0029460732475854456,0,0,1,0.0031788361862242656
4131,1433E,Signaling by Hippo,0.002811324183130637,1,0,1,0.003033440886735403
4132,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0029460732475854456,0,0,1,0.0031788361862242656
4133,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002811324183130637,1,0,1,0.003033440886735403
4134,1433E,Anchoring of the basal body to the plasma membrane,0.0029460732475854456,0,0,1,0.0031788361862242656
4135,1433E,Anchoring of the basal body to the plasma membrane,0.002811324183130637,1,0,1,0.003033440886735403
4136,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.0031417670824642604,0,0,1,0.0033899913719426175
4137,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.002656536514405161,1,0,1,0.00286642377576265
4138,ACTA,Smooth Muscle Contraction,0.0031417670824642604,0,0,1,0.0033899913719426175
4139,ACTA,Smooth Muscle Contraction,0.002656536514405161,1,0,1,0.00286642377576265
4140,H4,Packaging Of Telomere Ends,0.0012361057432523617,0,0,1,0.0013337678110585689
4141,H4,Packaging Of Telomere Ends,0.0009568894020048901,1,0,1,0.00103249118459653
4142,H4,Inhibition of DNA recombination at telomere,0.0012361057432523617,0,0,1,0.0013337678110585689
4143,H4,Inhibition of DNA recombination at telomere,0.0009568894020048901,1,0,1,0.00103249118459653
4144,H4,Pre-NOTCH Transcription and Translation,0.0012361057432523617,0,0,1,0.0013337678110585689
4145,H4,Pre-NOTCH Transcription and Translation,0.0009568894020048901,1,0,1,0.00103249118459653
4146,H4,RHO GTPase Effectors,0.0012361057432523617,0,0,1,0.0013337678110585689
4147,H4,RHO GTPase Effectors,0.0009568894020048901,1,0,1,0.00103249118459653
4148,H4,Formation of the beta-catenin:TCF transactivating complex,0.0012361057432523617,0,0,1,0.0013337678110585689
4149,H4,Formation of the beta-catenin:TCF transactivating complex,0.0009568894020048901,1,0,1,0.00103249118459653
4150,H4,Transcriptional regulation by RUNX1,0.0012361057432523617,0,0,1,0.0013337678110585689
4151,H4,Transcriptional regulation by RUNX1,0.0009568894020048901,1,0,1,0.00103249118459653
4152,H4,Oxidative Stress Induced Senescence,0.0012361057432523617,0,0,1,0.0013337678110585689
4153,H4,Oxidative Stress Induced Senescence,0.0009568894020048901,1,0,1,0.00103249118459653
4154,H4,Senescence-Associated Secretory Phenotype (SASP),0.0012361057432523617,0,0,1,0.0013337678110585689
4155,H4,Senescence-Associated Secretory Phenotype (SASP),0.0009568894020048901,1,0,1,0.00103249118459653
4156,H4,DNA Damage/Telomere Stress Induced Senescence,0.0012361057432523617,0,0,1,0.0013337678110585689
4157,H4,DNA Damage/Telomere Stress Induced Senescence,0.0009568894020048901,1,0,1,0.00103249118459653
4158,H4,SUMO E3 ligases SUMOylate target proteins,0.0012361057432523617,0,0,1,0.0013337678110585689
4159,H4,SUMO E3 ligases SUMOylate target proteins,0.0009568894020048901,1,0,1,0.00103249118459653
4160,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0012361057432523617,0,0,1,0.0013337678110585689
4161,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0009568894020048901,1,0,1,0.00103249118459653
4162,H4,B-WICH complex positively regulates rRNA expression,0.0012361057432523617,0,0,1,0.0013337678110585689
4163,H4,B-WICH complex positively regulates rRNA expression,0.0009568894020048901,1,0,1,0.00103249118459653
4164,H4,SIRT1 negatively regulates rRNA expression,0.0012361057432523617,0,0,1,0.0013337678110585689
4165,H4,SIRT1 negatively regulates rRNA expression,0.0009568894020048901,1,0,1,0.00103249118459653
4166,H4,NoRC negatively regulates rRNA expression,0.0012361057432523617,0,0,1,0.0013337678110585689
4167,H4,NoRC negatively regulates rRNA expression,0.0009568894020048901,1,0,1,0.00103249118459653
4168,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0012361057432523617,0,0,1,0.0013337678110585689
4169,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0009568894020048901,1,0,1,0.00103249118459653
4170,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0012361057432523617,0,0,1,0.0013337678110585689
4171,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0009568894020048901,1,0,1,0.00103249118459653
4172,H4,Assembly of the ORC complex at the origin of replication,0.0012361057432523617,0,0,1,0.0013337678110585689
4173,H4,Assembly of the ORC complex at the origin of replication,0.0009568894020048901,1,0,1,0.00103249118459653
4174,H4,Mitotic Prophase,0.0012361057432523617,0,0,1,0.0013337678110585689
4175,H4,Mitotic Prophase,0.0009568894020048901,1,0,1,0.00103249118459653
4176,H4,G2/M DNA damage checkpoint,0.0012361057432523617,0,0,1,0.0013337678110585689
4177,H4,G2/M DNA damage checkpoint,0.0009568894020048901,1,0,1,0.00103249118459653
4178,H4,RNA Polymerase I Promoter Opening,0.0012361057432523617,0,0,1,0.0013337678110585689
4179,H4,RNA Polymerase I Promoter Opening,0.0009568894020048901,1,0,1,0.00103249118459653
4180,H4,RNA Polymerase I Promoter Escape,0.0012361057432523617,0,0,1,0.0013337678110585689
4181,H4,RNA Polymerase I Promoter Escape,0.0009568894020048901,1,0,1,0.00103249118459653
4182,H4,Depurination,0.0012361057432523617,0,0,1,0.0013337678110585689
4183,H4,Depurination,0.0009568894020048901,1,0,1,0.00103249118459653
4184,H4,Depyrimidination,0.0012361057432523617,0,0,1,0.0013337678110585689
4185,H4,Depyrimidination,0.0009568894020048901,1,0,1,0.00103249118459653
4186,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.0012361057432523617,0,0,1,0.0013337678110585689
4187,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.0009568894020048901,1,0,1,0.00103249118459653
4188,H4,Estrogen-dependent gene expression,0.0012361057432523617,0,0,1,0.0013337678110585689
4189,H4,Estrogen-dependent gene expression,0.0009568894020048901,1,0,1,0.00103249118459653
4190,H4,HCMV Early Events,0.0012361057432523617,0,0,1,0.0013337678110585689
4191,H4,HCMV Early Events,0.0009568894020048901,1,0,1,0.00103249118459653
4192,H4,HCMV Late Events,0.0012361057432523617,0,0,1,0.0013337678110585689
4193,H4,HCMV Late Events,0.0009568894020048901,1,0,1,0.00103249118459653
4194,H4,Transcriptional regulation of granulopoiesis,0.0012361057432523617,0,0,1,0.0013337678110585689
4195,H4,Transcriptional regulation of granulopoiesis,0.0009568894020048901,1,0,1,0.00103249118459653
4196,H4,Meiotic synapsis,0.0012361057432523617,0,0,1,0.0013337678110585689
4197,H4,Meiotic synapsis,0.0009568894020048901,1,0,1,0.00103249118459653
4198,H4,Meiotic recombination,0.0012361057432523617,0,0,1,0.0013337678110585689
4199,H4,Meiotic recombination,0.0009568894020048901,1,0,1,0.00103249118459653
4200,H4,Transcriptional regulation by small RNAs,0.0012361057432523617,0,0,1,0.0013337678110585689
4201,H4,Transcriptional regulation by small RNAs,0.0009568894020048901,1,0,1,0.00103249118459653
4202,H4,PRC2 methylates histones and DNA,0.0012361057432523617,0,0,1,0.0013337678110585689
4203,H4,PRC2 methylates histones and DNA,0.0009568894020048901,1,0,1,0.00103249118459653
4204,H4,DNA methylation,0.0012361057432523617,0,0,1,0.0013337678110585689
4205,H4,DNA methylation,0.0009568894020048901,1,0,1,0.00103249118459653
4206,H4,HDACs deacetylate histones,0.0012361057432523617,0,0,1,0.0013337678110585689
4207,H4,HDACs deacetylate histones,0.0009568894020048901,1,0,1,0.00103249118459653
4208,H4,PKMTs methylate histone lysines,0.0012361057432523617,0,0,1,0.0013337678110585689
4209,H4,PKMTs methylate histone lysines,0.0009568894020048901,1,0,1,0.00103249118459653
4210,H4,HDMs demethylate histones,0.0012361057432523617,0,0,1,0.0013337678110585689
4211,H4,HDMs demethylate histones,0.0009568894020048901,1,0,1,0.00103249118459653
4212,H4,HATs acetylate histones,0.0012361057432523617,0,0,1,0.0013337678110585689
4213,H4,HATs acetylate histones,0.0009568894020048901,1,0,1,0.00103249118459653
4214,H4,RMTs methylate histone arginines,0.0012361057432523617,0,0,1,0.0013337678110585689
4215,H4,RMTs methylate histone arginines,0.0009568894020048901,1,0,1,0.00103249118459653
4216,H4,Amyloid fiber formation,0.0012361057432523617,0,0,1,0.0013337678110585689
4217,H4,Amyloid fiber formation,0.0009568894020048901,1,0,1,0.00103249118459653
4218,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0012361057432523617,0,0,1,0.0013337678110585689
4219,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0009568894020048901,1,0,1,0.00103249118459653
4220,H4,Nonhomologous End-Joining (NHEJ),0.0012361057432523617,0,0,1,0.0013337678110585689
4221,H4,Nonhomologous End-Joining (NHEJ),0.0009568894020048901,1,0,1,0.00103249118459653
4222,H4,Defective pyroptosis,0.0012361057432523617,0,0,1,0.0013337678110585689
4223,H4,Defective pyroptosis,0.0009568894020048901,1,0,1,0.00103249118459653
4224,RAP1A,Signaling by NTRK1 (TRKA),0.006572714436333627,0,0,1,0.007092010529290134
4225,RAP1A,Signaling by NTRK1 (TRKA),0.006050700170453638,1,0,1,0.0065287530340922065
4226,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.006572714436333627,0,0,1,0.007092010529290134
4227,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.006050700170453638,1,0,1,0.0065287530340922065
4228,RAP1A,RAF/MAP kinase cascade,0.006572714436333627,0,0,1,0.007092010529290134
4229,RAP1A,RAF/MAP kinase cascade,0.006050700170453638,1,0,1,0.0065287530340922065
4230,RAP1A,Signaling by RAS mutants,0.006572714436333627,0,0,1,0.007092010529290134
4231,RAP1A,Signaling by RAS mutants,0.006050700170453638,1,0,1,0.0065287530340922065
4232,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.006572714436333627,0,0,1,0.007092010529290134
4233,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.006050700170453638,1,0,1,0.0065287530340922065
4234,RAP1A,Signaling by high-kinase activity BRAF mutants,0.006572714436333627,0,0,1,0.007092010529290134
4235,RAP1A,Signaling by high-kinase activity BRAF mutants,0.006050700170453638,1,0,1,0.0065287530340922065
4236,RAP1A,Signaling by BRAF and RAF1 fusions,0.006572714436333627,0,0,1,0.007092010529290134
4237,RAP1A,Signaling by BRAF and RAF1 fusions,0.006050700170453638,1,0,1,0.0065287530340922065
4238,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006572714436333627,0,0,1,0.007092010529290134
4239,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006050700170453638,1,0,1,0.0065287530340922065
4240,RAP1A,Signaling by RAF1 mutants,0.006572714436333627,0,0,1,0.007092010529290134
4241,RAP1A,Signaling by RAF1 mutants,0.006050700170453638,1,0,1,0.0065287530340922065
4242,RAP1A,MET promotes cell motility,0.006572714436333627,0,0,1,0.007092010529290134
4243,RAP1A,MET promotes cell motility,0.006050700170453638,1,0,1,0.0065287530340922065
4244,RAP1A,Rap1 signalling,0.006572714436333627,0,0,1,0.007092010529290134
4245,RAP1A,Rap1 signalling,0.006050700170453638,1,0,1,0.0065287530340922065
4246,RAP1A,Neutrophil degranulation,0.006572714436333627,0,0,1,0.007092010529290134
4247,RAP1A,Neutrophil degranulation,0.006050700170453638,1,0,1,0.0065287530340922065
4248,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006572714436333627,0,0,1,0.007092010529290134
4249,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006050700170453638,1,0,1,0.0065287530340922065
4250,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.006572714436333627,0,0,1,0.007092010529290134
4251,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.006050700170453638,1,0,1,0.0065287530340922065
4252,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.000232879684335785,0,0,1,0.00025127900951200195
4253,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0002785477892757626,1,0,1,0.00030055525363066675
4254,PPIA,HIV Life Cycle,0.000232879684335785,0,0,1,0.00025127900951200195
4255,PPIA,HIV Life Cycle,0.0002785477892757626,1,0,1,0.00030055525363066675
4256,PPIA,Host Interactions of HIV factors,0.000232879684335785,0,0,1,0.00025127900951200195
4257,PPIA,Host Interactions of HIV factors,0.0002785477892757626,1,0,1,0.00030055525363066675
4258,PPIA,Interleukin-12 family signaling,0.000232879684335785,0,0,1,0.00025127900951200195
4259,PPIA,Interleukin-12 family signaling,0.0002785477892757626,1,0,1,0.00030055525363066675
4260,PPIA,Platelet degranulation ,0.000232879684335785,0,0,1,0.00025127900951200195
4261,PPIA,Platelet degranulation ,0.0002785477892757626,1,0,1,0.00030055525363066675
4262,PPIA,Neutrophil degranulation,0.000232879684335785,0,0,1,0.00025127900951200195
4263,PPIA,Neutrophil degranulation,0.0002785477892757626,1,0,1,0.00030055525363066675
4264,PPIA,Basigin interactions,0.000232879684335785,0,0,1,0.00025127900951200195
4265,PPIA,Basigin interactions,0.0002785477892757626,1,0,1,0.00030055525363066675
4266,1433Z,Activation of BH3-only proteins,0.002848189707583515,0,0,1,0.0030732190773323244
4267,1433Z,Activation of BH3-only proteins,0.002622631963792325,1,0,1,0.002829840499208312
4268,1433Z,RHO GTPase Effectors,0.002848189707583515,0,0,1,0.0030732190773323244
4269,1433Z,RHO GTPase Effectors,0.002622631963792325,1,0,1,0.002829840499208312
4270,1433Z,Deactivation of the beta-catenin transactivating complex,0.002848189707583515,0,0,1,0.0030732190773323244
4271,1433Z,Deactivation of the beta-catenin transactivating complex,0.002622631963792325,1,0,1,0.002829840499208312
4272,1433Z,Transcriptional Regulation by TP53,0.002848189707583515,0,0,1,0.0030732190773323244
4273,1433Z,Transcriptional Regulation by TP53,0.002622631963792325,1,0,1,0.002829840499208312
4274,1433Z,FOXO-mediated transcription,0.002848189707583515,0,0,1,0.0030732190773323244
4275,1433Z,FOXO-mediated transcription,0.002622631963792325,1,0,1,0.002829840499208312
4276,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.002848189707583515,0,0,1,0.0030732190773323244
4277,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.002622631963792325,1,0,1,0.002829840499208312
4278,1433Z,G2/M DNA damage checkpoint,0.002848189707583515,0,0,1,0.0030732190773323244
4279,1433Z,G2/M DNA damage checkpoint,0.002622631963792325,1,0,1,0.002829840499208312
4280,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.002848189707583515,0,0,1,0.0030732190773323244
4281,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.002622631963792325,1,0,1,0.002829840499208312
4282,1433Z,Negative regulation of NOTCH4 signaling,0.002848189707583515,0,0,1,0.0030732190773323244
4283,1433Z,Negative regulation of NOTCH4 signaling,0.002622631963792325,1,0,1,0.002829840499208312
4284,1433Z,SARS-CoV-2 Infection,0.002848189707583515,0,0,1,0.0030732190773323244
4285,1433Z,SARS-CoV-2 Infection,0.002622631963792325,1,0,1,0.002829840499208312
4286,1433Z,Rap1 signalling,0.002848189707583515,0,0,1,0.0030732190773323244
4287,1433Z,Rap1 signalling,0.002622631963792325,1,0,1,0.002829840499208312
4288,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002848189707583515,0,0,1,0.0030732190773323244
4289,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002622631963792325,1,0,1,0.002829840499208312
4290,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.002848189707583515,0,0,1,0.0030732190773323244
4291,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.002622631963792325,1,0,1,0.002829840499208312
4292,1433Z,GP1b-IX-V activation signalling,0.002848189707583515,0,0,1,0.0030732190773323244
4293,1433Z,GP1b-IX-V activation signalling,0.002622631963792325,1,0,1,0.002829840499208312
4294,TPM4,RHO GTPase cycle,0.002476453005025784,0,0,1,0.002672112253933858
4295,TPM4,RHO GTPase cycle,0.0022783828132863465,1,0,1,0.002458392960488001
4296,TPM4,Signaling by ALK fusions and activated point mutants,0.002476453005025784,0,0,1,0.002672112253933858
4297,TPM4,Signaling by ALK fusions and activated point mutants,0.0022783828132863465,1,0,1,0.002458392960488001
4298,TPM4,Striated Muscle Contraction,0.002476453005025784,0,0,1,0.002672112253933858
4299,TPM4,Striated Muscle Contraction,0.0022783828132863465,1,0,1,0.002458392960488001
4300,TPM4,Smooth Muscle Contraction,0.002476453005025784,0,0,1,0.002672112253933858
4301,TPM4,Smooth Muscle Contraction,0.0022783828132863465,1,0,1,0.002458392960488001
4302,TBA1B,Activation of NMDA receptors and postsynaptic events,0.0074188334944968425,0,0,1,0.008004979642379104
4303,TBA1B,Activation of NMDA receptors and postsynaptic events,0.007331806320386628,1,0,1,0.007911076637600413
4304,TBA1B,Gap junction trafficking,0.0074188334944968425,0,0,1,0.008004979642379104
4305,TBA1B,Gap junction trafficking,0.007331806320386628,1,0,1,0.007911076637600413
4306,TBA1B,RHO GTPase Effectors,0.0074188334944968425,0,0,1,0.008004979642379104
4307,TBA1B,RHO GTPase Effectors,0.007331806320386628,1,0,1,0.007911076637600413
4308,TBA1B,RHO GTPase cycle,0.0074188334944968425,0,0,1,0.008004979642379104
4309,TBA1B,RHO GTPase cycle,0.007331806320386628,1,0,1,0.007911076637600413
4310,TBA1B,COPI-mediated anterograde transport,0.0074188334944968425,0,0,1,0.008004979642379104
4311,TBA1B,COPI-mediated anterograde transport,0.007331806320386628,1,0,1,0.007911076637600413
4312,TBA1B,Mitotic Metaphase and Anaphase,0.0074188334944968425,0,0,1,0.008004979642379104
4313,TBA1B,Mitotic Metaphase and Anaphase,0.007331806320386628,1,0,1,0.007911076637600413
4314,TBA1B,L1CAM interactions,0.0074188334944968425,0,0,1,0.008004979642379104
4315,TBA1B,L1CAM interactions,0.007331806320386628,1,0,1,0.007911076637600413
4316,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0074188334944968425,0,0,1,0.008004979642379104
4317,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.007331806320386628,1,0,1,0.007911076637600413
4318,TBA1B,G2/M Transition,0.0074188334944968425,0,0,1,0.008004979642379104
4319,TBA1B,G2/M Transition,0.007331806320386628,1,0,1,0.007911076637600413
4320,TBA1B,Golgi-to-ER retrograde transport,0.0074188334944968425,0,0,1,0.008004979642379104
4321,TBA1B,Golgi-to-ER retrograde transport,0.007331806320386628,1,0,1,0.007911076637600413
4322,TBA1B,Mitotic Prometaphase,0.0074188334944968425,0,0,1,0.008004979642379104
4323,TBA1B,Mitotic Prometaphase,0.007331806320386628,1,0,1,0.007911076637600413
4324,TBA1B,HCMV Early Events,0.0074188334944968425,0,0,1,0.008004979642379104
4325,TBA1B,HCMV Early Events,0.007331806320386628,1,0,1,0.007911076637600413
4326,TBA1B,Aggrephagy,0.0074188334944968425,0,0,1,0.008004979642379104
4327,TBA1B,Aggrephagy,0.007331806320386628,1,0,1,0.007911076637600413
4328,TBA1B,MHC class II antigen presentation,0.0074188334944968425,0,0,1,0.008004979642379104
4329,TBA1B,MHC class II antigen presentation,0.007331806320386628,1,0,1,0.007911076637600413
4330,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0074188334944968425,0,0,1,0.008004979642379104
4331,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.007331806320386628,1,0,1,0.007911076637600413
4332,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0074188334944968425,0,0,1,0.008004979642379104
4333,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.007331806320386628,1,0,1,0.007911076637600413
4334,TBA1B,Post-chaperonin tubulin folding pathway,0.0074188334944968425,0,0,1,0.008004979642379104
4335,TBA1B,Post-chaperonin tubulin folding pathway,0.007331806320386628,1,0,1,0.007911076637600413
4336,TBA1B,Intraflagellar transport,0.0074188334944968425,0,0,1,0.008004979642379104
4337,TBA1B,Intraflagellar transport,0.007331806320386628,1,0,1,0.007911076637600413
4338,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.0074188334944968425,0,0,1,0.008004979642379104
4339,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.007331806320386628,1,0,1,0.007911076637600413
4340,TBA1B,Kinesins,0.0074188334944968425,0,0,1,0.008004979642379104
4341,TBA1B,Kinesins,0.007331806320386628,1,0,1,0.007911076637600413
4342,TBA4A,Activation of NMDA receptors and postsynaptic events,0.0027824174156800534,0,0,1,0.00300225025748883
4343,TBA4A,Activation of NMDA receptors and postsynaptic events,0.0029788030214452496,1,0,1,0.0032141518694299544
4344,TBA4A,Gap junction trafficking,0.0027824174156800534,0,0,1,0.00300225025748883
4345,TBA4A,Gap junction trafficking,0.0029788030214452496,1,0,1,0.0032141518694299544
4346,TBA4A,RHO GTPase Effectors,0.0027824174156800534,0,0,1,0.00300225025748883
4347,TBA4A,RHO GTPase Effectors,0.0029788030214452496,1,0,1,0.0032141518694299544
4348,TBA4A,COPI-mediated anterograde transport,0.0027824174156800534,0,0,1,0.00300225025748883
4349,TBA4A,COPI-mediated anterograde transport,0.0029788030214452496,1,0,1,0.0032141518694299544
4350,TBA4A,Mitotic Metaphase and Anaphase,0.0027824174156800534,0,0,1,0.00300225025748883
4351,TBA4A,Mitotic Metaphase and Anaphase,0.0029788030214452496,1,0,1,0.0032141518694299544
4352,TBA4A,L1CAM interactions,0.0027824174156800534,0,0,1,0.00300225025748883
4353,TBA4A,L1CAM interactions,0.0029788030214452496,1,0,1,0.0032141518694299544
4354,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0027824174156800534,0,0,1,0.00300225025748883
4355,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0029788030214452496,1,0,1,0.0032141518694299544
4356,TBA4A,G2/M Transition,0.0027824174156800534,0,0,1,0.00300225025748883
4357,TBA4A,G2/M Transition,0.0029788030214452496,1,0,1,0.0032141518694299544
4358,TBA4A,Golgi-to-ER retrograde transport,0.0027824174156800534,0,0,1,0.00300225025748883
4359,TBA4A,Golgi-to-ER retrograde transport,0.0029788030214452496,1,0,1,0.0032141518694299544
4360,TBA4A,Mitotic Prometaphase,0.0027824174156800534,0,0,1,0.00300225025748883
4361,TBA4A,Mitotic Prometaphase,0.0029788030214452496,1,0,1,0.0032141518694299544
4362,TBA4A,Platelet degranulation ,0.0027824174156800534,0,0,1,0.00300225025748883
4363,TBA4A,Platelet degranulation ,0.0029788030214452496,1,0,1,0.0032141518694299544
4364,TBA4A,HCMV Early Events,0.0027824174156800534,0,0,1,0.00300225025748883
4365,TBA4A,HCMV Early Events,0.0029788030214452496,1,0,1,0.0032141518694299544
4366,TBA4A,Aggrephagy,0.0027824174156800534,0,0,1,0.00300225025748883
4367,TBA4A,Aggrephagy,0.0029788030214452496,1,0,1,0.0032141518694299544
4368,TBA4A,MHC class II antigen presentation,0.0027824174156800534,0,0,1,0.00300225025748883
4369,TBA4A,MHC class II antigen presentation,0.0029788030214452496,1,0,1,0.0032141518694299544
4370,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0027824174156800534,0,0,1,0.00300225025748883
4371,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0029788030214452496,1,0,1,0.0032141518694299544
4372,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0027824174156800534,0,0,1,0.00300225025748883
4373,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0029788030214452496,1,0,1,0.0032141518694299544
4374,TBA4A,Post-chaperonin tubulin folding pathway,0.0027824174156800534,0,0,1,0.00300225025748883
4375,TBA4A,Post-chaperonin tubulin folding pathway,0.0029788030214452496,1,0,1,0.0032141518694299544
4376,TBA4A,Anchoring of the basal body to the plasma membrane,0.0027824174156800534,0,0,1,0.00300225025748883
4377,TBA4A,Anchoring of the basal body to the plasma membrane,0.0029788030214452496,1,0,1,0.0032141518694299544
4378,TBA4A,Intraflagellar transport,0.0027824174156800534,0,0,1,0.00300225025748883
4379,TBA4A,Intraflagellar transport,0.0029788030214452496,1,0,1,0.0032141518694299544
4380,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.0027824174156800534,0,0,1,0.00300225025748883
4381,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.0029788030214452496,1,0,1,0.0032141518694299544
4382,TBA4A,Kinesins,0.0027824174156800534,0,0,1,0.00300225025748883
4383,TBA4A,Kinesins,0.0029788030214452496,1,0,1,0.0032141518694299544
4384,HBB,Cytoprotection by HMOX1,0.01730989238518911,0,0,1,0.018677509915540923
4385,HBB,Cytoprotection by HMOX1,0.017674155160784723,1,0,1,0.01907055231301249
4386,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.01730989238518911,0,0,1,0.018677509915540923
4387,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.017674155160784723,1,0,1,0.01907055231301249
4388,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.01730989238518911,0,0,1,0.018677509915540923
4389,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.017674155160784723,1,0,1,0.01907055231301249
4390,HBB,Neutrophil degranulation,0.01730989238518911,0,0,1,0.018677509915540923
4391,HBB,Neutrophil degranulation,0.017674155160784723,1,0,1,0.01907055231301249
4392,HBB,Scavenging of heme from plasma,0.01730989238518911,0,0,1,0.018677509915540923
4393,HBB,Scavenging of heme from plasma,0.017674155160784723,1,0,1,0.01907055231301249
4394,HBB,Heme signaling,0.01730989238518911,0,0,1,0.018677509915540923
4395,HBB,Heme signaling,0.017674155160784723,1,0,1,0.01907055231301249
4396,HBB,Chaperone Mediated Autophagy,0.01730989238518911,0,0,1,0.018677509915540923
4397,HBB,Chaperone Mediated Autophagy,0.017674155160784723,1,0,1,0.01907055231301249
4398,HBB,Late endosomal microautophagy,0.01730989238518911,0,0,1,0.018677509915540923
4399,HBB,Late endosomal microautophagy,0.017674155160784723,1,0,1,0.01907055231301249
4400,HBA,Cytoprotection by HMOX1,0.00031680090117636915,0,0,1,0.0003418306619882138
4401,HBA,Cytoprotection by HMOX1,0.0005142642731091958,1,0,1,0.0005548951920939694
4402,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.00031680090117636915,0,0,1,0.0003418306619882138
4403,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0005142642731091958,1,0,1,0.0005548951920939694
4404,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.00031680090117636915,0,0,1,0.0003418306619882138
4405,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0005142642731091958,1,0,1,0.0005548951920939694
4406,HBA,Scavenging of heme from plasma,0.00031680090117636915,0,0,1,0.0003418306619882138
4407,HBA,Scavenging of heme from plasma,0.0005142642731091958,1,0,1,0.0005548951920939694
4408,HBA,Heme signaling,0.00031680090117636915,0,0,1,0.0003418306619882138
4409,HBA,Heme signaling,0.0005142642731091958,1,0,1,0.0005548951920939694
4410,GSTO1,Methylation,0.00011674880171691863,0,0,1,0.00012597287453739684
4411,GSTO1,Methylation,0.0003417744099351694,1,0,1,0.00036877727419635457
4412,GSTO1,Glutathione conjugation,0.00011674880171691863,0,0,1,0.00012597287453739684
4413,GSTO1,Glutathione conjugation,0.0003417744099351694,1,0,1,0.00036877727419635457
4414,GSTO1,Vitamin C (ascorbate) metabolism,0.00011674880171691863,0,0,1,0.00012597287453739684
4415,GSTO1,Vitamin C (ascorbate) metabolism,0.0003417744099351694,1,0,1,0.00036877727419635457
4416,GSTO1,Interleukin-12 family signaling,0.00011674880171691863,0,0,1,0.00012597287453739684
4417,GSTO1,Interleukin-12 family signaling,0.0003417744099351694,1,0,1,0.00036877727419635457
4418,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0008888206906173461,0,0,1,0.0009590445100830156
4419,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0006138168567607257,1,0,1,0.0006623132122002137
4420,NGAL,Interleukin-4 and Interleukin-13 signaling,0.00724741616237831,0,0,1,0.007820018993918985
4421,NGAL,Interleukin-4 and Interleukin-13 signaling,0.007585036514986617,1,0,1,0.008184314007614482
4422,NGAL,Metal sequestration by antimicrobial proteins,0.00724741616237831,0,0,1,0.007820018993918985
4423,NGAL,Metal sequestration by antimicrobial proteins,0.007585036514986617,1,0,1,0.008184314007614482
4424,NGAL,Neutrophil degranulation,0.00724741616237831,0,0,1,0.007820018993918985
4425,NGAL,Neutrophil degranulation,0.007585036514986617,1,0,1,0.008184314007614482
4426,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4427,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4428,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4429,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4430,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4431,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4432,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4433,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4434,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4435,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4436,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4437,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4438,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0024048196981311777,0,0,1,0.00259481935285541
4439,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.002460976967025393,1,0,1,0.0026554134873110844
4440,S10AC,TRAF6 mediated NF-kB activation,0.0024048196981311777,0,0,1,0.00259481935285541
4441,S10AC,TRAF6 mediated NF-kB activation,0.002460976967025393,1,0,1,0.0026554134873110844
4442,S10AC,Interleukin-1 family signaling,0.0024048196981311777,0,0,1,0.00259481935285541
4443,S10AC,Interleukin-1 family signaling,0.002460976967025393,1,0,1,0.0026554134873110844
4444,S10AC,Neutrophil degranulation,0.0024048196981311777,0,0,1,0.00259481935285541
4445,S10AC,Neutrophil degranulation,0.002460976967025393,1,0,1,0.0026554134873110844
4446,S10AC,Advanced glycosylation endproduct receptor signaling,0.0024048196981311777,0,0,1,0.00259481935285541
4447,S10AC,Advanced glycosylation endproduct receptor signaling,0.002460976967025393,1,0,1,0.0026554134873110844
4448,BASP1,RHO GTPase cycle,0.002152842491826353,0,0,1,0.0023229339670585852
4449,BASP1,RHO GTPase cycle,0.0018992521586672713,1,0,1,0.002049308004709061
4450,LV321,Initial triggering of complement,0.015783099177739738,0,0,1,0.017030088046210527
4451,LV321,Initial triggering of complement,0.01585099074303192,1,0,1,0.017103343578695022
4452,LV321,Regulation of Complement cascade,0.015783099177739738,0,0,1,0.017030088046210527
4453,LV321,Regulation of Complement cascade,0.01585099074303192,1,0,1,0.017103343578695022
4454,LV321,FCGR activation,0.015783099177739738,0,0,1,0.017030088046210527
4455,LV321,FCGR activation,0.01585099074303192,1,0,1,0.017103343578695022
4456,LV321,Regulation of actin dynamics for phagocytic cup formation,0.015783099177739738,0,0,1,0.017030088046210527
4457,LV321,Regulation of actin dynamics for phagocytic cup formation,0.01585099074303192,1,0,1,0.017103343578695022
4458,LV321,Role of phospholipids in phagocytosis,0.015783099177739738,0,0,1,0.017030088046210527
4459,LV321,Role of phospholipids in phagocytosis,0.01585099074303192,1,0,1,0.017103343578695022
4460,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.015783099177739738,0,0,1,0.017030088046210527
4461,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.01585099074303192,1,0,1,0.017103343578695022
4462,LV321,FCERI mediated MAPK activation,0.015783099177739738,0,0,1,0.017030088046210527
4463,LV321,FCERI mediated MAPK activation,0.01585099074303192,1,0,1,0.017103343578695022
4464,LV321,FCERI mediated Ca+2 mobilization,0.015783099177739738,0,0,1,0.017030088046210527
4465,LV321,FCERI mediated Ca+2 mobilization,0.01585099074303192,1,0,1,0.017103343578695022
4466,LV321,FCERI mediated NF-kB activation,0.015783099177739738,0,0,1,0.017030088046210527
4467,LV321,FCERI mediated NF-kB activation,0.01585099074303192,1,0,1,0.017103343578695022
4468,LV321,Parasite infection,0.015783099177739738,0,0,1,0.017030088046210527
4469,LV321,Parasite infection,0.01585099074303192,1,0,1,0.017103343578695022
4470,LV321,Leishmania parasite growth and survival,0.015783099177739738,0,0,1,0.017030088046210527
4471,LV321,Leishmania parasite growth and survival,0.01585099074303192,1,0,1,0.017103343578695022
4472,LV321,Potential therapeutics for SARS,0.015783099177739738,0,0,1,0.017030088046210527
4473,LV321,Potential therapeutics for SARS,0.01585099074303192,1,0,1,0.017103343578695022
4474,LV321,CD22 mediated BCR regulation,0.015783099177739738,0,0,1,0.017030088046210527
4475,LV321,CD22 mediated BCR regulation,0.01585099074303192,1,0,1,0.017103343578695022
4476,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.015783099177739738,0,0,1,0.017030088046210527
4477,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01585099074303192,1,0,1,0.017103343578695022
4478,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.015783099177739738,0,0,1,0.017030088046210527
4479,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01585099074303192,1,0,1,0.017103343578695022
4480,LV321,Scavenging of heme from plasma,0.015783099177739738,0,0,1,0.017030088046210527
4481,LV321,Scavenging of heme from plasma,0.01585099074303192,1,0,1,0.017103343578695022
4482,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.00224011425258747,0,0,1,0.002417100882755714
4483,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.002083991249188936,1,0,1,0.002248642935176839
4484,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.00224011425258747,0,0,1,0.002417100882755714
4485,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.002083991249188936,1,0,1,0.002248642935176839
4486,PGBM,Diseases associated with glycosaminoglycan metabolism,0.00224011425258747,0,0,1,0.002417100882755714
4487,PGBM,Diseases associated with glycosaminoglycan metabolism,0.002083991249188936,1,0,1,0.002248642935176839
4488,PGBM,SARS-CoV-2 Infection,0.00224011425258747,0,0,1,0.002417100882755714
4489,PGBM,SARS-CoV-2 Infection,0.002083991249188936,1,0,1,0.002248642935176839
4490,PGBM,Integrin cell surface interactions,0.00224011425258747,0,0,1,0.002417100882755714
4491,PGBM,Integrin cell surface interactions,0.002083991249188936,1,0,1,0.002248642935176839
4492,PGBM,Laminin interactions,0.00224011425258747,0,0,1,0.002417100882755714
4493,PGBM,Laminin interactions,0.002083991249188936,1,0,1,0.002248642935176839
4494,PGBM,ECM proteoglycans,0.00224011425258747,0,0,1,0.002417100882755714
4495,PGBM,ECM proteoglycans,0.002083991249188936,1,0,1,0.002248642935176839
4496,PGBM,Retinoid metabolism and transport,0.00224011425258747,0,0,1,0.002417100882755714
4497,PGBM,Retinoid metabolism and transport,0.002083991249188936,1,0,1,0.002248642935176839
4498,PGBM,Amyloid fiber formation,0.00224011425258747,0,0,1,0.002417100882755714
4499,PGBM,Amyloid fiber formation,0.002083991249188936,1,0,1,0.002248642935176839
4500,DHSO,Fructose biosynthesis,0.0003999658993658765,0,0,1,0.0004315663485970763
4501,DHSO,Fructose biosynthesis,0.0005599729440291413,1,0,1,0.0006042152072238123
4502,DHSO,Formation of xylulose-5-phosphate,0.0003999658993658765,0,0,1,0.0004315663485970763
4503,DHSO,Formation of xylulose-5-phosphate,0.0005599729440291413,1,0,1,0.0006042152072238123
4504,CAP1,Signaling by ROBO receptors,0.00062783882021904,0,0,1,0.0006774430209650621
4505,CAP1,Signaling by ROBO receptors,0.0006070420766870181,1,0,1,0.0006550031712602392
4506,CAP1,Platelet degranulation ,0.00062783882021904,0,0,1,0.0006774430209650621
4507,CAP1,Platelet degranulation ,0.0006070420766870181,1,0,1,0.0006550031712602392
4508,CAP1,Neutrophil degranulation,0.00062783882021904,0,0,1,0.0006774430209650621
4509,CAP1,Neutrophil degranulation,0.0006070420766870181,1,0,1,0.0006550031712602392
4510,DSC2,Formation of the cornified envelope,0.0001567242320409908,0,0,1,0.00016910667800891486
4511,DSC2,Formation of the cornified envelope,0.0001827478357123861,1,0,1,0.00019718635088004593
4512,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0031125092995353044,0,0,1,0.0033584219942363823
4513,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0028806333682344604,1,0,1,0.0031082260421371986
4514,NUCB1,Post-translational protein phosphorylation,0.0031125092995353044,0,0,1,0.0033584219942363823
4515,NUCB1,Post-translational protein phosphorylation,0.0028806333682344604,1,0,1,0.0031082260421371986
4516,FHR3,Regulation of Complement cascade,0.0033475424706315,0,0,1,0.003612024632886308
4517,FHR3,Regulation of Complement cascade,0.003450597052384789,1,0,1,0.003723221336465234
4518,ACY1,Defective ACY1 causes encephalopathy,0.0014654377616049412,0,0,1,0.0015812188610949218
4519,ACY1,Defective ACY1 causes encephalopathy,0.001499259546593142,1,0,1,0.0016177128328898546
4520,ACY1,Aflatoxin activation and detoxification,0.0014654377616049412,0,0,1,0.0015812188610949218
4521,ACY1,Aflatoxin activation and detoxification,0.001499259546593142,1,0,1,0.0016177128328898546
4522,ACY1,Paracetamol ADME,0.0014654377616049412,0,0,1,0.0015812188610949218
4523,ACY1,Paracetamol ADME,0.001499259546593142,1,0,1,0.0016177128328898546
4524,FHR1,Regulation of Complement cascade,0.000700789224053248,0,0,1,0.0007561570799919084
4525,FHR1,Regulation of Complement cascade,0.0007216028745157624,1,0,1,0.0007786151724075979
4526,HGFA,MET Receptor Activation,0.0038763842777067717,0,0,1,0.00418264909868902
4527,HGFA,MET Receptor Activation,0.0034360674595518502,1,0,1,0.0037075437916158976
4528,AK1C1,Bile acid and bile salt metabolism,0.0034423639396360763,0,0,1,0.0037143377431084422
4529,AK1C1,Bile acid and bile salt metabolism,0.003759594085083033,1,0,1,0.004056631563037889
4530,AK1C1,Retinoid metabolism and transport,0.0034423639396360763,0,0,1,0.0037143377431084422
4531,AK1C1,Retinoid metabolism and transport,0.003759594085083033,1,0,1,0.004056631563037889
4532,1433F,Activation of BH3-only proteins,0.002121386041593117,0,0,1,0.002288992210052534
4533,1433F,Activation of BH3-only proteins,0.002288894359177599,1,0,1,0.002469735001110941
4534,1433F,RHO GTPase Effectors,0.002121386041593117,0,0,1,0.002288992210052534
4535,1433F,RHO GTPase Effectors,0.002288894359177599,1,0,1,0.002469735001110941
4536,1433F,Transcriptional Regulation by TP53,0.002121386041593117,0,0,1,0.002288992210052534
4537,1433F,Transcriptional Regulation by TP53,0.002288894359177599,1,0,1,0.002469735001110941
4538,1433F,G2/M DNA damage checkpoint,0.002121386041593117,0,0,1,0.002288992210052534
4539,1433F,G2/M DNA damage checkpoint,0.002288894359177599,1,0,1,0.002469735001110941
4540,1433F,SARS-CoV-2 Infection,0.002121386041593117,0,0,1,0.002288992210052534
4541,1433F,SARS-CoV-2 Infection,0.002288894359177599,1,0,1,0.002469735001110941
4542,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002121386041593117,0,0,1,0.002288992210052534
4543,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002288894359177599,1,0,1,0.002469735001110941
4544,EF1A2,Eukaryotic Translation Elongation,0.00028084597991740644,0,0,1,0.0003030350193936147
4545,EF1A2,Eukaryotic Translation Elongation,0.00015402636169407438,1,0,1,0.00016619565470304555
4546,ITIH3,Platelet degranulation ,0.004039032196790989,0,0,1,0.004358147481569601
4547,ITIH3,Platelet degranulation ,0.004602271790705951,1,0,1,0.004965887429691585
4548,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0015297005855245515,0,0,1,0.0016505589531215002
4549,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0015852335520321504,1,0,1,0.0017104794603958581
4550,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0015297005855245515,0,0,1,0.0016505589531215002
4551,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0015852335520321504,1,0,1,0.0017104794603958581
4552,PSME1,Antigen processing-Cross presentation,0.0015297005855245515,0,0,1,0.0016505589531215002
4553,PSME1,Antigen processing-Cross presentation,0.0015852335520321504,1,0,1,0.0017104794603958581
4554,PSME1,PTEN Regulation,0.0015297005855245515,0,0,1,0.0016505589531215002
4555,PSME1,PTEN Regulation,0.0015852335520321504,1,0,1,0.0017104794603958581
4556,PSME1,Host Interactions of HIV factors,0.0015297005855245515,0,0,1,0.0016505589531215002
4557,PSME1,Host Interactions of HIV factors,0.0015852335520321504,1,0,1,0.0017104794603958581
4558,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0015297005855245515,0,0,1,0.0016505589531215002
4559,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0015852335520321504,1,0,1,0.0017104794603958581
4560,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0015297005855245515,0,0,1,0.0016505589531215002
4561,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0015852335520321504,1,0,1,0.0017104794603958581
4562,PSME1,Degradation of AXIN,0.0015297005855245515,0,0,1,0.0016505589531215002
4563,PSME1,Degradation of AXIN,0.0015852335520321504,1,0,1,0.0017104794603958581
4564,PSME1,Degradation of DVL,0.0015297005855245515,0,0,1,0.0016505589531215002
4565,PSME1,Degradation of DVL,0.0015852335520321504,1,0,1,0.0017104794603958581
4566,PSME1,Downstream TCR signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4567,PSME1,Downstream TCR signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4568,PSME1,Transcriptional regulation by RUNX3,0.0015297005855245515,0,0,1,0.0016505589531215002
4569,PSME1,Transcriptional regulation by RUNX3,0.0015852335520321504,1,0,1,0.0017104794603958581
4570,PSME1,Transcriptional regulation by RUNX2,0.0015297005855245515,0,0,1,0.0016505589531215002
4571,PSME1,Transcriptional regulation by RUNX2,0.0015852335520321504,1,0,1,0.0017104794603958581
4572,PSME1,Transcriptional regulation by RUNX1,0.0015297005855245515,0,0,1,0.0016505589531215002
4573,PSME1,Transcriptional regulation by RUNX1,0.0015852335520321504,1,0,1,0.0017104794603958581
4574,PSME1,FCERI mediated NF-kB activation,0.0015297005855245515,0,0,1,0.0016505589531215002
4575,PSME1,FCERI mediated NF-kB activation,0.0015852335520321504,1,0,1,0.0017104794603958581
4576,PSME1,Mitotic Metaphase and Anaphase,0.0015297005855245515,0,0,1,0.0016505589531215002
4577,PSME1,Mitotic Metaphase and Anaphase,0.0015852335520321504,1,0,1,0.0017104794603958581
4578,PSME1,Regulation of ornithine decarboxylase (ODC),0.0015297005855245515,0,0,1,0.0016505589531215002
4579,PSME1,Regulation of ornithine decarboxylase (ODC),0.0015852335520321504,1,0,1,0.0017104794603958581
4580,PSME1,Signaling by ROBO receptors,0.0015297005855245515,0,0,1,0.0016505589531215002
4581,PSME1,Signaling by ROBO receptors,0.0015852335520321504,1,0,1,0.0017104794603958581
4582,PSME1,PCP/CE pathway,0.0015297005855245515,0,0,1,0.0016505589531215002
4583,PSME1,PCP/CE pathway,0.0015852335520321504,1,0,1,0.0017104794603958581
4584,PSME1,Interleukin-1 family signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4585,PSME1,Interleukin-1 family signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4586,PSME1,G2/M Transition,0.0015297005855245515,0,0,1,0.0016505589531215002
4587,PSME1,G2/M Transition,0.0015852335520321504,1,0,1,0.0017104794603958581
4588,PSME1,G1/S Transition,0.0015297005855245515,0,0,1,0.0016505589531215002
4589,PSME1,G1/S Transition,0.0015852335520321504,1,0,1,0.0017104794603958581
4590,PSME1,Hh mutants are degraded by ERAD,0.0015297005855245515,0,0,1,0.0016505589531215002
4591,PSME1,Hh mutants are degraded by ERAD,0.0015852335520321504,1,0,1,0.0017104794603958581
4592,PSME1,CLEC7A (Dectin-1) signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4593,PSME1,CLEC7A (Dectin-1) signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4594,PSME1,Degradation of GLI1 by the proteasome,0.0015297005855245515,0,0,1,0.0016505589531215002
4595,PSME1,Degradation of GLI1 by the proteasome,0.0015852335520321504,1,0,1,0.0017104794603958581
4596,PSME1,Degradation of GLI2 by the proteasome,0.0015297005855245515,0,0,1,0.0016505589531215002
4597,PSME1,Degradation of GLI2 by the proteasome,0.0015852335520321504,1,0,1,0.0017104794603958581
4598,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0015297005855245515,0,0,1,0.0016505589531215002
4599,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0015852335520321504,1,0,1,0.0017104794603958581
4600,PSME1,Defective CFTR causes cystic fibrosis,0.0015297005855245515,0,0,1,0.0016505589531215002
4601,PSME1,Defective CFTR causes cystic fibrosis,0.0015852335520321504,1,0,1,0.0017104794603958581
4602,PSME1,NIK-->noncanonical NF-kB signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4603,PSME1,NIK-->noncanonical NF-kB signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4604,PSME1,RAF/MAP kinase cascade,0.0015297005855245515,0,0,1,0.0016505589531215002
4605,PSME1,RAF/MAP kinase cascade,0.0015852335520321504,1,0,1,0.0017104794603958581
4606,PSME1,UCH proteinases,0.0015297005855245515,0,0,1,0.0016505589531215002
4607,PSME1,UCH proteinases,0.0015852335520321504,1,0,1,0.0017104794603958581
4608,PSME1,Ub-specific processing proteases,0.0015297005855245515,0,0,1,0.0016505589531215002
4609,PSME1,Ub-specific processing proteases,0.0015852335520321504,1,0,1,0.0017104794603958581
4610,PSME1,Orc1 removal from chromatin,0.0015297005855245515,0,0,1,0.0016505589531215002
4611,PSME1,Orc1 removal from chromatin,0.0015852335520321504,1,0,1,0.0017104794603958581
4612,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0015297005855245515,0,0,1,0.0016505589531215002
4613,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0015852335520321504,1,0,1,0.0017104794603958581
4614,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0015297005855245515,0,0,1,0.0016505589531215002
4615,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0015852335520321504,1,0,1,0.0017104794603958581
4616,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0015297005855245515,0,0,1,0.0016505589531215002
4617,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0015852335520321504,1,0,1,0.0017104794603958581
4618,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0015297005855245515,0,0,1,0.0016505589531215002
4619,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0015852335520321504,1,0,1,0.0017104794603958581
4620,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0015297005855245515,0,0,1,0.0016505589531215002
4621,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0015852335520321504,1,0,1,0.0017104794603958581
4622,PSME1,Negative regulation of NOTCH4 signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4623,PSME1,Negative regulation of NOTCH4 signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4624,PSME1,KEAP1-NFE2L2 pathway,0.0015297005855245515,0,0,1,0.0016505589531215002
4625,PSME1,KEAP1-NFE2L2 pathway,0.0015852335520321504,1,0,1,0.0017104794603958581
4626,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0015297005855245515,0,0,1,0.0016505589531215002
4627,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0015852335520321504,1,0,1,0.0017104794603958581
4628,PSME1,Degradation of beta-catenin by the destruction complex,0.0015297005855245515,0,0,1,0.0016505589531215002
4629,PSME1,Degradation of beta-catenin by the destruction complex,0.0015852335520321504,1,0,1,0.0017104794603958581
4630,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015297005855245515,0,0,1,0.0016505589531215002
4631,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015852335520321504,1,0,1,0.0017104794603958581
4632,PSME1,Hedgehog ligand biogenesis,0.0015297005855245515,0,0,1,0.0016505589531215002
4633,PSME1,Hedgehog ligand biogenesis,0.0015852335520321504,1,0,1,0.0017104794603958581
4634,PSME1,Hedgehog 'on' state,0.0015297005855245515,0,0,1,0.0016505589531215002
4635,PSME1,Hedgehog 'on' state,0.0015852335520321504,1,0,1,0.0017104794603958581
4636,PSME1,MAPK6/MAPK4 signaling,0.0015297005855245515,0,0,1,0.0016505589531215002
4637,PSME1,MAPK6/MAPK4 signaling,0.0015852335520321504,1,0,1,0.0017104794603958581
4638,PSME1,Neddylation,0.0015297005855245515,0,0,1,0.0016505589531215002
4639,PSME1,Neddylation,0.0015852335520321504,1,0,1,0.0017104794603958581
4640,LRP1,Scavenging of heme from plasma,0.004172685653126488,0,0,1,0.004502360611287758
4641,LRP1,Scavenging of heme from plasma,0.004547690512845292,1,0,1,0.004906993801946237
4642,LRP1,Retinoid metabolism and transport,0.004172685653126488,0,0,1,0.004502360611287758
4643,LRP1,Retinoid metabolism and transport,0.004547690512845292,1,0,1,0.004906993801946237
4644,LG3BP,Platelet degranulation ,0.0014263695025874767,0,0,1,0.0015390639025923507
4645,LG3BP,Platelet degranulation ,0.0016244122188557716,1,0,1,0.0017527535497889257
4646,BST1,Nicotinate metabolism,0.0011168420695563932,0,0,1,0.001205081369892346
4647,BST1,Nicotinate metabolism,0.0009487682085212631,1,0,1,0.001023728353006297
4648,BST1,Neutrophil degranulation,0.0011168420695563932,0,0,1,0.001205081369892346
4649,BST1,Neutrophil degranulation,0.0009487682085212631,1,0,1,0.001023728353006297
4650,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0011168420695563932,0,0,1,0.001205081369892346
4651,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.0009487682085212631,1,0,1,0.001023728353006297
4652,FBLN3,Molecules associated with elastic fibres,0.003910407957907106,0,0,1,0.004219360917004464
4653,FBLN3,Molecules associated with elastic fibres,0.003549963368156265,1,0,1,0.0038304383720650912
4654,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002334250274968023,0,0,1,0.0025186743906838605
4655,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0022357542911777273,1,0,1,0.002412396450131308
4656,FSTL1,Post-translational protein phosphorylation,0.002334250274968023,0,0,1,0.0025186743906838605
4657,FSTL1,Post-translational protein phosphorylation,0.0022357542911777273,1,0,1,0.002412396450131308
4658,FSTL1,Signaling by BMP,0.002334250274968023,0,0,1,0.0025186743906838605
4659,FSTL1,Signaling by BMP,0.0022357542911777273,1,0,1,0.002412396450131308
4660,LMAN2,COPII-mediated vesicle transport,0.003360308869741857,0,0,1,0.0036257996778527035
4661,LMAN2,COPII-mediated vesicle transport,0.0037564378823541724,1,0,1,0.00405322599549004
4662,LMAN2,Cargo concentration in the ER,0.003360308869741857,0,0,1,0.0036257996778527035
4663,LMAN2,Cargo concentration in the ER,0.0037564378823541724,1,0,1,0.00405322599549004
4664,TRAP1,Respiratory electron transport,0.00027027778911966986,0,0,1,0.00029163185847142756
4665,TRAP1,Respiratory electron transport,0.00012454762781999307,1,0,1,0.0001343878691906499
4666,SPP24,Platelet degranulation ,0.004588650492951274,0,0,1,0.0049511899423696415
4667,SPP24,Platelet degranulation ,0.004874917154666036,1,0,1,0.005260073920021699
4668,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004588650492951274,0,0,1,0.0049511899423696415
4669,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004874917154666036,1,0,1,0.005260073920021699
4670,SPP24,Post-translational protein phosphorylation,0.004588650492951274,0,0,1,0.0049511899423696415
4671,SPP24,Post-translational protein phosphorylation,0.004874917154666036,1,0,1,0.005260073920021699
4672,MMRN1,Platelet degranulation ,0.00084868756433328,0,0,1,0.000915740551431391
4673,MMRN1,Platelet degranulation ,0.0009519731005032858,1,0,1,0.001027186456640938
4674,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,9.65789750504579e-05,0,0,1,0.00010420947305721795
4675,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,8.451817563278988e-05,1,0,1,9.119577570427605e-05
4676,APOF,LDL remodeling,0.0003589503929958937,0,0,1,0.0003873102948984551
4677,APOF,LDL remodeling,0.0003512852656342602,1,0,1,0.0003790395622379048
4678,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,6.682564793057585e-05,0,0,1,7.210539927467847e-05
4679,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,6.582126255428496e-05,1,0,1,7.102165956057438e-05
4680,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0059831114679885404,0,0,1,0.0064558242929782204
4681,TBB2A,Activation of NMDA receptors and postsynaptic events,0.005983074040462573,1,0,1,0.006455783908383573
4682,TBB2A,Gap junction trafficking,0.0059831114679885404,0,0,1,0.0064558242929782204
4683,TBB2A,Gap junction trafficking,0.005983074040462573,1,0,1,0.006455783908383573
4684,TBB2A,RHO GTPase Effectors,0.0059831114679885404,0,0,1,0.0064558242929782204
4685,TBB2A,RHO GTPase Effectors,0.005983074040462573,1,0,1,0.006455783908383573
4686,TBB2A,COPI-mediated anterograde transport,0.0059831114679885404,0,0,1,0.0064558242929782204
4687,TBB2A,COPI-mediated anterograde transport,0.005983074040462573,1,0,1,0.006455783908383573
4688,TBB2A,Mitotic Metaphase and Anaphase,0.0059831114679885404,0,0,1,0.0064558242929782204
4689,TBB2A,Mitotic Metaphase and Anaphase,0.005983074040462573,1,0,1,0.006455783908383573
4690,TBB2A,L1CAM interactions,0.0059831114679885404,0,0,1,0.0064558242929782204
4691,TBB2A,L1CAM interactions,0.005983074040462573,1,0,1,0.006455783908383573
4692,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0059831114679885404,0,0,1,0.0064558242929782204
4693,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.005983074040462573,1,0,1,0.006455783908383573
4694,TBB2A,G2/M Transition,0.0059831114679885404,0,0,1,0.0064558242929782204
4695,TBB2A,G2/M Transition,0.005983074040462573,1,0,1,0.006455783908383573
4696,TBB2A,Golgi-to-ER retrograde transport,0.0059831114679885404,0,0,1,0.0064558242929782204
4697,TBB2A,Golgi-to-ER retrograde transport,0.005983074040462573,1,0,1,0.006455783908383573
4698,TBB2A,Mitotic Prometaphase,0.0059831114679885404,0,0,1,0.0064558242929782204
4699,TBB2A,Mitotic Prometaphase,0.005983074040462573,1,0,1,0.006455783908383573
4700,TBB2A,HCMV Early Events,0.0059831114679885404,0,0,1,0.0064558242929782204
4701,TBB2A,HCMV Early Events,0.005983074040462573,1,0,1,0.006455783908383573
4702,TBB2A,Aggrephagy,0.0059831114679885404,0,0,1,0.0064558242929782204
4703,TBB2A,Aggrephagy,0.005983074040462573,1,0,1,0.006455783908383573
4704,TBB2A,MHC class II antigen presentation,0.0059831114679885404,0,0,1,0.0064558242929782204
4705,TBB2A,MHC class II antigen presentation,0.005983074040462573,1,0,1,0.006455783908383573
4706,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0059831114679885404,0,0,1,0.0064558242929782204
4707,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005983074040462573,1,0,1,0.006455783908383573
4708,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0059831114679885404,0,0,1,0.0064558242929782204
4709,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.005983074040462573,1,0,1,0.006455783908383573
4710,TBB2A,Post-chaperonin tubulin folding pathway,0.0059831114679885404,0,0,1,0.0064558242929782204
4711,TBB2A,Post-chaperonin tubulin folding pathway,0.005983074040462573,1,0,1,0.006455783908383573
4712,TBB2A,Intraflagellar transport,0.0059831114679885404,0,0,1,0.0064558242929782204
4713,TBB2A,Intraflagellar transport,0.005983074040462573,1,0,1,0.006455783908383573
4714,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0059831114679885404,0,0,1,0.0064558242929782204
4715,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.005983074040462573,1,0,1,0.006455783908383573
4716,TBB2A,Kinesins,0.0059831114679885404,0,0,1,0.0064558242929782204
4717,TBB2A,Kinesins,0.005983074040462573,1,0,1,0.006455783908383573
4718,DAG1,Signaling by ROBO receptors,0.00012983157309160259,0,0,1,0.00014008928766325146
4719,DAG1,Signaling by ROBO receptors,4.9543713180355554e-05,1,0,1,5.3458055866977415e-05
4720,DAG1,Diseases associated with O-glycosylation of proteins,0.00012983157309160259,0,0,1,0.00014008928766325146
4721,DAG1,Diseases associated with O-glycosylation of proteins,4.9543713180355554e-05,1,0,1,5.3458055866977415e-05
4722,DAG1,ECM proteoglycans,0.00012983157309160259,0,0,1,0.00014008928766325146
4723,DAG1,ECM proteoglycans,4.9543713180355554e-05,1,0,1,5.3458055866977415e-05
4724,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.00012983157309160259,0,0,1,0.00014008928766325146
4725,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,4.9543713180355554e-05,1,0,1,5.3458055866977415e-05
4726,KRT81,Formation of the cornified envelope,1.9255119415599135e-05,0,0,1,2.0776425168159606e-05
4727,KRT81,Formation of the cornified envelope,2.255686338230589e-05,1,0,1,2.4339032855397932e-05
4728,ITIH4,Platelet degranulation ,5.998053406249444e-06,0,0,1,6.471946761784799e-06
4729,ITIH4,Platelet degranulation ,6.849087327035855e-06,1,0,1,7.39021905026825e-06
4730,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0019769830454606564,0,0,1,0.0021331802424168736
4731,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.00226400976049869,1,0,1,0.0024428843235777134
4732,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0019769830454606564,0,0,1,0.0021331802424168736
4733,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.00226400976049869,1,0,1,0.0024428843235777134
4734,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0023544911435844067,0,0,1,0.002540514446986298
4735,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0021823771385243163,1,0,1,0.0023548020829473474
4736,GANAB,SARS-CoV-1 Infection,0.0023544911435844067,0,0,1,0.002540514446986298
4737,GANAB,SARS-CoV-1 Infection,0.0021823771385243163,1,0,1,0.0023548020829473474
4738,GANAB,SARS-CoV-2 Infection,0.0023544911435844067,0,0,1,0.002540514446986298
4739,GANAB,SARS-CoV-2 Infection,0.0021823771385243163,1,0,1,0.0023548020829473474
4740,PCOC1,Crosslinking of collagen fibrils,0.0006434272111315901,0,0,1,0.0006942630172629941
4741,PCOC1,Crosslinking of collagen fibrils,0.0006534694985020906,1,0,1,0.0007050987242543166
4742,PON3,Arachidonic acid metabolism,0.0006077450529119232,0,0,1,0.0006557616881313371
4743,PON3,Arachidonic acid metabolism,0.0005467359401639745,1,0,1,0.0005899323760286716
4744,PON3,Atorvastatin ADME,0.0006077450529119232,0,0,1,0.0006557616881313371
4745,PON3,Atorvastatin ADME,0.0005467359401639745,1,0,1,0.0005899323760286716
4746,FCN2,Initial triggering of complement,0.0003782320247410098,0,0,1,0.00040811532707851387
4747,FCN2,Initial triggering of complement,0.0004060757512585648,1,0,1,0.0004381589268043109
4748,BGH3,Amyloid fiber formation,0.0002207819272219543,0,0,1,0.0002382254345144639
4749,BGH3,Amyloid fiber formation,0.00020875675221153264,1,0,1,0.00022525017617689962
4750,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0010912155798223466,0,0,1,0.0011774301860803828
4751,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0010035157436353377,1,0,1,0.001082801373634633
4752,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0010912155798223466,0,0,1,0.0011774301860803828
4753,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0010035157436353377,1,0,1,0.001082801373634633
4754,ECM1,Platelet degranulation ,9.22245120439887e-05,0,0,1,9.951097325315369e-05
4755,ECM1,Platelet degranulation ,0.00010520481178370271,1,0,1,0.00011351681867958977
4756,UGPA,Glucuronidation,0.0020445667216942337,0,0,1,0.002206103560187549
4757,UGPA,Glucuronidation,0.0020532860022891932,1,0,1,0.0022155117324710516
4758,UGPA,Glycogen synthesis,0.0020445667216942337,0,0,1,0.002206103560187549
4759,UGPA,Glycogen synthesis,0.0020532860022891932,1,0,1,0.0022155117324710516
4760,TKFC,Fructose catabolism,0.001086809427458017,0,0,1,0.00117267591305298
4761,TKFC,Fructose catabolism,0.0012452312929478163,1,0,1,0.001343614350894221
4762,TKFC,SARS-CoV-2 Infection,0.001086809427458017,0,0,1,0.00117267591305298
4763,TKFC,SARS-CoV-2 Infection,0.0012452312929478163,1,0,1,0.001343614350894221
4764,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0023100585938664155,0,0,1,0.0024925713766619194
4765,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.002126356205553748,1,0,1,0.0022943550560247006
4766,CTRB2,Activation of Matrix Metalloproteinases,0.0023100585938664155,0,0,1,0.0024925713766619194
4767,CTRB2,Activation of Matrix Metalloproteinases,0.002126356205553748,1,0,1,0.0022943550560247006
4768,OLFM4,Neutrophil degranulation,0.0011391640204237775,0,0,1,0.0012291669302980544
4769,OLFM4,Neutrophil degranulation,0.001111007663712371,1,0,1,0.0011987860001362487
4770,LDH6A,Pyruvate metabolism,0.00045263827002296845,0,0,1,0.0004884002504683926
4771,LDH6A,Pyruvate metabolism,0.00046053743887265833,1,0,1,0.0004969235157337996
4772,TBA1A,Activation of NMDA receptors and postsynaptic events,0.002228915266459808,0,0,1,0.0024050170887153547
4773,TBA1A,Activation of NMDA receptors and postsynaptic events,0.002417943417094648,1,0,1,0.002608979948751357
4774,TBA1A,Gap junction trafficking,0.002228915266459808,0,0,1,0.0024050170887153547
4775,TBA1A,Gap junction trafficking,0.002417943417094648,1,0,1,0.002608979948751357
4776,TBA1A,RHO GTPase Effectors,0.002228915266459808,0,0,1,0.0024050170887153547
4777,TBA1A,RHO GTPase Effectors,0.002417943417094648,1,0,1,0.002608979948751357
4778,TBA1A,COPI-mediated anterograde transport,0.002228915266459808,0,0,1,0.0024050170887153547
4779,TBA1A,COPI-mediated anterograde transport,0.002417943417094648,1,0,1,0.002608979948751357
4780,TBA1A,Mitotic Metaphase and Anaphase,0.002228915266459808,0,0,1,0.0024050170887153547
4781,TBA1A,Mitotic Metaphase and Anaphase,0.002417943417094648,1,0,1,0.002608979948751357
4782,TBA1A,L1CAM interactions,0.002228915266459808,0,0,1,0.0024050170887153547
4783,TBA1A,L1CAM interactions,0.002417943417094648,1,0,1,0.002608979948751357
4784,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.002228915266459808,0,0,1,0.0024050170887153547
4785,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.002417943417094648,1,0,1,0.002608979948751357
4786,TBA1A,G2/M Transition,0.002228915266459808,0,0,1,0.0024050170887153547
4787,TBA1A,G2/M Transition,0.002417943417094648,1,0,1,0.002608979948751357
4788,TBA1A,Golgi-to-ER retrograde transport,0.002228915266459808,0,0,1,0.0024050170887153547
4789,TBA1A,Golgi-to-ER retrograde transport,0.002417943417094648,1,0,1,0.002608979948751357
4790,TBA1A,Mitotic Prometaphase,0.002228915266459808,0,0,1,0.0024050170887153547
4791,TBA1A,Mitotic Prometaphase,0.002417943417094648,1,0,1,0.002608979948751357
4792,TBA1A,HCMV Early Events,0.002228915266459808,0,0,1,0.0024050170887153547
4793,TBA1A,HCMV Early Events,0.002417943417094648,1,0,1,0.002608979948751357
4794,TBA1A,Aggrephagy,0.002228915266459808,0,0,1,0.0024050170887153547
4795,TBA1A,Aggrephagy,0.002417943417094648,1,0,1,0.002608979948751357
4796,TBA1A,MHC class II antigen presentation,0.002228915266459808,0,0,1,0.0024050170887153547
4797,TBA1A,MHC class II antigen presentation,0.002417943417094648,1,0,1,0.002608979948751357
4798,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002228915266459808,0,0,1,0.0024050170887153547
4799,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002417943417094648,1,0,1,0.002608979948751357
4800,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.002228915266459808,0,0,1,0.0024050170887153547
4801,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.002417943417094648,1,0,1,0.002608979948751357
4802,TBA1A,Post-chaperonin tubulin folding pathway,0.002228915266459808,0,0,1,0.0024050170887153547
4803,TBA1A,Post-chaperonin tubulin folding pathway,0.002417943417094648,1,0,1,0.002608979948751357
4804,TBA1A,Anchoring of the basal body to the plasma membrane,0.002228915266459808,0,0,1,0.0024050170887153547
4805,TBA1A,Anchoring of the basal body to the plasma membrane,0.002417943417094648,1,0,1,0.002608979948751357
4806,TBA1A,Intraflagellar transport,0.002228915266459808,0,0,1,0.0024050170887153547
4807,TBA1A,Intraflagellar transport,0.002417943417094648,1,0,1,0.002608979948751357
4808,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.002228915266459808,0,0,1,0.0024050170887153547
4809,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.002417943417094648,1,0,1,0.002608979948751357
4810,TBA1A,Kinesins,0.002228915266459808,0,0,1,0.0024050170887153547
4811,TBA1A,Kinesins,0.002417943417094648,1,0,1,0.002608979948751357
4812,DCXR,Essential pentosuria,6.118059627624461e-05,0,0,1,6.601434417732117e-05
4813,DCXR,Essential pentosuria,2.9905944719151496e-05,1,0,1,3.2268749371515426e-05
4814,DCXR,Formation of xylulose-5-phosphate,6.118059627624461e-05,0,0,1,6.601434417732117e-05
4815,DCXR,Formation of xylulose-5-phosphate,2.9905944719151496e-05,1,0,1,3.2268749371515426e-05
4816,K2C1B,Formation of the cornified envelope,8.911541141666627e-05,0,0,1,9.615622924302245e-05
4817,K2C1B,Formation of the cornified envelope,0.00010327077682935245,1,0,1,0.00011142997976499387
4818,URP2,Platelet degranulation ,0.0013448019579906636,0,0,1,0.0014510518809637914
4819,URP2,Platelet degranulation ,0.0015350581971385205,1,0,1,0.0016563398581564237
4820,C163A,Leishmania parasite growth and survival,0.00449536949005657,0,0,1,0.004850539007186003
4821,C163A,Leishmania parasite growth and survival,0.004683716860260271,1,0,1,0.005053767299786809
4822,C163A,Scavenging of heme from plasma,0.00449536949005657,0,0,1,0.004850539007186003
4823,C163A,Scavenging of heme from plasma,0.004683716860260271,1,0,1,0.005053767299786809
4824,K2C78,Formation of the cornified envelope,1.4732627520667545e-05,0,0,1,1.58966208729687e-05
4825,K2C78,Formation of the cornified envelope,1.7081380383388024e-05,1,0,1,1.843094366980783e-05
4826,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0029532043990911916,0,0,1,0.0031865307547399983
4827,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002758734658709727,1,0,1,0.0029766963766039846
4828,LIRA3,Neutrophil degranulation,0.0029532043990911916,0,0,1,0.0031865307547399983
4829,LIRA3,Neutrophil degranulation,0.002758734658709727,1,0,1,0.0029766963766039846
4830,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00496040604581746,0,0,1,0.005352317105399068
4831,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004598830071821188,1,0,1,0.004962173787967753
4832,GOLM1,Post-translational protein phosphorylation,0.00496040604581746,0,0,1,0.005352317105399068
4833,GOLM1,Post-translational protein phosphorylation,0.004598830071821188,1,0,1,0.004962173787967753
4834,TXND5,Lysosome Vesicle Biogenesis,0.0004964573357938207,0,0,1,0.000535681366792669
4835,TXND5,Lysosome Vesicle Biogenesis,0.0004398150382257882,1,0,1,0.0004745638825862882
4836,TXND5,Golgi Associated Vesicle Biogenesis,0.0004964573357938207,0,0,1,0.000535681366792669
4837,TXND5,Golgi Associated Vesicle Biogenesis,0.0004398150382257882,1,0,1,0.0004745638825862882
4838,TXND5,Neutrophil degranulation,0.0004964573357938207,0,0,1,0.000535681366792669
4839,TXND5,Neutrophil degranulation,0.0004398150382257882,1,0,1,0.0004745638825862882
4840,BHMT1,Choline catabolism,0.0008879653294570744,0,0,1,0.0009581215686691213
4841,BHMT1,Choline catabolism,0.0008593286829030451,1,0,1,0.0009272224019927089
4842,H2B1A,Packaging Of Telomere Ends,0.0013612562596487501,0,0,1,0.0014688062017610235
4843,H2B1A,Packaging Of Telomere Ends,0.0013287219694272305,1,0,1,0.001433701446937276
4844,H2B1A,Inhibition of DNA recombination at telomere,0.0013612562596487501,0,0,1,0.0014688062017610235
4845,H2B1A,Inhibition of DNA recombination at telomere,0.0013287219694272305,1,0,1,0.001433701446937276
4846,H2B1A,Pre-NOTCH Transcription and Translation,0.0013612562596487501,0,0,1,0.0014688062017610235
4847,H2B1A,Pre-NOTCH Transcription and Translation,0.0013287219694272305,1,0,1,0.001433701446937276
4848,H2B1A,RHO GTPase Effectors,0.0013612562596487501,0,0,1,0.0014688062017610235
4849,H2B1A,RHO GTPase Effectors,0.0013287219694272305,1,0,1,0.001433701446937276
4850,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.0013612562596487501,0,0,1,0.0014688062017610235
4851,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.0013287219694272305,1,0,1,0.001433701446937276
4852,H2B1A,Transcriptional regulation by RUNX1,0.0013612562596487501,0,0,1,0.0014688062017610235
4853,H2B1A,Transcriptional regulation by RUNX1,0.0013287219694272305,1,0,1,0.001433701446937276
4854,H2B1A,Oxidative Stress Induced Senescence,0.0013612562596487501,0,0,1,0.0014688062017610235
4855,H2B1A,Oxidative Stress Induced Senescence,0.0013287219694272305,1,0,1,0.001433701446937276
4856,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.0013612562596487501,0,0,1,0.0014688062017610235
4857,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.0013287219694272305,1,0,1,0.001433701446937276
4858,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.0013612562596487501,0,0,1,0.0014688062017610235
4859,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.0013287219694272305,1,0,1,0.001433701446937276
4860,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0013612562596487501,0,0,1,0.0014688062017610235
4861,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0013287219694272305,1,0,1,0.001433701446937276
4862,H2B1A,B-WICH complex positively regulates rRNA expression,0.0013612562596487501,0,0,1,0.0014688062017610235
4863,H2B1A,B-WICH complex positively regulates rRNA expression,0.0013287219694272305,1,0,1,0.001433701446937276
4864,H2B1A,SIRT1 negatively regulates rRNA expression,0.0013612562596487501,0,0,1,0.0014688062017610235
4865,H2B1A,SIRT1 negatively regulates rRNA expression,0.0013287219694272305,1,0,1,0.001433701446937276
4866,H2B1A,NoRC negatively regulates rRNA expression,0.0013612562596487501,0,0,1,0.0014688062017610235
4867,H2B1A,NoRC negatively regulates rRNA expression,0.0013287219694272305,1,0,1,0.001433701446937276
4868,H2B1A,Ub-specific processing proteases,0.0013612562596487501,0,0,1,0.0014688062017610235
4869,H2B1A,Ub-specific processing proteases,0.0013287219694272305,1,0,1,0.001433701446937276
4870,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0013612562596487501,0,0,1,0.0014688062017610235
4871,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0013287219694272305,1,0,1,0.001433701446937276
4872,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0013612562596487501,0,0,1,0.0014688062017610235
4873,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0013287219694272305,1,0,1,0.001433701446937276
4874,H2B1A,Assembly of the ORC complex at the origin of replication,0.0013612562596487501,0,0,1,0.0014688062017610235
4875,H2B1A,Assembly of the ORC complex at the origin of replication,0.0013287219694272305,1,0,1,0.001433701446937276
4876,H2B1A,Mitotic Prophase,0.0013612562596487501,0,0,1,0.0014688062017610235
4877,H2B1A,Mitotic Prophase,0.0013287219694272305,1,0,1,0.001433701446937276
4878,H2B1A,G2/M DNA damage checkpoint,0.0013612562596487501,0,0,1,0.0014688062017610235
4879,H2B1A,G2/M DNA damage checkpoint,0.0013287219694272305,1,0,1,0.001433701446937276
4880,H2B1A,RNA Polymerase I Promoter Opening,0.0013612562596487501,0,0,1,0.0014688062017610235
4881,H2B1A,RNA Polymerase I Promoter Opening,0.0013287219694272305,1,0,1,0.001433701446937276
4882,H2B1A,RNA Polymerase I Promoter Escape,0.0013612562596487501,0,0,1,0.0014688062017610235
4883,H2B1A,RNA Polymerase I Promoter Escape,0.0013287219694272305,1,0,1,0.001433701446937276
4884,H2B1A,Depurination,0.0013612562596487501,0,0,1,0.0014688062017610235
4885,H2B1A,Depurination,0.0013287219694272305,1,0,1,0.001433701446937276
4886,H2B1A,Depyrimidination,0.0013612562596487501,0,0,1,0.0014688062017610235
4887,H2B1A,Depyrimidination,0.0013287219694272305,1,0,1,0.001433701446937276
4888,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.0013612562596487501,0,0,1,0.0014688062017610235
4889,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.0013287219694272305,1,0,1,0.001433701446937276
4890,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.0013612562596487501,0,0,1,0.0014688062017610235
4891,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.0013287219694272305,1,0,1,0.001433701446937276
4892,H2B1A,Estrogen-dependent gene expression,0.0013612562596487501,0,0,1,0.0014688062017610235
4893,H2B1A,Estrogen-dependent gene expression,0.0013287219694272305,1,0,1,0.001433701446937276
4894,H2B1A,HCMV Early Events,0.0013612562596487501,0,0,1,0.0014688062017610235
4895,H2B1A,HCMV Early Events,0.0013287219694272305,1,0,1,0.001433701446937276
4896,H2B1A,HCMV Late Events,0.0013612562596487501,0,0,1,0.0014688062017610235
4897,H2B1A,HCMV Late Events,0.0013287219694272305,1,0,1,0.001433701446937276
4898,H2B1A,Transcriptional regulation of granulopoiesis,0.0013612562596487501,0,0,1,0.0014688062017610235
4899,H2B1A,Transcriptional regulation of granulopoiesis,0.0013287219694272305,1,0,1,0.001433701446937276
4900,H2B1A,Meiotic synapsis,0.0013612562596487501,0,0,1,0.0014688062017610235
4901,H2B1A,Meiotic synapsis,0.0013287219694272305,1,0,1,0.001433701446937276
4902,H2B1A,Meiotic recombination,0.0013612562596487501,0,0,1,0.0014688062017610235
4903,H2B1A,Meiotic recombination,0.0013287219694272305,1,0,1,0.001433701446937276
4904,H2B1A,Transcriptional regulation by small RNAs,0.0013612562596487501,0,0,1,0.0014688062017610235
4905,H2B1A,Transcriptional regulation by small RNAs,0.0013287219694272305,1,0,1,0.001433701446937276
4906,H2B1A,PRC2 methylates histones and DNA,0.0013612562596487501,0,0,1,0.0014688062017610235
4907,H2B1A,PRC2 methylates histones and DNA,0.0013287219694272305,1,0,1,0.001433701446937276
4908,H2B1A,DNA methylation,0.0013612562596487501,0,0,1,0.0014688062017610235
4909,H2B1A,DNA methylation,0.0013287219694272305,1,0,1,0.001433701446937276
4910,H2B1A,HDACs deacetylate histones,0.0013612562596487501,0,0,1,0.0014688062017610235
4911,H2B1A,HDACs deacetylate histones,0.0013287219694272305,1,0,1,0.001433701446937276
4912,H2B1A,HATs acetylate histones,0.0013612562596487501,0,0,1,0.0014688062017610235
4913,H2B1A,HATs acetylate histones,0.0013287219694272305,1,0,1,0.001433701446937276
4914,H2B1A,Amyloid fiber formation,0.0013612562596487501,0,0,1,0.0014688062017610235
4915,H2B1A,Amyloid fiber formation,0.0013287219694272305,1,0,1,0.001433701446937276
4916,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0013612562596487501,0,0,1,0.0014688062017610235
4917,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0013287219694272305,1,0,1,0.001433701446937276
4918,H2B1A,Nonhomologous End-Joining (NHEJ),0.0013612562596487501,0,0,1,0.0014688062017610235
4919,H2B1A,Nonhomologous End-Joining (NHEJ),0.0013287219694272305,1,0,1,0.001433701446937276
4920,H2B1A,Defective pyroptosis,0.0013612562596487501,0,0,1,0.0014688062017610235
4921,H2B1A,Defective pyroptosis,0.0013287219694272305,1,0,1,0.001433701446937276
4922,CBPB2,Regulation of Complement cascade,0.0007425653213507152,0,0,1,0.0008012338172784829
4923,CBPB2,Regulation of Complement cascade,0.0006864782802191864,1,0,1,0.0007407154591306407
4924,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0007425653213507152,0,0,1,0.0008012338172784829
4925,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0006864782802191864,1,0,1,0.0007407154591306407
4926,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0016073863560450263,0,0,1,0.001734382510016291
4927,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0016034206719875025,1,0,1,0.0017301035057534061
4928,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0016073863560450263,0,0,1,0.001734382510016291
4929,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0016034206719875025,1,0,1,0.0017301035057534061
4930,PSB7,Antigen processing-Cross presentation,0.0016073863560450263,0,0,1,0.001734382510016291
4931,PSB7,Antigen processing-Cross presentation,0.0016034206719875025,1,0,1,0.0017301035057534061
4932,PSB7,PTEN Regulation,0.0016073863560450263,0,0,1,0.001734382510016291
4933,PSB7,PTEN Regulation,0.0016034206719875025,1,0,1,0.0017301035057534061
4934,PSB7,Host Interactions of HIV factors,0.0016073863560450263,0,0,1,0.001734382510016291
4935,PSB7,Host Interactions of HIV factors,0.0016034206719875025,1,0,1,0.0017301035057534061
4936,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0016073863560450263,0,0,1,0.001734382510016291
4937,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0016034206719875025,1,0,1,0.0017301035057534061
4938,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0016073863560450263,0,0,1,0.001734382510016291
4939,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0016034206719875025,1,0,1,0.0017301035057534061
4940,PSB7,Degradation of AXIN,0.0016073863560450263,0,0,1,0.001734382510016291
4941,PSB7,Degradation of AXIN,0.0016034206719875025,1,0,1,0.0017301035057534061
4942,PSB7,Degradation of DVL,0.0016073863560450263,0,0,1,0.001734382510016291
4943,PSB7,Degradation of DVL,0.0016034206719875025,1,0,1,0.0017301035057534061
4944,PSB7,Downstream TCR signaling,0.0016073863560450263,0,0,1,0.001734382510016291
4945,PSB7,Downstream TCR signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
4946,PSB7,Transcriptional regulation by RUNX3,0.0016073863560450263,0,0,1,0.001734382510016291
4947,PSB7,Transcriptional regulation by RUNX3,0.0016034206719875025,1,0,1,0.0017301035057534061
4948,PSB7,Transcriptional regulation by RUNX2,0.0016073863560450263,0,0,1,0.001734382510016291
4949,PSB7,Transcriptional regulation by RUNX2,0.0016034206719875025,1,0,1,0.0017301035057534061
4950,PSB7,Transcriptional regulation by RUNX1,0.0016073863560450263,0,0,1,0.001734382510016291
4951,PSB7,Transcriptional regulation by RUNX1,0.0016034206719875025,1,0,1,0.0017301035057534061
4952,PSB7,FCERI mediated NF-kB activation,0.0016073863560450263,0,0,1,0.001734382510016291
4953,PSB7,FCERI mediated NF-kB activation,0.0016034206719875025,1,0,1,0.0017301035057534061
4954,PSB7,Mitotic Metaphase and Anaphase,0.0016073863560450263,0,0,1,0.001734382510016291
4955,PSB7,Mitotic Metaphase and Anaphase,0.0016034206719875025,1,0,1,0.0017301035057534061
4956,PSB7,Regulation of ornithine decarboxylase (ODC),0.0016073863560450263,0,0,1,0.001734382510016291
4957,PSB7,Regulation of ornithine decarboxylase (ODC),0.0016034206719875025,1,0,1,0.0017301035057534061
4958,PSB7,Signaling by ROBO receptors,0.0016073863560450263,0,0,1,0.001734382510016291
4959,PSB7,Signaling by ROBO receptors,0.0016034206719875025,1,0,1,0.0017301035057534061
4960,PSB7,PCP/CE pathway,0.0016073863560450263,0,0,1,0.001734382510016291
4961,PSB7,PCP/CE pathway,0.0016034206719875025,1,0,1,0.0017301035057534061
4962,PSB7,Interleukin-1 family signaling,0.0016073863560450263,0,0,1,0.001734382510016291
4963,PSB7,Interleukin-1 family signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
4964,PSB7,G2/M Transition,0.0016073863560450263,0,0,1,0.001734382510016291
4965,PSB7,G2/M Transition,0.0016034206719875025,1,0,1,0.0017301035057534061
4966,PSB7,G1/S Transition,0.0016073863560450263,0,0,1,0.001734382510016291
4967,PSB7,G1/S Transition,0.0016034206719875025,1,0,1,0.0017301035057534061
4968,PSB7,Hh mutants are degraded by ERAD,0.0016073863560450263,0,0,1,0.001734382510016291
4969,PSB7,Hh mutants are degraded by ERAD,0.0016034206719875025,1,0,1,0.0017301035057534061
4970,PSB7,CLEC7A (Dectin-1) signaling,0.0016073863560450263,0,0,1,0.001734382510016291
4971,PSB7,CLEC7A (Dectin-1) signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
4972,PSB7,Degradation of GLI1 by the proteasome,0.0016073863560450263,0,0,1,0.001734382510016291
4973,PSB7,Degradation of GLI1 by the proteasome,0.0016034206719875025,1,0,1,0.0017301035057534061
4974,PSB7,Degradation of GLI2 by the proteasome,0.0016073863560450263,0,0,1,0.001734382510016291
4975,PSB7,Degradation of GLI2 by the proteasome,0.0016034206719875025,1,0,1,0.0017301035057534061
4976,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0016073863560450263,0,0,1,0.001734382510016291
4977,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0016034206719875025,1,0,1,0.0017301035057534061
4978,PSB7,Defective CFTR causes cystic fibrosis,0.0016073863560450263,0,0,1,0.001734382510016291
4979,PSB7,Defective CFTR causes cystic fibrosis,0.0016034206719875025,1,0,1,0.0017301035057534061
4980,PSB7,NIK-->noncanonical NF-kB signaling,0.0016073863560450263,0,0,1,0.001734382510016291
4981,PSB7,NIK-->noncanonical NF-kB signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
4982,PSB7,RAF/MAP kinase cascade,0.0016073863560450263,0,0,1,0.001734382510016291
4983,PSB7,RAF/MAP kinase cascade,0.0016034206719875025,1,0,1,0.0017301035057534061
4984,PSB7,UCH proteinases,0.0016073863560450263,0,0,1,0.001734382510016291
4985,PSB7,UCH proteinases,0.0016034206719875025,1,0,1,0.0017301035057534061
4986,PSB7,Ub-specific processing proteases,0.0016073863560450263,0,0,1,0.001734382510016291
4987,PSB7,Ub-specific processing proteases,0.0016034206719875025,1,0,1,0.0017301035057534061
4988,PSB7,Orc1 removal from chromatin,0.0016073863560450263,0,0,1,0.001734382510016291
4989,PSB7,Orc1 removal from chromatin,0.0016034206719875025,1,0,1,0.0017301035057534061
4990,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0016073863560450263,0,0,1,0.001734382510016291
4991,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0016034206719875025,1,0,1,0.0017301035057534061
4992,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0016073863560450263,0,0,1,0.001734382510016291
4993,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0016034206719875025,1,0,1,0.0017301035057534061
4994,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0016073863560450263,0,0,1,0.001734382510016291
4995,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0016034206719875025,1,0,1,0.0017301035057534061
4996,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0016073863560450263,0,0,1,0.001734382510016291
4997,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0016034206719875025,1,0,1,0.0017301035057534061
4998,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0016073863560450263,0,0,1,0.001734382510016291
4999,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0016034206719875025,1,0,1,0.0017301035057534061
5000,PSB7,Negative regulation of NOTCH4 signaling,0.0016073863560450263,0,0,1,0.001734382510016291
5001,PSB7,Negative regulation of NOTCH4 signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
5002,PSB7,KEAP1-NFE2L2 pathway,0.0016073863560450263,0,0,1,0.001734382510016291
5003,PSB7,KEAP1-NFE2L2 pathway,0.0016034206719875025,1,0,1,0.0017301035057534061
5004,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0016073863560450263,0,0,1,0.001734382510016291
5005,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0016034206719875025,1,0,1,0.0017301035057534061
5006,PSB7,Neutrophil degranulation,0.0016073863560450263,0,0,1,0.001734382510016291
5007,PSB7,Neutrophil degranulation,0.0016034206719875025,1,0,1,0.0017301035057534061
5008,PSB7,Degradation of beta-catenin by the destruction complex,0.0016073863560450263,0,0,1,0.001734382510016291
5009,PSB7,Degradation of beta-catenin by the destruction complex,0.0016034206719875025,1,0,1,0.0017301035057534061
5010,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0016073863560450263,0,0,1,0.001734382510016291
5011,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0016034206719875025,1,0,1,0.0017301035057534061
5012,PSB7,Hedgehog ligand biogenesis,0.0016073863560450263,0,0,1,0.001734382510016291
5013,PSB7,Hedgehog ligand biogenesis,0.0016034206719875025,1,0,1,0.0017301035057534061
5014,PSB7,Hedgehog 'on' state,0.0016073863560450263,0,0,1,0.001734382510016291
5015,PSB7,Hedgehog 'on' state,0.0016034206719875025,1,0,1,0.0017301035057534061
5016,PSB7,MAPK6/MAPK4 signaling,0.0016073863560450263,0,0,1,0.001734382510016291
5017,PSB7,MAPK6/MAPK4 signaling,0.0016034206719875025,1,0,1,0.0017301035057534061
5018,PSB7,Neddylation,0.0016073863560450263,0,0,1,0.001734382510016291
5019,PSB7,Neddylation,0.0016034206719875025,1,0,1,0.0017301035057534061
5020,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0018026769782106082,0,0,1,0.0019451026260483679
5021,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0016041830744749556,1,0,1,0.001730926144028802
5022,PARK7,Aggrephagy,0.0018026769782106082,0,0,1,0.0019451026260483679
5023,PARK7,Aggrephagy,0.0016041830744749556,1,0,1,0.001730926144028802
5024,PARK7,Chaperone Mediated Autophagy,0.0018026769782106082,0,0,1,0.0019451026260483679
5025,PARK7,Chaperone Mediated Autophagy,0.0016041830744749556,1,0,1,0.001730926144028802
5026,PARK7,Late endosomal microautophagy,0.0018026769782106082,0,0,1,0.0019451026260483679
5027,PARK7,Late endosomal microautophagy,0.0016041830744749556,1,0,1,0.001730926144028802
5028,RARR2,Platelet degranulation ,0.00022213417487364494,0,0,1,0.0002396845203574429
5029,RARR2,Platelet degranulation ,0.00025345326588042857,1,0,1,0.0002734780656786975
5030,FUCO2,Neutrophil degranulation,0.00013852807411135853,0,0,1,0.0001494728806060928
5031,FUCO2,Neutrophil degranulation,0.00010833042873249117,1,0,1,0.00011688938393037839
5032,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00013852807411135853,0,0,1,0.0001494728806060928
5033,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00010833042873249117,1,0,1,0.00011688938393037839
5034,FUCO2,Post-translational protein phosphorylation,0.00013852807411135853,0,0,1,0.0001494728806060928
5035,FUCO2,Post-translational protein phosphorylation,0.00010833042873249117,1,0,1,0.00011688938393037839
5036,COL11,Initial triggering of complement,5.604493922911994e-05,0,0,1,6.047292986428004e-05
5037,COL11,Initial triggering of complement,6.540017800098497e-05,1,0,1,7.056730601841885e-05
5038,COL11,Scavenging by Class A Receptors,5.604493922911994e-05,0,0,1,6.047292986428004e-05
5039,COL11,Scavenging by Class A Receptors,6.540017800098497e-05,1,0,1,7.056730601841885e-05
5040,FHR5,Regulation of Complement cascade,0.0015485227566387038,0,0,1,0.0016708682236700211
5041,FHR5,Regulation of Complement cascade,0.0015988335622144707,1,0,1,0.0017251539782599376
5042,CHM4A,HIV Life Cycle,0.0023002981576913345,0,0,1,0.002482039789325417
5043,CHM4A,HIV Life Cycle,0.0019783737438653286,1,0,1,0.0021346808169244893
5044,CHM4A,Mitotic Metaphase and Anaphase,0.0023002981576913345,0,0,1,0.002482039789325417
5045,CHM4A,Mitotic Metaphase and Anaphase,0.0019783737438653286,1,0,1,0.0021346808169244893
5046,CHM4A,HCMV Late Events,0.0023002981576913345,0,0,1,0.002482039789325417
5047,CHM4A,HCMV Late Events,0.0019783737438653286,1,0,1,0.0021346808169244893
5048,CHM4A,SARS-CoV-1 Infection,0.0023002981576913345,0,0,1,0.002482039789325417
5049,CHM4A,SARS-CoV-1 Infection,0.0019783737438653286,1,0,1,0.0021346808169244893
5050,CHM4A,SARS-CoV-2 Infection,0.0023002981576913345,0,0,1,0.002482039789325417
5051,CHM4A,SARS-CoV-2 Infection,0.0019783737438653286,1,0,1,0.0021346808169244893
5052,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0023002981576913345,0,0,1,0.002482039789325417
5053,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0019783737438653286,1,0,1,0.0021346808169244893
5054,CHM4A,Pyroptosis,0.0023002981576913345,0,0,1,0.002482039789325417
5055,CHM4A,Pyroptosis,0.0019783737438653286,1,0,1,0.0021346808169244893
5056,CHM4A,Late endosomal microautophagy,0.0023002981576913345,0,0,1,0.002482039789325417
5057,CHM4A,Late endosomal microautophagy,0.0019783737438653286,1,0,1,0.0021346808169244893
5058,TBB1,Activation of NMDA receptors and postsynaptic events,0.01602805336782088,0,0,1,0.01729439554231076
5059,TBB1,Activation of NMDA receptors and postsynaptic events,0.016075996115493277,1,0,1,0.01734612614381327
5060,TBB1,Gap junction trafficking,0.01602805336782088,0,0,1,0.01729439554231076
5061,TBB1,Gap junction trafficking,0.016075996115493277,1,0,1,0.01734612614381327
5062,TBB1,RHO GTPase Effectors,0.01602805336782088,0,0,1,0.01729439554231076
5063,TBB1,RHO GTPase Effectors,0.016075996115493277,1,0,1,0.01734612614381327
5064,TBB1,COPI-mediated anterograde transport,0.01602805336782088,0,0,1,0.01729439554231076
5065,TBB1,COPI-mediated anterograde transport,0.016075996115493277,1,0,1,0.01734612614381327
5066,TBB1,Mitotic Metaphase and Anaphase,0.01602805336782088,0,0,1,0.01729439554231076
5067,TBB1,Mitotic Metaphase and Anaphase,0.016075996115493277,1,0,1,0.01734612614381327
5068,TBB1,L1CAM interactions,0.01602805336782088,0,0,1,0.01729439554231076
5069,TBB1,L1CAM interactions,0.016075996115493277,1,0,1,0.01734612614381327
5070,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.01602805336782088,0,0,1,0.01729439554231076
5071,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.016075996115493277,1,0,1,0.01734612614381327
5072,TBB1,G2/M Transition,0.01602805336782088,0,0,1,0.01729439554231076
5073,TBB1,G2/M Transition,0.016075996115493277,1,0,1,0.01734612614381327
5074,TBB1,Golgi-to-ER retrograde transport,0.01602805336782088,0,0,1,0.01729439554231076
5075,TBB1,Golgi-to-ER retrograde transport,0.016075996115493277,1,0,1,0.01734612614381327
5076,TBB1,Mitotic Prometaphase,0.01602805336782088,0,0,1,0.01729439554231076
5077,TBB1,Mitotic Prometaphase,0.016075996115493277,1,0,1,0.01734612614381327
5078,TBB1,HCMV Early Events,0.01602805336782088,0,0,1,0.01729439554231076
5079,TBB1,HCMV Early Events,0.016075996115493277,1,0,1,0.01734612614381327
5080,TBB1,Aggrephagy,0.01602805336782088,0,0,1,0.01729439554231076
5081,TBB1,Aggrephagy,0.016075996115493277,1,0,1,0.01734612614381327
5082,TBB1,MHC class II antigen presentation,0.01602805336782088,0,0,1,0.01729439554231076
5083,TBB1,MHC class II antigen presentation,0.016075996115493277,1,0,1,0.01734612614381327
5084,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.01602805336782088,0,0,1,0.01729439554231076
5085,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.016075996115493277,1,0,1,0.01734612614381327
5086,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.01602805336782088,0,0,1,0.01729439554231076
5087,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.016075996115493277,1,0,1,0.01734612614381327
5088,TBB1,Post-chaperonin tubulin folding pathway,0.01602805336782088,0,0,1,0.01729439554231076
5089,TBB1,Post-chaperonin tubulin folding pathway,0.016075996115493277,1,0,1,0.01734612614381327
5090,TBB1,Intraflagellar transport,0.01602805336782088,0,0,1,0.01729439554231076
5091,TBB1,Intraflagellar transport,0.016075996115493277,1,0,1,0.01734612614381327
5092,TBB1,Carboxyterminal post-translational modifications of tubulin,0.01602805336782088,0,0,1,0.01729439554231076
5093,TBB1,Carboxyterminal post-translational modifications of tubulin,0.016075996115493277,1,0,1,0.01734612614381327
5094,TBB1,Kinesins,0.01602805336782088,0,0,1,0.01729439554231076
5095,TBB1,Kinesins,0.016075996115493277,1,0,1,0.01734612614381327
5096,RETN,FOXO-mediated transcription,0.0013042887939567057,0,0,1,0.00140733785859346
5097,RETN,FOXO-mediated transcription,0.0013734283042140306,1,0,1,0.0014819399335024728
5098,RETN,Neutrophil degranulation,0.0013042887939567057,0,0,1,0.00140733785859346
5099,RETN,Neutrophil degranulation,0.0013734283042140306,1,0,1,0.0014819399335024728
5100,SAE1,Processing and activation of SUMO,2.186235860032563e-05,0,0,1,2.358965673778984e-05
5101,SAE1,Processing and activation of SUMO,9.951295539091612e-05,1,0,1,0.00010737526090161834
5102,GRHPR,Glyoxylate metabolism and glycine degradation,0.00016594235615533155,0,0,1,0.00017905310637005253
5103,GRHPR,Glyoxylate metabolism and glycine degradation,0.00021190232194688482,1,0,1,0.00022864427064119193
5104,CATZ,COPII-mediated vesicle transport,0.01942085151094943,0,0,1,0.02095525140146867
5105,CATZ,COPII-mediated vesicle transport,0.020190293702762575,1,0,1,0.02178548557319131
5106,CATZ,Cargo concentration in the ER,0.01942085151094943,0,0,1,0.02095525140146867
5107,CATZ,Cargo concentration in the ER,0.020190293702762575,1,0,1,0.02178548557319131
5108,CATZ,Lysosome Vesicle Biogenesis,0.01942085151094943,0,0,1,0.02095525140146867
5109,CATZ,Lysosome Vesicle Biogenesis,0.020190293702762575,1,0,1,0.02178548557319131
5110,CATZ,Neutrophil degranulation,0.01942085151094943,0,0,1,0.02095525140146867
5111,CATZ,Neutrophil degranulation,0.020190293702762575,1,0,1,0.02178548557319131
5112,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.01942085151094943,0,0,1,0.02095525140146867
5113,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.020190293702762575,1,0,1,0.02178548557319131
5114,FBLN5,Molecules associated with elastic fibres,0.0006721455842656118,0,0,1,0.0007252503675614768
5115,FBLN5,Molecules associated with elastic fibres,0.000609596500872082,1,0,1,0.0006577594150301803
5116,DMBT1,Surfactant metabolism,2.2005808049622524e-05,0,0,1,2.374443982089636e-05
5117,DMBT1,Surfactant metabolism,2.8279490578597688e-05,1,0,1,3.0513792572167626e-05
5118,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004810035683597865,0,0,1,0.005190066302860108
5119,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004458064920133135,1,0,1,0.004810287083076057
5120,ZPI,Post-translational protein phosphorylation,0.004810035683597865,0,0,1,0.005190066302860108
5121,ZPI,Post-translational protein phosphorylation,0.004458064920133135,1,0,1,0.004810287083076057
5122,MINP1,Synthesis of IPs in the ER lumen,0.0008792753263454264,0,0,1,0.0009487449870201932
5123,MINP1,Synthesis of IPs in the ER lumen,0.0008128420508001,1,0,1,0.0008770629606327055
5124,TLN1,Semaphorin interactions,0.006515291822142899,0,0,1,0.007030051077315651
5125,TLN1,Semaphorin interactions,0.006707738840486854,1,0,1,0.007237702922477381
5126,TLN1,IRE1alpha activates chaperones,0.006515291822142899,0,0,1,0.007030051077315651
5127,TLN1,IRE1alpha activates chaperones,0.006707738840486854,1,0,1,0.007237702922477381
5128,TLN1,RAF/MAP kinase cascade,0.006515291822142899,0,0,1,0.007030051077315651
5129,TLN1,RAF/MAP kinase cascade,0.006707738840486854,1,0,1,0.007237702922477381
5130,TLN1,Signaling by RAS mutants,0.006515291822142899,0,0,1,0.007030051077315651
5131,TLN1,Signaling by RAS mutants,0.006707738840486854,1,0,1,0.007237702922477381
5132,TLN1,Signaling by moderate kinase activity BRAF mutants,0.006515291822142899,0,0,1,0.007030051077315651
5133,TLN1,Signaling by moderate kinase activity BRAF mutants,0.006707738840486854,1,0,1,0.007237702922477381
5134,TLN1,Signaling by high-kinase activity BRAF mutants,0.006515291822142899,0,0,1,0.007030051077315651
5135,TLN1,Signaling by high-kinase activity BRAF mutants,0.006707738840486854,1,0,1,0.007237702922477381
5136,TLN1,Signaling by BRAF and RAF1 fusions,0.006515291822142899,0,0,1,0.007030051077315651
5137,TLN1,Signaling by BRAF and RAF1 fusions,0.006707738840486854,1,0,1,0.007237702922477381
5138,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006515291822142899,0,0,1,0.007030051077315651
5139,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.006707738840486854,1,0,1,0.007237702922477381
5140,TLN1,Signaling by RAF1 mutants,0.006515291822142899,0,0,1,0.007030051077315651
5141,TLN1,Signaling by RAF1 mutants,0.006707738840486854,1,0,1,0.007237702922477381
5142,TLN1,Platelet degranulation ,0.006515291822142899,0,0,1,0.007030051077315651
5143,TLN1,Platelet degranulation ,0.006707738840486854,1,0,1,0.007237702922477381
5144,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006515291822142899,0,0,1,0.007030051077315651
5145,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.006707738840486854,1,0,1,0.007237702922477381
5146,TLN1,p130Cas linkage to MAPK signaling for integrins,0.006515291822142899,0,0,1,0.007030051077315651
5147,TLN1,p130Cas linkage to MAPK signaling for integrins,0.006707738840486854,1,0,1,0.007237702922477381
5148,TLN1,Smooth Muscle Contraction,0.006515291822142899,0,0,1,0.007030051077315651
5149,TLN1,Smooth Muscle Contraction,0.006707738840486854,1,0,1,0.007237702922477381
5150,HYOU1,IRE1alpha activates chaperones,0.002439249187591486,0,0,1,0.0026319690425514676
5151,HYOU1,IRE1alpha activates chaperones,0.002575585009374966,1,0,1,0.002779076465667694
5152,HYOU1,Scavenging by Class F Receptors,0.002439249187591486,0,0,1,0.0026319690425514676
5153,HYOU1,Scavenging by Class F Receptors,0.002575585009374966,1,0,1,0.002779076465667694
5154,COL10,Initial triggering of complement,0.0008651044047534621,0,0,1,0.0009334544512585306
5155,COL10,Initial triggering of complement,0.0009311998806272944,1,0,1,0.0010047719891458356
5156,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0009624919890484307,0,1,2,0.029445740752576367
5157,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0010556538047239883,1,1,2,0.032295861796320185
5158,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.00023139491703053257,0,1,2,0.00707911838838394
5159,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.00029783439475371173,1,1,2,0.009111716746638812
5160,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,8.805186134850374e-05,0,1,2,0.0026937910253291243
5161,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.0006968859874177724,1,1,2,0.02131999471485926
5162,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,3.916838863915473e-05,0,1,2,0.0011982876020661338
5163,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,8.848238664237821e-05,1,1,2,0.0027069621855414683
5164,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.000179115753841567,0,1,2,0.005479729818359745
5165,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.0005340299018977627,1,1,2,0.0163377007022695
5166,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),5.554329066702242e-05,0,1,2,0.0016992487793514933
5167,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),5.1689687688849516e-05,1,1,2,0.001581354609270327
5168,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.00012093233716162407,0,1,2,0.0036997110512939136
5169,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.0001542400583957715,1,1,2,0.004718701895559983
5170,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0011894771557611724,0,1,2,0.036389950626272684
5171,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0011575612845869424,1,1,2,0.035413540973847295
5172,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.0002738617261153801,0,1,2,0.008378315332493419
5173,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.00038886228200378053,1,1,2,0.011896554022916034
5174,Downregulation of ERBB2 signaling,Signaling by ERBB2,1.2432012188886196e-05,0,1,2,0.00038033543355381886
5175,Downregulation of ERBB2 signaling,Signaling by ERBB2,3.060573819766432e-05,1,1,2,0.0009363284502768994
5176,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,5.2668822058876684e-05,0,1,2,0.0016113094942457973
5177,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,0.00012967289637041783,1,1,2,0.003967113007282281
5178,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,6.237125914291634e-05,0,1,2,0.001908138403260685
5179,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,4.7508491449358795e-05,1,1,2,0.0014534383025326344
5180,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,7.196983992798777e-05,0,1,2,0.0022017900124229636
5181,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,5.481924754349166e-05,1,1,2,0.001677097960070129
5182,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,4.076440901978155e-05,0,1,2,0.0012471150239028895
5183,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,3.105005877538739e-05,1,1,2,0.0009499216528090092
5184,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,5.773335910816968e-05,0,1,2,0.001766250051343562
5185,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,4.3975165165951084e-05,1,1,2,0.0013453424316897528
5186,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,8.996993083201232e-05,0,1,2,0.0027524709700969346
5187,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,6.852939421454115e-05,1,1,2,0.002096535658408424
5188,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,2.5053966101040715e-05,0,1,2,0.0007664817983206717
5189,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,1.908434467168263e-05,1,1,2,0.0005838517847725198
5190,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.0008335098728214992,0,1,2,0.02549976094250878
5191,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.00072892069019872,1,1,2,0.022300039810202035
5192,Nuclear signaling by ERBB4,Signaling by ERBB4,0.0001824728579175409,0,1,2,0.005582434482320922
5193,Nuclear signaling by ERBB4,Signaling by ERBB4,0.00023248302023214744,1,1,2,0.007112406982108732
5194,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.0033569523965221986,0,1,2,0.1027000235965172
5195,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.00324125597277695,1,1,2,0.09916049605928448
5196,PTEN Regulation,PIP3 activates AKT signaling,0.0005022806554582834,0,1,2,0.015366388639017067
5197,PTEN Regulation,PIP3 activates AKT signaling,0.0006687535198580008,1,1,2,0.020459331607092228
5198,Defensins,Antimicrobial peptides,0.0007267935773901021,0,1,2,0.02223496455448383
5199,Defensins,Antimicrobial peptides,0.0007886074015914346,1,1,2,0.024126049221232345
5200,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.00039862649985783114,0,1,2,0.012195273005363154
5201,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0003354431371311269,1,1,2,0.01026228972872737
5202,Antagonism of Activin by Follistatin,Signaling by Activin,2.9249853650981094e-05,0,1,2,0.0008948475597278457
5203,Antagonism of Activin by Follistatin,Signaling by Activin,2.1597356249003496e-05,1,1,2,0.0006607329310635877
5204,Methylation,Phase II - Conjugation of compounds,8.585979509613632e-05,0,1,2,0.0026267286338348354
5205,Methylation,Phase II - Conjugation of compounds,7.019802196737147e-05,1,1,2,0.0021475843744304373
5206,Glucuronidation,Phase II - Conjugation of compounds,0.0011240159442725902,0,1,2,0.034387280593924624
5207,Glucuronidation,Phase II - Conjugation of compounds,0.0009221067477483303,1,1,2,0.02821022569470178
5208,Glutathione conjugation,Phase II - Conjugation of compounds,0.0005825732689118013,0,1,2,0.017822799193079508
5209,Glutathione conjugation,Phase II - Conjugation of compounds,0.00048075271673345317,1,1,2,0.014707779414377793
5210,Packaging Of Telomere Ends,Telomere Maintenance,0.0001128125347634068,0,1,2,0.0034513000524486826
5211,Packaging Of Telomere Ends,Telomere Maintenance,0.00015052898260516182,1,1,2,0.004605168092799203
5212,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0003212391474335163,0,1,2,0.009827743776088733
5213,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.00043200827781978053,1,1,2,0.013216529484286605
5214,Gap junction trafficking,Gap junction trafficking and regulation,0.0023193314380478116,0,1,2,0.07095584484975859
5215,Gap junction trafficking,Gap junction trafficking and regulation,0.002707049796784607,1,1,2,0.08281740256273777
5216,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.004514224306088484,0,1,2,0.13810471165321248
5217,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.004203955873284333,1,1,2,0.1286125974953673
5218,Methionine salvage pathway,Sulfur amino acid metabolism,7.515823678356052e-05,0,1,2,0.0022993333772444668
5219,Methionine salvage pathway,Sulfur amino acid metabolism,9.601605124771595e-05,1,1,2,0.002937441334884781
5220,Cysteine formation from homocysteine,Sulfur amino acid metabolism,1.2644988271766818e-06,0,1,2,3.868510602752445e-05
5221,Cysteine formation from homocysteine,Sulfur amino acid metabolism,1.7829688844154626e-06,1,1,2,5.454678079171656e-05
5222,HIV Life Cycle,HIV Infection,2.9997314883682216e-05,0,1,2,0.0009177148146568744
5223,HIV Life Cycle,HIV Infection,2.4029237177577064e-05,1,1,2,0.0007351320285923971
5224,Host Interactions of HIV factors,HIV Infection,0.001631993957562372,0,1,2,0.0499279698230659
5225,Host Interactions of HIV factors,HIV Infection,0.0013102425282947175,1,1,2,0.040084553689958176
5226,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0008654181763328476,0,1,2,0.026475939075667677
5227,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0009900272321829106,1,1,2,0.030288132834923615
5228,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0012500513927686068,0,1,2,0.038243112314370935
5229,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0014249326465990938,1,1,2,0.043593295091340425
5230,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,6.126771739521549e-05,0,1,2,0.0018743774945132053
5231,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,7.000614226247611e-05,1,1,2,0.002141714154095808
5232,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.004010049338830868,0,1,2,0.12268036989377219
5233,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.004612826276373502,1,1,2,0.14112126460922858
5234,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00014767420240483867,0,1,2,0.0045178311397224185
5235,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",7.14323225414167e-05,1,1,2,0.002185345618292866
5236,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,3.155140555766896e-05,0,1,2,0.0009652594712492398
5237,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,4.157159699692177e-05,1,1,2,0.0012718095129832256
5238,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.00012983066202044332,0,1,2,0.003971939568420629
5239,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.0001710613765681046,1,1,2,0.005233320385537045
5240,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0022696215453227825,0,1,2,0.06943505856719771
5241,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.002436444843139422,1,1,2,0.0745387224261095
5242,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0009233103365204442,0,1,2,0.02824704736528152
5243,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0008787890927123953,1,1,2,0.02688499862298483
5244,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.0003020544114406221,0,1,2,0.009240820696332109
5245,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.00034967929968843237,1,1,2,0.010697819953127874
5246,Initial triggering of complement,Complement cascade,0.0031987612362475676,0,1,2,0.0978604447243842
5247,Initial triggering of complement,Complement cascade,0.003376571419236522,1,1,2,0.10330023291071212
5248,Terminal pathway of complement,Complement cascade,0.00018335794836351246,0,1,2,0.005609512259706299
5249,Terminal pathway of complement,Complement cascade,0.00019360432086159562,1,1,2,0.005922981911054953
5250,Activation of C3 and C5,Complement cascade,0.0013703025113500189,0,1,2,0.041921982687574015
5251,Activation of C3 and C5,Complement cascade,0.0014495682706183288,1,1,2,0.0443469784532825
5252,Regulation of Complement cascade,Complement cascade,0.007405328661297972,0,1,2,0.22655293802890175
5253,Regulation of Complement cascade,Complement cascade,0.007790510960209455,1,1,2,0.23833690947519104
5254,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0013474805718942662,0,1,2,0.04122378579832045
5255,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.0012828851093217963,1,1,2,0.03924760182344689
5256,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,4.9365619084558905e-05,0,1,2,0.0015102538391945153
5257,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,4.703842065320411e-05,1,1,2,0.0014390573175931001
5258,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.000831299976941106,0,1,2,0.02543215308506721
5259,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0007927415524288032,1,1,2,0.024252526257066746
5260,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.00045515800075008884,0,1,2,0.013924754329434415
5261,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0004334485702656821,1,1,2,0.013260592685282013
5262,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.00042724885263396574,0,1,2,0.013070923285224793
5263,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.00040699262477232877,1,1,2,0.012451219806104342
5264,Virus Assembly and Release,Influenza Infection,0.0028805893496610226,0,1,2,0.08812653837109807
5265,Virus Assembly and Release,Influenza Infection,0.0024494588452701766,1,1,2,0.07493686281299683
5266,Influenza Viral RNA Transcription and Replication,Influenza Infection,3.0205634288904548e-05,0,1,2,0.0009240879785581888
5267,Influenza Viral RNA Transcription and Replication,Influenza Infection,2.5684288137502637e-05,1,1,2,0.0007857653866387869
5268,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.00023818615809432231,0,1,2,0.007286884402052592
5269,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.00024723309549396313,1,1,2,0.00756365945712394
5270,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,9.43036609593643e-05,0,1,2,0.0028850537814591342
5271,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,8.986978536995593e-05,1,1,2,0.0027494071967390133
5272,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0015129533504174711,0,1,2,0.04628613290712076
5273,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0014416148546539868,1,1,2,0.04410365775321626
5274,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0016090758210339118,0,1,2,0.04922682995444593
5275,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0015289689751322537,1,1,2,0.04677610263020207
5276,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,8.018780457996754e-06,0,1,2,0.0002453204111874608
5277,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,1.612555770691415e-05,1,1,2,0.0004933329286178728
5278,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.00044499221755055863,0,1,2,0.01361375016519591
5279,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0005782296582462247,1,1,2,0.01768991410411877
5280,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.0009210844075520678,0,1,2,0.02817894900385904
5281,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.000732656858417613,1,1,2,0.022414341271443598
5282,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0008980649816597482,0,1,2,0.027474710366227867
5283,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0008169846742627367,1,1,2,0.024994201708579734
5284,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0008980649816597482,0,1,2,0.027474710366227867
5285,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0008169846742627367,1,1,2,0.024994201708579734
5286,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.00045157811201382476,0,1,2,0.013815233962667189
5287,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.0002973256564700932,1,1,2,0.009096152798283096
5288,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0006273820392986333,0,1,2,0.019193644302717073
5289,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0006449917459273517,1,1,2,0.019732382143673875
5290,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0014613013632697402,0,1,2,0.04470593167925271
5291,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0015092888068465981,1,1,2,0.04617402267535548
5292,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,4.076294955363361e-05,0,1,2,0.0012470703741163786
5293,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.00010260267972626025,1,1,2,0.0031389475882557826
5294,Bile acid and bile salt metabolism,Metabolism of steroids,0.000512458567803975,0,1,2,0.01567776387303847
5295,Bile acid and bile salt metabolism,Metabolism of steroids,0.0005118444225255795,1,1,2,0.015658975184033454
5296,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,0.00014244865794807993,0,1,2,0.004357964845648736
5297,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,0.00012372941691107068,1,1,2,0.00378528276108852
5298,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.002048486585408682,0,1,2,0.06266982542754368
5299,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0017770923320009995,1,1,2,0.05436699806013635
5300,RHO GTPase Effectors,Signaling by Rho GTPases,0.0024706618797002496,0,1,2,0.07558553216515748
5301,RHO GTPase Effectors,Signaling by Rho GTPases,0.0021557563111552253,1,1,2,0.06595155303761499
5302,RHO GTPase cycle,Signaling by Rho GTPases,0.003987144751590677,0,1,2,0.12197964454167212
5303,RHO GTPase cycle,Signaling by Rho GTPases,0.003483773436649547,1,1,2,0.10657988910402542
5304,Metabolism of steroid hormones,Metabolism of steroids,0.0014599505158306178,0,1,2,0.04466460489010405
5305,Metabolism of steroid hormones,Metabolism of steroids,0.0014575121280055706,1,1,2,0.044590006725581596
5306,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.0003852621710393578,0,1,2,0.011786414992830492
5307,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.00042777238789616,1,1,2,0.013086939920979493
5308,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,0.00016982319436162168,0,1,2,0.005195440389992776
5309,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,0.0001891708006345046,1,1,2,0.0057873461980166635
5310,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,0.0014333321237548565,0,1,2,0.04385026224493751
5311,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,0.0015854477165703428,1,1,2,0.048503969872049926
5312,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,0.0007931320709758438,0,1,2,0.024264473481590245
5313,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,0.0008759929158259183,1,1,2,0.02679945453468655
5314,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,3.563432645326732e-05,0,1,2,0.0010901692175879357
5315,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,3.9414311277141675e-05,1,1,2,0.001205811170392674
5316,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.0006688735884381458,0,1,2,0.02046300489302469
5317,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.0007370315870502964,1,1,2,0.022548178359592483
5318,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.005464013513119426,0,1,2,0.16716183324804054
5319,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.006594033849857321,1,1,2,0.20173280761388415
5320,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.001133738484531932,0,1,2,0.034684724524046175
5321,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.0013696014045611567,1,1,2,0.0419005335649012
5322,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.00010353019908582913,0,1,2,0.0031673234032398244
5323,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.00012516406831461306,1,1,2,0.003829173384366116
5324,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0031952787894018305,0,1,2,0.09775390541998379
5325,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.003701465701306006,1,1,2,0.11323979906883738
5326,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0010441436681503547,0,1,2,0.03194372951737099
5327,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0012121912511550666,1,1,2,0.03708484821711824
5328,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,0.0001097279752381534,0,1,2,0.0033569334071675123
5329,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,8.408373651036527e-05,1,1,2,0.0025723932614129773
5330,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,0.00010744161824997415,0,1,2,0.003286986357313802
5331,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,8.24104644474725e-05,1,1,2,0.0025212024609355824
5332,Degradation of AXIN,TCF dependent signaling in response to WNT,0.00018450274424708368,0,1,2,0.005644535265804855
5333,Degradation of AXIN,TCF dependent signaling in response to WNT,0.00014137034037418062,1,1,2,0.004324975625903252
5334,Degradation of DVL,TCF dependent signaling in response to WNT,0.0001898217735288199,0,1,2,0.005807261562820804
5335,Degradation of DVL,TCF dependent signaling in response to WNT,0.00014540890927795165,1,1,2,0.004448528501464769
5336,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,2.938436858244131e-05,0,1,2,0.0008989628062381508
5337,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,3.167070789421207e-05,1,1,2,0.000968909315313395
5338,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0008187193092453526,0,1,2,0.02504726979909855
5339,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0008822824719876128,1,1,2,0.026991872385737053
5340,Downstream TCR signaling,TCR signaling,0.0004271348804347023,0,1,2,0.013067436507287214
5341,Downstream TCR signaling,TCR signaling,0.00031840291894695837,1,1,2,0.00974097437989581
5342,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0018684813811584414,0,1,2,0.05716288444644795
5343,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0018142616687327972,1,1,2,0.05550412820335113
5344,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0019312901538190393,0,1,2,0.05908440780227342
5345,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0018755890013684015,1,1,2,0.05738032952074636
5346,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0019662869022795348,0,1,2,0.06015507144838822
5347,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0019082679823137975,1,1,2,0.058380085167469044
5348,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,1.5510733472486512e-05,0,1,2,0.0004745234681534216
5349,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,1.8072156080961577e-05,1,1,2,0.0005528856643536329
5350,Catecholamine biosynthesis,Metabolism of amine-derived hormones,0.0003189008831213869,0,1,2,0.00975620871342911
5351,Catecholamine biosynthesis,Metabolism of amine-derived hormones,0.00016967861057916404,1,1,2,0.005191017104787582
5352,Ethanol oxidation,Phase I - Functionalization of compounds,0.00036245734978971694,0,1,2,0.01108874180482853
5353,Ethanol oxidation,Phase I - Functionalization of compounds,0.0002787206782310629,1,1,2,0.008526966382014393
5354,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.00013569800679154773,0,1,2,0.004151440608431084
5355,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,0.00010568044814741976,1,1,2,0.0032331064717136364
5356,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0005142680203183166,0,1,2,0.01573312087366564
5357,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.0005211137779648804,1,1,2,0.015942554725800844
5358,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.001509352831878156,0,1,2,0.04617598140800196
5359,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.001528799149915964,1,1,2,0.046770907127954765
5360,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0005007119504928899,0,1,2,0.015318396884016672
5361,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0005057798323832685,1,1,2,0.015473439770613885
5362,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.001357760016071552,0,1,2,0.04153826721922474
5363,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.00137162109149358,1,1,2,0.04196232231586244
5364,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.001492645537276379,0,1,2,0.045664851267576356
5365,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0015024721490438727,1,1,2,0.045965479081494995
5366,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0009877966204536884,0,1,2,0.03021989121271202
5367,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0009968552881218784,1,1,2,0.030497025134610924
5368,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.00153840122748079,0,1,2,0.047064665714911455
5369,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0015559564406733746,1,1,2,0.04760173642553224
5370,FOXO-mediated transcription,Generic Transcription Pathway,0.0019118084037472727,0,1,2,0.05848839810188426
5371,FOXO-mediated transcription,Generic Transcription Pathway,0.0019253752315610958,1,1,2,0.05890345121316847
5372,Arachidonic acid metabolism,Fatty acid metabolism,0.000953364312241926,0,1,2,0.02916649561809648
5373,Arachidonic acid metabolism,Fatty acid metabolism,0.0011016350761262098,1,1,2,0.03370257750158258
5374,DAP12 signaling,DAP12 interactions,0.0005060149463436877,0,1,2,0.015480632666559607
5375,DAP12 signaling,DAP12 interactions,0.0006132033671747194,1,1,2,0.018759872896485095
5376,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0005067331068858039,0,1,2,0.015502603518662792
5377,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.00041276069666006755,1,1,2,0.01262768376775923
5378,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,2.0421006935814982e-07,0,1,2,6.247446035712564e-06
5379,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,3.1977522816362127e-07,1,1,2,9.782957754184646e-06
5380,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.001122408626027512,0,1,2,0.034338107533899216
5381,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.001233167067357499,1,1,2,0.037726566229318165
5382,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0008108649490168318,0,1,2,0.02480697953414266
5383,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0008905469143125326,1,1,2,0.02724470838742139
5384,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.00012336283856863398,0,1,2,0.0037740679447994287
5385,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.00013542429099591875,1,1,2,0.004143066757583822
5386,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.001564169251281792,0,1,2,0.04785299284613326
5387,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0017177846009758468,1,1,2,0.05255258288342748
5388,Retinoid cycle disease events,Diseases associated with visual transduction,0.0011506761860194576,0,1,2,0.035202903555789894
5389,Retinoid cycle disease events,Diseases associated with visual transduction,0.0010242293859846542,1,1,2,0.031334487262269624
5390,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0002910779135466631,0,1,2,0.008905014149332938
5391,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0002598946463839032,1,1,2,0.007951017221420064
5392,Mitotic Metaphase and Anaphase,M Phase,0.0010638556072346242,0,1,2,0.03254678144363152
5393,Mitotic Metaphase and Anaphase,M Phase,0.0008701391523194009,1,1,2,0.02662036898945493
5394,Oxidative Stress Induced Senescence,Cellular Senescence,7.200754189122064e-08,0,1,2,2.202943437332314e-06
5395,Oxidative Stress Induced Senescence,Cellular Senescence,8.38165060817649e-06,1,1,2,0.00025642178189040524
5396,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,4.1713414701642173e-07,0,1,2,1.276148174930377e-05
5397,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,4.607704494361542e-05,1,1,2,0.0014096457274370513
5398,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,1.5265010537390822e-06,0,1,2,4.6700600938377175e-05
5399,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,0.00016671956254867836,1,1,2,0.005100490261788873
5400,EPH-Ephrin signaling,Axon guidance,0.0016112795729895878,0,1,2,0.04929424984937303
5401,EPH-Ephrin signaling,Axon guidance,0.002155136118805482,1,1,2,0.0659325793491531
5402,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.0007186210918007418,0,1,2,0.021984941806547628
5403,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.0005621041673293803,1,1,2,0.017196583218825
5404,Processing and activation of SUMO,SUMOylation,4.7769776726151275e-05,0,1,2,0.001461431863632819
5405,Processing and activation of SUMO,SUMOylation,3.7431799410114766e-05,1,1,2,0.001145159724833013
5406,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.0008045637337393903,0,1,2,0.02461420499305879
5407,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.000675489268360252,1,1,2,0.020665399923949525
5408,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0010033884683556002,0,1,2,0.03069689623342622
5409,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0012267932247292872,1,1,2,0.037531569782840106
5410,HSF1 activation,Cellular response to heat stress,0.0004932762904597136,0,1,2,0.015090916011289963
5411,HSF1 activation,Cellular response to heat stress,0.0006048460840247571,1,1,2,0.018504196593897935
5412,HSF1-dependent transactivation,Cellular response to heat stress,0.0001791366186656281,0,1,2,0.005480368140763611
5413,HSF1-dependent transactivation,Cellular response to heat stress,0.00021944965812205434,1,1,2,0.006713674310881333
5414,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.0003322731287577578,0,1,2,0.01016530892700869
5415,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,0.00035957101066135997,1,1,2,0.011000439362143635
5416,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.001712028805953499,0,1,2,0.052376494510764156
5417,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0015789584588674188,1,1,2,0.048305442505410884
5418,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.003300129509564916,0,1,2,0.10096162783094692
5419,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.0028956769687889998,1,1,2,0.08858811740393267
5420,Semaphorin interactions,Axon guidance,0.0002442318882761659,0,1,2,0.007471842828325411
5421,Semaphorin interactions,Axon guidance,0.0003256494873918806,1,1,2,0.009962670329787237
5422,L1CAM interactions,Axon guidance,0.0012098112138119177,0,1,2,0.037012035182427835
5423,L1CAM interactions,Axon guidance,0.0016153132493248754,1,1,2,0.04941765304545168
5424,NCAM signaling for neurite out-growth,Axon guidance,0.0013380908048323667,0,1,2,0.04093652247584322
5425,NCAM signaling for neurite out-growth,Axon guidance,0.0017880903954695289,1,1,2,0.054703464367762314
5426,Signaling by ROBO receptors,Axon guidance,0.00124943254174165,0,1,2,0.03822417966130828
5427,Signaling by ROBO receptors,Axon guidance,0.0016649004754678268,1,1,2,0.05093468656080415
5428,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.00038027148088228083,0,1,2,0.01163373365084134
5429,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.00035063500842322053,1,1,2,0.010727058172208915
5430,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00026542853981178875,0,1,2,0.008120316907115113
5431,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.00024482408252879395,1,1,2,0.0074899599645057244
5432,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,4.685710609161712e-05,0,1,2,0.001433510319139185
5433,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,4.386366758808435e-05,1,1,2,0.0013419313604187597
5434,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.002354356914293021,0,1,2,0.07202738737165698
5435,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.002482022907740126,1,1,2,0.07593310273213509
5436,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0005301122489375606,0,1,2,0.016217847036226286
5437,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0005589251837060752,1,1,2,0.01709932783520246
5438,PERK regulates gene expression,Unfolded Protein Response (UPR),0.0001853136205636948,0,1,2,0.005669342593110447
5439,PERK regulates gene expression,Unfolded Protein Response (UPR),0.00019600649017306181,1,1,2,0.005996472034187468
5440,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0005639871157351687,0,1,2,0.017254188696312806
5441,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0003500157963268672,1,1,2,0.010708114472866435
5442,G alpha (q) signalling events,GPCR downstream signalling,0.003674487148843279,0,1,2,0.11241443795338267
5443,G alpha (q) signalling events,GPCR downstream signalling,0.003147114457048398,1,1,2,0.09628040282449492
5444,G alpha (s) signalling events,GPCR downstream signalling,0.00026906692276800945,0,1,2,0.008231626801126166
5445,G alpha (s) signalling events,GPCR downstream signalling,0.0002307698273322482,1,1,2,0.007059994874201776
5446,G alpha (i) signalling events,GPCR downstream signalling,0.0006496147102931596,0,1,2,0.01987381356520556
5447,G alpha (i) signalling events,GPCR downstream signalling,0.0005574530984707357,1,1,2,0.01705429199002274
5448,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.001141279020945755,0,1,2,0.03491541390422097
5449,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.000938575104434373,1,1,2,0.02871404595202942
5450,Peroxisomal lipid metabolism,Fatty acid metabolism,1.0024150750117163e-05,0,1,2,0.00030667116984995664
5451,Peroxisomal lipid metabolism,Fatty acid metabolism,1.1679694019524807e-05,1,1,2,0.0003573195892345644
5452,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0017276318720784425,0,1,2,0.05285384273317858
5453,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.001899932919332059,1,1,2,0.05812508865164421
5454,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,9.097179717916977e-06,0,1,2,0.000278312129972336
5455,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,1.7154482828374286e-05,1,1,2,0.0005248110736051178
5456,Adherens junctions interactions,Cell-cell junction organization,0.0005850943341404976,0,1,2,0.01789992672659583
5457,Adherens junctions interactions,Cell-cell junction organization,0.0002241436768448087,1,1,2,0.006857279514842163
5458,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,2.2059905874508937e-05,0,1,2,0.0006748838190842765
5459,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,4.334448046089771e-05,1,1,2,0.0013260477481672674
5460,Netrin-1 signaling,Axon guidance,0.0008562752782988052,0,1,2,0.026196228274641874
5461,Netrin-1 signaling,Axon guidance,0.0011433498652574296,1,1,2,0.03497876772475594
5462,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0008160401185326312,0,1,2,0.024965304695958836
5463,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0007339327715271792,1,1,2,0.02245337557726078
5464,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0007689321209909394,0,1,2,0.023524118796471975
5465,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0007369374720534931,1,1,2,0.022545299077657326
5466,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,1.9534616088397647e-05,0,1,2,0.0005976270427027118
5467,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,1.8924697527230214e-05,1,1,2,0.0005789676626385969
5468,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.00012445267466508388,0,1,2,0.0038074095533780004
5469,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",2.1483451007912417e-05,1,1,2,0.0006572482015929107
5470,Glycosphingolipid metabolism,Sphingolipid metabolism,1.4911262165166287e-06,0,1,2,4.5618370335038056e-05
5471,Glycosphingolipid metabolism,Sphingolipid metabolism,6.0606526744777515e-06,1,1,2,0.00018541495355251284
5472,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.00413455463203718,0,1,2,0.1264893892183913
5473,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.003630439414700959,1,1,2,0.11106687540216034
5474,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,5.4313538203132336e-05,0,1,2,0.0016616266768783605
5475,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,2.6996837429275427e-05,1,1,2,0.000825920511679079
5476,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.0002635099115044189,0,1,2,0.00806161986611925
5477,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,0.00011644825287172959,1,1,2,0.003562528420149656
5478,Interleukin-1 family signaling,Signaling by Interleukins,0.0014900736439813044,0,1,2,0.04558616873923144
5479,Interleukin-1 family signaling,Signaling by Interleukins,0.0017116270500404577,1,1,2,0.05236420349889514
5480,Interleukin-12 family signaling,Signaling by Interleukins,0.0015188975663477321,0,1,2,0.046467985684340074
5481,Interleukin-12 family signaling,Signaling by Interleukins,0.0017408102374550556,1,1,2,0.05325701152298443
5482,Other interleukin signaling,Signaling by Interleukins,0.00043189114209477947,0,1,2,0.013212945923872087
5483,Other interleukin signaling,Signaling by Interleukins,0.0004944360774970846,1,1,2,0.015126397645235184
5484,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00016597950633088961,0,1,2,0.005077849550199279
5485,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00019055560567267095,1,1,2,0.00582971185987222
5486,Interleukin-10 signaling,Signaling by Interleukins,0.0006329937188828201,0,1,2,0.019365323718340943
5487,Interleukin-10 signaling,Signaling by Interleukins,0.0007252002915341412,1,1,2,0.022186220790594683
5488,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.004342114803390965,0,1,2,0.13283932570179652
5489,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.004981401382246986,1,1,2,0.15239716834545997
5490,G2/M Transition,Mitotic G2-G2/M phases,0.0013237717784553146,0,1,2,0.04049845717937792
5491,G2/M Transition,Mitotic G2-G2/M phases,0.0011909922295065675,1,1,2,0.036436301628915355
5492,G1/S Transition,Mitotic G1 phase and G1/S transition,0.00025838589700223716,0,1,2,0.00790485970150442
5493,G1/S Transition,Mitotic G1 phase and G1/S transition,0.00024013455419359767,1,1,2,0.007346492136013385
5494,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0009063539202619116,0,1,2,0.027728295788205903
5495,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0007219464025771079,1,1,2,0.022086673810716755
5496,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,4.246487560521928e-05,0,1,2,0.001299137792718577
5497,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,2.874994607585298e-05,1,1,2,0.0008795537712860067
5498,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,7.488205207361413e-05,0,1,2,0.002290883994328618
5499,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,4.931268028940394e-05,1,1,2,0.0015086342703506978
5500,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.00042142423017139664,0,1,2,0.012892729258712422
5501,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0002784755660286464,1,1,2,0.008519467607531308
5502,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,7.360660932439107e-05,0,1,2,0.002251864078354558
5503,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,8.388419598001443e-05,1,1,2,0.0025662886716676108
5504,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,9.511850538880632e-05,0,1,2,0.002909982506161302
5505,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.00010788358597437763,1,1,2,0.0033005075784583613
5506,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.00046414720830701605,0,1,2,0.014199763242032294
5507,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,0.0004590447051062559,1,1,2,0.014043661177653226
5508,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.00561165441643728,0,1,2,0.1716786456610683
5509,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.0061645226853822045,1,1,2,0.188592672897568
5510,RA biosynthesis pathway,Signaling by Retinoic Acid,0.0006872126911427282,0,1,2,0.021024057317375656
5511,RA biosynthesis pathway,Signaling by Retinoic Acid,0.0006318496992510821,1,1,2,0.019330324460294836
5512,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0006017881248832661,0,1,2,0.01841064374032942
5513,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0005830656798328467,1,1,2,0.017837863634643507
5514,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,7.497904643969378e-05,0,1,2,0.002293851365476159
5515,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,7.441494741821468e-05,1,1,2,0.002276593753221456
5516,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,2.586385495912206e-05,0,1,2,0.000791258916078338
5517,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,2.6552540566626705e-05,1,1,2,0.0008123280346677416
5518,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.00022733182698478533,0,1,2,0.0069548153318361875
5519,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.0002243087194074178,1,1,2,0.006862328700255678
5520,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.002365063216211638,0,1,2,0.07235492775048767
5521,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0021729968755607844,1,1,2,0.06647899762488484
5522,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.004257024708203971,0,1,2,0.1302361446758792
5523,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.003910362757839418,1,1,2,0.11963063519074678
5524,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.000576639181781502,0,1,2,0.01764125628858765
5525,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.0005626786748507584,1,1,2,0.017214159260732248
5526,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.0008055333689753752,0,1,2,0.024643869268822373
5527,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.0005446399043876227,1,1,2,0.016662294970331386
5528,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,7.617142037664356e-05,0,1,2,0.0023303299380014885
5529,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,5.154884876787946e-05,1,1,2,0.001577045891481562
5530,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,1.5482722479494745e-06,0,1,2,4.7366652134529985e-05
5531,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,1.0394189742394625e-06,1,1,2,3.1799185860261756e-05
5532,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.0004459687307947509,0,1,2,0.013643624861460521
5533,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.00045745305960736004,1,1,2,0.01399496759758839
5534,Defective ABCA1 causes TGD,ABC transporter disorders,0.0009677399260302385,0,1,2,0.02960629210636472
5535,Defective ABCA1 causes TGD,ABC transporter disorders,0.0009938191851688316,1,1,2,0.03040414093248688
5536,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.00035112065360228445,0,1,2,0.010741915627858591
5537,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,0.0003188102110016189,1,1,2,0.009753434760229962
5538,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,1.5619753132038264e-05,0,1,2,0.0004778587318944412
5539,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,1.4195949969083207e-05,1,1,2,0.0004342999913583023
5540,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,7.012337348832887e-06,0,1,2,0.00021453006361900435
5541,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,6.367266381938445e-06,1,1,2,0.00019479525784990223
5542,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,0.00032509524486764956,0,1,2,0.009945714259639894
5543,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,0.0002967496099396764,1,1,2,0.009078529673115223
5544,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.0009129862339856724,0,1,2,0.027931199700884375
5545,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.000891920697176829,1,1,2,0.027286736845354216
5546,Fructose biosynthesis,Fructose metabolism,0.00043435971322954475,0,1,2,0.013288467493392322
5547,Fructose biosynthesis,Fructose metabolism,0.0005496081403786472,1,1,2,0.01681428936680835
5548,Fructose catabolism,Fructose metabolism,0.0015734675330653165,0,1,2,0.04813745733826141
5549,Fructose catabolism,Fructose metabolism,0.00198672872405344,1,1,2,0.06078045284513094
5550,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.0006415213600424371,0,1,2,0.01962621182304645
5551,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.00043246082420864693,1,1,2,0.013230374340967698
5552,Essential pentosuria,Diseases of carbohydrate metabolism,0.0001139319493934939,0,1,2,0.003485546563970066
5553,Essential pentosuria,Diseases of carbohydrate metabolism,7.718569971378504e-05,1,1,2,0.002361360021110742
5554,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,3.181568199579487e-05,0,1,2,0.0009733445416421514
5555,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,2.1473216861522815e-05,1,1,2,0.0006569351059777356
5556,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0002725023229686485,0,1,2,0.008336726796596649
5557,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0002582458073751089,1,1,2,0.00790057390703602
5558,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0005441178532502515,0,1,2,0.016646323738751766
5559,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0004961980938939329,1,1,2,0.015180303421713054
5560,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.00012249372139194747,0,1,2,0.0037474788413476446
5561,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,8.619318311199701e-05,1,1,2,0.0026369280507616767
5562,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,8.297474687424256e-05,0,1,2,0.0025384656841509075
5563,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,5.838540603993655e-05,1,1,2,0.0017861982744246728
5564,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.0001456643807614455,0,1,2,0.004456344199837567
5565,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.0001024971459628432,1,1,2,0.0031357189693440608
5566,UCH proteinases,Deubiquitination,0.0009165629156967725,0,1,2,0.02804062195438662
5567,UCH proteinases,Deubiquitination,0.0008295193472484641,1,1,2,0.02537767786771219
5568,Ub-specific processing proteases,Deubiquitination,0.0007463524801551103,0,1,2,0.02283333460511944
5569,Ub-specific processing proteases,Deubiquitination,0.0006739633525588337,1,1,2,0.020618717227771196
5570,Metalloprotease DUBs,Deubiquitination,0.0007136949803680182,0,1,2,0.021834236136457127
5571,Metalloprotease DUBs,Deubiquitination,0.0006444755010306836,1,1,2,0.019716588543763333
5572,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.0001388718838446342,0,1,2,0.004248539765566025
5573,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,3.796140435004721e-05,1,1,2,0.0011613620516471325
5574,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,8.164617017124935e-05,0,1,2,0.0024978202288002327
5575,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,2.4750958459662797e-05,1,1,2,0.0007572118152396854
5576,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.0012285658391192555,0,1,2,0.037585799786180596
5577,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.0019588613087156165,1,1,2,0.059927898541491297
5578,Signaling by RAS mutants,Oncogenic MAPK signaling,0.001065750875204685,0,1,2,0.03260476381640767
5579,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0008650655501090417,1,1,2,0.026465151099781235
5580,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0002931820889746935,0,1,2,0.008969387676444555
5581,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,0.00023810464120591253,1,1,2,0.007284390536970719
5582,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0004152980052822386,0,1,2,0.01270530823918116
5583,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,0.0003372887000902362,1,1,2,0.010318751464570198
5584,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.00039299605438524544,0,1,2,0.01202301948056116
5585,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0003195005848397159,1,1,2,0.009774555527249606
5586,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.001585013644034916,0,1,2,0.048490690190253684
5587,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0012893300132418516,1,1,2,0.039444772264515
5588,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00017344057572093636,0,1,2,0.00530610777727658
5589,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.00014070773113796046,1,1,2,0.004304704267791179
5590,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00013393159309392407,0,1,2,0.004097400304310269
5591,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00010920306291761032,1,1,2,0.0033408746427472224
5592,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0019105875691214655,0,1,2,0.05845104882490085
5593,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.0020863239875325234,1,1,2,0.06382739385031168
5594,MET Receptor Activation,Signaling by MET,0.003180120723360839,0,1,2,0.0972901711883932
5595,MET Receptor Activation,Signaling by MET,0.002820277524369885,1,1,2,0.08628140470552513
5596,MET promotes cell motility,Signaling by MET,0.002629317995767148,0,1,2,0.08043933553772922
5597,MET promotes cell motility,Signaling by MET,0.0023303572026634354,1,1,2,0.07129315862500524
5598,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0005902935702276106,0,1,2,0.01805898816261248
5599,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0005546143186317446,1,1,2,0.01696744453971283
5600,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.00013936157984062447,0,1,2,0.004263521148797859
5601,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.00012802341831654,1,1,2,0.003916650142443718
5602,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.00021042105295994892,0,1,2,0.006437460098206622
5603,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,2.7897209281491087e-05,1,1,2,0.0008534657966714982
5604,Mitotic Prophase,M Phase,0.00022833186073209315,0,1,2,0.006985409596310187
5605,Mitotic Prophase,M Phase,0.00018535682756919413,1,1,2,0.005670664435055216
5606,Mitotic Prometaphase,M Phase,0.0005873943639320108,0,1,2,0.017970292071694503
5607,Mitotic Prometaphase,M Phase,0.0004786313775487846,1,1,2,0.014642880792476753
5608,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.00048194114749549043,0,1,2,0.01474413735243807
5609,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.0007167134016223524,1,1,2,0.021926579398269686
5610,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.00018686756969448954,0,1,2,0.0057168829194390956
5611,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.00028037887883935276,1,1,2,0.00857769609798402
5612,Cyclin A:Cdk2-associated events at S phase entry,S Phase,0.000318121847067232,0,1,2,0.009732375482660888
5613,Cyclin A:Cdk2-associated events at S phase entry,S Phase,0.00034247971040410146,1,1,2,0.010477561247597219
5614,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.0003962316754117031,0,1,2,0.012122007585400194
5615,Ubiquitin-dependent degradation of Cyclin D,S Phase,0.0004211886336785634,1,1,2,0.012885521600540593
5616,G2/M DNA damage checkpoint,G2/M Checkpoints,0.00047614108316338386,0,1,2,0.014566694638509277
5617,G2/M DNA damage checkpoint,G2/M Checkpoints,0.0005174682662679212,1,1,2,0.015831026740570263
5618,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00045891685731476174,0,1,2,0.01403974990050291
5619,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0004564289277671681,1,1,2,0.013963636094567192
5620,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00042728842430127164,0,1,2,0.013072133910424685
5621,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00042447288997209397,1,1,2,0.012985997615390262
5622,Glycolysis,Glucose metabolism,7.271630819142653e-05,0,1,2,0.002224626889212946
5623,Glycolysis,Glucose metabolism,0.00010070430816995213,1,1,2,0.00308087026674542
5624,Gluconeogenesis,Glucose metabolism,0.0010185120831010864,0,1,2,0.03115957648853951
5625,Gluconeogenesis,Glucose metabolism,0.0014128515756359169,1,1,2,0.043223696084135295
5626,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0010557505035346064,0,1,2,0.03229882012547091
5627,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0009607054669080147,1,1,2,0.029391085266199348
5628,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.00018752402065729256,0,1,2,0.005736965876063585
5629,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.0001747025856578451,1,1,2,0.005344716740106629
5630,mRNA Splicing - Major Pathway,mRNA Splicing,3.565374010274051e-05,0,1,2,0.0010907631438709109
5631,mRNA Splicing - Major Pathway,mRNA Splicing,3.0016420039302715e-06,1,1,2,9.182993031158331e-05
5632,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.00013197187435404583,0,1,2,0.004037446174178265
5633,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,5.646135713656501e-05,1,1,2,0.0017273353998775618
5634,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,1.504540183532299e-05,0,1,2,0.00046028746940455356
5635,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,6.451069506378341e-06,1,1,2,0.00019735906628113158
5636,Depurination,"Base-Excision Repair, AP Site Formation",0.00018596413109056204,0,1,2,0.005689243812599964
5637,Depurination,"Base-Excision Repair, AP Site Formation",6.949359534094887e-05,1,1,2,0.0021260336871968123
5638,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.00034626665631852424,0,1,2,0.010593416162660319
5639,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.00012833572691306472,1,1,2,0.003926204671803656
5640,Utilization of Ketone Bodies,Ketone body metabolism,0.00010684921529294419,0,1,2,0.0032688628361912937
5641,Utilization of Ketone Bodies,Ketone body metabolism,8.210656211910342e-05,1,1,2,0.0025119051064878767
5642,Synthesis of Ketone Bodies,Ketone body metabolism,1.0553425421259513e-06,0,1,2,3.2286339267434684e-05
5643,Synthesis of Ketone Bodies,Ketone body metabolism,8.109655046458405e-07,1,1,2,2.4810055855833327e-05
5644,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.016072073357645423,0,1,2,0.4916966695104654
5645,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.018719014583621175,1,1,2,0.5726751566191689
5646,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.00012456292198190038,0,1,2,0.0038107823751225797
5647,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.00016004553927094397,1,1,2,0.004896310319047616
5648,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,1.0899028535978534e-06,0,1,2,3.3343650895488884e-05
5649,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,8.454899928741118e-06,1,1,2,0.0002586627153508289
5650,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0028535783198397743,0,1,2,0.08730018366827823
5651,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0031892009507525168,1,1,2,0.09756796469191537
5652,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0006730779282709894,0,1,2,0.020591629237083943
5653,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.00046878865202112745,1,1,2,0.014341760006554478
5654,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.00016489029173195983,0,1,2,0.005044526955238549
5655,Extra-nuclear estrogen signaling,ESR-mediated signaling,9.675536342304744e-05,1,1,2,0.0029600592838108356
5656,Estrogen-dependent gene expression,ESR-mediated signaling,4.0762304145876745e-05,0,1,2,0.001247050629007116
5657,Estrogen-dependent gene expression,ESR-mediated signaling,2.383334351634403e-05,1,1,2,0.000729139008360152
5658,Pyrimidine catabolism,Nucleotide catabolism,0.00032358879858899553,0,1,2,0.009899627199089099
5659,Pyrimidine catabolism,Nucleotide catabolism,0.00035054693362326363,1,1,2,0.010724363679417417
5660,Pyrimidine salvage,Nucleotide salvage,0.00021808321738111167,0,1,2,0.006671870472231897
5661,Pyrimidine salvage,Nucleotide salvage,0.0002163516657068006,1,1,2,0.006618896710079485
5662,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.00037910852926001935,0,1,2,0.011598155202016269
5663,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.00037959582635428056,1,1,2,0.011613063195090876
5664,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.0006650510029430734,0,1,2,0.020346059648001152
5665,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.0007460247310518753,1,1,2,0.022823307700754983
5666,VLDL assembly,Plasma lipoprotein assembly,0.001181594450342042,0,1,2,0.03614879319032341
5667,VLDL assembly,Plasma lipoprotein assembly,0.0011455647211429702,1,1,2,0.03504652732478588
5668,Chylomicron assembly,Plasma lipoprotein assembly,0.003915702953721242,0,1,2,0.1197940090424706
5669,Chylomicron assembly,Plasma lipoprotein assembly,0.003786610215320252,1,1,2,0.11584464494256386
5670,HDL assembly,Plasma lipoprotein assembly,0.0018416157883772637,0,1,2,0.05634097913274145
5671,HDL assembly,Plasma lipoprotein assembly,0.0017749035164873325,1,1,2,0.0543000351192454
5672,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.001836847163819281,0,1,2,0.05619509149515233
5673,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.001952031390586247,1,1,2,0.059718949271380946
5674,Chylomicron remodeling,Plasma lipoprotein remodeling,0.005337132002023281,0,1,2,0.16328011773815257
5675,Chylomicron remodeling,Plasma lipoprotein remodeling,0.005661572363169398,1,1,2,0.1732057969881438
5676,LDL remodeling,Plasma lipoprotein remodeling,0.00071834183302902,0,1,2,0.021976398378146595
5677,LDL remodeling,Plasma lipoprotein remodeling,0.0007640133511207144,1,1,2,0.023373637728506494
5678,HDL remodeling,Plasma lipoprotein remodeling,0.0009228425289620646,0,1,2,0.028232735620100386
5679,HDL remodeling,Plasma lipoprotein remodeling,0.0009814354353087158,1,1,2,0.030025281999555672
5680,HDL clearance,Plasma lipoprotein clearance,0.0007162758988973413,0,1,2,0.021913194775887573
5681,HDL clearance,Plasma lipoprotein clearance,0.0007276317452730533,1,1,2,0.022260606819011056
5682,Chylomicron clearance,Plasma lipoprotein clearance,0.001234192793405479,0,1,2,0.03775794650430813
5683,Chylomicron clearance,Plasma lipoprotein clearance,0.0012515363965576397,1,1,2,0.038288543379861345
5684,LDL clearance,Plasma lipoprotein clearance,0.0012461883923000035,0,1,2,0.03812493064468448
5685,LDL clearance,Plasma lipoprotein clearance,0.0012640988759812899,1,1,2,0.038672870227801234
5686,VLDL clearance,Plasma lipoprotein clearance,0.0022892195423385906,0,1,2,0.07003462463731927
5687,VLDL clearance,Plasma lipoprotein clearance,0.002321577238641718,1,1,2,0.07102455114843183
5688,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,0.0008126123119533683,0,1,2,0.0248604370139091
5689,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,0.0009423637229095523,1,1,2,0.02882995203613184
5690,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,8.377518306209215e-06,0,1,2,0.00025629536141748256
5691,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,1.288930364656456e-05,1,1,2,0.00039432545722609623
5692,NADPH regeneration,Metabolism of cofactors,0.00027453848876272485,0,1,2,0.008399019689196109
5693,NADPH regeneration,Metabolism of cofactors,0.00042271500581894845,1,1,2,0.012932218257602818
5694,Triglyceride catabolism,Triglyceride metabolism,0.0007247932330452993,0,1,2,0.022173767555793814
5695,Triglyceride catabolism,Triglyceride metabolism,0.0007374309958928885,1,1,2,0.022560397566990645
5696,Glycogen synthesis,Glycogen metabolism,0.00029116207828489373,0,1,2,0.008907589020698775
5697,Glycogen synthesis,Glycogen metabolism,0.0004389579764544275,1,1,2,0.01342914322718816
5698,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.000247044568398754,0,1,2,0.007557891803955364
5699,Glycogen breakdown (glycogenolysis),Glycogen metabolism,0.00037649491714546456,1,1,2,0.01151819636014678
5700,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,6.061540805527935e-06,0,1,2,0.00018544212435180844
5701,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,2.2955685778924817e-06,1,1,2,7.022886215521654e-05
5702,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.00011733051602883886,0,1,2,0.0035895197016308383
5703,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,9.031087978428332e-05,1,1,2,0.0027629017005057765
5704,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.0004271482071696179,0,1,2,0.013067844215180752
5705,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,0.0003274245290413091,1,1,2,0.010016974590839604
5706,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.00022859996966341593,0,1,2,0.006993611915056742
5707,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.0001760489864257882,1,1,2,0.005385907491212119
5708,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0003549785258655902,0,1,2,0.01085994040917045
5709,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00030031167043489406,1,1,2,0.009187504616367343
5710,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00012655061782425038,0,1,2,0.0038715924152421624
5711,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00010706185351712823,1,1,2,0.0032753681267232194
5712,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0019079884781604052,0,1,2,0.058371534232049625
5713,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.001464705023939435,1,1,2,0.04481006065988834
5714,Interferon gamma signaling,Interferon Signaling,0.0007522344119327803,0,1,2,0.02301328190880645
5715,Interferon gamma signaling,Interferon Signaling,0.0009584202746433827,1,1,2,0.029321173849003374
5716,Interferon alpha/beta signaling,Interferon Signaling,0.00013551246725000964,0,1,2,0.004145764354185183
5717,Interferon alpha/beta signaling,Interferon Signaling,0.00017268606591945476,1,1,2,0.005283024883847337
5718,HCMV Early Events,HCMV Infection,0.00046466766725643537,0,1,2,0.014215685763436457
5719,HCMV Early Events,HCMV Infection,0.0004100884317646584,1,1,2,0.012545930547755579
5720,HCMV Late Events,HCMV Infection,0.000448711343781838,0,1,2,0.013727530256956078
5721,HCMV Late Events,HCMV Infection,0.00039678995315739485,1,1,2,0.012139087106013996
5722,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0009402181322911929,0,1,2,0.02876431148449272
5723,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.0009121716964121636,1,1,2,0.027906280363896977
5724,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.00042944378374916897,0,1,2,0.013138073322132567
5725,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0004178185627779385,1,1,2,0.012782420239504112
5726,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001063015471769783,0,1,2,0.03252107898441498
5727,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.000930275305449868,1,1,2,0.02846012827585442
5728,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0005098654819448711,0,1,2,0.015598432995664796
5729,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0004468512636321975,1,1,2,0.013670624393334838
5730,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0008144841570507803,0,1,2,0.02491770280530739
5731,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0007120619966978363,1,1,2,0.021784277888126244
5732,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0009568564017475486,0,1,2,0.029273329922628218
5733,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0008375536811096632,1,1,2,0.025623474107772756
5734,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0010759352474754753,0,1,2,0.03291633668041655
5735,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0009406175568680435,1,1,2,0.028776531173252705
5736,Parasite infection,Leishmania infection,0.006135158010632343,0,1,2,0.18769431258931962
5737,Parasite infection,Leishmania infection,0.005592431277182186,1,1,2,0.1710905477014003
5738,Cell recruitment (pro-inflammatory response),Leishmania infection,2.3587152701765034e-05,0,1,2,0.0007216072356449053
5739,Cell recruitment (pro-inflammatory response),Leishmania infection,2.1578033846481047e-05,1,1,2,0.0006601417963197489
5740,Leishmania parasite growth and survival,Leishmania infection,0.003918611283249144,0,1,2,0.11988298424255134
5741,Leishmania parasite growth and survival,Leishmania infection,0.00357745562502411,1,1,2,0.10944593003049446
5742,Lipophagy,Selective autophagy,0.00010912020140191695,0,1,2,0.0033383396411708613
5743,Lipophagy,Selective autophagy,9.30848724237876e-05,1,1,2,0.002847767100988905
5744,Aggrephagy,Selective autophagy,0.0008414324975698644,0,1,2,0.025742139639760016
5745,Aggrephagy,Selective autophagy,0.0007187246361960812,1,1,2,0.021988109564260148
5746,SARS-CoV-1 Infection,SARS-CoV Infections,0.0007832348406736856,0,1,2,0.023961685218454657
5747,SARS-CoV-1 Infection,SARS-CoV Infections,0.0007302450978386333,1,1,2,0.022340557720438536
5748,Potential therapeutics for SARS,SARS-CoV Infections,0.008841506875190438,0,1,2,0.2704902713698111
5749,Potential therapeutics for SARS,SARS-CoV Infections,0.00822930465740986,1,1,2,0.2517610268690424
5750,SARS-CoV-2 Infection,SARS-CoV Infections,0.0026035448019683825,0,1,2,0.07965085023956622
5751,SARS-CoV-2 Infection,SARS-CoV Infections,0.002419323246370671,1,1,2,0.07401491744335717
5752,ALK mutants bind TKIs,Signaling by ALK in cancer,0.00023752465306946154,0,1,2,0.007266646825334853
5753,ALK mutants bind TKIs,Signaling by ALK in cancer,0.000206811671516031,1,1,2,0.00632703745419081
5754,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.0005301081080688163,0,1,2,0.016217720353667968
5755,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.0004597402693737725,1,1,2,0.014064940736684463
5756,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,7.483025922473037e-05,0,1,2,0.0022892994836849747
5757,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,8.219049966934714e-05,1,1,2,0.002514473027438914
5758,Cytoprotection by HMOX1,Cellular response to chemical stress,0.002045435529119762,0,1,2,0.06257648375454557
5759,Cytoprotection by HMOX1,Cellular response to chemical stress,0.002243671112713249,1,1,2,0.06864115096097131
5760,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0006879849966177668,0,1,2,0.021047684637975243
5761,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0007550127288141085,1,1,2,0.023098279601823073
5762,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0008348508875011854,0,1,2,0.02554078691576647
5763,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,0.0008064989287959179,1,1,2,0.0246734088644557
5764,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.0033840106809899834,0,1,2,0.10352782397170324
5765,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.003270844014817461,1,1,2,0.10006568989488468
5766,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.005208665161626413,0,1,2,0.15934990188111603
5767,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0048457587487064305,1,1,2,0.14824742178374503
5768,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.003138667060621477,0,1,2,0.09602196966551634
5769,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.002920669796628772,1,1,2,0.08935272878524014
5770,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0024903500633323954,0,1,2,0.07618785733535911
5771,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0026965041244693564,1,1,2,0.08249477636263455
5772,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0015141860661363655,0,1,2,0.04632384566514182
5773,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0014607517743267333,1,1,2,0.044689117977195554
5774,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.0011925847304155468,0,1,2,0.036485021378739366
5775,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.0017379999387533947,1,1,2,0.053171035402717476
5776,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.00037466446957902614,0,1,2,0.01146219705301923
5777,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0004374058994168687,1,1,2,0.013381660174242268
5778,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0003187162201963171,0,1,2,0.009750559277714229
5779,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0003280552821706806,1,1,2,0.01003627136768313
5780,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0006209149895463876,0,1,2,0.01899579634906615
5781,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0007610680277290764,1,1,2,0.023283530766568642
5782,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006477176182427987,0,1,2,0.19815775387917528
5783,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005738960666591689,1,1,2,0.17557335531152
5784,MHC class II antigen presentation,MHC class II antigen presentation,0.0010198823184812986,0,1,2,0.031201496417468607
5785,MHC class II antigen presentation,MHC class II antigen presentation,0.0008813714282344639,1,1,2,0.02696400061280313
5786,Rap1 signalling,Rap1 signalling,0.0006708334849615009,0,1,2,0.02052296446212785
5787,Rap1 signalling,Rap1 signalling,0.0005908869156579992,1,1,2,0.018077140517041138
5788,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0034141606734010566,0,1,2,0.10445020968538209
5789,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.0034701353739668168,1,1,2,0.10616265668786777
5790,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.005015182122709423,0,1,2,0.15343063037673405
5791,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.005094450393759568,1,1,2,0.15585570298596702
5792,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.003519196828407682,0,1,2,0.10766360514754097
5793,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.0035803501484679146,1,1,2,0.10953448285784088
5794,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0026370657342340564,0,1,2,0.08067636389839215
5795,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.002674691710732683,1,1,2,0.08182746412794985
5796,Collagen degradation,Collagen degradation,0.0020344920682873633,0,1,2,0.06224168791803647
5797,Collagen degradation,Collagen degradation,0.0018135767539206426,1,1,2,0.055483174445578834
5798,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.004829296523045438,0,1,2,0.14774378909428937
5799,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0042443413275274604,1,1,2,0.1298481190678573
5800,Fibronectin matrix formation,Fibronectin matrix formation,0.0006881418618831959,0,1,2,0.021052483653438713
5801,Fibronectin matrix formation,Fibronectin matrix formation,0.00047336046057656255,1,1,2,0.0144816264065095
5802,Integrin cell surface interactions,Integrin cell surface interactions,0.010382758180397408,0,1,2,0.3176421301739166
5803,Integrin cell surface interactions,Integrin cell surface interactions,0.008958671374421101,1,1,2,0.27407471208101364
5804,Laminin interactions,Laminin interactions,0.0009209550108759383,0,1,2,0.02817499034132168
5805,Laminin interactions,Laminin interactions,0.0007912286412344353,1,1,2,0.024206241413849434
5806,ECM proteoglycans,ECM proteoglycans,0.003889768374938285,0,1,2,0.1190005864560393
5807,ECM proteoglycans,ECM proteoglycans,0.0037426070787963304,1,1,2,0.11449844677662939
5808,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.000595516253194243,0,1,2,0.018218766914454763
5809,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0008754301070590979,1,1,2,0.026782236395492
5810,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0005950405510096365,0,1,2,0.018204213647141646
5811,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0007178019900493382,1,1,2,0.021959882836606843
5812,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0006948050853679888,0,1,2,0.021256333195608584
5813,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0007056975271552801,1,1,2,0.02158956819463253
5814,Meiotic synapsis,Meiotic synapsis,0.0005657556803726038,0,1,2,0.017308294804634364
5815,Meiotic synapsis,Meiotic synapsis,0.0004492964242748106,1,1,2,0.013745429760236613
5816,Meiotic recombination,Meiotic recombination,0.0004911408822711867,0,1,2,0.015025586973089389
5817,Meiotic recombination,Meiotic recombination,0.0006319474804816612,1,1,2,0.019333315904170586
5818,Nephrin family interactions,Nephrin family interactions,6.74342442531876e-05,0,1,2,0.002063031481527854
5819,Nephrin family interactions,Nephrin family interactions,7.524193855109236e-05,1,1,2,0.0023018940848402894
5820,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0038206364941288486,0,1,2,0.11688561878543541
5821,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0033209913917138087,1,1,2,0.10159986023221025
5822,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.0002830020018639819,0,1,2,0.008657945909332275
5823,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,0.00045035735480875396,1,1,2,0.013777887054234328
5824,Cristae formation,Cristae formation,2.918684691242864e-05,0,1,2,0.0008929199799555558
5825,Cristae formation,Cristae formation,1.3816633478806276e-05,1,1,2,0.0004226954739566414
5826,Signaling by Hippo,Signaling by Hippo,2.8824724525596444e-05,0,1,2,0.0008818414857502098
5827,Signaling by Hippo,Signaling by Hippo,3.236722596700048e-06,1,1,2,9.90218054330629e-05
5828,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0004537651049152676,0,1,2,0.01388214114395945
5829,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.00039909838061854923,1,1,2,0.012209709362968552
5830,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0013034737627701058,0,1,2,0.0398774752756747
5831,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0015114342003168227,1,1,2,0.04623965719559596
5832,mTORC1-mediated signalling,mTORC1-mediated signalling,3.2111691371028425e-05,0,1,2,0.0009824004251431419
5833,mTORC1-mediated signalling,mTORC1-mediated signalling,2.882530549565369e-05,1,1,2,0.0008818592595019763
5834,Neutrophil degranulation,Neutrophil degranulation,0.01357207194281121,0,1,2,0.415213546139162
5835,Neutrophil degranulation,Neutrophil degranulation,0.013371252504293807,1,1,2,0.4090698304595047
5836,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0015209026078082388,0,1,2,0.04652932638298071
5837,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,0.0014775751721269141,1,1,2,0.0452038000897099
5838,Heme biosynthesis,Heme biosynthesis,0.00010942970683984754,0,1,2,0.0033478084128494984
5839,Heme biosynthesis,Heme biosynthesis,0.0001444790777441085,1,1,2,0.00442008194959665
5840,Heme degradation,Heme degradation,0.0012061191769741223,0,1,2,0.03689908384276821
5841,Heme degradation,Heme degradation,0.0012737250728605432,1,1,2,0.038967366702540716
5842,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,7.510995104288061e-05,0,1,2,0.002297856160375875
5843,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.00013330128742078767,1,1,2,0.004078117216599168
5844,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002709782150486717,0,1,2,0.08290099409354751
5845,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0031250065466641294,1,1,2,0.09560405039230485
5846,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.00022526521327866553,0,1,2,0.006891590939198606
5847,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.000301950167825756,1,1,2,0.009237631547234365
5848,eNOS activation,eNOS activation,0.00037768383687459086,0,1,2,0.011554569257290669
5849,eNOS activation,eNOS activation,0.0004554409815076118,1,1,2,0.01393341162541069
5850,PECAM1 interactions,PECAM1 interactions,0.00021461852217422953,0,1,2,0.006565874247837958
5851,PECAM1 interactions,PECAM1 interactions,8.501086067553842e-05,1,1,2,0.002600756986123172
5852,Basigin interactions,Basigin interactions,0.0005320697608112823,0,1,2,0.016277733651189893
5853,Basigin interactions,Basigin interactions,0.0005100697667027513,1,1,2,0.015604682726663797
5854,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,8.387551581752935e-06,0,1,2,0.0002566023117442605
5855,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,5.281551410689645e-05,1,1,2,0.001615797278108523
5856,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,9.457580505719912e-05,0,1,2,0.0028933795489910906
5857,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,2.075562136951703e-05,1,1,2,0.00063498154058369
5858,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",2.921501475915041e-05,0,1,2,0.000893781725426235
5859,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",6.5832595926925325e-06,1,1,2,0.00020140318826443937
5860,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0005700378591427579,0,1,2,0.017439300493364104
5861,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0005933515863337864,1,1,2,0.018152542758914814
5862,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.00023327737059541202,0,1,2,0.007136708727088998
5863,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.00014023129336161825,1,1,2,0.004290128496349408
5864,DNA methylation,DNA methylation,1.2307957263146818e-05,0,1,2,0.0003765401924256166
5865,DNA methylation,DNA methylation,5.555828420256148e-05,1,1,2,0.0016997074800632614
5866,Abacavir metabolism,Abacavir metabolism,0.0015198020778674011,0,1,2,0.04649565761513944
5867,Abacavir metabolism,Abacavir metabolism,0.0013935451201784114,1,1,2,0.042633049212554675
5868,Scavenging of heme from plasma,Scavenging of heme from plasma,0.011271178642831121,0,1,2,0.34482178352559856
5869,Scavenging of heme from plasma,Scavenging of heme from plasma,0.012387699705626195,1,1,2,0.3789797714714083
5870,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.002253371060620187,0,1,2,0.06893790371801356
5871,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.002386128533722361,1,1,2,0.07299938389697953
5872,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.004055858646946338,0,1,2,0.12408182468630155
5873,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.004360633307078388,1,1,2,0.13340586658204281
5874,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.005953949205960877,0,1,2,0.18215054958126017
5875,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0065942238563972445,1,1,2,0.20173862052804814
5876,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.000871089770165175,0,1,2,0.026649451461787103
5877,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0009212265962560195,1,1,2,0.028183299015871757
5878,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.0003925578786947881,0,1,2,0.012009614269990997
5879,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.00048593255730035404,1,1,2,0.014866247478744161
5880,Retinoid metabolism and transport,Retinoid metabolism and transport,0.01034333282186708,0,1,2,0.31643598103234394
5881,Retinoid metabolism and transport,Retinoid metabolism and transport,0.011740391414059559,1,1,2,0.35917651870947265
5882,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.01034333282186708,0,1,2,0.31643598103234394
5883,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.011740391414059559,1,1,2,0.35917651870947265
5884,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0008509076879771981,0,1,2,0.026032016338465306
5885,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0007946542334228942,1,1,2,0.024311041350527487
5886,Heme signaling,Heme signaling,0.003965015155578537,0,1,2,0.12130262867603678
5887,Heme signaling,Heme signaling,0.00405468815582329,1,1,2,0.12404601557977947
5888,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.005415312549060521,0,1,2,0.16567191335426898
5889,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.004858848559767163,1,1,2,0.14864788141081745
5890,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",0.00010865304872519725,0,1,2,0.0033240479309363065
5891,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",9.335413439354549e-05,1,1,2,0.0028560046949078505
5892,Syndecan interactions,Syndecan interactions,0.002093802864108814,0,1,2,0.06405619685676962
5893,Syndecan interactions,Syndecan interactions,0.0019456164285202248,1,1,2,0.0595226948484008
5894,HDACs deacetylate histones,HDACs deacetylate histones,2.7269320692842788e-05,0,1,2,0.0008342566553869897
5895,HDACs deacetylate histones,HDACs deacetylate histones,4.70791573240111e-06,1,1,2,0.00014403035840154226
5896,PKMTs methylate histone lysines,PKMTs methylate histone lysines,4.4814024537724136e-05,0,1,2,0.001371005851094956
5897,PKMTs methylate histone lysines,PKMTs methylate histone lysines,5.611195711026084e-05,1,1,2,0.00171664612379988
5898,HDMs demethylate histones,HDMs demethylate histones,7.8347383896471e-05,0,1,2,0.002396899694862788
5899,HDMs demethylate histones,HDMs demethylate histones,8.02236135844699e-06,1,1,2,0.0002454299625058283
5900,HATs acetylate histones,HATs acetylate histones,0.0007970245517791833,0,1,2,0.024383557049997742
5901,HATs acetylate histones,HATs acetylate histones,0.0006501722399434584,1,1,2,0.01989087019916342
5902,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0005417523881381688,0,1,2,0.01657395651570764
5903,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0006158911851040709,1,1,2,0.01884210193406499
5904,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00023270490744380367,0,1,2,0.007119195229060482
5905,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00013244230071146983,1,1,2,0.004051838036886215
5906,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.0002081225052431061,0,1,2,0.006367140094562234
5907,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,4.6819329228320326e-05,1,1,2,0.0014323546027947998
5908,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0007635337474008945,0,1,2,0.0233589651006213
5909,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.000931105582640157,1,1,2,0.02848552913859012
5910,Intracellular oxygen transport,Intracellular oxygen transport,0.00014437439288788784,0,1,2,0.004416879301499763
5911,Intracellular oxygen transport,Intracellular oxygen transport,0.00010026196944939632,1,1,2,0.0030673376956294883
5912,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.001712655471783364,0,1,2,0.05239566624390549
5913,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0016209453788178507,1,1,2,0.04958995808988022
5914,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0009037285145799008,0,1,2,0.027647976142990714
5915,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0007805301883005692,1,1,2,0.02387894116083049
5916,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009244357123194883,0,1,2,0.28281476248228
5917,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00866013924824074,1,1,2,0.26494164947494137
5918,Surfactant metabolism,Surfactant metabolism,0.0007359971040083716,0,1,2,0.022516530179854832
5919,Surfactant metabolism,Surfactant metabolism,0.000884546776554392,1,1,2,0.027061144780745946
5920,Amyloid fiber formation,Amyloid fiber formation,0.0067988559720106425,0,1,2,0.20799897832277692
5921,Amyloid fiber formation,Amyloid fiber formation,0.006338626726937946,1,1,2,0.1939190782390759
5922,Striated Muscle Contraction,Striated Muscle Contraction,0.00018881341893575154,0,1,2,0.005776412736781727
5923,Striated Muscle Contraction,Striated Muscle Contraction,0.00017451165143332522,1,1,2,0.005338875445072511
5924,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0033435597023829663,0,1,2,0.10229029779714481
5925,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0028986746921873417,1,1,2,0.08867982745143424
5926,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",6.235620513545352e-05,0,1,2,0.0019076778525173213
5927,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00014497001296452557,1,1,2,0.004435101244708916
5928,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0022454771301151292,0,1,2,0.06869640287040589
5929,Platelet sensitization by LDL,Platelet sensitization by LDL,0.002625345135917693,1,1,2,0.0803177929145132
5930,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.0014706117295039197,0,1,2,0.04499076587378375
5931,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.000565839735403036,1,1,2,0.01731086631968407
5932,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,8.021481726245838e-05,0,1,2,0.0024540305171379317
5933,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,2.583476162575001e-05,1,1,2,0.0007903688569798216
5934,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,1.6088866522068203e-05,0,1,2,0.0004922104266862497
5935,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,7.370667902553882e-05,1,1,2,0.002254925533941422
5936,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",1.9651964483576496e-05,0,1,2,0.0006012171093853275
5937,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",1.650475354987672e-05,1,1,2,0.000504933755028251
5938,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.00020540432950231965,0,1,2,0.006283982313413042
5939,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.0001226189703926887,1,1,2,0.0037513106130894454
5940,Pyroptosis,Pyroptosis,0.00032808462541045934,0,1,2,0.010037169072226333
5941,Pyroptosis,Pyroptosis,1.1500378216074599e-05,1,1,2,0.00035183373925210904
5942,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.0003665643683518738,0,1,2,0.011214388776671745
5943,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.00027670613546509535,1,1,2,0.008465335007731157
5944,Hedgehog 'on' state,Hedgehog 'on' state,0.000779202627078727,0,1,2,0.02383832677233029
5945,Hedgehog 'on' state,Hedgehog 'on' state,0.0005562986877521326,1,1,2,0.01701897483504508
5946,Physiological factors,Physiological factors,0.0007018890115432441,0,1,2,0.021473053392805426
5947,Physiological factors,Physiological factors,0.0008293224197889989,1,1,2,0.025371653220250756
5948,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.0002606521261138065,0,1,2,0.007974190974558638
5949,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.0004422263971719076,1,1,2,0.013529134780585313
5950,Intraflagellar transport,Intraflagellar transport,0.00017008564317014436,0,1,2,0.0052034695472891615
5951,Intraflagellar transport,Intraflagellar transport,0.00019779757265799466,1,1,2,0.006051267036242451
5952,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0008097768576287005,0,1,2,0.024773691301830512
5953,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0006183103131964647,1,1,2,0.018916110881117453
5954,Metallothioneins bind metals,Metallothioneins bind metals,0.0013799448555801065,0,1,2,0.042216973161964315
5955,Metallothioneins bind metals,Metallothioneins bind metals,0.001074510847683996,1,1,2,0.03287275968708553
5956,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0003289805017023658,0,1,2,0.010064576823499085
5957,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00022559592198376777,1,1,2,0.006901708387349721
5958,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.00016144542539677786,0,1,2,0.004939137360117523
5959,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.0002388219855826416,1,1,2,0.007306336419936836
5960,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.00025260979200538716,0,1,2,0.007728149981078532
5961,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),7.927176317915989e-06,1,1,2,0.00024251794447462333
5962,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0007728928580490902,0,1,2,0.023645290544320737
5963,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.000630893116825367,1,1,2,0.01930105951218454
5964,RAB geranylgeranylation,RAB geranylgeranylation,0.00014366600404021787,0,1,2,0.004395207397112145
5965,RAB geranylgeranylation,RAB geranylgeranylation,0.0001057055712199902,1,1,2,0.003233875067702211
5966,Protein methylation,Protein methylation,0.00021053921530741113,0,1,2,0.006441075066320308
5967,Protein methylation,Protein methylation,0.00018877106849686244,1,1,2,0.005775117099978018
5968,Neddylation,Neddylation,2.6325674155221654e-05,0,1,2,0.0008053874579027288
5969,Neddylation,Neddylation,9.465545922952382e-06,1,1,2,0.0002895816427567559
5970,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0013442004894992957,0,1,2,0.04112343747651792
5971,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0012332537999706497,1,1,2,0.03772921966027727
5972,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.01327740318956785,0,1,2,0.4061986765977883
5973,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.011730585149295317,1,1,2,0.35887651337614573
5974,Formation of the cornified envelope,Formation of the cornified envelope,0.0010591433675775383,0,1,2,0.03240261880239879
5975,Formation of the cornified envelope,Formation of the cornified envelope,0.001222581118781818,1,1,2,0.0374027078482341
5976,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,7.373458696141218e-05,0,1,2,0.0022557793278992076
5977,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,0.00012095344100089278,1,1,2,0.003700356685945486
5978,Choline catabolism,Choline catabolism,0.0006738555273235155,0,1,2,0.0206154185053279
5979,Choline catabolism,Choline catabolism,0.0006073681261720292,1,1,2,0.018581354014510925
5980,Urea cycle,Urea cycle,0.0007437025660086267,0,1,2,0.022752265166763826
5981,Urea cycle,Urea cycle,0.000786950736558841,1,1,2,0.024075366483486304
5982,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00031099406611853435,0,1,2,0.009514313626204293
5983,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00030507896675165586,1,1,2,0.009333351618764594
5984,Tryptophan catabolism,Tryptophan catabolism,0.00015661137810335884,0,1,2,0.00479124822960285
5985,Tryptophan catabolism,Tryptophan catabolism,0.00026910529923043216,1,1,2,0.008232800861145738
5986,Threonine catabolism,Threonine catabolism,8.752429196950592e-05,0,1,2,0.002677650972902999
5987,Threonine catabolism,Threonine catabolism,8.404625147401627e-05,1,1,2,0.0025712464729981195
5988,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,5.238745014916427e-06,0,1,2,0.0001602701418123896
5989,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,1.181739783125598e-05,1,1,2,0.0003615323938989299
5990,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,0.0001519570962652021,0,1,2,0.004648858705372854
5991,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,7.155024283444315e-05,1,1,2,0.002188953181179033
5992,Alanine metabolism,Alanine metabolism,0.00011882684481558196,0,1,2,0.003635297235403992
5993,Alanine metabolism,Alanine metabolism,7.449628862256455e-05,1,1,2,0.0022790822435601204
5994,Lactose synthesis,Lactose synthesis,0.0007463761449798767,0,1,2,0.022834058588594584
5995,Lactose synthesis,Lactose synthesis,0.0008041024804091042,1,1,2,0.02460009376289853
5996,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,5.418258780688727e-05,0,1,2,0.0016576204810209885
5997,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,5.234809121409019e-06,1,1,2,0.0001601497301090533
5998,Galactose catabolism,Galactose catabolism,3.472379490479701e-05,0,1,2,0.001062313114650595
5999,Galactose catabolism,Galactose catabolism,2.280874816733558e-05,1,1,2,0.0006977933251061793
6000,Pentose phosphate pathway,Pentose phosphate pathway,0.0007787844328656017,0,1,2,0.023825532859732542
6001,Pentose phosphate pathway,Pentose phosphate pathway,0.0009149641164791926,1,1,2,0.02799170951894617
6002,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.00020662006803225572,0,1,2,0.006321175684353
6003,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,0.00013342001354127813,1,1,2,0.004081749432351922
6004,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0018165198524078127,0,1,2,0.055573213340498036
6005,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0019001739483686109,1,1,2,0.05813246250888656
6006,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,3.602781956146828e-06,0,1,2,0.00011022074435512147
6007,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,4.927363326838001e-06,1,1,2,0.00015074396957762454
6008,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.000886592459842935,0,1,2,0.027123728844262014
6009,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0011657082285258487,1,1,2,0.0356627823201446
6010,Signaling by SCF-KIT,Signaling by SCF-KIT,0.000433987286669435,0,1,2,0.013277073761222969
6011,Signaling by SCF-KIT,Signaling by SCF-KIT,0.00041638723948077917,1,1,2,0.012738631433757329
6012,Signaling by PDGF,Signaling by PDGF,0.00360800095028632,0,1,2,0.11038041025381912
6013,Signaling by PDGF,Signaling by PDGF,0.0033064895651477855,1,1,2,0.10115620248714775
6014,Signaling by MST1,Signaling by MST1,5.875070456321888e-05,0,1,2,0.0017973739369094121
6015,Signaling by MST1,Signaling by MST1,6.601573823440768e-05,1,1,2,0.002019634797752587
6016,Signaling by BMP,Signaling by BMP,0.0007430688579916023,0,1,2,0.022732877990356695
6017,Signaling by BMP,Signaling by BMP,0.0006230778885462011,1,1,2,0.01906196642003524
6018,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,6.01548751850108e-05,0,1,2,0.0018403320545583145
6019,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,0.0001745741972020672,1,1,2,0.005340788922288427
6020,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0013169975817315085,0,1,2,0.04029121260715727
6021,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0012890688652381261,1,1,2,0.03943678290304161
6022,Mitochondrial protein import,Mitochondrial protein import,0.00032535095063697855,0,1,2,0.009953537125573609
6023,Mitochondrial protein import,Mitochondrial protein import,0.0006157447482110001,1,1,2,0.018837621956216823
6024,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.003704666136278926,0,1,2,0.11333771071857615
6025,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.003391702865822784,1,1,2,0.10376315276714752
6026,Late endosomal microautophagy,Late endosomal microautophagy,0.003234887473566535,0,1,2,0.09896566308522693
6027,Late endosomal microautophagy,Late endosomal microautophagy,0.0032552155290128818,1,1,2,0.09958756400231292
6028,Defective pyroptosis,Defective pyroptosis,0.00029882212559944796,0,1,2,0.00914193462559033
6029,Defective pyroptosis,Defective pyroptosis,4.525713572907838e-05,1,1,2,0.0013845620545892647
6030,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.0012875695705588442,0,1,2,0.03939091463302983
6031,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.0014037505020193445,1,1,2,0.04294526482721788
6032,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0013913104215741137,0,1,2,0.042564682559625595
6033,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.0015125179659207788,1,1,2,0.046272813088189105
6034,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0013149319929652847,0,1,2,0.04022801957074375
6035,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0017115678308376422,1,1,2,0.05236239179208249
6036,Aspirin ADME,Aspirin ADME,1.1604257104143774e-05,0,1,2,0.0003550117301783243
6037,Aspirin ADME,Aspirin ADME,9.23386531799982e-06,1,1,2,0.0002824937842514837
6038,Paracetamol ADME,Paracetamol ADME,0.00032928006512520367,0,1,2,0.010073741436803098
6039,Paracetamol ADME,Paracetamol ADME,0.0003142378694368138,1,1,2,0.009613552053795608
6040,Atorvastatin ADME,Atorvastatin ADME,0.002651786020680902,0,1,2,0.08112670503727894
6041,Atorvastatin ADME,Atorvastatin ADME,0.0023959147825886856,1,1,2,0.07329877687929712
6042,Kinesins,Kinesins,0.0009627664321063396,0,1,2,0.02945413685272731
6043,Kinesins,Kinesins,0.0011312803884114449,1,1,2,0.03460952341906831
6044,Stimuli-sensing channels,Stimuli-sensing channels,0.0003481862873741193,0,1,2,0.010652143880965309
6045,Stimuli-sensing channels,Stimuli-sensing channels,0.0002973797848729494,1,1,2,0.009097808761071347
6046,Aspirin ADME,Aspirin ADME,6.373654940716733e-06,0,2,3,0.0002896625405069596
6047,Aspirin ADME,Aspirin ADME,1.53564037778627e-05,1,2,3,0.0006979001801509785
6048,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0001937606671466104,0,2,3,0.008805811989831243
6049,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0001399775497096319,1,2,3,0.006361538715221329
6050,Complement cascade,Innate Immune System,0.008061205164024917,0,2,3,0.36635638249608465
6051,Complement cascade,Innate Immune System,0.008129884751785237,1,2,3,0.3694776534240945
6052,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,0.0001466516340921468,0,2,3,0.006664854827527165
6053,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,0.0001712529010092112,1,2,3,0.007782904916709645
6054,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0025033788318978623,0,2,3,0.11377068244885823
6055,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0020720049608523067,1,2,3,0.09416609880609736
6056,Protein methylation,Post-translational protein modification,0.00017639606291292392,0,2,3,0.008016645424648174
6057,Protein methylation,Post-translational protein modification,0.00015662242749385767,1,2,3,0.007117995980362279
6058,Protein ubiquitination,Post-translational protein modification,2.7423864044825072e-06,0,2,3,0.00012463282376639316
6059,Protein ubiquitination,Post-translational protein modification,2.433648344890571e-06,1,2,3,0.00011060165146032967
6060,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.00021761609370211468,0,2,3,0.009889965983923605
6061,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.00011526822761804093,1,2,3,0.005238577858722543
6062,Glucose metabolism,Metabolism of carbohydrates,0.0006538792833453045,0,2,3,0.02971675375594964
6063,Glucose metabolism,Metabolism of carbohydrates,0.0008591493980929954,1,2,3,0.03904563388532875
6064,GPCR ligand binding,Signaling by GPCR,0.0024252878095770334,0,2,3,0.11022169146540639
6065,GPCR ligand binding,Signaling by GPCR,0.0019671224459671065,1,2,3,0.08939951887684414
6066,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.00025447745701967506,0,2,3,0.011565198836098356
6067,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.00020926889222513031,1,2,3,0.009510611969871059
6068,Triglyceride metabolism,Metabolism of lipids,0.00043647030458184114,0,2,3,0.019836200493590778
6069,Triglyceride metabolism,Metabolism of lipids,0.0005104902214952744,1,2,3,0.023200172559961863
6070,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,0.00017696012697948998,0,2,3,0.008042280359712894
6071,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,0.00020770714096822,1,2,3,0.00943963529464714
6072,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0029415403247791496,0,2,3,0.13368374212353892
6073,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0024319125904488223,1,2,3,0.11052276688845218
6074,Uptake and actions of bacterial toxins,Infectious disease,0.0003951060127292294,0,2,3,0.017956323723394698
6075,Uptake and actions of bacterial toxins,Infectious disease,0.0003583121222618502,1,2,3,0.01628415729972612
6076,Chaperonin-mediated protein folding,Protein folding,0.0009597127672956655,0,2,3,0.04361592224830515
6077,Chaperonin-mediated protein folding,Protein folding,0.0007992605101208028,1,2,3,0.03632387257262561
6078,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,3.5942413940877786e-05,0,2,3,0.0016334694976281004
6079,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,3.130082485161741e-05,1,2,3,0.0014225238941886155
6080,Formation of the cornified envelope,Keratinization,0.000840904697846175,0,2,3,0.03821646972858705
6081,Formation of the cornified envelope,Keratinization,0.0010223512024216082,1,2,3,0.04646264181827305
6082,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.004340696913034966,0,2,3,0.1972710018184691
6083,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.0035700504119934823,1,2,3,0.16224754582645506
6084,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.00018275078388114708,0,2,3,0.008305447475745934
6085,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.0002998161128743959,1,2,3,0.013625697931233298
6086,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0016167114186828257,0,2,3,0.0734744414559751
6087,Collagen biosynthesis and modifying enzymes,Collagen formation,0.001860093717186828,1,2,3,0.08453540028647696
6088,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.002927939309059487,0,2,3,0.13306561880128867
6089,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0032950155781387973,1,2,3,0.14974807896744452
6090,Infection with Mycobacterium tuberculosis,Infectious disease,0.0015210089313465384,0,2,3,0.06912506486240214
6091,Infection with Mycobacterium tuberculosis,Infectious disease,0.0013733129191678018,1,2,3,0.06241274634055433
6092,Neddylation,Post-translational protein modification,8.02115832054066e-05,0,2,3,0.00364536379604364
6093,Neddylation,Post-translational protein modification,7.112694485537456e-05,1,2,3,0.0032324955989834897
6094,Diseases of glycosylation,Diseases of metabolism,0.001419722631104984,0,2,3,0.06452192156088853
6095,Diseases of glycosylation,Diseases of metabolism,0.0011603840886891704,1,2,3,0.05273580170560045
6096,Abacavir metabolism,Abacavir ADME,0.0011905144376214594,0,2,3,0.05410513115616944
6097,Abacavir metabolism,Abacavir ADME,0.0010256099708688756,1,2,3,0.04661074257931821
6098,RIPK1-mediated regulated necrosis,Regulated Necrosis,6.122916632496829e-05,0,2,3,0.002782672742057646
6099,RIPK1-mediated regulated necrosis,Regulated Necrosis,1.162717977270707e-05,1,2,3,0.0005284186959005233
6100,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.00025625665445356085,0,2,3,0.011646057755126199
6101,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,0.00026002830527431796,1,2,3,0.011817467404504364
6102,Retinoid metabolism and transport,Visual phototransduction,0.003337858680849119,0,2,3,0.1516951630329771
6103,Retinoid metabolism and transport,Visual phototransduction,0.0041710163244715655,1,2,3,0.18955955354975196
6104,Homology Directed Repair,DNA Double-Strand Break Repair,9.450587061413293e-05,0,2,3,0.0042949941328065365
6105,Homology Directed Repair,DNA Double-Strand Break Repair,4.045210354396052e-05,1,2,3,0.0018384206848945813
6106,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0011327190644806252,0,2,3,0.05147851349813238
6107,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0013303338037076173,1,2,3,0.060459480923970764
6108,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0025595819424931204,0,2,3,0.11632493678970984
6109,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0028722676586767195,1,2,3,0.1305355176530338
6110,Clathrin-mediated endocytosis,Membrane Trafficking,0.0022369211015757172,0,2,3,0.10166101792815051
6111,Clathrin-mediated endocytosis,Membrane Trafficking,0.0026429030883264202,1,2,3,0.12011162041229555
6112,Meiotic recombination,Meiosis,0.00041218307269446085,0,2,3,0.01873242230731998
6113,Meiotic recombination,Meiosis,0.00039508015264194305,1,2,3,0.017955148463884924
6114,C-type lectin receptors (CLRs),Innate Immune System,0.000890179910735848,0,2,3,0.040455872941092756
6115,C-type lectin receptors (CLRs),Innate Immune System,0.0008998616377842457,1,2,3,0.04089587693870774
6116,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.000915420318718437,0,2,3,0.04160296997845555
6117,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.0011698667768844948,1,2,3,0.05316676001430113
6118,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.0004309643446504197,0,2,3,0.019585971958080237
6119,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.000494272449153262,1,2,3,0.02246312589181849
6120,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.000642689442459717,0,2,3,0.02920821073488308
6121,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0007528886143669903,1,2,3,0.03421641597870734
6122,Metabolism of cofactors,Metabolism of vitamins and cofactors,0.000300201504311796,0,2,3,0.013643212758108187
6123,Metabolism of cofactors,Metabolism of vitamins and cofactors,0.00035255921053855367,1,2,3,0.01602270558315501
6124,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0007906719063612399,0,2,3,0.035933547585229465
6125,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0010113620389953818,1,2,3,0.04596321895561508
6126,Signaling by BMP,Signaling by TGFB family members,0.00045166925847297537,0,2,3,0.020526945072345617
6127,Signaling by BMP,Signaling by TGFB family members,0.00041591223319604375,1,2,3,0.018901900905533085
6128,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.00012634927400843784,0,2,3,0.005742176512677426
6129,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,2.3833537098501742e-05,1,2,3,0.0010831591872217904
6130,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.0010061142930377779,0,2,3,0.04572472543185934
6131,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.001410828274068384,1,2,3,0.06411770105015159
6132,Collagen degradation,Degradation of the extracellular matrix,0.0014178425543529252,0,2,3,0.06443647799461223
6133,Collagen degradation,Degradation of the extracellular matrix,0.0012613624958248693,1,2,3,0.05732495223529376
6134,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.0012098576250139104,0,2,3,0.05498421809352559
6135,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.0014152903229614822,1,2,3,0.06432048711721405
6136,HDACs deacetylate histones,Chromatin modifying enzymes,1.557434211842216e-05,0,2,3,0.0007078047912395144
6137,HDACs deacetylate histones,Chromatin modifying enzymes,1.4073289617044792e-05,1,2,3,0.0006395866832579107
6138,Fructose metabolism,Metabolism of carbohydrates,0.000883747262317532,0,2,3,0.04016352933285407
6139,Fructose metabolism,Metabolism of carbohydrates,0.001159217641785896,1,2,3,0.052682790368069374
6140,Cell-extracellular matrix interactions,Cell junction organization,0.00018614103610161691,0,2,3,0.00845952376011884
6141,Cell-extracellular matrix interactions,Cell junction organization,5.0285118080258445e-05,1,2,3,0.002285300222290063
6142,Striated Muscle Contraction,Striated Muscle Contraction,1.1081703765588221e-05,0,2,3,0.0005036285295866453
6143,Striated Muscle Contraction,Striated Muscle Contraction,2.617471610240803e-05,1,2,3,0.0011895583984060704
6144,ER to Golgi Anterograde Transport,Membrane Trafficking,0.0053079280529345855,0,2,3,0.24122861041929813
6145,ER to Golgi Anterograde Transport,Membrane Trafficking,0.006254762129295462,1,2,3,0.2842592367315551
6146,Physiological factors,Cardiac conduction,0.0005743642323068343,0,2,3,0.026103045152867693
6147,Physiological factors,Cardiac conduction,0.0006926941884254726,1,2,3,0.03148076892772072
6148,ESR-mediated signaling,Signaling by Nuclear Receptors,0.00012359194852251676,0,2,3,0.0056168647547166686
6149,ESR-mediated signaling,Signaling by Nuclear Receptors,8.531343857309063e-05,1,2,3,0.0038772270520322422
6150,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,6.0623908727090266e-05,0,2,3,0.002755165690751418
6151,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,4.981847202240412e-05,1,2,3,0.0022640926288616616
6152,Toll-like Receptor Cascades,Innate Immune System,0.004114395895157941,0,2,3,0.18698633338767412
6153,Toll-like Receptor Cascades,Innate Immune System,0.004153502676490462,1,2,3,0.1887636134157257
6154,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.00019312508053796287,0,2,3,0.008776926580519716
6155,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.0002278164357752151,1,2,3,0.010353539400811787
6156,DNA Double Strand Break Response,DNA Double-Strand Break Repair,9.963502858833332e-05,0,2,3,0.004528098206260087
6157,DNA Double Strand Break Response,DNA Double-Strand Break Repair,4.3117938563833986e-05,1,2,3,0.0019595744893617767
6158,Late endosomal microautophagy,Late endosomal microautophagy,0.0025811386294662952,0,2,3,0.1173046203106475
6159,Late endosomal microautophagy,Late endosomal microautophagy,0.0026706241556288053,1,2,3,0.12137145560184699
6160,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.00045719446886020404,0,2,3,0.020778048480435064
6161,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0004059482956563443,1,2,3,0.018449071330030927
6162,Glycogen metabolism,Metabolism of carbohydrates,0.00021337603332843475,0,2,3,0.009697268595821056
6163,Glycogen metabolism,Metabolism of carbohydrates,0.0002783681450940397,1,2,3,0.012650955355151705
6164,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0021084350450109924,0,2,3,0.09582173137899919
6165,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0024877367440543216,1,2,3,0.11305979882780617
6166,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0019900142083921915,0,2,3,0.09043987737168073
6167,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0023037022509621845,1,2,3,0.10469601081201121
6168,Ketone body metabolism,Metabolism of lipids,5.36938867905216e-05,0,2,3,0.0024402180227984824
6169,Ketone body metabolism,Metabolism of lipids,6.361080177157419e-05,1,2,3,0.0028909105711277766
6170,Aflatoxin activation and detoxification,Biological oxidations,0.000441592625308355,0,2,3,0.020068993835673808
6171,Aflatoxin activation and detoxification,Biological oxidations,0.000464633167454546,1,2,3,0.021116113900189387
6172,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.003564697315838809,0,2,3,0.16200426446808797
6173,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.004676070598119016,1,2,3,0.21251267940286983
6174,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.00016424276714891068,0,2,3,0.0074643164141698195
6175,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.00016397730773860532,1,2,3,0.007452252120149239
6176,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.004367136582883783,0,2,3,0.19847260153006446
6177,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.004880655794780372,1,2,3,0.22181043216266705
6178,Signaling by Activin,Signaling by TGFB family members,1.696695604399186e-05,0,2,3,0.0007710947075242712
6179,Signaling by Activin,Signaling by TGFB family members,1.5886389364065204e-05,1,2,3,0.0007219863556279056
6180,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,2.3061250628112853e-05,0,2,3,0.0010480611997887208
6181,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,3.0412534670176683e-05,1,2,3,0.0013821539034914764
6182,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.0004214683155320624,0,2,3,0.019154407346450648
6183,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.00034814207231950907,1,2,3,0.015821960564762944
6184,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0006094857465844447,0,2,3,0.02769920734657441
6185,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.00044104993188132845,1,2,3,0.0200443301288602
6186,TCF dependent signaling in response to WNT,Signaling by WNT,0.00023785333883550309,0,2,3,0.010809685029388623
6187,TCF dependent signaling in response to WNT,Signaling by WNT,0.00016123037310270167,1,2,3,0.007327412593591353
6188,Basigin interactions,Cell surface interactions at the vascular wall,0.00038114143656760763,0,2,3,0.017321677724246302
6189,Basigin interactions,Cell surface interactions at the vascular wall,0.0003267864349860853,1,2,3,0.014851414116660253
6190,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.0004920366034336136,0,2,3,0.02236151374661156
6191,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.00035444543762726727,1,2,3,0.01610842866285916
6192,Diseases associated with visual transduction,Diseases of the neuronal system,0.0010833447723901676,0,2,3,0.04923460744804327
6193,Diseases associated with visual transduction,Diseases of the neuronal system,0.0008723440373917886,1,2,3,0.0396452886793066
6194,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,0.0001628499128855765,0,2,3,0.007401015575290712
6195,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,0.00018939670147422779,1,2,3,0.00860748349619532
6196,Metallothioneins bind metals,Response to metal ions,0.0008814854479472463,0,2,3,0.04006073699427504
6197,Metallothioneins bind metals,Response to metal ions,0.0006876190382172354,1,2,3,0.031250119337109666
6198,Defective pyroptosis,Diseases of programmed cell death,0.0002552911976787679,0,2,3,0.011602180785830345
6199,Defective pyroptosis,Diseases of programmed cell death,0.000184757423001732,1,2,3,0.00839664290300951
6200,DAP12 interactions,Innate Immune System,0.00010020160132171441,0,2,3,0.0045538471523294335
6201,DAP12 interactions,Innate Immune System,0.0001009957116593796,1,2,3,0.004589936965786619
6202,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.00017786846195425217,0,2,3,0.008083561323126855
6203,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,0.0003199014441634063,1,2,3,0.014538512970988874
6204,HCMV Infection,Infectious disease,0.0006697979680514739,0,2,3,0.03044020783314821
6205,HCMV Infection,Infectious disease,0.0006037114206264959,1,2,3,0.027436782420491634
6206,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.00024271622552684373,0,2,3,0.011030687911771335
6207,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.0004038895503072126,1,2,3,0.018355507838810722
6208,Alanine metabolism,Metabolism of amino acids and derivatives,0.00010833037464787291,0,2,3,0.004923274294959702
6209,Alanine metabolism,Metabolism of amino acids and derivatives,0.00012697925694737933,1,2,3,0.005770807252851967
6210,SARS-CoV Infections,Infectious disease,0.007923803561425302,0,2,3,0.360111912462968
6211,SARS-CoV Infections,Infectious disease,0.007154571170879838,1,2,3,0.32515272333865297
6212,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,4.3667481971472925e-05,0,2,3,0.0019845495062172777
6213,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.0002828211581193803,1,2,3,0.012853330770486898
6214,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,0.0003445505741789627,0,2,3,0.015658738287232542
6215,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,0.0002850053107977146,1,2,3,0.012952593629795414
6216,ROS and RNS production in phagocytes,Innate Immune System,3.30388770104643e-05,0,2,3,0.001501512890070558
6217,ROS and RNS production in phagocytes,Innate Immune System,3.3317924521725215e-05,1,2,3,0.00151419472047804
6218,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.0001487096287140351,0,2,3,0.006758384200558896
6219,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,0.00012311877444138493,1,2,3,0.0055953604831931025
6220,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.00030218660603319826,0,2,3,0.013733429378420151
6221,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0005021177111605841,1,2,3,0.022819668338047643
6222,Switching of origins to a post-replicative state,Synthesis of DNA,0.0005503056083398406,0,2,3,0.02500965647648018
6223,Switching of origins to a post-replicative state,Synthesis of DNA,0.0009601037646158754,1,2,3,0.04363369184489563
6224,Intraflagellar transport,Cilium Assembly,1.0556032234868932e-05,0,2,3,0.00047973841434246974
6225,Intraflagellar transport,Cilium Assembly,5.3189544776917806e-05,1,2,3,0.0024172972669207816
6226,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0020958320394129258,0,2,3,0.09524896447311632
6227,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.002016908679555248,1,2,3,0.09166214637041728
6228,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0040507213958941675,0,2,3,0.18409252796616835
6229,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.003591892530099964,1,2,3,0.16324020129331426
6230,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",4.851265385260224e-07,0,2,3,2.2047473062762466e-05
6231,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",5.685506532534153e-07,1,2,3,2.5838836297240184e-05
6232,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,1.3806444840724907e-07,0,2,3,6.274594287157724e-06
6233,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,1.6176549557656018e-07,1,2,3,7.351732224431424e-06
6234,Cellular response to heat stress,Cellular responses to stress,0.000988762977552445,0,2,3,0.04493616279843036
6235,Cellular response to heat stress,Cellular responses to stress,0.0010268546737885722,1,2,3,0.04666731040629494
6236,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.0016016813914272157,0,2,3,0.07279137406069826
6237,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.001428336866471606,1,2,3,0.06491341142408781
6238,Phospholipid metabolism,Metabolism of lipids,0.00016156898163899314,0,2,3,0.007342801284973584
6239,Phospholipid metabolism,Metabolism of lipids,0.00018900270721739315,1,2,3,0.008589577698275385
6240,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.00027154640766866576,0,2,3,0.012340928877144252
6241,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.00030740233500334095,1,2,3,0.013970467830946952
6242,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
6243,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
6244,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0010384207290674871,0,2,3,0.0471929511864903
6245,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0014475102085270918,1,2,3,0.06578477942587933
6246,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007518155345072349,0,2,3,0.3416764787920482
6247,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.007055995262150342,1,2,3,0.3206727587938267
6248,Signaling by Interleukins,Cytokine Signaling in Immune system,0.0036285135731911095,0,2,3,0.16490451234818965
6249,Signaling by Interleukins,Cytokine Signaling in Immune system,0.003952942433897988,1,2,3,0.17964878214004712
6250,M Phase,"Cell Cycle, Mitotic",0.0008053588730035699,0,2,3,0.03660102395624868
6251,M Phase,"Cell Cycle, Mitotic",0.000650532379646999,1,2,3,0.029564647525364415
6252,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0027506577936340666,0,2,3,0.1250087323490584
6253,Smooth Muscle Contraction,Smooth Muscle Contraction,0.002219852059230713,1,2,3,0.10088528371980963
6254,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.001628915559285815,0,2,3,0.0740290812042274
6255,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.0011276072758770776,1,2,3,0.05124619880786275
6256,Eukaryotic Translation Elongation,Translation,0.00021512153161893366,0,2,3,0.009776595994931811
6257,Eukaryotic Translation Elongation,Translation,0.0001721395658023539,1,2,3,0.007823201038628493
6258,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.00017434926257540914,0,2,3,0.00792362479658004
6259,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.00013142662888867562,1,2,3,0.005972926298686348
6260,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,1.911624084982577e-06,0,2,3,8.687729318589021e-05
6261,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,1.0272216169227022e-06,1,2,3,4.6683986815897e-05
6262,Urea cycle,Metabolism of amino acids and derivatives,0.0003927810704529596,0,2,3,0.017850662420336987
6263,Urea cycle,Metabolism of amino acids and derivatives,0.0004560851498051003,1,2,3,0.020727633423654784
6264,HDMs demethylate histones,Chromatin modifying enzymes,3.1492267256301904e-05,0,2,3,0.0014312243484519013
6265,HDMs demethylate histones,Chromatin modifying enzymes,2.844095297405147e-05,1,2,3,0.0012925517257412593
6266,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0007373349682893604,0,2,3,0.03350955175733082
6267,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.0008277169627641949,1,2,3,0.03761712870951557
6268,Intrinsic Pathway for Apoptosis,Apoptosis,0.0007828927298154061,0,2,3,0.035580008515060574
6269,Intrinsic Pathway for Apoptosis,Apoptosis,0.0008739860015339219,1,2,3,0.03971991077749915
6270,Regulation of Apoptosis,Apoptosis,0.0005203776309220605,0,2,3,0.023649524173790088
6271,Regulation of Apoptosis,Apoptosis,0.000580200855529256,1,2,3,0.026368301293388925
6272,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.00032381912195281377,0,2,3,0.01471655908611789
6273,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0003232959709123406,1,2,3,0.01469278351921604
6274,O-linked glycosylation,Post-translational protein modification,0.0006397009948689932,0,2,3,0.029072395205276824
6275,O-linked glycosylation,Post-translational protein modification,0.0005681585406932754,1,2,3,0.025821016016507818
6276,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,2.780424375335618e-05,0,2,3,0.0012636152972483067
6277,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,5.244212684374361e-06,1,2,3,0.00023833294761700397
6278,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.005396250359869252,0,2,3,0.24524258106064792
6279,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.00482317039083379,1,2,3,0.21919790162812836
6280,Cellular response to hypoxia,Cellular responses to stress,0.0006228215089019311,0,2,3,0.028305275737224644
6281,Cellular response to hypoxia,Cellular responses to stress,0.0006463693057412456,1,2,3,0.02937544892972737
6282,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.00026791662333115106,0,2,3,0.01217596661256037
6283,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.00019519771004183895,1,2,3,0.008871121062838978
6284,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.001330568586854497,0,2,3,0.060470151078446645
6285,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.0013446295021518988,1,2,3,0.06110917538785499
6286,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0004790196812943274,0,2,3,0.0217699356377372
6287,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0005897053424860132,1,2,3,0.026800250287132215
6288,Regulation of insulin secretion,Integration of energy metabolism,1.311277029193055e-05,0,2,3,0.0005959341054973496
6289,Regulation of insulin secretion,Integration of energy metabolism,1.4795215209536157e-05,1,2,3,0.0006723959274236336
6290,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.004458602171265132,0,2,3,0.2026294244120585
6291,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.0051913625641342755,1,2,3,0.23593107612611966
6292,Lactose synthesis,Metabolism of carbohydrates,0.00036368294863677877,0,2,3,0.016528244440754916
6293,Lactose synthesis,Metabolism of carbohydrates,0.0004767378113228915,1,2,3,0.021666231835259567
6294,Threonine catabolism,Metabolism of amino acids and derivatives,2.9089391015683457e-05,0,2,3,0.0013220211922008536
6295,Threonine catabolism,Metabolism of amino acids and derivatives,3.449525221791797e-05,1,2,3,0.0015677005557735496
6296,Rab regulation of trafficking,Membrane Trafficking,5.630286968501726e-06,0,2,3,0.00025587880772473087
6297,Rab regulation of trafficking,Membrane Trafficking,6.653567317016495e-06,1,2,3,0.00030238367630619565
6298,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.00031008316506510406,0,2,3,0.01409230311283474
6299,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.00038774097244337704,1,2,3,0.01762160584174292
6300,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.003326722192650777,0,2,3,0.15118904472348874
6301,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.002942809204008275,1,2,3,0.13374140868762557
6302,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.0001438233493900043,0,2,3,0.006536318196705504
6303,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.00011686695809582185,1,2,3,0.005311235123053181
6304,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.006157328639725772,0,2,3,0.2798311915390048
6305,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.00569781287135811,1,2,3,0.2589476473078801
6306,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,8.078326776891723e-05,0,2,3,0.0036713450586904816
6307,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,2.09113439363288e-05,1,2,3,0.0009503547126965511
6308,G2/M Checkpoints,Cell Cycle Checkpoints,0.000465913180323696,0,2,3,0.021174286453144994
6309,G2/M Checkpoints,Cell Cycle Checkpoints,0.0003636404085530861,1,2,3,0.016526311127949247
6310,Heme biosynthesis,Metabolism of porphyrins,5.0398420700048516e-05,0,2,3,0.002290449469464526
6311,Heme biosynthesis,Metabolism of porphyrins,6.0818764277807226e-05,1,2,3,0.0027640212617507185
6312,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,8.721558284984591e-05,0,2,3,0.003963673517794908
6313,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.00010233528610115172,1,2,3,0.004650816404603285
6314,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.005956511172795823,0,2,3,0.270704670227426
6315,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.0060170391995901205,1,2,3,0.27345547838635303
6316,Stimuli-sensing channels,Ion channel transport,0.00025692141765224126,0,2,3,0.01167626914855059
6317,Stimuli-sensing channels,Ion channel transport,0.0001998199863616416,1,2,3,0.009081188961740426
6318,PKMTs methylate histone lysines,Chromatin modifying enzymes,3.69667624606033e-05,0,2,3,0.0016800229112264317
6319,PKMTs methylate histone lysines,Chromatin modifying enzymes,3.338515819753714e-05,1,2,3,0.0015172502792625126
6320,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,1.0852781933105386e-05,0,2,3,0.0004932247533873912
6321,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,1.0030120051851554e-05,1,2,3,0.00045583736220938326
6322,Gap junction trafficking and regulation,Membrane Trafficking,0.0017024810998312507,0,2,3,0.07737240329592544
6323,Gap junction trafficking and regulation,Membrane Trafficking,0.0020065219689665054,1,2,3,0.09119010309154041
6324,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.012647574053456385,0,2,3,0.5747924017929512
6325,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.014779610328453903,1,2,3,0.6716867347326834
6326,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0012854662785836506,0,2,3,0.05842039323652113
6327,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0011906623351630211,1,2,3,0.05411185263356695
6328,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0003496602209149084,0,2,3,0.0158909556363664
6329,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0004986970675721143,1,2,3,0.02266421086172973
6330,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.00458144812315974,0,2,3,0.20821238596987174
6331,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.004626044662776015,1,2,3,0.21023915821958136
6332,Pentose phosphate pathway,Metabolism of carbohydrates,0.0005143776348025615,0,2,3,0.023376843249709418
6333,Pentose phosphate pathway,Metabolism of carbohydrates,0.0006755332775355783,1,2,3,0.03070085958339381
6334,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0003571033744227255,0,2,3,0.016229223517905515
6335,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0004566401137935827,1,2,3,0.020752854788835186
6336,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,3.240038552879317e-05,0,2,3,0.0014724954634302454
6337,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.00016342755128183247,1,2,3,0.007427267420881691
6338,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.00010948620710754161,0,2,3,0.004975803239463622
6339,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.00011585850229873055,1,2,3,0.005265403983637656
6340,Integrin cell surface interactions,Integrin cell surface interactions,0.008754219200394193,0,2,3,0.39785168750535355
6341,Integrin cell surface interactions,Integrin cell surface interactions,0.007749989964698519,1,2,3,0.35221263199189956
6342,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0007389250695268856,0,2,3,0.03358181684987331
6343,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0006797462451080112,1,2,3,0.030892325689020034
6344,Nucleotide catabolism,Metabolism of nucleotides,0.00021261399985329869,0,2,3,0.00966263657472604
6345,Nucleotide catabolism,Metabolism of nucleotides,0.00032879796247774115,1,2,3,0.014942831704990991
6346,Axon guidance,Nervous system development,0.002762758503498238,0,2,3,0.12555867149603073
6347,Axon guidance,Nervous system development,0.003857955109803394,1,2,3,0.17533190746309704
6348,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.00277004425455137,0,2,3,0.1258897859318107
6349,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.0032655937675372115,1,2,3,0.1484109503521619
6350,Syndecan interactions,Non-integrin membrane-ECM interactions,0.001583198300879,0,2,3,0.07195137581567022
6351,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0015422554441859879,1,2,3,0.0700906519459879
6352,Influenza Infection,Infectious disease,0.0019193832403592145,0,2,3,0.08722992235698436
6353,Influenza Infection,Infectious disease,0.0017337413553226118,1,2,3,0.07879308344048094
6354,PECAM1 interactions,Cell surface interactions at the vascular wall,0.000189545957861507,0,2,3,0.008614266728850416
6355,PECAM1 interactions,Cell surface interactions at the vascular wall,0.0001622437207212594,1,2,3,0.007373466050883646
6356,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.00128484170760809,0,2,3,0.058392008453034966
6357,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.0015020284555096926,1,2,3,0.06826246202273328
6358,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0005457305199494537,0,2,3,0.02480173312033214
6359,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0003925315017113462,1,2,3,0.01783932030715401
6360,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.003184573379500459,0,2,3,0.14472882892420985
6361,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.003214187351477449,1,2,3,0.1460746906687103
6362,Laminin interactions,Laminin interactions,0.0007920410895167152,0,2,3,0.03599577264681865
6363,Laminin interactions,Laminin interactions,0.0007445526620093308,1,2,3,0.033837573201694206
6364,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.00015048876670107348,0,2,3,0.0068392404179147765
6365,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,8.14880118828872e-05,1,2,3,0.0037033734587778124
6366,Nephrin family interactions,Nephrin family interactions,1.0636017373144569e-05,0,2,3,0.0004833734869297404
6367,Nephrin family interactions,Nephrin family interactions,1.3422205961433065e-05,1,2,3,0.0006099969819764286
6368,Phase I - Functionalization of compounds,Biological oxidations,0.00031318892615672667,0,2,3,0.014233450171527866
6369,Phase I - Functionalization of compounds,Biological oxidations,0.00032816546475563274,1,2,3,0.014914086675842899
6370,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00040824229896922287,0,2,3,0.018553326554657988
6371,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.0004775883732994165,1,2,3,0.021704887197884385
6372,Molecules associated with elastic fibres,Elastic fibre formation,0.0030996284312398833,0,2,3,0.14086834859616376
6373,Molecules associated with elastic fibres,Elastic fibre formation,0.002380007868669054,1,2,3,0.10816386077965304
6374,Transcriptional regulation by small RNAs,Gene Silencing by RNA,1.663919932184399e-05,0,2,3,0.0007561991969124417
6375,Transcriptional regulation by small RNAs,Gene Silencing by RNA,1.550938990059573e-05,1,2,3,0.0007048529175340562
6376,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,6.774138670806451e-06,0,2,3,0.0003078632645449707
6377,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,6.8558158363411314e-06,1,2,3,0.0003115752344414023
6378,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0005920163423278761,0,2,3,0.026905277950463782
6379,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0006136062232869222,1,2,3,0.02788647003350066
6380,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.000739771398123897,0,2,3,0.03362027981873407
6381,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0005787753430922749,1,2,3,0.02630351624338843
6382,Metabolism of steroids,Metabolism of lipids,0.001180641513201408,0,2,3,0.0536564378402706
6383,Metabolism of steroids,Metabolism of lipids,0.0013828244539278482,1,2,3,0.06284501563475704
6384,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,1.687772194145509e-05,0,2,3,0.0007670392986448956
6385,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,1.9043887323277887e-05,1,2,3,0.000865484691985637
6386,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.00011451437283274876,0,2,3,0.005204317533318654
6387,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,6.044930460310146e-05,1,2,3,0.002747230483306394
6388,Fatty acid metabolism,Metabolism of lipids,0.0009393959993758471,0,2,3,0.04269258914268788
6389,Fatty acid metabolism,Metabolism of lipids,0.0011055447486190437,1,2,3,0.05024352643933827
6390,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.008850576038821601,0,2,3,0.40223080229485975
6391,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.009963399896514602,1,2,3,0.4528051413129462
6392,Fibronectin matrix formation,Fibronectin matrix formation,0.0006709688457097703,0,2,3,0.030493420534538483
6393,Fibronectin matrix formation,Fibronectin matrix formation,0.0005445407142209054,1,2,3,0.02474766019777096
6394,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.0045664946492782596,0,2,3,0.2075327976843115
6395,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.004230865713543608,1,2,3,0.19227951976186194
6396,Neutrophil degranulation,Innate Immune System,0.009337298490815252,0,2,3,0.4243508045977148
6397,Neutrophil degranulation,Innate Immune System,0.009420538564639477,1,2,3,0.428133803752859
6398,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,9.91453760737689e-05,0,2,3,0.004505845041842874
6399,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.00011527726498267536,1,2,3,0.005238988578478138
6400,Post-chaperonin tubulin folding pathway,Protein folding,0.0007619327397454374,0,2,3,0.034627442988821866
6401,Post-chaperonin tubulin folding pathway,Protein folding,0.000633103687869152,1,2,3,0.028772568383170348
6402,Nucleotide salvage,Metabolism of nucleotides,0.00014566614421103927,0,2,3,0.006620067416652142
6403,Nucleotide salvage,Metabolism of nucleotides,0.0002252662661097323,1,2,3,0.010237642222364209
6404,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.004445434504941659,0,2,3,0.202030995454846
6405,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.004997574679509853,1,2,3,0.22712402718765493
6406,MHC class II antigen presentation,Adaptive Immune System,0.0005171903999629042,0,2,3,0.02350467456624171
6407,MHC class II antigen presentation,Adaptive Immune System,0.00047795570693172823,1,2,3,0.021721581354398778
6408,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.0005731926748315648,0,2,3,0.02604980155593737
6409,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.0006767118792292119,1,2,3,0.030754423317860005
6410,Mitochondrial protein import,Mitochondrial protein import,0.0002337221850514955,0,2,3,0.010621937102738862
6411,Mitochondrial protein import,Mitochondrial protein import,0.0004953542162790351,1,2,3,0.022512288800197258
6412,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.00012771248254163462,0,2,3,0.005804130046503678
6413,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.00010602693055261625,1,2,3,0.004818590016511335
6414,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0002875732977751492,0,2,3,0.013069300548947966
6415,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.00023353177448228734,1,2,3,0.010613283542147769
6416,Intracellular oxygen transport,Intracellular oxygen transport,0.0001685094197455328,0,2,3,0.007658222335041526
6417,Intracellular oxygen transport,Intracellular oxygen transport,0.00015112294640857727,1,2,3,0.006868061888000958
6418,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,5.343292288368199e-05,0,2,3,0.0024283580352499126
6419,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,6.262944267897789e-05,1,2,3,0.0028463108915789052
6420,Sphingolipid metabolism,Metabolism of lipids,3.6411410514839796e-07,0,2,3,1.6547839146096413e-05
6421,Sphingolipid metabolism,Metabolism of lipids,4.2611592808346663e-07,1,2,3,1.9365626697271106e-05
6422,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.001081275882218809,0,2,3,0.04914058290660831
6423,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0012225211636784177,1,2,3,0.05555973603660344
6424,SUMOylation,Post-translational protein modification,0.00044153044873382894,0,2,3,0.020066168106213277
6425,SUMOylation,Post-translational protein modification,0.0003916657495816859,1,2,3,0.01779997459991707
6426,Signaling by Hippo,Signaling by Hippo,4.3835791245783184e-06,0,2,3,0.00019921986325727292
6427,Signaling by Hippo,Signaling by Hippo,1.2510284962748604e-05,1,2,3,0.0005685530450709142
6428,ECM proteoglycans,ECM proteoglycans,0.003249910838591556,0,2,3,0.1476982106316652
6429,ECM proteoglycans,ECM proteoglycans,0.0031479257294752946,1,2,3,0.1430633086679932
6430,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,2.0694051984548877e-05,0,2,3,0.0009404794779419678
6431,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,1.7081801397485683e-05,1,2,3,0.0007763140670860707
6432,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0003960002058496078,0,2,3,0.01799696198407273
6433,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0003470826192218131,1,2,3,0.01577381175867272
6434,Kinesins,Factors involved in megakaryocyte development and platelet production,0.0007617649588307055,0,2,3,0.03461981787474496
6435,Kinesins,Factors involved in megakaryocyte development and platelet production,0.0009095515866647475,1,2,3,0.041336254592693675
6436,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.002389013493499685,0,2,3,0.10857313806114324
6437,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0026742313778110355,1,2,3,0.12153539248754232
6438,ABC transporter disorders,Disorders of transmembrane transporters,0.0008710336907521802,0,2,3,0.039585737552032825
6439,ABC transporter disorders,Disorders of transmembrane transporters,0.0007611446534307712,1,2,3,0.03459162694823475
6440,Cell-cell junction organization,Cell junction organization,0.000636117697043422,0,2,3,0.02890954560623165
6441,Cell-cell junction organization,Cell junction organization,0.00017199128997162915,1,2,3,0.007816462369180115
6442,Diseases associated with surfactant metabolism,Diseases of metabolism,0.00010885352173014931,0,2,3,0.0049470496819739775
6443,Diseases associated with surfactant metabolism,Diseases of metabolism,8.936268010681184e-05,1,2,3,0.004061252324924107
6444,Hedgehog 'on' state,Signaling by Hedgehog,0.0006319191898001009,0,2,3,0.028718736677014578
6445,Hedgehog 'on' state,Signaling by Hedgehog,0.0004603460738508147,1,2,3,0.020921278999932253
6446,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0018231263349055857,0,2,3,0.08285534920635487
6447,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0018434687773454547,1,2,3,0.08377984913803559
6448,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,2.1877014336565044e-05,0,2,3,0.000994241390595896
6449,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,2.4179943096399224e-05,1,2,3,0.00109890224867258
6450,Unfolded Protein Response (UPR),Cellular responses to stress,0.0020782252013001805,0,2,3,0.09444878914114908
6451,Unfolded Protein Response (UPR),Cellular responses to stress,0.00215699677549613,1,2,3,0.09802870906363634
6452,Pyroptosis,Regulated Necrosis,0.0002995352801614596,0,2,3,0.013612934969032923
6453,Pyroptosis,Regulated Necrosis,5.618097875412786e-05,1,2,3,0.002553248518385936
6454,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.001279641589030689,0,2,3,0.05815567944368668
6455,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0011773606781616762,1,2,3,0.05350733422210609
6456,Asparagine N-linked glycosylation,Post-translational protein modification,0.0026609313138275564,0,2,3,0.12093094647372558
6457,Asparagine N-linked glycosylation,Post-translational protein modification,0.0023617559264190882,1,2,3,0.10733436749668016
6458,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0013348061184406863,0,2,3,0.06066273354112324
6459,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0014984751932975845,1,2,3,0.06810097744771001
6460,Nucleosome assembly,Chromosome Maintenance,0.00015478117663908126,0,2,3,0.0070343169288187134
6461,Nucleosome assembly,Chromosome Maintenance,0.00017019944280036726,1,2,3,0.007735028559434281
6462,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,4.904088269578703e-06,0,2,3,0.00022287536433166313
6463,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,2.821423330582699e-06,1,2,3,0.00012822480309708904
6464,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.00023593817786604632,0,2,3,0.010722646995944309
6465,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",6.676364355371334e-05,1,2,3,0.0030341972989041343
6466,Signaling by NOTCH4,Signaling by NOTCH,0.00030876173542916755,0,2,3,0.014032248298288487
6467,Signaling by NOTCH4,Signaling by NOTCH,0.0002843220454754677,1,2,3,0.012921541373135266
6468,Cellular Senescence,Cellular responses to stress,2.489885059731023e-05,0,2,3,0.0011315743300827443
6469,Cellular Senescence,Cellular responses to stress,2.5851256774937308e-05,1,2,3,0.0011748581908458372
6470,Selective autophagy,Macroautophagy,0.000719181614658737,0,2,3,0.032684539016560085
6471,Selective autophagy,Macroautophagy,0.0005756569689765456,1,2,3,0.026161795962479768
6472,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,1.7174102443580825e-05,0,2,3,0.0007805088588895257
6473,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,2.2678060645375808e-05,1,2,3,0.0010306464220938445
6474,DNA methylation,Epigenetic regulation of gene expression,1.426234718261791e-05,0,2,3,0.000648178754095654
6475,DNA methylation,Epigenetic regulation of gene expression,7.5557917398327845e-06,1,2,3,0.00034338693438200904
6476,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0003924239550542552,0,2,3,0.01783443265035336
6477,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0004527214356736901,1,2,3,0.020574763211836593
6478,Cristae formation,Mitochondrial biogenesis,1.7015378883418938e-05,0,2,3,0.0007732953730478162
6479,Cristae formation,Mitochondrial biogenesis,3.121743458602093e-05,1,2,3,0.0014187340692905152
6480,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0028468227281337024,0,2,3,0.12937912570953072
6481,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0025215883079605797,1,2,3,0.11459824577738606
6482,Platelet sensitization by LDL,Platelet homeostasis,0.0017880970839238822,0,2,3,0.08126338008882447
6483,Platelet sensitization by LDL,Platelet homeostasis,0.0019451203320083247,1,2,3,0.08839959210247318
6484,Heme degradation,Metabolism of porphyrins,0.0008175716149708024,0,2,3,0.03715605460941214
6485,Heme degradation,Metabolism of porphyrins,0.0009855208217080266,1,2,3,0.0447888170278562
6486,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,5.0252519872628906e-05,0,2,3,0.002283818736435279
6487,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,1.2264559380644376e-05,1,2,3,0.0005573855913819546
6488,HIV Infection,Infectious disease,0.0009251599073953306,0,2,3,0.04204560360482575
6489,HIV Infection,Infectious disease,0.0008357009444807772,1,2,3,0.03797997552957362
6490,Amyloid fiber formation,Amyloid fiber formation,0.005648856304954582,0,2,3,0.2567227255744565
6491,Amyloid fiber formation,Amyloid fiber formation,0.00527251756672437,1,2,3,0.23961931536149506
6492,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0004526740372663577,0,2,3,0.02057260910352486
6493,Diseases of carbohydrate metabolism,Diseases of metabolism,0.00037035236449203997,1,2,3,0.01683134838320259
6494,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.00262200475432716,0,2,3,0.11916185696025842
6495,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0018880285265671167,1,2,3,0.08580494938019714
6496,Paracetamol ADME,Paracetamol ADME,0.00027471431991822707,0,2,3,0.012484900510194073
6497,Paracetamol ADME,Paracetamol ADME,0.0001690204035185161,1,2,3,0.007681444937961968
6498,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.0002261905080861955,0,2,3,0.010279646108899585
6499,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.00018608282328690015,1,2,3,0.008456878171056087
6500,Choline catabolism,Metabolism of amino acids and derivatives,0.00040239173831650986,0,2,3,0.018287437001831906
6501,Choline catabolism,Metabolism of amino acids and derivatives,0.00046593448884474733,1,2,3,0.021175254858306486
6502,Surfactant metabolism,Surfactant metabolism,0.0006281302441493608,0,2,3,0.028546541032091144
6503,Surfactant metabolism,Surfactant metabolism,0.0007200817354411508,1,2,3,0.03272544667080592
6504,Anchoring of the basal body to the plasma membrane,Cilium Assembly,8.04529587791573e-05,0,2,3,0.003656333555555141
6505,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.00040245122963824544,1,2,3,0.01829014069501146
6506,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00015567530172120315,0,2,3,0.007074952097372298
6507,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00011246912787707211,1,2,3,0.005111367592455725
6508,mTORC1-mediated signalling,MTOR signalling,9.65008649700394e-06,0,2,3,0.00043856603421956397
6509,mTORC1-mediated signalling,MTOR signalling,1.9174047747583244e-05,1,2,3,0.0008714000732744638
6510,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0006509612054893902,0,2,3,0.029584136309130944
6511,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0008482223374206417,1,2,3,0.03854903339721513
6512,RMTs methylate histone arginines,Chromatin modifying enzymes,0.0005188941116405962,0,2,3,0.02358210289542517
6513,RMTs methylate histone arginines,Chromatin modifying enzymes,0.00046830184146529064,1,2,3,0.021282843577921935
6514,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.00045151860006929686,0,2,3,0.020520098122461423
6515,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0003112518848865875,1,2,3,0.01414541774733889
6516,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.004059471414560297,0,2,3,0.18449018875262274
6517,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0036199005980355045,1,2,3,0.1645130797576115
6518,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.001139156559171776,0,2,3,0.05177107735420601
6519,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.0010097648834441013,1,2,3,0.04589063326673298
6520,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.0015051952072705414,0,2,3,0.06840638091522656
6521,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.0012457183363949297,1,2,3,0.05661397446716523
6522,Phase II - Conjugation of compounds,Biological oxidations,0.0005103939255301763,0,2,3,0.023195796211673426
6523,Phase II - Conjugation of compounds,Biological oxidations,0.0005342138142926463,1,2,3,0.02427833512501384
6524,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0005715407874959056,0,2,3,0.025974728479856393
6525,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0006363820197293535,1,2,3,0.02892155823971004
6526,S Phase,"Cell Cycle, Mitotic",0.0003180872208152626,0,2,3,0.014456062234487088
6527,S Phase,"Cell Cycle, Mitotic",0.0002561767537069196,1,2,3,0.011642426517872883
6528,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.003641748723506074,0,2,3,0.16550600824024575
6529,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004074890575793688,1,2,3,0.1851909410614461
6530,SLC transporter disorders,Disorders of transmembrane transporters,0.00041231105804702867,0,2,3,0.018738238838449654
6531,SLC transporter disorders,Disorders of transmembrane transporters,0.0003610106178408993,1,2,3,0.01640679542372947
6532,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0030014324001967907,0,2,3,0.13640564829559748
6533,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.003034012071536078,1,2,3,0.13788629173437744
6534,Degradation of beta-catenin by the destruction complex,Signaling by WNT,3.186232249087577e-05,0,2,3,0.0014480421932162606
6535,Degradation of beta-catenin by the destruction complex,Signaling by WNT,2.1575546524369806e-05,1,2,3,0.000980540628133263
6536,Antimicrobial peptides,Innate Immune System,0.0016981184406783237,0,2,3,0.07717413417948334
6537,Antimicrobial peptides,Innate Immune System,0.0017104972358235196,1,2,3,0.07773671142652983
6538,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.0006837752741679045,0,2,3,0.03107543236864424
6539,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.0005921378064764819,1,2,3,0.0269107981134147
6540,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0004607262489116692,0,2,3,0.02093855675892435
6541,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0003773252832312816,1,2,3,0.01714824557571521
6542,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,2.9676854743835672e-05,0,2,3,0.0013487195681774365
6543,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,3.462386569784333e-05,1,2,3,0.0015735456333130673
6544,TCR signaling,Adaptive Immune System,0.00043627655553185227,0,2,3,0.019827395209564173
6545,TCR signaling,Adaptive Immune System,0.00040286269371184364,1,2,3,0.01830884044107465
6546,Transferrin endocytosis and recycling,Iron uptake and transport,0.0011027008157422338,0,2,3,0.0501142786482686
6547,Transferrin endocytosis and recycling,Iron uptake and transport,0.0010278321606165264,1,2,3,0.046711734103613164
6548,Type I hemidesmosome assembly,Cell junction organization,0.0011487317533465102,0,2,3,0.05220623976828378
6549,Type I hemidesmosome assembly,Cell junction organization,0.00031002780718457265,1,2,3,0.014089787271537878
6550,Leishmania infection,Infectious disease,0.007101586910236316,0,2,3,0.322744755588965
6551,Leishmania infection,Infectious disease,0.00641593500986346,1,2,3,0.2915840364705415
6552,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,6.2083686909394e-05,0,2,3,0.002821508010942222
6553,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,3.291915700174286e-05,1,2,3,0.0014960719927834718
6554,Heme signaling,Cellular responses to stress,0.002943442965503588,0,2,3,0.13377021115128504
6555,Heme signaling,Cellular responses to stress,0.003047091701137106,1,2,3,0.13848071969986403
6556,Meiotic synapsis,Meiosis,0.0004799051494349745,0,2,3,0.021810177375569492
6557,Meiotic synapsis,Meiosis,0.0004610951245316149,1,2,3,0.02095532099391956
6558,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00012549356596309736,0,2,3,0.00570328727743469
6559,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.00014134014650911316,1,2,3,0.0064234644476771265
6560,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0043828260454271606,0,2,3,0.19918563818199728
6561,Generic Transcription Pathway,RNA Polymerase II Transcription,0.004339054148780027,1,2,3,0.19719634335766983
6562,Atorvastatin ADME,Atorvastatin ADME,0.002402419361798517,0,2,3,0.1091823925478169
6563,Atorvastatin ADME,Atorvastatin ADME,0.001912616099995527,1,2,3,0.08692237714345379
6564,Post-translational protein phosphorylation,Post-translational protein modification,0.010529617224043856,0,2,3,0.4785379353058292
6565,Post-translational protein phosphorylation,Post-translational protein modification,0.009319956137915142,1,2,3,0.42356264928555265
6566,Cellular response to chemical stress,Cellular responses to stress,0.0015620107634579958,0,2,3,0.07098846897908452
6567,Cellular response to chemical stress,Cellular responses to stress,0.0016183038173646007,1,2,3,0.07354681096012197
6568,p75 NTR receptor-mediated signalling,Death Receptor Signalling,2.7626681063945095e-05,0,2,3,0.0012555456323241055
6569,p75 NTR receptor-mediated signalling,Death Receptor Signalling,1.4437484262922832e-05,1,2,3,0.000656138182726472
6570,Rap1 signalling,Adaptive Immune System,0.0005911918129186233,0,2,3,0.0268678056860208
6571,Rap1 signalling,Adaptive Immune System,0.0005463436582128149,1,2,3,0.02482959832306105
6572,Neurotransmitter clearance,Transmission across Chemical Synapses,2.020667432892272e-05,0,2,3,0.0009183296986978591
6573,Neurotransmitter clearance,Transmission across Chemical Synapses,0.00012289186003423916,1,2,3,0.005585047938152175
6574,RAB geranylgeranylation,Post-translational protein modification,0.0001269527423251778,0,2,3,0.005769602246792036
6575,RAB geranylgeranylation,Post-translational protein modification,0.00011143733444214376,1,2,3,0.005064475830912364
6576,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.001110742790721512,0,2,3,0.05047976107944162
6577,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.0016386323072462498,1,2,3,0.07447067679198113
6578,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.0038861905975257588,0,2,3,0.1766151214403497
6579,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.003215672891565191,1,2,3,0.14614220378635515
6580,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0009687305799161549,0,2,3,0.04402575342645377
6581,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0007875486006620728,1,2,3,0.035791603179387683
6582,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.00010394829239430692,0,2,3,0.004724122459774905
6583,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.00012043376500514569,1,2,3,0.005473335261900097
6584,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.00469805244380647,0,2,3,0.21351168504815252
6585,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0043438181897120865,1,2,3,0.19741285401165015
6586,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,7.903854983245158e-05,0,2,3,0.00359205312421248
6587,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,8.655805537879738e-05,1,2,3,0.003933790965399371
6588,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0005819362808930843,0,2,3,0.026447170909711486
6589,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0006428066689447102,1,2,3,0.02921353830937113
6590,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.00014993225061819734,0,2,3,0.006813948514933164
6591,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,6.434789571964453e-05,1,2,3,0.0029244091692753496
6592,Telomere Maintenance,Chromosome Maintenance,0.00029886912244971123,0,2,3,0.013582660199382212
6593,Telomere Maintenance,Chromosome Maintenance,0.00032877128170791063,1,2,3,0.014941619148044675
6594,Tryptophan catabolism,Metabolism of amino acids and derivatives,5.909454554663777e-05,0,2,3,0.002685660951582426
6595,Tryptophan catabolism,Metabolism of amino acids and derivatives,6.915446604883376e-05,1,2,3,0.0031428526503907168
6596,Galactose catabolism,Metabolism of carbohydrates,7.650931903905682e-06,0,2,3,0.0003477107551545383
6597,Galactose catabolism,Metabolism of carbohydrates,1.0194804273548167e-05,1,2,3,0.0004633217413421965
6598,Hedgehog 'off' state,Signaling by Hedgehog,0.0005827820181972736,0,2,3,0.02648560700617601
6599,Hedgehog 'off' state,Signaling by Hedgehog,0.00042450862874829907,1,2,3,0.019292580005363522
6600,Apoptotic execution phase,Apoptosis,0.0001549566573961177,0,2,3,0.007042291976474421
6601,Apoptotic execution phase,Apoptosis,0.00017271204155804297,1,2,3,0.007849218258467648
6602,Beta-catenin independent WNT signaling,Signaling by WNT,0.00023425250862298223,0,2,3,0.010646038638582328
6603,Beta-catenin independent WNT signaling,Signaling by WNT,0.00015874419288290179,1,2,3,0.007214423533887972
6604,HATs acetylate histones,Chromatin modifying enzymes,0.0006619023926532463,0,2,3,0.03008137880178592
6605,HATs acetylate histones,Chromatin modifying enzymes,0.000598643522198472,1,2,3,0.027206462400448696
6606,Interferon Signaling,Cytokine Signaling in Immune system,0.00035211605995755235,0,2,3,0.016002565785140536
6607,Interferon Signaling,Cytokine Signaling in Immune system,0.00038423471235849625,1,2,3,0.017462257365348857
6608,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.00011114147406866929,0,2,3,0.005051029908876566
6609,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.0007071737655981754,1,2,3,0.03213882010060709
6610,Deubiquitination,Post-translational protein modification,0.001158988930274063,0,2,3,0.052672396150281166
6611,Deubiquitination,Post-translational protein modification,0.0010281842413557265,1,2,3,0.046727735064181146
6612,GPCR downstream signalling,Signaling by GPCR,0.0027622283020112565,0,2,3,0.12553457550854347
6613,GPCR downstream signalling,Signaling by GPCR,0.0022442346593985955,1,2,3,0.10199339609402612
6614,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.00029036632816617687,0,2,3,0.013196234982377968
6615,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.00023995090644651402,1,2,3,0.010905012870123946
6616,Diseases of the neuronal system,Disease,0.0006410934656742029,0,3,4,0.04991524112518396
6617,Diseases of the neuronal system,Disease,0.0005246535549910428,1,3,4,0.04084928346137823
6618,Signaling by Nuclear Receptors,Signal Transduction,0.0011811542910891148,0,3,4,0.09196412754535942
6619,Signaling by Nuclear Receptors,Signal Transduction,0.0009988636838140035,1,3,4,0.0777710650604308
6620,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.0006958489403283845,0,3,4,0.05417847709096172
6621,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.0008308100244903471,1,3,4,0.06468648476715302
6622,Platelet homeostasis,Hemostasis,0.000946978103714476,0,3,4,0.0737312777591138
6623,Platelet homeostasis,Hemostasis,0.001158485859165618,1,3,4,0.0901991739060313
6624,RNA Polymerase II Transcription,Gene expression (Transcription),0.0032514166664138126,0,3,4,0.25315379986256803
6625,RNA Polymerase II Transcription,Gene expression (Transcription),0.00274561222953101,1,3,4,0.21377210003095026
6626,"Cell Cycle, Mitotic",Cell Cycle,0.0015129014708387936,0,3,4,0.11779380973123306
6627,"Cell Cycle, Mitotic",Cell Cycle,0.0011539929697050866,1,3,4,0.08984935960783785
6628,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0003625837251320263,0,3,4,0.028230601366369196
6629,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.00036417353621042515,1,3,4,0.028354383322621572
6630,Intracellular oxygen transport,Transport of small molecules,0.00011460157729743514,0,3,4,0.00892282587549397
6631,Intracellular oxygen transport,Transport of small molecules,0.00011504446689893181,1,3,4,0.008957309055301916
6632,Cytokine Signaling in Immune system,Immune System,0.0022628174120503295,0,3,4,0.17618191853815665
6633,Cytokine Signaling in Immune system,Immune System,0.002204330482633547,1,3,4,0.17162815322807015
6634,Miscellaneous transport and binding events,Transport of small molecules,0.0006311711835830162,0,3,4,0.049142696824529104
6635,Miscellaneous transport and binding events,Transport of small molecules,0.0006336142778309295,1,3,4,0.04933291501424017
6636,Base Excision Repair,DNA Repair,0.00012773097851474327,0,3,4,0.009945074989984657
6637,Base Excision Repair,DNA Repair,0.00014559245605596515,1,3,4,0.01133576138137463
6638,DNA Replication Pre-Initiation,DNA Replication,1.0446646170218325e-05,0,3,4,0.0008133710456517447
6639,DNA Replication Pre-Initiation,DNA Replication,1.818673964445831e-05,1,3,4,0.0014160111485138913
6640,Activation of HOX genes during differentiation,Developmental Biology,0.000437585024155851,0,3,4,0.03407016786630097
6641,Activation of HOX genes during differentiation,Developmental Biology,0.000577228048859979,1,3,4,0.04494270927058165
6642,SLC-mediated transmembrane transport,Transport of small molecules,0.0006852819208688743,0,3,4,0.05335573383660447
6643,SLC-mediated transmembrane transport,Transport of small molecules,0.000689657950624678,1,3,4,0.0536964494921637
6644,Metabolism of nucleotides,Metabolism,0.0003086550459556747,0,3,4,0.024031739314609876
6645,Metabolism of nucleotides,Metabolism,0.0003725679162016604,1,3,4,0.029007965871491074
6646,Meiosis,Cell Cycle,0.00028807603718329725,0,3,4,0.02242946719675224
6647,Meiosis,Cell Cycle,0.0003059557604501606,1,3,4,0.02382157419191321
6648,Meiosis,Reproduction,0.00028807603718329725,0,3,4,0.02242946719675224
6649,Meiosis,Reproduction,0.0003059557604501606,1,3,4,0.02382157419191321
6650,Post-translational protein modification,Metabolism of proteins,0.012050501777169605,0,3,4,0.9382465024102377
6651,Post-translational protein modification,Metabolism of proteins,0.010418652226993194,1,3,4,0.8111914501622512
6652,Late endosomal microautophagy,Autophagy,0.0015207772173501629,0,3,4,0.11840701171690984
6653,Late endosomal microautophagy,Autophagy,0.0015592791982271593,1,3,4,0.12140475816446006
6654,Mitochondrial protein import,Protein localization,0.0001929630644857146,0,3,4,0.015024015073885727
6655,Mitochondrial protein import,Protein localization,0.0004113359456823673,1,3,4,0.03202642674044202
6656,Chaperone Mediated Autophagy,Autophagy,0.0017248657350440529,0,3,4,0.13429724943889104
6657,Chaperone Mediated Autophagy,Autophagy,0.0017696058886485845,1,3,4,0.1377806971336814
6658,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0023021841867678933,0,3,4,0.17924699743469713
6659,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.001943899740310447,1,3,4,0.15135113592015337
6660,Ion channel transport,Transport of small molecules,0.00017011806254837818,0,3,4,0.013245313774835305
6661,Ion channel transport,Transport of small molecules,0.00016913780412626997,1,3,4,0.013168991306857773
6662,Signaling by TGFB family members,Signal Transduction,0.0004994639120316908,0,3,4,0.03888802949531095
6663,Signaling by TGFB family members,Signal Transduction,0.0004208718517475063,1,3,4,0.03276888798217054
6664,Sensory processing of sound,Sensory Perception,0.000752386607155131,0,3,4,0.058580473716125465
6665,Sensory processing of sound,Sensory Perception,0.0011818024838097093,1,3,4,0.09201459553119365
6666,Chromosome Maintenance,Cell Cycle,0.00027524042995038893,0,3,4,0.021430092746187544
6667,Chromosome Maintenance,Cell Cycle,0.00020873347430428642,1,3,4,0.01625189189822544
6668,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.011732876327975343,0,3,4,0.9135163316427767
6669,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.013304239507609358,1,3,4,1.0358619430181506
6670,MTOR signalling,Signal Transduction,8.438039750065703e-06,0,3,4,0.0006569818775262005
6671,MTOR signalling,Signal Transduction,7.1724949539960414e-06,1,3,4,0.0005584471442418634
6672,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,5.486739570793968e-05,0,3,4,0.004271950087328579
6673,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,2.8288081027009562e-05,1,3,4,0.0022024969228893855
6674,Epigenetic regulation of gene expression,Gene expression (Transcription),6.427889337932887e-05,0,3,4,0.00500472494898227
6675,Epigenetic regulation of gene expression,Gene expression (Transcription),5.4617567451487047e-05,1,3,4,0.004252498574673396
6676,Integration of energy metabolism,Metabolism,0.0007215262622139562,0,3,4,0.056177701512972314
6677,Integration of energy metabolism,Metabolism,0.0008625163341700197,1,3,4,0.06715512339410619
6678,Metabolism of carbohydrates,Metabolism,0.0028406040257929516,0,3,4,0.2211681174125075
6679,Metabolism of carbohydrates,Metabolism,0.0033869096364166277,1,3,4,0.2637032199246574
6680,Striated Muscle Contraction,Muscle contraction,2.2814935192627674e-06,0,3,4,0.00017763603161948132
6681,Striated Muscle Contraction,Muscle contraction,1.4374064827885983e-06,1,3,4,0.00011191580483173621
6682,Dissolution of Fibrin Clot,Hemostasis,0.001479642183312535,0,3,4,0.11520425696644371
6683,Dissolution of Fibrin Clot,Hemostasis,0.0018129535322562635,1,3,4,0.14115572464329795
6684,Membrane Trafficking,Vesicle-mediated transport,0.007987670067814178,0,3,4,0.6219163020856272
6685,Membrane Trafficking,Vesicle-mediated transport,0.009060852355711782,1,3,4,0.7054737793332713
6686,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.00010784058504593001,0,3,4,0.008396418141600638
6687,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,0.00014213032379378394,1,3,4,0.011066201362552232
6688,"Platelet activation, signaling and aggregation",Hemostasis,0.009116229283972644,0,3,4,0.7097854013898243
6689,"Platelet activation, signaling and aggregation",Hemostasis,0.011120775923094092,1,3,4,0.8658584768394381
6690,Signaling by GPCR,Signal Transduction,0.003027194780103552,0,3,4,0.23569598735944083
6691,Signaling by GPCR,Signal Transduction,0.0025575590887456203,1,3,4,0.19913036934854597
6692,Apoptosis,Programmed Cell Death,0.002821806010312381,0,3,4,0.2197045126097338
6693,Apoptosis,Programmed Cell Death,0.003640155665925704,1,3,4,0.28342083881139385
6694,Peroxisomal protein import,Protein localization,5.2781818067160205e-05,0,3,4,0.004109567975516971
6695,Peroxisomal protein import,Protein localization,0.00011013407432377183,1,3,4,0.008574988157442412
6696,ECM proteoglycans,Extracellular matrix organization,0.002068873485768563,0,3,4,0.16108153401787687
6697,ECM proteoglycans,Extracellular matrix organization,0.0018571605634254715,1,3,4,0.14459766367151589
6698,Diseases of metabolism,Disease,0.0013807999301207019,0,3,4,0.10750844478679797
6699,Diseases of metabolism,Disease,0.0011290517407663476,1,3,4,0.0879074470426765
6700,Adaptive Immune System,Immune System,0.008189813620022808,0,3,4,0.6376551056932787
6701,Adaptive Immune System,Immune System,0.007999222773651126,1,3,4,0.6228157904260568
6702,Collagen formation,Extracellular matrix organization,0.001297426701906564,0,3,4,0.10101704374698678
6703,Collagen formation,Extracellular matrix organization,0.0011635400597697298,1,3,4,0.09059269163060203
6704,Mitochondrial biogenesis,Organelle biogenesis and maintenance,5.379817249225501e-06,0,3,4,0.0004188700861614794
6705,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.00013288159843796165,1,3,4,0.010346099878206297
6706,Chromatin modifying enzymes,Chromatin organization,0.00023117549214172564,0,3,4,0.017999217041390653
6707,Chromatin modifying enzymes,Chromatin organization,0.00027877623436628105,1,3,4,0.021705388844869722
6708,Nucleotide Excision Repair,DNA Repair,0.0010201517390669324,0,3,4,0.07942854320976542
6709,Nucleotide Excision Repair,DNA Repair,0.0011697282677535744,1,3,4,0.09107450264597647
6710,Nervous system development,Developmental Biology,0.0024582900127522104,0,3,4,0.191401324942713
6711,Nervous system development,Developmental Biology,0.003245294344803066,1,3,4,0.252677118729771
6712,Cellular responses to stress,Cellular responses to stimuli,0.0038881272012076806,0,3,4,0.3027277880138243
6713,Cellular responses to stress,Cellular responses to stimuli,0.0043138528046256395,1,3,4,0.3358745868591755
6714,Cell junction organization,Cell-Cell communication,0.0009378221569628901,0,3,4,0.07301839997404055
6715,Cell junction organization,Cell-Cell communication,0.000164617865971195,1,3,4,0.012817071009800588
6716,Degradation of the extracellular matrix,Extracellular matrix organization,0.004014090570399276,0,3,4,0.312535237758343
6717,Degradation of the extracellular matrix,Extracellular matrix organization,0.003610268509449573,1,3,4,0.2810938386126267
6718,RNA Polymerase I Transcription,Gene expression (Transcription),3.397950503843579e-06,0,3,4,0.0002645628567628958
6719,RNA Polymerase I Transcription,Gene expression (Transcription),2.87939449113613e-06,1,3,4,0.00022418832512734768
6720,Cell Cycle Checkpoints,Cell Cycle,0.0006422933697232717,0,3,4,0.050008665100225363
6721,Cell Cycle Checkpoints,Cell Cycle,0.0004895125065559114,1,3,4,0.03811321766138338
6722,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0011846256713397452,0,3,4,0.09223440760829094
6723,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0010655890745435196,1,3,4,0.08296627316309535
6724,Translation,Metabolism of proteins,7.880935145294643e-05,0,3,4,0.006136059703176414
6725,Translation,Metabolism of proteins,6.829618420548893e-05,1,3,4,0.005317509357175993
6726,Protein folding,Metabolism of proteins,0.000998047633038368,0,3,4,0.0777075277239624
6727,Protein folding,Metabolism of proteins,0.0008634367506601848,1,3,4,0.0672267865969028
6728,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.00022754689052817412,0,3,4,0.017716695795760455
6729,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,7.266908617869679e-05,1,3,4,0.005657981485026986
6730,Death Receptor Signalling,Signal Transduction,0.00012929836084367706,0,3,4,0.01006711065416321
6731,Death Receptor Signalling,Signal Transduction,0.00010936920413466093,1,3,4,0.008515435717801202
6732,Reversible hydration of carbon dioxide,Metabolism,0.00128718647435259,0,3,4,0.1002197443594539
6733,Reversible hydration of carbon dioxide,Metabolism,0.0015409414476380335,1,3,4,0.11997698937354422
6734,Iron uptake and transport,Transport of small molecules,0.000797727325031398,0,3,4,0.0621106810677208
6735,Iron uptake and transport,Transport of small molecules,0.0007984004549750049,1,3,4,0.062163090654220626
6736,Aspirin ADME,Drug ADME,8.723686004448913e-06,0,3,4,0.000679222162956421
6737,Aspirin ADME,Drug ADME,6.716729003149643e-06,1,3,4,0.0005229614178209551
6738,Fertilization,Reproduction,0.0007986004816605903,0,3,4,0.062178664639570745
6739,Fertilization,Reproduction,0.0012287658906037298,1,3,4,0.09567114469242768
6740,Transmission across Chemical Synapses,Neuronal System,8.108914692002145e-05,0,3,4,0.006313563525236864
6741,Transmission across Chemical Synapses,Neuronal System,0.0004836730775423348,1,3,4,0.03765856241553785
6742,Smooth Muscle Contraction,Muscle contraction,0.001809690046563143,0,3,4,0.1409016311545905
6743,Smooth Muscle Contraction,Muscle contraction,0.0011290802399647267,1,3,4,0.0879096659770989
6744,Regulated Necrosis,Programmed Cell Death,0.0001192648528861658,0,3,4,0.009285906358930009
6745,Regulated Necrosis,Programmed Cell Death,0.00015373453637342513,1,3,4,0.01196969999417772
6746,Peptide hormone metabolism,Metabolism of proteins,0.0028358633617244777,0,3,4,0.2207990114977833
6747,Peptide hormone metabolism,Metabolism of proteins,0.002455269128404325,1,3,4,0.19116612028269137
6748,Abacavir ADME,Drug ADME,0.000644435161666479,0,3,4,0.050175424031659394
6749,Abacavir ADME,Drug ADME,0.0004963214225426782,1,3,4,0.03864335671516888
6750,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0006247640534032447,0,3,4,0.04864384062809695
6751,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0007668313647930821,1,3,4,0.05970513587398246
6752,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.009883841110179977,0,3,4,0.769551303629036
6753,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.009868643703521229,1,3,4,0.7683680405660579
6754,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.0003148307541171865,0,3,4,0.024512577099590958
6755,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.0003786954794729051,1,3,4,0.029485055117553415
6756,Visual phototransduction,Sensory Perception,0.002116613097314257,0,3,4,0.16479851812255797
6757,Visual phototransduction,Sensory Perception,0.0033043406566624373,1,3,4,0.25727443729846644
6758,Fibronectin matrix formation,Extracellular matrix organization,0.000657379379390477,0,3,4,0.051183254844894645
6759,Fibronectin matrix formation,Extracellular matrix organization,0.0005911713756934963,1,3,4,0.0460283302576094
6760,Infectious disease,Disease,0.010909788289184992,0,3,4,0.849431077115547
6761,Infectious disease,Disease,0.008938224135393587,1,3,4,0.6959260027395763
6762,Laminin interactions,Extracellular matrix organization,0.0005082211981554489,0,3,4,0.03956986774803734
6763,Laminin interactions,Extracellular matrix organization,0.00045575278285620393,1,3,4,0.03548470116727385
6764,Inositol phosphate metabolism,Metabolism,0.00025392927151794237,0,3,4,0.019770815793966733
6765,Inositol phosphate metabolism,Metabolism,0.0003033898930880241,1,3,4,0.023621796944235926
6766,Biological oxidations,Metabolism,0.0008080003718835845,0,3,4,0.06291053575065371
6767,Biological oxidations,Metabolism,0.0009681002857784431,1,3,4,0.07537584109857036
6768,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.004873843767685079,0,3,4,0.3794752245908987
6769,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.005937222784147404,1,3,4,0.4622694236525876
6770,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.00021328282961121658,0,3,4,0.016606102601138695
6771,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.00010862336713823121,1,3,4,0.008457365193750984
6772,Atorvastatin ADME,Drug ADME,0.0016200606569630811,0,3,4,0.12613717446752337
6773,Atorvastatin ADME,Drug ADME,0.0012402587422911892,1,3,4,0.09656597281642396
6774,Integrin cell surface interactions,Extracellular matrix organization,0.006352489263372263,0,3,4,0.49460187991918886
6775,Integrin cell surface interactions,Extracellular matrix organization,0.005706138889217982,1,3,4,0.4442773383278394
6776,Metabolism of amino acids and derivatives,Metabolism,0.00042896349476298685,0,3,4,0.03339889956993781
6777,Metabolism of amino acids and derivatives,Metabolism,0.0005141895613784679,1,3,4,0.04003456175187713
6778,Disorders of transmembrane transporters,Disease,0.0005902860022312476,0,3,4,0.04595939548878048
6779,Disorders of transmembrane transporters,Disease,0.00048408944633896074,1,3,4,0.03769098069772815
6780,Signaling by NOTCH,Signal Transduction,0.0006570847602082115,0,3,4,0.05116031593144399
6781,Signaling by NOTCH,Signal Transduction,0.0005543955974493049,1,3,4,0.04316498514974025
6782,Elastic fibre formation,Extracellular matrix organization,0.0018620270671211377,0,3,4,0.14497656740148968
6783,Elastic fibre formation,Extracellular matrix organization,0.0016709817235702454,1,3,4,0.13010186519382042
6784,MAPK family signaling cascades,Signal Transduction,0.00035877296889642217,0,3,4,0.027933897646000686
6785,MAPK family signaling cascades,Signal Transduction,0.0003029735373748584,1,3,4,0.023589379680717795
6786,Signaling by Hedgehog,Signal Transduction,0.0010187048894295004,0,3,4,0.07931589216527479
6787,Signaling by Hedgehog,Signal Transduction,0.0008611045380045349,1,3,4,0.06704520159675069
6788,Integrin signaling,Signal Transduction,0.000129012966309953,0,3,4,0.010044889967587244
6789,Integrin signaling,Signal Transduction,0.00010926887735725661,1,3,4,0.008507624321252055
6790,Cell surface interactions at the vascular wall,Hemostasis,0.00019030386569435603,0,3,4,0.01481697108423771
6791,Cell surface interactions at the vascular wall,Hemostasis,0.00023482608188108619,1,3,4,0.018283450272340327
6792,Nephrin family interactions,Cell-Cell communication,3.778622463812553e-07,0,3,4,2.942017997389641e-05
6793,Nephrin family interactions,Cell-Cell communication,6.68409411967256e-08,1,3,4,5.204204808670309e-06
6794,Diseases of hemostasis,Disease,0.0013736346044510128,0,3,4,0.10695055583972084
6795,Diseases of hemostasis,Disease,0.0011237601148726148,1,3,4,0.08749544349471931
6796,ABC-family proteins mediated transport,Transport of small molecules,0.0009963679544550057,0,3,4,0.07757674872528213
6797,ABC-family proteins mediated transport,Transport of small molecules,0.000999630745597339,1,3,4,0.07783078813658606
6798,Macroautophagy,Autophagy,0.0005335195724607426,0,3,4,0.041539587486478145
6799,Macroautophagy,Autophagy,0.00055745042224468,1,3,4,0.043402832397326806
6800,Metabolism of lipids,Metabolism,0.0014463187061968105,0,3,4,0.11260970642986683
6801,Metabolism of lipids,Metabolism,0.0017334776022228957,1,3,4,0.13496776543973335
6802,Synthesis of DNA,DNA Replication,0.0005316828593398289,0,3,4,0.0413965818512362
6803,Synthesis of DNA,DNA Replication,0.0008990661813489472,1,3,4,0.07000087761358834
6804,Paracetamol ADME,Drug ADME,0.00023118756350110441,0,3,4,0.018000156911856288
6805,Paracetamol ADME,Drug ADME,0.00017881905041576828,1,3,4,0.013922768671324283
6806,Gene Silencing by RNA,Gene expression (Transcription),3.1479303609012925e-05,0,3,4,0.0024509640391425715
6807,Gene Silencing by RNA,Gene expression (Transcription),2.6689586643158237e-05,1,3,4,0.0020780388884851803
6808,Cilium Assembly,Organelle biogenesis and maintenance,1.078109564029243e-05,0,3,4,0.0008394111269141276
6809,Cilium Assembly,Organelle biogenesis and maintenance,0.0002695733554598216,1,3,4,0.020988856943895337
6810,Diseases of Immune System,Disease,0.0032398245205210213,0,3,4,0.25225124073760724
6811,Diseases of Immune System,Disease,0.00265273285767762,1,3,4,0.20654055503814328
6812,Surfactant metabolism,Metabolism of proteins,0.0005693581144441851,0,3,4,0.04432995981198185
6813,Surfactant metabolism,Metabolism of proteins,0.0004943332089169417,1,3,4,0.038488555320597424
6814,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0020795967447384102,0,3,4,0.16191644200834404
6815,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0017052024526549303,1,3,4,0.1327662753542723
6816,Response to metal ions,Cellular responses to stimuli,0.0002229927186514639,0,3,4,0.017362110076948833
6817,Response to metal ions,Cellular responses to stimuli,0.00024848927872274845,1,3,4,0.01934726046759041
6818,Metabolism of vitamins and cofactors,Metabolism,0.0032754927519514847,0,3,4,0.25502835276212005
6819,Metabolism of vitamins and cofactors,Metabolism,0.0039012341162560915,1,3,4,0.3037482863655907
6820,Cardiac conduction,Muscle contraction,0.0004744498583022505,0,3,4,0.036940446825582354
6821,Cardiac conduction,Muscle contraction,0.00029984704863939747,1,3,4,0.023345952711856733
6822,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.0049353559617884455,0,3,4,0.38426453561215473
6823,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.004256813069999529,1,3,4,0.3314334994670514
6824,Amyloid fiber formation,Metabolism of proteins,0.0043712392187444495,0,3,4,0.34034266655647466
6825,Amyloid fiber formation,Metabolism of proteins,0.003778212070756126,1,3,4,0.29416984672514557
6826,Signaling by Hippo,Signal Transduction,1.4125398039747477e-05,0,3,4,0.00109979696704865
6827,Signaling by Hippo,Signal Transduction,1.1966858892265009e-05,1,3,4,0.0009317341060250582
6828,DNA Double-Strand Break Repair,DNA Repair,5.556234774530822e-05,0,3,4,0.004326058731969355
6829,DNA Double-Strand Break Repair,DNA Repair,6.349998792908688e-05,1,3,4,0.0049440797303920885
6830,Signaling by WNT,Signal Transduction,0.00011657182193024104,0,3,4,0.009076228212575478
6831,Signaling by WNT,Signal Transduction,9.860669659550088e-05,1,3,4,0.007677471851855656
6832,Keratinization,Developmental Biology,0.0005911084885459179,0,3,4,0.04602343389334564
6833,Keratinization,Developmental Biology,0.0007804679835923405,1,3,4,0.060766876715127004
6834,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00024531547372437973,0,3,4,0.01910014947635407
6835,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00032332748066134324,1,3,4,0.025174128303798466
6836,Innate Immune System,Immune System,0.016951700707431884,0,3,4,1.3198515873244259
6837,Innate Immune System,Immune System,0.016541495950271688,1,3,4,1.2879132343998396
6838,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.004388185470694831,0,3,4,0.34166209390609187
6839,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.003712389732633407,1,3,4,0.2890449498813387
6840,Metabolism of porphyrins,Metabolism,0.000603879876841044,0,3,4,0.047017808287076454
6841,Metabolism of porphyrins,Metabolism,0.0007185950849210106,1,3,4,0.05594948140281384
6842,Transcriptional regulation of testis differentiation,Developmental Biology,0.00035336999141388027,0,3,4,0.02751322431477058
6843,Transcriptional regulation of testis differentiation,Developmental Biology,0.00046841800322615276,1,3,4,0.03647080937538786
6844,Intracellular signaling by second messengers,Signal Transduction,5.465239612097624e-05,0,3,4,0.004255210318792943
6845,Intracellular signaling by second messengers,Signal Transduction,4.616233091023029e-05,1,3,4,0.00359417776292802
6846,Diseases of programmed cell death,Disease,0.00044830873983604157,0,3,4,0.03490511141602458
6847,Diseases of programmed cell death,Disease,0.0003672407936695284,1,3,4,0.02859319857166353
6848,Platelet Adhesion to exposed collagen,Hemostasis,0.0008624268746946958,0,3,4,0.06714815812067758
6849,Platelet Adhesion to exposed collagen,Hemostasis,0.001057045269256681,1,3,4,0.08230105642972764
6850,Cell-Cell communication,root,0.0004076596454221241,0,4,5,0.07166563813261889
6851,Cell-Cell communication,root,0.00017402174344169908,1,4,5,0.030592626551952096
6852,Muscle contraction,root,0.0006884148888881707,0,4,5,0.12102177114215089
6853,Muscle contraction,root,4.891306443136993e-07,1,4,5,8.598805436987186e-05
6854,Extracellular matrix organization,root,0.0073022861089460395,0,4,5,1.2837252833369983
6855,Extracellular matrix organization,root,0.006890688477142248,1,4,5,1.211367356158434
6856,Organelle biogenesis and maintenance,root,5.83710389321368e-06,0,4,5,0.0010261495834849928
6857,Organelle biogenesis and maintenance,root,0.00012899067003218078,1,4,5,0.02267626630405891
6858,Circadian Clock,root,0.00022180727452602393,0,4,5,0.038993214191962784
6859,Circadian Clock,root,7.357010199484648e-05,1,4,5,0.0129334565394203
6860,Signal Transduction,root,0.004526455849797154,0,4,5,0.7957406395203466
6861,Signal Transduction,root,0.003837809557444416,1,4,5,0.6746781881756283
6862,Chromatin organization,root,0.00010669265210102215,0,4,5,0.01875632548559904
6863,Chromatin organization,root,0.00011865551133875367,1,4,5,0.020859368920950555
6864,Metabolism of proteins,root,0.013868163952914377,0,4,5,2.4379916692128214
6865,Metabolism of proteins,root,0.011255104839801789,1,4,5,1.9786218225223118
6866,Disease,root,0.007712136310874485,0,4,5,1.355776016319338
6867,Disease,root,0.006532038978184574,1,4,5,1.1483175902633307
6868,Programmed Cell Death,root,0.0013401692797894308,0,4,5,0.23559871015044898
6869,Programmed Cell Death,root,0.0018137471004592953,1,4,5,0.31885261351048677
6870,Drug ADME,root,0.0005420451602276444,0,4,5,0.0952903058731444
6871,Drug ADME,root,0.00012269233749672518,1,4,5,0.021569033774683895
6872,Vesicle-mediated transport,root,0.009271547115834741,0,4,5,1.6299168877628585
6873,Vesicle-mediated transport,root,0.012608348520977112,1,4,5,2.2165189826887093
6874,Immune System,root,0.012334696638087431,0,4,5,2.168411604306494
6875,Immune System,root,0.011122779183400175,1,4,5,1.9553592732024747
6876,Metabolism,root,0.0042237445673284435,0,4,5,0.7425246848098923
6877,Metabolism,root,0.006162239164890101,1,4,5,1.083307624477707
6878,Hemostasis,root,0.01086060365778394,0,4,5,1.9092694123172096
6879,Hemostasis,root,0.011274373948496456,1,4,5,1.9820092879885591
6880,Sensory Perception,root,0.002042993385354445,0,4,5,0.35915358879964265
6881,Sensory Perception,root,0.0025285399079317964,1,4,5,0.44451156272308134
6882,DNA Repair,root,0.00034172674825185825,0,4,5,0.06007478482471625
6883,DNA Repair,root,0.0005411862316729336,1,4,5,0.09513930818751393
6884,Transport of small molecules,root,0.005467123408743646,0,4,5,0.9611078561177798
6885,Transport of small molecules,root,0.00565721708505104,1,4,5,0.9945258918996595
6886,Gene expression (Transcription),root,0.00164087831035431,0,4,5,0.28846267353185784
6887,Gene expression (Transcription),root,0.0015637861501090812,1,4,5,0.27491004716562634
6888,Protein localization,root,0.00019151060414515086,0,4,5,0.03366712847187486
6889,Protein localization,root,0.00014951141850663892,1,4,5,0.026283767195784888
6890,Cell Cycle,root,0.0011366938351291842,0,4,5,0.19982818993916993
6891,Cell Cycle,root,0.0005684025319624197,1,4,5,0.09992387185418572
6892,Neuronal System,root,0.00021994897620061237,0,4,5,0.03866652957447141
6893,Neuronal System,root,0.000347040956512501,1,4,5,0.06100901054571995
6894,Autophagy,root,0.0022677101183944614,0,4,5,0.39865827917858426
6895,Autophagy,root,0.001028807529716384,1,4,5,0.18086202291723455
6896,DNA Replication,root,2.3123172923078528e-06,0,4,5,0.0004065001188595409
6897,DNA Replication,root,0.0005119980893747803,1,4,5,0.09000809918217606
6898,Metabolism of RNA,root,6.225665906498535e-05,0,4,5,0.010944579013400008
6899,Metabolism of RNA,root,0.00011194329884366047,1,4,5,0.019679377236356682
6900,Cellular responses to stimuli,root,0.002621344886574661,0,4,5,0.46082646681283507
6901,Cellular responses to stimuli,root,0.00199498248166492,1,4,5,0.35071338116841955
6902,Developmental Biology,root,0.0010272883533161802,0,4,5,0.18059495516260343
6903,Developmental Biology,root,0.0019302516573588945,1,4,5,0.3393338495350194
6904,Reproduction,root,0.00030010630919908486,0,4,5,0.05275800633665132
6905,Reproduction,root,0.0007987293423260174,1,4,5,0.14041480106221593
